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HIV is now a chronic illness, requiring long-term care and adherence to treatment. The 
continuum of care depicts the stages of the HIV care pathway, including diagnosis, 
Antiretroviral Therapy (ART) uptake and viral suppression. It is a widely used framework that 
monitors the success of HIV care and potential for transmission in a population. However, it 
has limitations and does not capture information on important health indicators, particularly 
mortality. 
The UK Collaborative HIV Cohort (CHIC) Study is an observational database of HIV-positive 
individuals accessing care. Linkage to HIV surveillance data is used to improve ascertainment 
of deaths, and, alongside additional data collected from participating centres, classify a 
principal cause of death. 
Late diagnosis occurs in approximately 56% of those aged ≥50 years, but 42% of those ≤50, 
and is associated with an increased rate of death in the subsequent year. Late ART initiation 
is associated with lower CD4 counts over time on ART, leaving individuals at a higher risk of 
clinical progression for longer. Engagement in care (EIC) during the first 5 years on ART 
correlates with life expectancy, but is generally high (median 93% of months in care). 
Unsuppressed viral load is highly predictive of age at death in those on ART. 
A longitudinal continuum of care provides information on person-time spent with 
unsuppressed viral load and incorporates additional outcomes of mortality and loss to follow-
up. It has shown disparities in care across demographic subgroups in the UK, with younger 
HIV-positive individuals having lower levels of EIC and being slower to initiate ART than older 
individuals, who have higher mortality. Women and those of black ethnicity spend less time 
on ART with a suppressed viral load. 
Targeted improvements in testing rates, adherence and engagement support are needed in 
those identified at high risk of sub-optimal care engagement, to reduce mortality and achieve 
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1Chapter 1: Introduction 
 
1.1 Human Immunodeficiency Virus (HIV)  
1.1.1 The History of HIV 
The first case reports of what is now known to be HIV/AIDS infection were made in 1981, 
with the appearance of cases of Pneumocystis Carinii pneumonia (PCP) and Kaposi’s Sarcoma 
(KS) in clusters of previously healthy men in the United States (US) (1-3). These cases were 
notable at the time as mortality associated with these conditions was remarkably high and 
these conditions were previously rare. Also, in common with other infections found to be 
present in the majority of these individuals (e.g. cytomegalovirus and thrush), these illnesses 
were related to severe immunosuppression (4-7). These initial cases occurred exclusively in 
young, gay men, generating speculation that lifestyles of gay men were somehow responsible 
(4, 8). However, in the year following the initial case reports, new cases began to be reported 
outside the original clusters of only gay men, in recipients of blood products (9), injecting 
drug users (7) and children (10), pointing to the potential for multiple routes through which 
this disease could occur (11, 12).  
Whilst the cause of this cluster of diseases was unknown, in 1982, the name Acquired 
Immunodeficiency Syndrome (AIDS) was given and a case definition, based on a set of clinical 
criteria and indicator diseases, was created by the US Centers for Disease Control (CDC), to 
define AIDS and enable surveillance (13-15). Whilst 1-2 new cases were being diagnosed daily 
in the US (14), numerous cases were also starting to be reported across Europe, pointing to 
unrelated epidemics (16-21). Soon after, a disease known as ‘slim disease’ in people living in 
Uganda came to be recognised as AIDS (22). 
HIV, the virus now known to cause AIDS, was discovered in 1983. The virus was, in fact, 
discovered independently by two different laboratories. The Pasteur Institute was the first to 
publish in 1983 on a new virus they called the Lymphadenopathy Associated Virus (LAV), 
which they had isolated from an individual with lymphadenopathy syndrome (23). In 1984, 
Robert Gallo published on a virus called the Human T-cell Lymphotropic Virus 3 (HTLV-III) 
(24). After discovering that these were the same virus, it was renamed Human 
Immunodeficiency Virus. This discovery allowed the development of diagnostic antibody tests 
in 1984 (25-27), and since then, much has been learned about the virus.  
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1.1.2 The lifecycle of HIV 
HIV is a retrovirus which, as with all viruses, invades and uses host cells in order to replicate. 
In the case of HIV this results in the destruction of the infected cell. HIV primarily infects CD4 
T-cells (28), which are an integral part of the body’s immune system, responsible for activating 
and coordinating the body’s immune response to harmful pathogens. The virus genetic 
material is stored as single-stranded ribonucleic acid (RNA) which is converted to deoxyribose 
nucleic acid (DNA) in the host cell using the viral reverse transcriptase enzyme. This DNA is 
then inserted into the host cell genome. Once integrated into the cell genome, it is able to 
replicate and create new copies of HIV which are released from the cell into the body to go 
on and infect other cells (29, 30). Each infected cell can create up to 1,000-10,000 new HIV 
virions before it dies, with up to 1010 created each day in an untreated individual (31, 32).  
The stages of the lifecycle of the HIV virion are shown in Figure 1.1.1. The first stage 
(attachment) occurs when the virus attaches to two CD4 receptors on the outside of the cell, 
known as CCR5 and CXCR4. The virus most commonly binds to the CCR5 receptor in the early 
stages of HIV infection, with a shift towards CXCR4 in the advanced stages of the disease. 
From here, its envelope fuses with the cell membrane, allowing the virus to enter the cell 
(fusion). Once inside the cell cytoplasm, the virus unpacks its cell content, and makes a copy 
of the viral RNA, before combining it into DNA via reverse transcription. This DNA, then 
integrates into the host cell’s genome using the enzyme integrase (integration). The cell then 
rapidly produces copies of messenger-RNA (transcription). Messenger RNA is translated into 
viral proteins (translation), which together with RNA, assemble to form new immature virus 
that are released from the cell surface (assembly/budding). The final stage is maturation, in 
which viral proteins are cleaved by the protease enzyme. This stage is necessary in order for 




Figure 1.1.1: The HIV lifecycle 
 
 
From Sarah Laskey and Robert Siliciano, 2014, Nature Reviews Microbiology, A mechanistic 
theory to explain the efficacy of antiretroviral therapy.(35) 
 
1.1.3 The course of HIV infection  
In the absence of treatment, HIV continues to replicate and infect more CD4 cells, resulting 
in reductions in the numbers of cells as they are destroyed. This in turn weakens the body’s 
ability to mount an immune response against opportunistic infections and cancers (37, 38). 
This depletion of the immune system eventually results in the development of AIDS and death 
(39-41). 
The initial weeks following HIV infection are referred to as primary or acute infection. During 
this initial period, HIV rapidly replicates and infects CD4 cells leading to extremely high levels 
of viraemia (>1 million copies of virus per millilitre (copies/ml)) in the plasma (42), which may 
first be detected between 4-11 days after infection (43, 44). This early phase of infection is 
characterised by rises in the amount of virus in the blood and rapid declines in CD4 count 
(Figure 1.1.2). However, the body does raise an initial immune response to the virus within 
the first few weeks of infection, producing antibodies to fight the virus (28, 45). This 
appearance of antibodies in the blood is known as seroconversion and occurs 2-3 months 
after infection, on average (46). During or prior to seroconversion, individuals may experience 
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mild symptoms similar to those experienced with other viruses such as influenza, and could 
include fever, rash, aches, diarrhoea and sore throat (28, 47, 48). Following this immune 
response there is a fall in the amount of virus in the blood, although it does not disappear 
completely (43), with some recovery of the number of CD4 cells in the blood (Figure 1.1.2) 
(49). 
A period of asymptomatic infection follows, which is highly variable in length, but lasts for an 
average of 10 years (50, 51). This phase is characterised by a gradual increase in the amount 
of virus (52), and a decline in the number of CD4 cells (53). A healthy HIV-negative individual 
could be expected to have between 500-1500 CD4 cells present per mm3 of blood (54, 55). 
In an untreated individual with HIV, the CD4 count typically declines by an average 30-60 
cells/mm3 per year (56). As the CD4 count falls and the immune system becomes 
compromised, individuals are at increased risk of developing opportunistic infections and 
malignancies (40, 57-59), the appearance of which constitute the final stage of infection 
known as AIDS. In 1993, the CDC developed a list of illnesses and opportunistic infections 
(indicator diseases) that are considered definitive of progression to AIDS (Table 1.1.1). 
However, in the US, AIDS will also be defined in the presence of a CD4 count <200 cells/mm3 
or a CD4 percentage value <14%, irrespective of the development of indicator diseases (60, 
61). 
 
Figure 1.1.2: CD4 and viral load changes following HIV infection 
From Giuseppe Pantaleo, Cecilia Graziosi, and Anthony S. Fauci, 1993, NEJM, The 
immunopathogenesis of Human Immunodeficiency Virus Infection (45) 
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1.1.4 Markers of disease progression 
Due to the fact that HIV predominantly infects CD4 cells, the well described 
immunopathogenesis of HIV and prognostic ability of CD4 to predict AIDS (40, 57, 58) and 
mortality (41, 62), the CD4 count is a routinely used marker of HIV progression in the clinical 
care of people living with HIV (PLWH). Until recently, HIV monitoring guidelines have also 
used the CD4 count to guide decisions around when to start treatment for HIV (Section 
1.3.4.1). 
The amount of virus in the plasma, otherwise known as the HIV viral load, has been 
demonstrated as another highly predictive marker of outcomes in untreated individuals (52, 
63), and is also a marker of treatment success. The goal of HIV treatment is to reduce the 
viral load to a level by which it is ‘undetectable’ by the assays used to measure it. A widely 
used definition of an undetectable viral load is to have ≤50 copies of virus per ml of plasma 
(copies/ml), however, some of the most sensitive assays used in clinical care in recent years 




Table 1.1.1: CDC list of AIDS-defining conditions 
Condition 
1. Bacterial infections, multiple or recurrent*  
2. Candidiasis of bronchi, trachea, or lungs 
3. Candidiasis of esophagus†  
4. Cervical cancer, invasive§  
5. Coccidioidomycosis, disseminated or extrapulmonary  
6. Cryptococcosis, extrapulmonary  
7. Cryptosporidiosis, chronic intestinal (>1 month's duration)  
8. Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month  
9. Cytomegalovirus retinitis (with loss of vision)†  
10. Encephalopathy, HIV related  
11. 
Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis (onset at age >1 month)  
12. Histoplasmosis, disseminated or extrapulmonary  
13. Isosporiasis, chronic intestinal (>1 month's duration)  
14. Kaposi sarcoma†  
15. Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex*†  
16. Lymphoma, Burkitt (or equivalent term)  
17. Lymphoma, immunoblastic (or equivalent term)  
18. Lymphoma, primary, of brain 
19. 
Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary†  
20. 
Mycobacterium tuberculosis of any site, pulmonary,†§ disseminated,† or 
extrapulmonary†  
21. 
Mycobacterium, other species or unidentified species, disseminated† or 
extrapulmonary†  
22. Pneumocystis jirovecii pneumonia (previously Pneumocystis Carinii)†  
23. Pneumonia, recurrent†§  
24. Progressive multifocal leukoencephalopathy  
25. Salmonella septicemia, recurrent  
26. Toxoplasmosis of brain, onset at age >1 month†  
27. Wasting syndrome attributed to HIV 
* Only among children aged <13 years. † Condition that might be diagnosed presumptively. § Only 




1.1.5 HIV Transmission 
HIV is present in most bodily fluids of an infected individual, although the quantities in sweat, 
tears and saliva are small, and the largest concentrations are found in the blood and in semen. 
Mucosal exposure to blood or bodily fluids from an infected person is required for the virus to 
be transmitted (64). The risk of transmission is highly dependent on the amount of virus 
present, with a higher viral load increasing the risk of transmission taking place (28, 65). The 
small concentration of virus in bodily fluids such as sweat and tears, as well as the fact that 
HIV cannot survive outside of the body, means that transmission through casual contacts 
including hand shaking or kissing is not possible (64, 66). Routes by which HIV can be 
transmitted between humans therefore include condomless sex, either between men or 
between men and women, through needle-stick injuries, sharing of injecting equipment and 
from mother-to-child during pregnancy, birth and breastfeeding (10, 64, 66). The 
predominant mode of transmission of HIV globally is through sexual intercourse (64, 66). 
Historically, some individuals acquired HIV through receipt of blood products (9, 66), although 
now all blood products are screened for HIV.  
 
1.2 Epidemiology of HIV 
1.2.1 The global HIV epidemic 
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 78 million people 
have been infected with HIV globally since the start of the epidemic and 35 million have died 
due to AIDS-related illness (67). By the end of 2016, 37 million (95% confidence interval (CI); 
31 million – 43 million) people were known to be living with HIV (67). Globally the prevalence 
of HIV has remained stable since 2000 at 0.8% (68). Nearly 26 of these 37 million individuals 
living with HIV live in Sub-Saharan Africa, where prevalence of HIV markedly higher than the 
rest of the world; 7.1% in Central and Southern Africa, and 2.2% in West and Central Africa 
(67).  
Following the start of the epidemic in the 1980’s, the number of new infections continued to 
rise each year until its peak in 1996 when 3.5 million new infections were reported. This 
number has steadily declined each year, such that, in 2016, the estimated number of new 
infections globally was 1.8 million (69). This decline in new diagnoses has been observed in 
most areas of the world including Africa, Asia, Europe and North America. However, in Eastern 
Europe and Central Asia there have been substantial 57% increases in the number of new 
infections in 2015 compared to 2010 (69).  
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1.2.2 The HIV epidemic in the UK 
Since the first reported cases of AIDS in 1981, the number of people infected with HIV in the 
UK has continued to rise, with around 101,200 people thought to be living with HIV at the 
end of 2015, 13% of whom were unaware of their positive status (Figure 1.2.1). Overall, the 
prevalence of HIV in the UK is estimated to be around 1.6 per 1,000 population. Whilst most 
regions have low prevalence <1 per 1,000 population there is a concentrated high prevalence 
of >5 per 1,000 persons in London, Manchester and Brighton (70). The prevalence is highest 
among men who have sex with men (MSM), with 1 in 17 thought to have HIV in 2015 
(prevalence rate 59 per 1,000). Amongst heterosexual men and women the prevalence is 
considerably lower (1 per 1,000), with a concentrated prevalence amongst black African men 
and women (22 per 1,000 and 43 per 1,000 respectively). The majority of black African men 
and women are thought to have acquired HIV in their country of origin prior to migrating to 
the UK (71, 72). Amongst heterosexuals who were born abroad but received a diagnosis of 
HIV in the UK, 31% of black African individuals are believed to have acquired their HIV since 
moving to the UK, compared to 59% of black Caribbean and 36% of white ethnicity (73). 
 
Figure 1.2.1: Estimated number of people living with HIV in the UK 
 
From Kirwan et al., HIV in the UK: 2016 Report (70) 
 
Transmission of HIV within the UK occurs largely through sexual contact, with a relatively 
small proportion of diagnoses (<3%) occurring amongst people who inject drugs (PWID) or 
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through mother-to-child transmission (MTCT) (70). Since the start of the epidemic, there has 
been a steady increase in the numbers of new diagnoses among MSM, reaching 3,360 new 
diagnoses in 2014 (74, 75). In 2015 and 2016, however, declines in the number of HIV 
diagnoses amongst MSM have been noted for the first time (76). Whereas new diagnoses 
amongst heterosexuals accounted for less than 1,000 new diagnoses in 1995, this rose steeply 
year on year to a peak of 4,840 diagnoses in 2005, overtaking the number of new diagnoses 
in MSM in 2000. Since this time, diagnoses amongst heterosexuals have declined just as 
rapidly as they increased and fell back below the number of newly diagnosed MSM in 2012 
and were estimated to total 2,490 new diagnoses in 2014 (74, 75). This decline is thought to 
be a result of changing migration patterns, with fewer new diagnoses reported amongst 
individuals who were born and acquired HIV abroad (70). 
Of 88,769 individuals who accessed HIV care in 2015, 61,097 (68.8%) were men and 27672 
(31.2%) women. The majority of men (68.6%) accessing care were reported to have acquired 
HIV through sex with other men, such that MSM contributed 47.2% of all HIV-positive 
individuals accessing care. Most MSM (86%) accessing care are of white ethnicity. 
Heterosexual men and women totalled 42,710 (48.1%) individuals accessing care, of whom 
61% were of black African ethnicity, 25% were white and 7% Caribbean or other black 
ethnicity (70). Only 2% of people who access HIV care are thought to have acquired HIV 
through MTCT and another 2% through injecting drug use (IDU) (75). 
A major change in the HIV epidemic in the UK, as well as world-wide, has been the increasing 
age of the population. This has arisen as a result of both increased survival (Section 1.4.4) 
and increasing numbers of new HIV diagnoses amongst older individuals. In 2015, 34% of 
HIV-positive individuals accessing care in the UK were aged over 50, compared with only 14% 
in 2006 (70). 
 
1.3 Treatment of HIV 
1.3.1 History of ART development 
All antiretrovirals act by interrupting the HIV life cycle and are separated into different classes 
according to which aspect of the HIV life cycle they act on (36). The first drug shown to have 
antiviral activity against HIV was approved by the US Food and Drug Administration (FDA) in 
1987, 6 years after the first case reports of AIDS in New York and California. This antiretroviral 
drug, zidovudine (ZDV), was approved when its clinical trial was stopped early and those 
receiving placebo offered ZDV, due to reduced mortality rates in those in the treatment arm 
(77). However, subsequent trials and wider use in the HIV-positive population showed that 
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the benefits noted in the first 6 months of exposure, were not maintained after this time, and 
severe side effects were experienced by those taking the drug, particularly at high 
concentrations (78-82). Zidovudine was the first of a class of drugs called nucleoside reverse 
transcriptase inhibitors (NRTIs) and was followed by three other antiretrovirals; didanosine 
(ddI) in 1991, zalcitabine (ddC) in 1992 and stavudine (d4T) in 1994, all of which acted by 
inhibiting the same part of the HIV life cycle. These antiretrovirals were either taken singly 
(monotherapy) or in a combination of two drugs (dual therapy). However, the benefits on 
survival remained minimal, and were frequently accompanied by treatment-limiting toxicity 
(83). During this time, pharmaceutical companies had been developing a new type of 
antiretroviral drug, which acted on HIV by inhibiting a different aspect of the HIV life cycle; 
this class of drug was called the protease inhibitor (PI). The first of these PIs, saquinavir 
(SQV), was granted accelerated approval by the FDA in 1995 (84).  
In 1996, at the XIth International AIDS Conference, results from the first trial of combination 
antiretroviral therapy (ART) were presented. These results showed that taking different types 
of antiretroviral drugs that acted on different parts of the HIV life cycle in combination resulted 
in more sustained benefits (85). These combination regimens were named highly active 
antiretroviral therapy (HAART) or combination antiretroviral therapy (cART or ART), and the 
definition was soon expanded to include any combinations of three or more antiretrovirals. In 
1996, a drug from another class of antiretrovirals called non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) was also approved by the FDA, providing further treatment options for 
people living with HIV (PLWH) (84). However, original ART regimens were associated with 
high levels of toxicity, and a very high pill burden, with regimens often containing up to 20 
tablets that had to be taken in thrice-daily regimens with complicated food requirements (86, 
87). For PIs, certain pharmacokinetic characteristics (low absorption and high hepatic 
metabolism) of early PIs meant that they had poor bioavailability (88). It was discovered that 
co-administration of PIs with low-doses of ritonavir, another PI which inhibits hepatic 
metabolism but was not often used due to high toxicity and low efficacy, boosted the 
bioavailability of this class of drugs (89). Boosted PI combinations (PI/r) are now commonly 
used in treating PLWH (90). 
Since the early ART period, new drugs have continuously been developed, with improvements 
in efficacy and reductions in toxicity over time. Two more classes of drugs have been and 
there are currently over 20 licensed drugs from 5 classes (Table 1.3.1) (84). Pill burden has 
also improved over time, with longer dosing intervals and the introduction of co-formulated 
antiretrovirals, which combine multiple drugs into a single tablet (91, 92). In 2006 the first 
‘one tablet once a day’ regimen called Atripla was approved (93). Currently there are 6 such 
single tablet regimens available (94).  
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1.3.2 Antiretroviral drug classes and their mechanism of action 
The points of action in the HIV life cycle of the different antiretroviral drug classes are shown 
in Figure 1.1.1. NRTIs were the first class of drugs to be developed. They work by inhibiting 
reverse transcriptase, the process by which HIV turns its genetic material from single-stranded 
RNA to full DNA (35, 64). Two nucleotide reverse transcriptase inhibitors, tenofovir disoproxil 
fumerate (TDF) and tenofovir alafanamide fumerate (TAF) are also licensed, but are generally 
considered in the group of NRTIs. NNRTIs similarly inhibit reverse transcription, but achieve 
this through a different mechanism. NRTIs are nucleoside or nucleotide analogues that are 
similar enough to be incorporated into the generated DNA string causing errors and preventing 
complete transcription of RNA into DNA. NNRTIs instead bind to reverse transcriptase, 
blocking transcription (35, 95). PIs bind to protease, preventing maturation and resulting in 
the release of immature HIV virions that are unable to infect other cells (35, 64). Entry 
(Fusion) inhibitors prevent the HIV envelope from fusing with the CD4 cell membrane, 
allowing the virus to enter the cell (35, 96). CCR5 entry inhibitors block the CCR5 receptor on 
the cell surface, preventing HIV from attaching to the cell (97). The newest class of 
antiretrovirals are the integrase inhibitors (INSTIs). These drugs prevent HIV DNA from being 
integrated into the cell’s genome (35).  
Around 85-90% of individuals will achieve an undetectable viral load <50 copies/ml within 6 
months of starting current ART regimens (64). However, HIV cannot be eliminated from the 
body entirely and so there is, as yet, no cure. One major reason for this is because certain 
cells, when infected with HIV may go into an inactive or latent state in which HIV is unable to 
replicate (35). These latent cells may be found in the brain, lymph nodes, and digestive tract 
and collectively are referred to as the HIV reservoir. Such latent cells may reactivate at any 
time. Once ART is stopped, some of these latent cells will reactivate and HIV will again become 
detectable (98, 99). One strategy for developing a HIV cure targets such latent cells, trying 
to force them to become active, as once they are reactivated they become a target for ART 











Zidovudine (AZT) 1987 
Didanosine (ddI) 1991 
Zalcitabine (ddC) 1992 
Stavudine (d4T) 1994 
Lamivudine (3TC) 1995 
Abacavir (ABC) 1998 




Tenofovir disoproxil fumerate (TDF) 2001 
Tenofovir alafanamide fumerate 
(TAF) 
2016 
Protease Inhibitors (PIs) 
Saquinavir hard gel (SQV) 1995 
Indinavir (IDV) 1996 
Ritonavir (/r) 1996 
Saquinavir soft gel 1997 
Nelfinavir (NFV) 1997 
Amprenavir (APV) 1999 
Lopinavir/ritonavir (LOP/r) 2000 
Atazanavir (ATV) 2003 
Fosamprenavir (fAPV) 2003 
Tipranavir (TPV) 2005 




Nevirapine (NVP) 1996 
Efavirenz (EFV) 1998 
Etravirine (TMC125) 2008 
Rilpivirine (RPV) 2011 
Fusion/entry inhibitors 
Enfuvirtide (T20) 2003 
Maraviroc (MVC) 2007 
Integrase Inhibitors (INSTIs) 
Raltegravir (RAL) 2007 
Dolutegravir (DTG) 2013 
Elvitegravir (ETG) 2012*/2014** 
*As part of co-formulated single-tablet regimen stribild **As a single pill formulation to be 




1.3.3 Side-effects of ART 
As with most chemical agents, antiretroviral drugs may cause side-effects or toxicities in some 
individuals. If severe, such side-effects may cause illness, changes to physical appearance 
and cause long-term harms as well as affecting an individual’s ability to adhere fully to ART 
(86, 103-105). It is therefore important to monitor for side-effects and select regimens to 
minimise toxicities and maximise the tolerability and adherence to these medications. Many 
side effects resolve if exposure to the responsible agent is removed. However, due to the life-
long need for ART, an alternative medication will need to be used in place of the discontinued 
agent. Early antiretroviral drugs had severe side-effects to the extent that some early NRTIs, 
namely zalcitabine and stavudine, are no longer endorsed in clinical practice (106, 107). Over 
time, the toxicity profile of antiretrovirals has dramatically improved as newer drugs have 
been developed, but some side-effects still remain.  
Severe effects of NRTIs include mitochondrial toxicity, manifesting as lactic acidosis, hepatic 
steatosis, peripheral neuropathy, and lipodystrophy (108, 109). The NRTI abacavir (ABC) can 
induce a hypersensitivity reaction presenting as a rash amongst people with the HLA B*5701 
allele (36, 110). If very severe, this hypersensitivity may cause hepatitis or even result in 
death (111). For this reason, people undergo genetic testing for the presence of this allele 
before commencing ABC (112). Links have also been made between ABC and myocardial 
infarction in observational studies (113), whilst declining renal function, greater risk of chronic 
kidney disease and low BMD have all been associated with TDF exposure (103, 114-116). 
Some of the earliest PIs (SQV, IDV, NFV) also carry a relatively high burden of toxicity. Severe 
effects of PIs include metabolic abnormalities such as dyslipidaemia, hyperglycaemia and 
lipodystrophy, and the earlier PIs were associated with severe gastrointestinal issues such as 
nausea, vomiting and diarrhoea (36, 106, 117). Some of the newer PIs have been linked to 
kidney dysfunction and decreased bone mineral density (104). ATV and LPV in particular have 
been identified as being associated with declining eGFR and increased incidence of chronic 
kidney disease (118). 
NNRTIs are associated with hypersensitivity reactions, often presenting with a rash. Efavirenz, 
has been widely used and is still a recommended treatment option by the World Health 
Organisation (WHO), has been linked to CNS disorders, sleep disturbance and suicidal ideation 
(106, 119, 120). For this reason it is not recommended to be used in individuals with previous 
history of mental health illness. Nevirapine is associated with hepatotoxicity, with the life 
threatening Stevens-Johnson syndrome occurring in the most extreme cases (106, 121). The 
newest class of INSTIs are generally more tolerable and have limited uncommon side-effects 
reported to date. There is some indication that neuropsychiatric side effects may be occurring, 
30 
 
particularly with dolutegravir (122, 123). However as this is a new class of drug it may take 
time for side-effects to be recognised.  
1.3.4 Resistance 
During replication, the HIV virus uses single stranded RNA to create new genetic material 
(DNA). RNA is a sequence of amino acids that code the genetic material of the HIV virus. As 
HIV replicates extremely rapidly, with between 1 and 10 billion new virions created each day 
in untreated individuals, it regularly creates spontaneous errors in the amino acid sequence 
i.e mutations of the genetic material, and new variants or strains of the virus (32, 124). These 
mutations may be of advantage or disadvantage to the virus. One strain of the virus (known 
as the “wild type”) is the fittest (i.e. has the highest replicative capacity) in the absence of 
treatment and so usually constitutes the majority virus in the absence of treatment. However, 
strains which contain mutations that confer resistance to a specific antiretroviral or 
antiretroviral drug class may become the fittest once drug pressure is added, meaning that 
this virus strain is able to replicate in the presence of ART (125). For some drugs, multiple 
resistance mutations must occur in order for the susceptibility of the virus to be reduced, 
whilst a single mutation may be sufficient to cause resistance to certain drugs (124). Further, 
certain mutations, alone or in combination, may cause resistance to multiple drugs, leading 
to class-wide resistance (125). 
The development of resistance in the presence of sub-optimal ART concentrations (most often 
caused by poor adherence) will lead to treatment failure and require changes to be made to 
the treatment regimen. It is also possible for individuals who have never received ART to be 
resistant to ARVs, as drug resistant virus may be transmitted (126). It is recommended that 
resistance tests are performed once an individual is diagnosed with HIV and following a 
rebound of HIV viral load on ART to ensure individuals are treated with appropriate agents 
(127). ARVs that do not easily confer resistance are said to have a high genetic barrier and 
are more ‘forgiving’ of lower rates of adherence (128). Where there are concerns over 
adherence, drugs with a higher genetic barrier (usually PIs) may be prescribed so as to 
minimise the risk of resistance development. Drug resistance has traditionally been a problem 
as it reduces treatment options and can influence treatment response and outcomes (129, 
130). However, in the UK, the prevalence of both developed and transmitted resistance has 
declined since 2002, with an estimated 33% of treatment experienced individuals resistant to 




1.3.4.1 When to start ART 
For many years guidelines have recommend that treatment be initiated immediately amongst 
those with primary infection, those who have progressed to symptomatic HIV or AIDS, and 
amongst those with other comorbidities such as hepatitis B (HBV) or hepatitis C virus (HCV) 
co-infection. However, the optimal timing of ART initiation for asymptomatic, chronically 
infected individuals has been widely debated in recent years. Until relatively recently, CD4 
count-guided treatment initiation was recommended. Prior to 2008, in the absence of good 
evidence as to the optimal timing of ART initiation and due to concerns over drug toxicity and 
resistance development, UK guidelines recommended the consideration of therapy initiation 
at CD4 counts of 200-350 cells/mm3 with a strong recommendation for treatment with a CD4 
count <200 cells/mm3 (133-136).  
In 2008, the threshold for ART initiation was increased to recommend ART initiation before 
the CD4 count fell below 350 cells/mm3, and before it reached 200 cells/mm3 (112). From this 
time a body of evidence started to grow around the potential benefits of earlier or immediate 
ART initiation. In 2009 the Swiss statement was released, which stated that an HIV positive 
person in receipt of ART with an undetectable viral load and without any concurrent sexually 
transmitted infections could not transmit HIV (137). This introduced the concept that HIV 
treatment could not only be used for the individual’s own health but also as a means of 
preventing HIV transmission. This led to questions over the need for CD4 count-guided ART 
initiation as opposed to immediate treatment for all in order to reduce onward transmission 
(TasP).  
In 2011 the HPTN 052 study demonstrated that earlier ART initiation reduced the risk of 
onward transmission between heterosexual couples by 96% (138). Subsequently, US 
guidelines changed in 2012 to recommend treatment with ART, regardless of an individual’s 
CD4 count (139) with WHO guidelines changing in 2013 to recommend ART initiation at CD4 
counts lower than 500 cells/mm3. However, earlier ART initiation confers extra years of 
exposure to drugs with potential side-effects and the requirement for an individual to maintain 
high levels of adherence for a longer time to avoid resistance. As there was still no evidence 
as to the potential risk to benefit ratio for an individual’s health of starting ART earlier, British 
HIV treatment guidelines remained unchanged (140) and European guidelines suggested that 
ART be considered irrespective of CD4 count but there was no strong recommendation for 
immediate ART. In 2015, the START study reported as to the benefits of immediate ART 
initiation amongst those with CD4 counts >500 cells/mm3, in terms of both AIDS and non-
AIDS morbidity and mortality (141). Subsequently UK guidelines were updated in 2015 and 




1.3.4.2 What drugs to start 
Treatment guidelines around the world differ somewhat as to the preferred choice of HIV 
treatment regimen for individuals newly starting ART. The first regimen started is referred to 
as first-line therapy. All guidelines recommend that first-line ART regimens should include a 
backbone of two NRTIs alongside a third agent from another class of ARVs (143-145). The 
choice of NRTI backbone and corresponding third agent differs by guidelines, according to 
setting, cost and availability of drugs in different regions. A summary of the recommended 
first-line ART regimen in various current guidelines is shown in Table 1.3.2. Guidelines in the 
UK currently recommend starting a NRTI backbone consisting of either TDF or TAF with FTC 
alongside an INSTI, boosted PI or RPV (142). In practice, however, the choice of initial ART 
regimen is also influenced by financial restraints, with EFV still used instead of INSTIs. 
 
Table 1.3.2: Current recommended first-line regimens 
Guideline body NRTI Third Agent 
WHO (2016) (143) 
Low-income countries 
TDF/FTC or TDF/3TC EFV 








TAF/FTC or TDF/FTC 
RPV 
DRV/r or DRV/c 
TDF /FTC EFV 
EACS (2017) (145) 
Europe 
ABC/3TC DTG 





DRV/r or DRV/c 
BHIVA (2016) (142)  
UK 










1.3.4.3 Treatment switches 
In the event that someone is unable to achieve or maintain an undetectable viral load on 
treatment, it may be necessary to change some or all of the components of the ART regimen 
being taken. Transient and low level increases in viral load (blips) may occur, but treatment 
switches in this situation are currently not recommended. Virological failure is defined in UK 
guidelines if people are unable to suppress the virus to below detectable levels after 24 weeks 
of therapy, or if a confirmed rebound (≥2 results) of viral load to above 200 copies/ml occurs 
after the person achieves an undetectable viral load (146). In this instance it is important to 
try and achieve an undetectable load through alternative regimens. If a person experiences 
viral load rebound that would be defined as virological failure, resistance testing should be 
performed and the reasons for this rebound, including poor adherence, should be 
investigated. Treatment switches may also be made in the event of toxicities or if a patient 
requests a change due to side effects. The choice of new drug(s) should be made based on 
the results of resistance testing to ensure any new drugs are fully active against HIV, bearing 
in mind any concerns of adherence and tolerability (146). A regimen containing 2 NRTIs 
alongside a third agent from another class is recommended where possible. However if class-
wide or multi-class resistance is present or the chance of new resistance development is high, 
the choice of active agents to choose from may be limited. Alternative combinations, such as 
combined third agents with no NRTI backbone, may need to be considered in consultation 
with a multi-disciplinary team (146). 
 
1.4 Changing outcomes for people with HIV in the ART era 
With effective and tolerable ART, individuals are able to achieve and then maintain long-term 
suppression of HIV (147). Long-term suppression is associated with favourable outcomes with 
regards to health and morbidity. This is because reducing the amount of virus in the blood 
allows the immune system to function better as CD4 cells aren’t depleted. This dramatically 
slows or halts disease progression, reducing the risk of AIDS but also lowering immune 
activation and inflammation which is believed to play a role in the development of some non-
AIDS illnesses (148-151). This has had large impacts on morbidity and mortality outcomes of 
PLWH. Another major benefit of viral suppression is the reduced potential for onward 
transmission of the virus (138, 152). This reduced infectiousness has important implications 
for reducing HIV incidence. 
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1.4.1 Declining AIDS incidence and mortality 
The rate of AIDS-defining illness approximately halved amongst PLWH in the year following 
the introduction of combination ART (153-155). The initial very rapid decline in AIDS illness 
in the first 3-5 years after ART was introduced was followed by continuing moderate declines 
in the rate of AIDS (156, 157). Once ART has been started the risk of progression to AIDS 
may be as low as 5%, but this is highly dependent on someone’s CD4 count at the time they 
start treatment. People who start ART with a low CD4 count will progress to AIDS more quickly 
(158, 159). With reductions in AIDS incidence on ART, the greatest burden of AIDS-related 
illness now occurs around the time of HIV diagnosis, in people who don’t get diagnosed until 
HIV is already in an advanced stage (160).  
Prior to the introduction of ART, median survival time following and AIDS diagnosis was just 
18 months, with improvements observed even with ZDV monotherapy in the early ART era 
(161, 162). Throughout the ART era, survival following AIDS diagnosis has continued to 
improve (163, 164), with approximately 85% of individuals surviving 5 years after their 
diagnosis in recent years (165, 166). Combined with the declining AIDS incidence, this has 
dramatically reduced rates of deaths due to AIDS-defining illness in the ART era (167) by as 
much as 95% in some settings (168). From a high of greater than 10 AIDS deaths per 100 
person years at the start of the ART era, this reduction was characterised by a rapid decline 
in the rate of AIDS deaths after the introduction of ART in 1996 (169, 170), followed by more 
moderate declines and eventual stabilisation of death rates since 2000 at <1 per 100 person 
years (168, 171-173).  
1.4.2 Non-AIDS morbidity and mortality 
Non-AIDS illnesses have become of increasing concern amongst PLWH in recent years as 
AIDS-free survival has increased. These non-AIDS conditions are traditionally related to aging 
in the general population e.g. malignancy, cardiovascular disease (CVD), liver disease, kidney 
disease, and osteoporosis (174-176). The prevalence and risk of co-morbidities among people 
living with HIV is significantly higher than in the general population (177). In fact, the 
comorbidity profile of PLWH is likened to that in the general population aged 10 years older, 
with a higher prevalence of multiple co-morbidities (174, 178). This has generated a 
hypothesis of premature or accelerated aging occurring in PLWH (174, 179). Whilst the aging 
of the population likely contributes to this increasing prevalence of non-AIDS illnesses in 
recent years, lifestyle factors, ART exposure and HIV itself may all contribute to the excess 
risk of non-AIDS co-morbidities in PLWH compared to the general population (176, 178, 180). 
For instance, smoking rates are significantly higher amongst PLWH than in the general 
population and smoking is a well-known risk factors for several conditions including stroke, 
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myocardial infarction and cancer (180, 181). The majority of liver-related morbidity and 
mortality amongst PLWH occurs in those who are co-infected with Hepatitis C Virus (HCV), 
which is more prevalent amongst PLWH than in the general population (182, 183). ART has 
also been linked to non-AIDS morbidity, with TDF and some PIs associated with renal 
impairment and bone mineral density loss (104, 118). Large observational studies also link 
ABC to myocardial infarction (113). These comorbidities present several challenges in the care 
and management of PLWH, of which polypharmacy and potential drug-drug interactions are 
one (184-186). 
The rate of all non-AIDS mortality has declined in the ART era, but with more moderate 
declines than for AIDS-related deaths (172). Whilst the rates of death due to both liver and 
cardiovascular disease have steadily decreased, deaths due to non-AIDS malignancies have 
remained largely stable (168, 173, 187). There is an excess risk of some non-AIDS illnesses 
in PLWH compared to the general population (188). Compared to the general population, 
rates of death due to non-AIDS malignancies are 1.3-3 times higher in HIV-positive individuals 
(171, 189, 190). Rates of liver-related death are 3-69 times higher than the general 
population, depending on the prevalence of HCV in the population studied (171, 189-191). 
Rates of CVD death are 1.5-3 times higher (171, 189, 190). Rates of non-AIDS infection may 
be markedly higher at >10 times the rate in the general population (189).  
1.4.3 Causes of death 
As a result of the decreased incidence of AIDS and AIDS-related mortality rates following the 
wide-spread roll out of HAART, the distribution of deaths attributable to AIDS and non-AIDS 
defining causes has also changed over time. Whereas almost all deaths in the pre-ART era 
were AIDS-related, the proportion of deaths attributed to AIDS declined in the ART era, 
representing 20-30% of all deaths the modern ART era in high-income countries (173, 192-
195). 
Conversely, the portion of deaths attributed to non-AIDS causes has increased in the ART era, 
to represent the majority of deaths occurring in HIV-positive individuals (196). The most 
common non-AIDS cause of death is malignancy, which has markedly increased in the ART 
era, contributing approximately one-quarter of deaths since 2009 and overtaking AIDS as a 
cause of death (172, 173, 196). This is followed by liver disease, contributing approximately 
7-15% of deaths (173, 196, 197). These deaths almost entirely occur in people with HCV co-
infection (172, 198), leading to higher proportions of liver related deaths in settings with a 
higher prevalence of HCV. Between 7-11% of deaths are attributed to CVD (168, 173, 195-
197, 199), and similar proportions were due to non-AIDs infections (196, 197). Approximately 
5% of deaths in PLWH are due to suicide (172, 195, 196).  
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1.4.4 Improvements in life expectancy 
The introduction of ART has vastly reduced all-cause mortality rates and improved the survival 
of people living with HIV (153, 192, 193, 200, 201). In the pre-ART era, only 50% of people 
newly infected with HIV could be expected to survive for 10 years. Since 2000, 10 year survival 
rates from HIV seroconversion are estimated to be 94% (202). Consequently, the life 
expectancy of people living with HIV has increased over time, contributing to an aging HIV 
population (167, 203). At the time when combination ART became available, a 20 year old 
with HIV could be expected to live to approximately 39 years of age; a 44 year gap in 
comparison to the life-expectancy of the general population at the time (204). Studies now 
estimate that with timely diagnosis and ART initiation, a person with HIV who remains on 
treatment can achieve a life expectancy approaching that of the general population (205-
208). However, a deficit does still exist (209) and it is unclear if this lower life expectancy in 
PLWH is attributable to HIV alone, a higher prevalence of high-risk lifestyle factors such as 
smoking (210, 211), or a combination of factors (212). 
 
1.5 The continuum of HIV care 
1.5.1 The spectrum of engagement with HIV care 
In order for treatment to be successful, both in terms of individual outcomes and preventing 
onward transmission of the virus, it is important that HIV-positive individuals are promptly 
diagnosed, engaged with HIV care, started on ART and remain adherent to therapy to 
maintain viral load suppression. This process was first visualised in a bar chart, as shown in 
Figure 1.5.1, for PLWH in the United States of America (US) by Gardner et al. By describing 
these benchmark stages of care for a given HIV population, it is possible to assess both the 
potential for onward HIV transmission amongst those who are not virally suppressed, monitor 
the delivery of HIV care and understand the level of engagement with HIV care. This 
visualisation has since come to be known as the cascade or continuum of care. From the 
illustration by Gardner et al., it became evident that only 19% of PLWH in the USA were 
believed to be on ART with an undetectable viral load, demonstrating poor engagement with 




Figure 1.5.1: Spectrum of engagement with HIV care in the USA  
 
From Gardner et al, The spectrum of engagement in HIV care and its relevance to test-and-
treat strategies for prevention of HIV infection 2011 (213) 
 
1.5.2 UNAIDS 90-90-90 targets 
In 2014, UNAIDS set a target to have 90% of the world’s HIV-positive individuals diagnosed, 
90% of those diagnosed on treatment and 90% of those treated with an undetectable viral 
load by 2020, in order to halt the HIV/AIDS epidemic (Figure 1.5.2) (214). Whilst the 
continuum of care had gained popularity and was already being reported in many different 
settings (215-217), these targets made this framework a key tool in monitoring HIV 
programme success world-wide. It has also generated a need to establish reliable and 









1.5.3 The HIV continuum of care in the UK 
In 2011, the HIV continuum of care for the UK was estimated as follows: 77% of PLWH were 
aware of their status; 73% were retained in care; 64% were on treatment and 58% had a 
suppressed viral load (215). This demonstrated that the largest gap in the continuum of care 
for the UK was in achieving HIV diagnosis. This correlates with high prevalence (47%) of 
individuals diagnosed at an advanced stage of HIV, when their CD4 count had dropped below 
350 cells/mm3 (218). The continuum of care has improved in recent years such that in 2015, 
87% of PLWH were aware of their status, 83% were receiving ART, and 78% had a 
suppressed viral load (Figure 1.5.3) (70). However, methods for defining the continuum of 
care also changed in this time. In 2015, the continuum of care surpassed two of the UNAIDS 
90-90-90 targets, with 96% of those diagnosed on ART and 94% of those on ART with viral 
load suppression (Figure 1.5.3). However, the target of 90% diagnosed still has not been 
achieved. Few countries are able to report a continuum of care that achieves the 90% targets 
for diagnosis, ART use and viral suppression rates (219, 220).  
Whilst the UK has a good continuum of care overall, this may not be the case within all 
subgroups of the population of PLWH. Observational studies of PLWH in the UK have found 
disparities across quality of care indicators and treatment responses according to certain 



















observed in the continuum of care (217, 225). However, in the UK, few data are available on 
the continuum of care in different populations (215). Further, whilst it is a useful public health 
monitoring tool, a cross-sectional continuum of care may have some limitations for assessing 
the success of HIV care, as mortality outcomes are not considered.  
 
Figure 1.5.3: Continuum of HIV Care in the UK in 2015 according to public health 
surveillance 
 
From Kirwan et al,. HIV in the UK: 2016 Report (2016) (70) 
 
1.6 Focus of thesis 
The aim of this thesis is to understand outcomes of people living with HIV in the established 
ART era, with particular reference to the quality of care indicators that compile the continuum 
of care. In particular I will consider how failure to achieve these care indicators impacts on 
mortality outcomes. A more detailed literature review of the current literature around the 
benchmarks of HIV care and how they impact on mortality follows this chapter. In subsequent 
chapters I present the methods of the UK CHIC Study (Chapter 3) and work undertaken to 
improve data on date and cause of death in UK CHIC analyses in order to enable analyses of 
mortality end-points (Chapter 4). In Chapter 5 I consider the impact of late diagnosis on both 
AIDS and non-AIDs mortality, particularly in relation to an aging HIV-positive population. 
Chapter 6 whether the disadvantages of late ART initiation remain over the long-term, if 
individuals are able to maintain viral suppression for a period following ART. I then investigate, 
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in Chapter 7, whether poor engagement in HIV care on ART correlates with lower life 
expectancy. My final analysis chapter presents a longitudinal HIV care continuum that I have 
devised, which incorporates the outcomes of death and loss to follow-up (LTFU). A final 
summary and discussion of the findings of my thesis is presented in Chapter 9. 
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2Chapter 2: Literature Review 
 
2.1 Introduction 
In this section I summarise the literature to date regarding the stages of the HIV care pathway 
in the continuum of care, and how they relate to mortality outcomes among PLWH. This 
review will start by discussing the strengths and limitations of the HIV continuum of care as 
a tool for monitoring programme performance, before discussing each of the following stages 
of the HIV care pathway in detail: diagnosis, retention in care, ART initiation and viral 
suppression. For each stage of the continuum I consider methodological issues involved with 
defining each stage, factors associated with sub-optimal achievement of these stages and, 
finally, how such sub-optimal achievement affects mortality outcomes. In terms of factors 
associated with the continuum stages, I focus on disparities according to demographic 
characteristics (age, sex, ethnicity and mode of acquisition) in the UK or other high-income 
countries in order to identify findings most relevant to the HIV-positive population in the UK. 
 
2.2 The continuum of HIV care as a measure of programmatic 
success 
2.2.1 Strengths of the continuum of care framework 
Since its first presentation as a 7-stage spectrum of engagement in care, the continuum of 
care has gained increasing visibility and is now a popular and widely used tool for monitoring 
programme performance. Drops between stages, or ‘leakages,’ along the continuum give 
valuable information as to the presence of gaps or disparities in HIV care in a population, and 
can direct interventions or health care resources. The continuum also creates the potential for 
easy comparisons in performance between countries and settings, although difficulties 
currently exist in generating comparable estimates (Section 2.2.2). For the stages of diagnosis 
onwards, it is not computationally intensive to generate, provided the data are available, as it 
only requires the calculation of proportions. As it is a cross-sectional measure it can be 
generated quickly and therefore gives real-time estimates of the current situation in a 
population. Finally, it is easily understood, giving comprehensive information on levels of 
engagement with HIV care services and a measure of the potential ongoing transmission 
within a given population at a particular point in time. Therefore, it is useful for conveying 
information to national and international health boards and health services providers who may 
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not be directly involved in providing HIV care but are involved in program evaluation or HIV 
care provision.  
2.2.2 Methodological considerations in generating a continuum of care 
2.2.2.1 Sources of data and a Population-based vs. a clinical cohort continuum 
The first bar of the HIV continuum of care is the total number of people that have HIV 
infection. This number cannot truly be known, unless the entire population were to be tested 
for HIV, so instead must be estimated (Section 2.3.1). The subsequent stages (from diagnosis 
onwards) can be measured accurately if suitable surveillance data are available, which give 
the true number in the continuum with some degree of measurement error. Such population-
based data are available in many countries, including the UK, for the purposes of public health 
surveillance, but not all countries have these systems in place. Further, in countries where 
some level of surveillance is in place, this may not cover all aspects of the continuum (e.g. 
laboratory test surveillance may give numbers diagnosed and numbers with viral suppression 
only), or the data itself may be limited or collected infrequently (e.g. a single annual report of 
viral load as in the UK). In settings where surveillance data are not sufficient to allow 
generation of all stages of the continuum, cohort data may be used instead of, or in 
combination with available surveillance data to generate estimates of the continuum of care 
(220).  
In order to generate an unbiased estimate of the continuum of care, nationally representative 
population-based data are needed. However, cohort studies may not have national coverage, 
may recruit participants from particular settings (e.g. large teaching hospitals) and may 
further have specific inclusion criteria or require patient consent. They would therefore include 
a selected sample of the population and may produce biased estimates. Difficulties in 
estimating the total number of people with HIV infection for such a selected sample mean 
that the first stage of the continuum is often diagnosis rather than HIV infection.  
In the UK, the continuum of care is estimated using a single national surveillance system, with 
modelled estimates of the total number of people who are HIV-infected (Section 2.3.1)(226). 
Different approaches are used in other settings according to the available data. The US 
continuum of care is generated using national surveillance datasets and the Medical 
Monitoring Project (MMP), which is a cross-sectional survey designed to obtain nationally 
representative estimates of people receiving care. National surveillance of name-based 
reporting of HIV diagnoses are used to generate estimates of undiagnosed infection; 
mandatory reporting of all CD4 counts and viral loads from 14 jurisdictions are used to 
estimate linkage to care the MMP is used to generate the stages of retention in care, ART use 
and viral suppression (217, 227, 228). In British Columbia (BC), Canada, data on testing and 
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diagnosis are acquired from the BC Centre for Disease Control, with data on HAART use and 
viral suppression from the BC Centre for Excellence in HIV/AIDS cohort, to generate a 
continuum of care from diagnosis onwards which has 100% coverage for the BC area (225). 
In Estonia, estimates of diagnosed HIV infection are generated using data from the Estonia 
Health Board and Cause of Death Registry, with linkage to and retention in care estimated 
from the Estonian Health Insurance Fund and ART use and viral suppression from the Estonian 
HIV cohort Study (229). Several studies report a cohort continuum of care, from diagnosis 
onwards, based on non-national clinical data (230-234).  
2.2.2.2 Which stages to include 
When originally suggested by Gardner et al., in 2011, the spectrum of engagement in care 
included 7 stages: HIV infection; diagnosis; linkage to care; retention in care; ART need; ART 
use; viral suppression (213). The UNAIDS targets focus on four of these stages, namely HIV 
infection, diagnosis, ART use and viral suppression. However, a continuum of care has been 
drawn using as few as 3 stages, omitting all stages prior to linkage to care (235). When 
constructing a continuum of care, the stages included will be determined by the data available, 
which varies from setting to setting. In a report produced by the European Centre for Disease 
Prevention and Control (ECDC), less than 70% of 40 countries in the EU and European 
Economic Area (EEA) were able to report data on viral suppression, with less than 50% of 
EEA countries able to do so (236).  
Because of the dependence of the stages in the continuum, people counted as being in a 
given stage have to satisfy the requirement of all previous stages. Thus the decision whether 
or not to include a stage in a continuum can alter the estimates for later stages of the care 
pathway. For example, viral suppression or ART use might be higher in a continuum of care 
that doesn’t include retention in care than for one that does, as in the former, people don’t 
need to also satisfy the definition of retention in care to be defined as on ART or virologically 
suppressed. Some studies have suggested also presenting an independent continuum of care, 
which presents the number and proportion of individuals achieving each stage, with no 
requirement to have satisfied any of the previous stages. Using independent instead of 
dependent measures of viral suppression, estimates increased from 43% to 61% of diagnosed 
individuals in New York (237) and from 52% to 62% of HIV Infected veterans in Atlanta (231).  
2.2.2.3 Defining the stages of the continuum of care 
A lack of standardisation means that the definitions used for each stage of the continuum of 
care differ between settings, and makes comparability of the continuum of care difficult. 
Definitions utilised in the continuum of care are discussed in relevant sections of this chapter. 
A Europe-wide initiative, led by the ECDC, recently generated a standardised definition of the 
continuum of care to generate country-specific estimates that could be compared, as well as 
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a Europe-wide estimate (220). Using the developed standardised definitions of the four stage 
continuum of care, across 11 countries in Europe, 84% of all HIV-infected individuals were 
diagnosed, 71% had ever initiated ART, and 60% were virologically suppressed in 2013. Only 
two of these 11 countries, namely Denmark and Sweden, achieved the UNAIDS 90-90-90 
targets. However, whilst these estimates are comparable between countries, they may not be 
the best estimates of the current situation in all countries.  
2.2.3 Limitations of a cross-sectional care continuum as a measure of 
programmatic success 
When assessing programmatic success, a traditional cross-sectional continuum may not 
always provide information that is sufficiently in-depth and detailed as required. For example, 
it may be useful to link the stages of care to clinically relevant patient outcomes such as 
disengagement from HIV care, mortality and AIDS-defining illness. In addition, the timing at 
which people enter into the stages of the care pathway is important in a model of optimal 
care (238), with late entry into the stages associated with poorer patient outcomes (Sections 
2.3.5, 2.5.4). Many quality of care indicators are linked to the timing of events in care such 
as late diagnosis, late ART intiatiation, time to linkage to HIV services from diagnosis, and 
time to achieving virologic suppression (221). These timings are not represented in the 
continuum of care. Furthermore, although it depicts progressive sequential stages through 
HIV care, in practice individuals may move backward as well as forward through these stages 
of care, as levels of engagement in care (EIC), ART use and viral suppression can change over 
time. A traditional continuum of care only includes those who are alive in the calendar year of 
assessment, potentially giving a ‘best-case’ scenario. Further, it is not known what happens 
to individuals that drop out between stages; whether they are still engaged with care but have 
not progressed onto the next stage, or whether they have disengaged from care, left the 
country or have died.  
2.2.4 Suggested alternatives to a cross-sectional care continuum 
Some of the previously mentioned limitations of a cross-sectional continuum of care can be 
resolved using longitudinal data. Some such ‘cohort’ continuums follow a group of people 
forward in time from diagnosis, or entry into HIV care and are interpreted differently to a 
cross-sectional continuum of care, instead providing information on how a cohort progresses 
through the stages of HIV care after diagnosis (239). An approach used in two studies of the 
HIV-positive population in Sothern Alberta, Canada, between 2006 and 2013, classified 
individuals according to the latest stage of the continuum achieved during the follow-up 
period, prior to death or loss to follow-up. The stages of the continuum of care were measured 
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longitudinally and included linkage to care (attending initial visit at the Southern Alberta 
Clinic), retention in care (at least 2 regular visits within 12 months of HIV diagnosis) and viral 
suppression (>12 consecutive months with an undetectable viral load over follow-up) (230). 
One important use of this continuum design was to incorporate the burden of mortality at 
each stage along the continuum of care, finding that 55% of deaths occurring in this 
population occurred in individuals who linked to care, but were not retained in care in the year 
following diagnosis. A limitation of this approach is that it still assumes only forward movement 
through the stages of care occurs (240). A recent study of diagnosed HIV-positive individuals 
in Massachusetts constructed a continuum of care for the 2 years following HIV diagnosis, 
defining linkage to care if a visit occurred within 90 days of diagnosis, retention in care if a 
visit occurred in each 6 months interval over the 2 year period, and viral suppression amongst 
those retained if viral load at 24 months was ≤400 copies/ml. A strength of the approach in 
this study is that incorporates some measure of timely achievement of the stages of the care 
continuum, which could also be extended to include timely ART initiation in settings where 
these data are available. A disadvantage analysis is that it only considers the short-term period 
of care following diagnosis, by design, so is only relevant to this population and does not give 
information about longer-term care engagement or outcomes (241). 
A methodology suggested by Lesko and others, utilising John’s Hopkins University clinic data, 
calculated the cumulative incidence of 9 events relating to ART initiation, viral suppression, 
death (and its timing in relation to other events) and loss to follow-up (LTFU, and its timing 
in relation to other events). From these cumulative incidence curves, the proportion of time 
over 10 years spent in each of the 7 following defined stages of care were calculated and 
presented as a stacked area chart: (i) Died prior to ART initiation (ii) LTFU prior to ART 
initiation (iii) Died after ART initiation (iv) LTFU after ART initiation (v) on ART and suppressed 
(vi) On ART and not suppressed (vii) in care and not on ART (242). This methodology provides 
several benefits over a cross-sectional continuum of care for understanding programmatic 
success and patient outcomes in care, firstly as it incorporates the end-points of mortality and 
LTFU. Whilst still presenting a single comprehensive figure, more detailed information about 
the amount of time spent in each stage of HIV is provided; person-time spent unsuppressed 
will have important implications for ongoing transmission and is a useful metric. Whilst some 
movement in and out of the stages of care is allowed for, the fixed end-points required for 
the survival analyses approach taken means that it is not truly flexible to changing health 
status over time. Retention in care is not encapsulated except through LTFU, which is a 
different measure of disengagement. Another disadvantage of this method is that it is quite 
computationally intensive to derive, and as with other longitudinal continuums of care, only 
includes stages after linkage to care.  
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A ‘states and transitions’ framework was hypothesised by Powers et al., to describe a 
population-based continuum of care, including the stages of HIV infection, diagnosis, 
engagement in care, ART use and viral suppression, as well as rates of transition in both 
directions between each of these stages (243). Further, this could be theoretically be extended 
beyond the currently defined states to include mortality and LTFU. However, the authors 
highlight several challenges in the estimation of this framework using current HIV surveillance 
and monitoring data, as no country has sufficiently detailed and representative data at each 
stage of the continuum of care to generate the required estimated rates of transition between 
stages. 
 
2.3 HIV Diagnosis 
2.3.1 Estimating the burden of undiagnosed HIV 
Estimates of the total number of people with HIV infection, and the proportion of those that 
remain unaware of their HIV-positive status can be achieved through a range of different 
methods. These include seroprevalence surveys, back-calculation and synthesis models (Table 
2.3.1) (244-246). Briefly, unlinked anonymous seroprevalence surveys, estimate the numbers 
with undiagnosed and diagnosed HIV infection by testing a sample of the population for HIV 
and asking about their status. The prevalence of HIV amongst the samples (seroprevalence) 
can be used to estimate prevalence and therefore number of HIV-infected individuals in the 
population and responses to questions about status give the proportion diagnosed (247-249). 
Back calculation methods use information on the CD4 count or AIDS defining illness at 
diagnosis and work backwards from this to estimate when they were likely infected with HIV. 
From this an incidence rate and the cumulative number of individuals that have acquired HIV 
can then be estimated. HIV prevalence estimates are generated by subtracting the cumulative 
number of deaths (217). In the UK, a Bayesian Multi Parameter Evidence Synthesis model is 
used to estimate the number of individuals living with undiagnosed HIV in the UK (226).  
2.3.2 The diagnosed HIV-positive population and definitions of late diagnosis 
In a traditional continuum of care, the diagnosed population of PLWH is ideally defined as the 
cumulative number of individuals with a confirmed diagnosis by the time of assessment, minus 
the cumulative number of deaths and the number of individuals who have left the country or 
population studied. However, lack of data on out-migration and death mean that slight 
variations of this are used in different countries. In the UK, the diagnosed population for the 
national care continuum is given by the number of people seen for care in the year of 
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assessment (Zheng Yin, personal communication, February 6, 2015). This is done under the 
assumption that loss to care and migration out of the country is low. The proportion of 
individuals with HIV that are diagnosed is generated using the number of diagnosed 
individuals and the estimated total number of people with HIV infection, discussed in the 
previous section. 
A consensus definition of late diagnosis was developed which defines it as diagnosis with a 
CD4 count ≤350 cells/mm3 or an AIDS-defining illness, regardless of CD4 count. This definition 
was chosen due to the recommendation that ART should be initiated by these thresholds, and 
so failure to diagnose before this time would delay optimal initiation of treatment, resulting in 
poorer outcomes. Diagnosis with a CD4 count <200 cells/mm3 would be considered diagnosis 
with advanced immunosuppression or very late diagnosis (250). This threshold has been 
shown as the best, of various immunological and clinical definitions, to predict short-term 
mortality (251). However, many different definitions of late diagnosis have been used in the 
literature. In the following sections I will refer to late diagnosis to indicate any marker of 
diagnosis at a stage that is not optimal, specifying definitions used where relevant. ‘Advanced’ 
diagnosis will reference advanced immunosuppression as defined above.  
48 
 
Table 2.3.1: Reported percentages of diagnosed HIV Infection according to continuum of care estimates 
Paper Region/population Data source Year Method  %1 
Gardner  
2011(213) 
US / General Review of literature 2006 (252) 79% 
Gourlay 
2017(220) 
Austria/ General ECDC modelling tool2,3 
2013 
ECDC modelling tool2 88% 
Belgium/ General ECDC modelling tool2,3 ECDC modelling tool2 84% 
Denmark/ General Clinical cohort ECDC modelling tool2 91% 
France/ General Estimated numbers in/out of care Other (country-specific) back-calculation tool 84% 
Germany/ General Surveillance data Other (country-specific) back-calculation tool 83% 
Greece/ General Surveillance data ECDC modelling tool2 78% 
Italy/ General Clinic-based survey Other (country-specific) back-calculation tool 90% 
The Netherlands/ General Clinical cohort ECDC modelling tool2 85% 
Spain/ General Statistical modelling Other (country-specific) back-calculation tool 82% 
Sweden/ General Clinical cohort Surveillance/survey estimates 90% 
UK/ General Surveillance data Multi-Parameter Evidence Synthesis Model 81% 
Europe/ General - - 84% 
Hall 
2013(217)  
US / General National surveillance data 2009 Back-calculation model 82% 
Hsieh 
2015(247) 
Baltimore, US / General - 2007 Seroprevalence survey 72% 
Iroh 
2015(253) 
US / before incarceration 
US / incarcerated 
US / after incarceration 






US / General - 
2007 
2013 








Paper Region/population Data source Year Method  %1 
Kirwan 
2016(70) 
UK / General National surveillance data 2015 Multi-Parameter Evidence Synthesis Model 87% 
Kohler 
2015(255) 
Switzerland / General European MSM internet survey 2012 Back-calculation 81% 
Krentz 
2014(240) 
Canada / General Public Health Canada data 2006-2013 
Diagnosed + estimated undiagnosed by public 




Estonia / General 
Estonian health board, Estonian 
Insurance fund, Estonian HIV 
Cohort Study, Estonian Causes of 
death registry 
2013 
UNAIDS spectrum estimate + HIV diagnoses 




South Africa / Men 
South Africa / Women 





US / Veterans 
Atlanta Veterans Affairs Medical 
Centre 




Public Health Agency Canada plus 
linked provincial datasets 
1996 
2011 






US / White MSM 
US / Black MSM 










Russia / General - 2011-2013 - 45-49% 
Raymond 
2016(234) 
Wellington, NZ / General  Clinic database 2015 





US / White MSM 
US / Black MSM  
CDC surveillance data 2009 









Paper Region/population Data source Year Method  %1 
Santos 
2014(248) 
San Francisco, US / 
Transwomen 
Respondent-driven sample study 
(262) 
2010 
Previous awareness of HIV status at positive HIV 




France / General HIV surveillance data 2010 Back-calculation model 81% 
Wirtz 
2016(249) 
Moscow, Russia / MSM Respondent-driven sample study 2010-2013 
Previous awareness of HIV status at positive HIV 




US / Adolescents Literature Review - (264) 40% 
1If range is given, then estimates are given for each calendar year within the interval; first and last estimates are presented. 
2This tool used back-calculation models to estimate both HIV incidence and the undiagnosed fraction from the number of diagnosed PLWH.  
3Tool also used to generate number of diagnosed HIV-positive individuals 






2.3.3 Rate of late diagnosis 
Most recent estimates of the proportion of HIV-infected individuals that are diagnosed and 
aware of their status range from 72-91% (Table 2.3.1), with extremely low rates of diagnosed 
HIV in Russia (249, 259), where HIV is highly stigmatised. In the UK, the proportion of all 
PLWH that have received a HIV diagnosis is estimated to have increased over time, from 76% 
in 2011 to 87% in 2015 (70, 218). To date, late diagnosis is defined using CD4 criteria in UK 
national surveillance estimates, which show a declining proportion of individuals being 
diagnosed with a CD4 count <350 cells/mm3 over time; from 47% in 2011 to 39% in 2015 
(70, 218). A single-centre UK cohort estimated that half of individuals have a CD4 count below 
this threshold at diagnosis (222). In a previous analysis of the UK Collaborative HIV Cohort 
(CHIC) Study, 46.4% of individuals had a CD4 count ≤350 cells/mm3 at diagnosis (223). 
As defined by a CD4 count <350 cells/mm3 or an AIDS defining illness, studies outside the UK 
report between 45-55% of new diagnoses occurring late, with the lowest estimate of 25.3% 
found in a study of only MSM in Spain (265) and highest estimate of 62% found in a large 
European cohort collaboration (266). Interestingly this was higher than in another study 
performed using data from the same collaboration, which reported a 53.8% rate of late 
diagnosis (267). Estimates of advanced immunosuppression vary greatly depending on the 
underlying population studied; between 23-65% of those newly diagnosed with HIV. However 
estimates in the region of 35-40% are most commonly reported (266, 268-273).  
2.3.4 Factors associated with late diagnosis 
2.3.4.1  Age 
Despite differing definitions and statistical adjustments, there is strong agreement amongst 
the published literature that older age at HIV diagnosis is associated with increased probability 
of being diagnosed late or with advanced immunosuppression (Table 2.3.2). Studies 
exclusively show an increasing proportion of individuals diagnosed late or with advanced 
disease with older age at diagnosis, with some studies showing over 70% of individuals 
diagnosed aged 50 or above having some form of late diagnosis (268, 274, 275). The largest 
study to show such an association was a study of HIV surveillance data in Florida on over 
25,000 HIV diagnoses. Those diagnosed aged above 60 had more than 5 times the odds of 
being diagnosed once HIV had progressed to AIDS than those aged 13-19 at diagnosis (276). 
A similarly large Italian clinical cohort found that, amongst newly diagnosed individuals who 
attended for care, the odds of late diagnosis increased with age above 25 such that those 
aged above 55 at diagnosis had 7.5-fold increased odds of late diagnosis (consensus 
definition); an association that has been present since the start of the epidemic in 1985 (272). 
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In the UK, similar associations have been found, but of slightly smaller magnitude, with those 
aged above 50 at diagnosis between 3 and 4 times as likely to be diagnosed with a CD4 count 
<350 cells/mm3 than those aged 15-24 (274, 277). Studies to consider both definitions of late 
diagnosis and advanced immunosuppression have found that the magnitude of association 
increases when considering advanced immunosuppression as opposed to late diagnosis (271, 
273, 278). The association between late diagnosis and age has largely been shown to remain 
across demographic groups, although prevalence is often lower amongst MSM, who tend to 
test more frequently (218, 274, 275, 277, 279).  
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Table 2.3.2: Papers describing the association between age and late diagnosis, ordered by age grouping 








HIV Surveillance - MSM 
1993-2002 


































AIDS (includes CD4 <200 or 







2.2 (1.8, 2.7) 
4.3 (3.5, 5.2) 







2.7 (1.0, 7.2) 
7.5 (2.8, 20.0) 




HIV surveillance - MSM 
1999-2013 










1.2 (0.9, 1.6) 
1.7 (1.3, 2.2) 




HIV surveillance - heterosexual 
2002-2011 
 










1.7 (1.5, 1.9) 
2.9 (2.5, 3.3) 














Multi-centre clinical cohort (MASTER) 
Diagnosed 1985-2013  







2.4 (2.2, 2.7) 
4.1 (3.7, 4.6) 
5.8 (5.0, 6.7) 














2.2 (1.2, 4.0) 
2.4 (1.2, 4.5) 
2.2 (1.1, 4.4) 




Mandatory reporting of HIV/AIDS 
2010-2011 
5545 













1.7 (1.4, 2.1) 
2.1 (1.7, 2.5) 
2.9 (2.5, 3.4) 
















1.7 (1.3, 2.3) 
2.6 (1.9, 3.5) 




Single centre clinical cohort 
diagnosed 2004-2005 









Single centre clinical cohort 
1985-2005 








1.5 (1.0, 2.3) 





Single centre (Zurich) chart review 
2009-2011 
281 







0.9 (0.5, 1.9) 
1.5 (0.7, 3.1) 














Multi-centre clinical cohort 
2004-2013 
7165 











1.59 (1.39, 1.82) 
2.18 (1.83, 2.60) 
3.60 (2.92, 4.44) 










1.96 (1.60, 2.40) 
3.15 (2.52, 3.96) 




Multi-centre clinical cohort 
1996 – 2005 
5702 













2.0 (1.6, 2.6) 
2.7 (2.1, 3.6) 
2.9 (2.0, 4.1) 















Nationally representative survey 
2003-2011 
1096 













2.0 (0.9, 4.2) 
2.5 (1.1, 5.5) 
6.8 (2.4, 19.7) 
7.3 (2.2, 24.0) 








1.5 (0.7, 2.8) 
2.1 (0.9, 4.8) 
 











0.8 (0.3, 2.3) 
2.0 (0.7, 5.8) 
1.5 (0.4, 4.9) 











2.0 (0.9, 4.4) 
2.4 (1.1, 5.4) 










Ratio (95% CI) 













3.1 (1.1, 9.0) 
5.6 (1.9, 16.4) 
11.9 (3.7, 38.2) 
21.4 (5.9, 76.9) 








1.7 (0.9, 3.4) 
1.2 (0.5, 2.8) 











2.1 (0.6, 7.3) 
6.1 (1.9, 19.8) 
3.1 (1.0, 10.0) 











1.9 (0.8, 4.1) 
2.3 (1.0, 5.1) 




Single centre clinical cohort 
Diagnosed 2007-2011 










1.3 (0.7, 2.4) 
1.7 (0.8, 3.3) 





Diagnosis 1994-2000  
7825 
AIDS in month of/month 









1.4 (0.9, 2.1) 
1.0 
1.2 (1.0, 1.4) 




Multiple STI and HIV testing centres 
2003-2011 









0.8 (0.6, 1.0) 
1.0 
1.3 (1.0, 1.7) 














Single centre clinical cohort 
2001-2008 





1.6 (0.9, 2.6) 




Multi-centre clinical cohort (HIV 
Outpatients Study) 
2000-2009 









Single centre clinical cohort  
2008-2009 
520 





3.0 (2.1, 4.3) 








HIV surveillance  
2000-2007 
9964 








- 0.3 (0.3, 0.5) 
0.6 (0.5, 0.7) 
1.0 
1.4 (1.3, 1.6) 
1.6 (1.4, 1.9) 
2.6 (2.0, 3.3) 
Nacher 
2005(292) 
French Guinea (FHDH) 
Multi-centre clinical cohort 
1992-2003 
1952 










0.4 (0.3, 0.7)* 
0.5 (0.4, 0.7)* 
1.00* 
1.3 (1.1, 1.7)* 














Single centre clinical cohort 
1985-2010 




















HIV surveillance  
2000-2009 







US, Manhattan  
Single centre cohort 
2006-2011 















4.0 (3.5, 4.6) 








Single centre clinical cohort 
1996-2010 




















Single centre clinical cohort 
Diagnosed 2007-2011 










1.3 (0.7, 2.4) 
1.7 (0.8, 3.3) 
2.8 (1.3, 6.4) 






2.3.4.2 Sex/Mode of Acquisition 
Studies considering gender differences in late diagnosis either found that males had at least 
30% higher odds of late diagnosis (272, 292, 297, 298) (maximum 2.4-fold increase (284)) 
or reported no difference (273, 280, 283, 289), with none showing females at higher risk. This 
may be explained by differences according to transmission risk groups, as the majority of men 
in HIV studies in high income stings are MSM, but was sometimes found to remain 
independently of this (276, 278). Those who acquired their HIV through sex between men 
and women are more likely to be diagnosed late than MSM (276), with estimated odds of late 
diagnosis between 1.4 and 2.2-fold higher (268, 272, 278, 287, 291, 299). This increased risk 
is predominantly driven by heterosexual men, who, in comparisons split by sex, are a group 
highlighted to be at particular risk of late diagnosis (222, 273, 300). In the UK, 67% of newly 
diagnosed heterosexual men are diagnosed late, compared to 36% of MSM, who are the risk 
group with the lowest proportion diagnosed late (221). This is likely due to better awareness 
of risk and higher testing amongst MSM (218).  
2.3.4.3 Ethnicity 
In the UK, a lower proportion of newly diagnosed white individuals were diagnosed late than 
individuals of either black or other non-white ethnicities. This has been evidenced by HIV 
surveillance data, with 66% of black African adults diagnosed with a CD4 <350 cells/mm3 
compared to just over 40% of white adults (221) and by a single centre study showing those 
of black, other and unknown ethnicities to have 2.6, 1.6 and 3.3-fold higher odds, respectively, 
of diagnosis with a CD4 <350 cells/mm3 (222). However, amongst two studies of MSM using 
surveillance data in the UK, whilst one found any non-white ethnicity to be associated with a 
72% increase in the odds of a CD4 <200 cells/mm3 at diagnosis (279), the other found no 
association between ethnicity and late diagnosis, defined by a CD4 count <350 cells/mm3 
(277). Black, Hispanic and other non-white ethnicity are also a risk factor for late diagnosis in 
the US (276, 291), where non-white ethnicity is also associated with lower socio-economic 
status and poorer access to healthcare.  
2.3.5 The impact of late diagnosis on mortality 
Individuals diagnosed late or with advanced disease (regardless of the definition used) are at 
a vastly increased risk of mortality (272, 292), with shorter estimated survival time (269, 301). 
Developing AIDS within 1 year of diagnosis has been shown to correlate strongly with AIDS-
related mortality (Hazard ratio (HR)=4.3), but also with non-AIDS mortality (HR=2.3) (302). 
However, it is likely that any excess risk of mortality as a result of late diagnosis is only present 
in the short-term. In fact, the higher risk of mortality with either late or advanced HIV 
diagnosis has been shown to disappear after longer than 2-4 years with diagnosed HIV. In 
the national Danish cohort, a 3- and 6-fold increased rate of 1-year mortality due to late and 
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advanced diagnosis decreased to a mortality ratio of 1.1 in the third year following diagnosis 
(271). Similarly, in Spain, late presentation was no longer associated with mortality after 4 
years diagnosed HIV, despite associations observed <1 and 1-4 years after diagnosis (278). 
Similar findings were made in by far the largest study of late diagnosis, which included data 
on over 84,000 individuals accessing care across Europe. Using first visit as a proxy for HIV 
diagnosis where none was available, the risk of progression to AIDS or death in those with 
late or advanced presentation was highest in the year following diagnosis (IRRs: 6.6-13.0 and 
7.0-14.6 across regions of Europe) and no difference was seen compared to non-late or non-
advanced presenters after 2 years (267).  
A relatively large proportion of studies demonstrating an association between late diagnosis 
and mortality have been undertaken using UK HIV/AIDS surveillance data on all HIV 
diagnoses. An advantage of these studies is that they consider all diagnosed individuals, not 
just those linked to care. These studies, conducted over various time periods between 1999 
and 2011, are also particularly relevant to this thesis as they consider a UK population. 
However, definition used depends only on CD4 count thresholds, without considering the 
occurrence of AIDS-defining events. From these combined studies we learn that: both MSM 
(279) and heterosexual men and women (300) diagnosed with CD4 counts below 200 
cells/mm3 experience higher rates of 1-year mortality than those with higher CD4 counts 
(14.1% vs. 1.1% MSM and 6.1% vs. 1.1% heterosexual); that low CD4 counts below 350 
cells/mm3 at diagnosis contribute a large burden of AIDS related mortality, with 98% of AIDS 
deaths within 1 year occurring amongst late presenters and a 10-fold increased risk of AIDS 
deaths in late presenters compared to non (303); and that older individuals also diagnosed 
with low CD4 counts have a particularly high risk of mortality compared to other groups (294). 
In a 2-year snap-shot of 2010-2011, the rate of 1-year mortality in those aged over 50 and 
diagnosed with a CD4 count <350 cells/mm3 was 107 per 1000 population. This compared to 
a rate of 33/1000 for those aged 40-49 with the same CD4 count or 17/1000 for non-late 
diagnoses in those aged over 50 years (221). This high excess mortality might suggest that 
the impact of a late diagnosis on mortality outcomes are worse for older individuals. This could 
be due to faster CD4 count declines in this group in the absence of treatment meaning CD4 
counts are lower at diagnosis, and/or subsequent poorer immunological recovery on ART 
(304-310). However, a single-centre study in Brighton with a largely white MSM population 
found that, despite an increased risk of mortality for both individuals with a low CD4 count 
and those of an older age, the interaction between the two covariates was not statistically 
significant, suggesting that the relative impact of late diagnosis is not greater for older PLWH 
(222).  
In a simulation model, Nakagawa et al., modelled and compared the impact of two diagnosis 
rates on life expectancy in MSM. They found that in a scenario where 97% of HIV-infected 
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MSM were diagnosed within 10 years, the risk of death 10 years after diagnosis was only 5%, 
compared to 13% in a scenario where only 74% were diagnosed by 10 years, with a median 
CD4 count of 142 cells/mm3 at diagnosis. This translated to a 4 year difference in life 
expectancy between the two diagnosis rates (207). This demonstrated, amongst MSM, that 
increased testing, leading to earlier diagnosis may have a beneficial impact on mortality. 
 
2.4 Retention in care 
2.4.1 Defining retention in care 
2.4.1.1 Comparing different definitions of retention 
There is no consensus definition for retention in care in the continuum, with a number of 
different definitions reported. The occurrence of a visit in a calendar may be a sufficient 
indication of retention. In the UK, retention in care is reported as the proportion of individuals 
seen for care in a given year that are also seen the following year (70, 311, 312). These are 
definitions likely driven by the availability of data. In the UK, the HIV/AIDS reporting system 
receives a single annual return for each attending individuals from HIV centres. However, as 
most individuals would be expected to attend for care on multiple occasions within a calendar 
year, this is generally not considered a sufficient measure of complete retention in care. 
Instead, measures that try to capture adherence to visit schedule are often used.  
In the US, the CDC recommend the HRSA HAB measure of >2 visits at least 90 days apart 
within a 12 month period to define retention in care when estimating the continuum of care 
(217). This is therefore widely reported in literature from the US and elsewhere. Other widely 
used measures of retention in care in the literature include visit constancy (at least one visit 
in each 3 or 6 month interval in a given time-frame), gaps in care (no gaps of greater than 6 
or 12 months between consecutive visits) and missed visits, where data on scheduled visits 
are available (Table 2.4.1). Previous studies have attempted to compare the predictive value 
of different measures of retention in care, often using viral suppression as the gold standard 
indicator of engagement. Mugavero et al., assessed the predictive value of 6 definitions of 
retention in care. The first 3 were based on missed visits and were: the number of missed 
visits, an indicator for any missed visits and the proportion of visits missed. The remaining 3 
definitions were based on visits that actually took place: number of 4 month intervals with at 
least one visit; indicator for any gaps >6 months between consecutive visits; indicator for at 
least 2 visits separated by 90 days in the year of study. Rates of retention in care were very 
different according to the definition used. Only 33% had no missed visits, 51% had at least 1 
visit in all 4-month intervals, 68% had no gaps between visits >6 months and 77% satisfied 
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the HRSA HAB definition of retention in care. The proportion of scheduled visits that were 
missed most strongly predicted viral load suppression, with 3.9 fold increased odds of viral 
load suppression per 50% higher percentage of visits missed and an area under the ROC 
Curve (AUROC) of 0.69. Of the three measures that did not involve missed visits, the HRSA 
HAB definition was the strongest predictor of viral suppression with those retained being 
nearly four times as likely to have viral suppression as those not retained in care, but had the 
smallest AUC of 0.59 with sensitivity of 91% and specificity of 27% (313).  
Whereas a traditional continuum is cross-sectional, assessing retention in care over 1 year, 
cohort analyses consider longer-term retention. In this situation, retention in care in care will 
often only be defined if individuals satisfy annual retention definitions, as described previously, 
for a number of years. This results in lower estimates of retention in care. This was recently 
demonstrated in an Infectious Disease Program in Atlanta, US which defined retention in care 
over 3 years only if an individual made at least 2 visits at least 90 days apart in each of the 3 
years of follow-up. Whereas 84% of individuals enrolling in the programme were defined as 
retained in care in the first year of follow-up, only 49% were able to be classified as 
continuously retained in care over 3 years (314). Within the Veterans Health Administration, 
retention in care over 2 years was approximately 40%, with smaller variations by definition. 
In this study again, the lowest estimate of retention in care was given by missed visits, with 
35% of individuals having attended more than three-quarters of their scheduled visits over 2 
years. Only 40% of veterans had at least 2 visits separated by 60 days in each year over both 
years and 44% had no gaps in care >6 months. Combining the definitions of missed visits or 
gaps in care to define retention in care gave much lower retention in care rates of 19% (315). 
When considered over an 8 year period, only 49% of PLWH who attended a HIV clinic in 
Kentucky between 2003 and 2011 were retention in care for all years for which they were 
considered to be in clinical follow up according to the HRSA HAB definition, despite 83% of 
all 12-month intervals meeting this criteria. Similarly, only 47% of people had a visit in every 
6 month interval, but 81% of 6 month intervals had a visit. The predictive ability of different 
definitions of retention in care over a long period of time remained low and similar to that 
shown by Mugavero et al., for one-year measures. However, in this analysis, which didn’t 
consider missed visits, visit constancy was best predictor of viral suppression. Having 100% 
of 6 month intervals over follow-up with at least one visit meant a 4.7-fold increased odds of 
suppression, with an AUROC of 0.62. Those retained in care according to the HRSA HAB 
definition were found to be 70% more likely to have viral suppression, but the AUC for this 
measure was low at 0.58, where an AUC of 0.5 indicates a test no better than chance for 
identifying those retained in care. Having no gaps in care of more than 12 months 
demonstrated 83% increased odds of viral suppression had a poor AUC of 0.57 (316).  
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A disadvantage of the above mentioned definitions is that they assume constant visit intervals 
(e.g. 3 or 6 months). In practice, an individual’s scheduled visits will vary as their clinical or 
health status changes and as standards of care change overtime. For example, someone who 
has started ART but is experiencing viral rebound will be scheduled for more regular visits 
than someone who has remained stable and suppressed on treatment for a number of years. 
Further, for a definition such as the HRSA HAB, individuals are required to survive for at least 
a year for retention to be defined. As part of the Retention an Engagement Across Care 
Services for HIV (REACH) study in the UK, a novel time-updated measure of retention in care 
was developed using data from the UK CHIC Study (317). This method is utilised in this thesis 
(Chapter 7) and defines anticipated visit intervals according to clinical factors at each observed 
attendance and defines people as retained in care or not on a month by month basis 
depending on their observed attendances in relation to the anticipated visit schedule. 
2.4.1.2 Laboratory measures as a proxy for attendance 
As most outpatient visits include measurement of the CD4 count and/or viral load, and this 
data is almost always readily available, many studies use the presence of laboratory 
monitoring as a surrogate for clinic attendance. However, a recent study of public health 
surveillance data in Massachusetts found that the ability of laboratory tests to correctly identify 
individuals that are out of care was poor. This study contacted clinics of individuals thought 
to be out of care according to laboratory monitoring surveillance. They found that only 37% 
of individuals presumed out of care were in fact not receiving care at the clinic (318). This 
could reflect the less detailed nature of surveillance as opposed to clinical cohort data. 
Laboratory monitoring has also been shown to have high sensitivity but low specificity when 
compared to actual clinic attendance. This means that whilst a large proportion of those truly 
retained in care would be identified correctly using laboratory monitoring, large numbers of 
people who are not truly retained in care would also be incorrectly classified as retained in 
care, over-estimating levels of retention. For example, in a cross-sectional study by Firth et 
al., when compared to two or more face-to-face outpatient visits with a HIV care provider, 
presence of two or more laboratory measures gave 90% sensitivity, meaning that 90% of 
people truly retained in care were classified as such using laboratory measures. However, 
amongst 40 individuals who were not truly retained in care, the specificity was only 28%, 
meaning that 72% were classified as retained in care according to laboratory monitoring 
(319).  
However, other studies have reported better performance of laboratory data as a surrogate 
for retention in care. One study focused on a population who attended at least once for care 
in the first 6 months of 2010. The laboratory measure of retention was defined as having at 
least two tests at least 90 days apart in 2011. ‘True’ retention in care was defined at least one 
visit in each of the three subsequent 6 month periods until the end of 2011. True non-retention 
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in care was only defined if a face-to-face visit occurred in the second half of 2010 but no visit 
occurred in 2011, with the remaining individuals excluded. These more specific definitions of 
true retention in care and the fact that laboratory-defined retention was assessed only in 
2011, may be responsible for the higher specificity of 72% which was observed. Sensitivity 
was still high at 92%. The area under the ROC curve (AUC) was high at 0.96, where 1 would 
indicate perfect agreement between laboratory and visit data (320). In another US study, 
whilst both sensitivity and specificity were very high (100% and 94%) using the Health 
Resources and Services Administration HIV/AIDS Bureau (HRSA HAB) definition of two tests 
at least three months apart within a year, this laboratory measure gave higher estimates of 
retention in care compared to clinic visits at the same frequency. Whereas 36% of newly 
diagnosed individuals were considered truly retained in care, laboratory measures estimated 
retention in care to be 40% (321). The use of this HRSA HAB measure, which doesn’t account 
for information on visit scheduling, may be problematic when comparing laboratory and clinic 
visits. In recent years, certainly for the UK, there has been a move towards less frequent face-
to-face clinic visits in individuals who are stable and responding well on treatment. So 
individuals may only attend for annual clinic visits but still be considered to be adhering to 
their visit schedule and therefore retained in care. Current monitoring guidelines also 
recommend that CD4 counts can be performed less frequently, and in those with viral 
suppression and who have demonstrated a maintained CD4 above 350 cells/mm3, may not be 
performed at all other than in the event of viral failure or HIV-related symptoms (322). There 
is therefore a changing landscape of visit scheduling, in which current measures of retention 
in care will need to be re-assessed. 
2.4.2 Estimated rates of retention in care 
In the UK, retention in care is thought to be high according to national HIV surveillance data; 
95% of individuals seen for care in a given year will also return to care the following year. 
This is the basis for estimates of retention in care in the HIV continuum of care in the UK. 
However, two studies considering cumulative loss to follow-up in the UK estimate that as 
many as 20% may become lost to care over 5 years (323, 324).  
Outside of the UK, estimated rates of retention in care are hugely variable. As well as reflecting 
true differences in retention, this may also be explained by the denominator populations used 
(325), the definition of retention in care used (313), whether CD4 and viral load are used as 
a proxy for clinic attendance (320) and whether retention is assessed longitudinally or for a 
single year (316). A meta-analysis by Marks et al., of 28 studies in the US reporting on 
retention in care rates using different definitions over different lengths of follow-up between 
1996 and 2006 reported an aggregated estimate of 59% retention in care, with individual 
estimates ranging from 19-92%. Estimates were lowest in the studies with longest intervals, 
65 
 
with data collection after 2003 and where all persons in the database were sampled as 
opposed to random or convenience sampling (326). Table 2.4.1 summarises retention in care 
rates in the US and elsewhere in studies published since this date that have presented at least 
two of the care continuum stages. 
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Table 2.4.1: Estimates of retention in care in studies reporting at least 2 stages of a (A) cross-sectional or (B) longitudinal HIV care 
continuum 







US  General - Review of literature HIV infected 50% 
Hall 
2013(217) 







Switzerland General 2012 
>1 visit in year (SHCS participants)  
Practitioner survey (non-SHCS) 
Extrapolation from ART use data 
HIV infected 79% 
Laisaar 
2016(229) 
Estonia General 2013 HRSA HAB HIV Infected 21% 
Mangal 
2014(231) 
US Veterans 2012 
>1 visit to clinic 8 months prior to end 
of 2012 






Seen in clinic in last year or on ART and 
in communication with regional service 











US Adolescents - Literature Review HIV Infected 11% 
Backus 
2015(328) 
US Veterans 2013 














US General 2009 HRSA HAB* Diagnosed 72% 
Helleberg 
2013(329) 
Denmark General 2010 >1 visit in last 13 months Diagnosed 88% 
Horberg 
2015(232) 
US General 2010 - 2012 >2 visits >60 days apart in year Diagnosed 78-80% 
Hu 
2012(330) 
US General 2009 HRSA HAB Diagnosed 52% 
Mahle Gray 
20147(331) 
US General 2010 HRSA HAB* Diagnosed 51% 
Singh 
2014(227) 
US MSM 2010 HRSA HAB Diagnosed 51% 
Torian 
2014(332) 
US General 2006 - 2010 HRSA HAB Diagnosed 68% 
Wester 
2016(333) 
US General 2013 HRSA HAB Diagnosed 55% 
Whiteside 
2014(228) 
US Black 2010 HRSA HAB Diagnosed 48% 
Wiewel 
2015(237) 
US General 2011 HRSA HAB* Diagnosed 70% 
Burchell 
2015(334) 
Canada General 2001-2011 HRSA HAB* Linked to care 76-80% 
Doshi 










US Veterans 2008 - 2013 >1 visit or VL in years Linked to care 75-91% 
Lourenco 
2014(225) 
Canada General 2011 HRSA HAB Linked to care 87% 
Paz-Bailey 
2014(336) 
US MSM 2008 Self-report a visit in last 6 months Study participants 88% 
Supervie 
2013(216) 
France  General 2010 ‘In care’ HIV Infected 74% 
van Beckhoven 
2015(337) 
Belgium General 2011 
CD4/VL in 2011, of those with CD4/VL 
in 2010 
Linked/ In care 2010 92% 













>1 visit in prior 12 months at 18 
months post-diagnosis 






























>1 visit in each 6 month interval, >60 
days apart over 24 months 





















>1 visit in each 6 month interval over 
24 months 
Linked to care 59% 
HRSA HAB=Health Resources and Services Administration HIV/AIDS Bureau definition (>2 visits within a year, >90 days apart); SHCS=Swiss HIV Cohort Study; 
MSM=Men who have sex with men; VL=Viral load. 







2.4.3 Factors associated with retention in care 
2.4.3.1 Age 
Studies that have investigated retention in care by age have largely found that younger adults 
have lower rates of retention in care (336, 342, 343). There have been few studies to consider 
an association between retention in care and age outside of the US. In a previous UK CHIC 
analysis using the REACH measure of engagement in care, those aged below 25 were 33% 
less likely to be engaged in care in any given month than those aged above 45 (317). In two 
multi-centre Canadian Studies, those aged older than 50 had a 15% increased likelihood of 
achieving initial retention in care compared to those aged 30-39 (344) and 6% more likely to 
be retained in care in any calendar year than those aged <35 (334). In a small retrospective 
cohort study in China, those aged younger than 50 were approximately 45% less likely than 
those older than 50 to have been retained in care over the last year as defined by no missed 
clinic visits (345). 
Five studies in the US considered HRSA HAB defined retention in care in a single calendar 
year, four of which utilised surveillance data. Doshi et al., investigated retention in care in 
2011 in the Ryan White HIV/AIDS Program, with over 276,000 people included in their 
analysis. Decreasing odds of retention in care were observed in younger age groups compared 
to those aged >65 years, with those aged between 19-24 and 25-34 being 42% less likely to 
be retained in care (335). Amongst over 87,000 PLWH in New York in 2010, rates of retention 
in care were high, ranging from 75% in those aged 20-29 to 86% in those aged >60. They 
saw linearly increasing prevalence rates of retention in care with increasing 10 year age groups 
above age 20, after adjusting for other demographic factors. Those aged between 50-59 and 
those aged >60 had 1.22 and 1.26 times higher prevalence rates of retention than those aged 
20-29 (332). Similarly in Tennessee, adults aged 45-54 and over 55 were more than 20% as 
likely to be retained in care as those aged 35-44 (333). In all the above studies, whilst the 
youngest adult age group was least likely to be retained, adolescents were found to have 
better rates of retention. Hall et al., who used this adolescent age group as the reference 
category, did not see such strong associations between retention and care and age. Compared 
to those aged between 13-24, a small 6% increased odds of retention in care was found for 
those aged between 45-64 only (346). According to Los Angeles surveillance data, those aged 
13-44 were 8% less likely to be retained in care than those aged above 44 (330).  
Longitudinal assessments have similarly noted poor retention amongst young adults. The NA-
ACCORD followed over 61,000 individuals between 2000 and 2008 and used the HRSA HAB 
measure of retention in care in each calendar year in follow-up observing a 20% decreased 
likelihood of incomplete retention for each ten year increment in age (340). Another multi-
centre US study found people age over 50 to be 50% more likely to be retained than those 
71 
 
aged below 50 by the same definition over a maximum 7 years of follow-up (347). Two studies 
by Crawford et al. investigated the effects of type and number of comorbidities on different 
measures of retention in care and found that older age was associated with higher odds of 
retention in care, independently of the burden of comorbidities (348, 349). Other measures 
including proportions of visits attended (350), annual laboratory measures (351) and intervals 
containing visits (341, 352, 353) have been assessed with similar conclusions drawn. Yehia et 
al., considered 3 separate definitions of retention in care in 17,425 people who had at least 
one outpatient visit between 2001 and 2009 in the HIV Research Network; one of 6 month 
gaps in care, one of 3 month intervals containing visits and the HRSA HAB measure. Only 
35% of people aged 18-29 had complete retention over all follow-up years as defined by no 
gaps >6 months between visits. For all measures of retention in care considered, those aged 
above 50 were approximately twice as likely to be retained in care as those aged below 30 
(354). Those aged above 40 had a 20% decreased risk of experiencing a gap in care >6 
months in an analysis of over 6000 publically insured individuals accessing care (355), whilst 
those aged <25 had a 40% increased risk of experiencing a gap in care >6 months compared 
to those aged above 45 in a single centre US study (356). 
Studies that have not reported an association between age and retention in care have 
generally not used the HRSA HAB definition of retention in care, with three studies considering 
retention in the year after initial diagnosis or linkage to HIV care (241, 357, 358). Patterns of 
engagement in care in a newly diagnosed group of individuals may differ from the wider 
population of people living with diagnosed HIV and could explain why no association was seen 
in these studies. One of the few studies to describe retention in care in a European setting 
also did not report an association between age and retention in care, but found that the overall 
retention rate was high at 92% (337, 359). Finally, a baseline analysis of a study aimed to 
understand and improve engagement in care in women of colour in the US also found no 
association. This measure of retention in care relied on self-reported HIV care engagement 
level (360).   
2.4.3.2 Mode of acquisition/sex 
In a UK setting women have poorer retention in care than men. In the UK CHIC analysis 
previously mentioned, women were less likely to be engaged in care in any given month (81% 
months in care compared to 85% in men), although this association was attenuated after 
adjusting for other demographic factors including route of acquisition (317). An analysis of 
HIV surveillance data from England, Wales and Northern Ireland, demonstrated that women 
were 50% more likely be lost to care than men (323). Studies in Canada and Australia, have 




In the US, whilst no differences are observed in the crude proportions of men and women 
retained in care (330, 333, 335, 340, 347, 351, 353, 357), in regression models that adjust 
for mode of HIV acquisition, men have lower rates of retention (333, 335, 343, 351, 353, 
355), being approximately 10% less likely to be retained in care than women (330, 332, 347, 
354). MSM have better engagement in care than either heterosexuals or PWID, with PWID 
reporting very low rates of retention in care. This is evidenced in a study of over 22,000 
American PLWH in which, heterosexuals were 15% less likely than MSM to be retained 
according to definitions of gaps in care, quarters with a clinic visit and the HRSA HAB criteria. 
PWID were between 24 and 33% less likely to be retained (354). Amongst over 15,000 PLWH 
in Tennessee and 32,000 in Los Angeles, PWID were 16% less likely to be retained than 
heterosexuals and 12% less likely than MSM. Differences between MSM and heterosexuals 
were smaller, with MSM approximately 5% more likely to be retained in care (330, 333). 
Combining both sex and mode of acquisition, in a large study of over 100,000 individuals, Hall 
et al., found that 50% of heterosexual females were retained in care according to the HRSA 
HAB definition, compared to 45% of heterosexual males. Amongst PWID, 37% of males and 
43% of females were retained in 2009 (347). This would also suggest that disparities exist 
between men and women that are masked in populations where the majority of males report 
MSM route of acquisition.  
In the UK, MSM have better retention in care than heterosexuals or PWID as measured 
through the time-updated measure of engagement in care and loss to care in HIV surveillance 
data. PWID are most likely to disengage from care, being half as likely to be in care as MSM 
in any given month of follow-up (317) and twice as likely to be lost to care (323).  
2.4.3.3 Ethnicity 
Black ethnicity is a risk factor for poor retention in care in both the UK and US (241, 332, 335, 
340, 342, 347, 354). In the UK CHIC Study, whereas those of white ethnicity were engaged 
in care for 86% of months, those of black African ethnicity were engaged in care for 81% of 
months. Those of any other specified ethnicity, of whom the majority were black Caribbean 
or other black ethnicity, were also less likely to be engaged in care than those of white 
ethnicity (317). Across England, Wales and Northern Ireland, those of black African Ethnicity 
were twice as likely to be lost to care (323). In the US, those of black ethnicity are between 
4 and 17% less likely to be retained in care than those of white ethnicity (333, 346) according 
analyses of surveillance data. In 2013, Adeyemi et al. drew attention to racial disparities in 
engagement in care in a clinical cohort in Chicago, including nearly 5000 individuals of whom 
65% were black. They found that black patients were 40% more likely to not be engaged in 
care in 2010 than those of white ethnicity, demonstrating large disparities in care for these 
ethnic groups than seen in surveillance estimates (343). This association has been shown to 
remain amongst sub-groups of men (362) and veterans (352). 
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One study by Olatosi et al. did not find those of black ethnicity to have worse engagement, 
but they were 18% less likely to be not in care than white individuals. In this analysis 
undertaken in South Carolina, nearly three quarters of the population were black. The authors 
speculate that white people might experience the disadvantages of being in a minority status 
in this setting (351). This is supported by another study that had similarly high majority of 
black ethnicity; 80% of the population living with HIV were black. The authors did not find 
that those of black ethnicity were of increased risk of being not in care. However they were 
at higher risk of being in transient care (353).  
2.4.4 The impact of poor engagement in care on mortality 
Poorer retention in HIV care correlates with poorer mortality outcomes. Different measures of 
EIC have been shown to be associated with a greater risk of mortality including missed visits 
(363), visit constancy and gaps in care (364). Amongst individuals newly diagnosed or 
initiating care, both Tripathi et al., and Teixeira da Silva et al., have demonstrated that failure 
to attend for a visit in fewer than 3 of four quarters over 2 initial years of care results in a 3-
4-fold higher risk of mortality (365, 366). Similarly, two US studies, in which approximately 
two-thirds of individuals had missed at least one visit in the year after linking to HIV care, 
linked missed visits to a higher risk of mortality. A single centre study of majority black 
ethnicity individuals found a 2.9-fold higher risk of mortality with any missed visits (367). The 
Kaiser Permanente Northern California cohort, which is a larger multi-centre clinical database, 
found a slightly smaller increased risk with any missed visits which was 1.7-fold higher than 
for no missed visits (368). 
Retention in care has been shown to be better in people on ART than amongst ART naïve 
individuals (340, 357, 364). Several studies have still reported an association between 
retention in care and mortality amongst people starting treatment. One of the largest such 
studies was conducted in a national Free ART program in China. In this study, of over 27,000 
individuals, missing 1-2 or 3-5 of 5 scheduled visits in the 6 months following ART initiation 
was associated with 30% and 70% increased risk of mortality. In a smaller single centre study 
in South Africa, 2 or more missed visits in the 6 months after ART initiation was associated 
with at least a 2-fold higher risk of mortality. In the US, Mugavero et al., found 3 separate 
measures of retention in care to be independently associated with mortality over the 2 years 
following ART initiation. Those not retained in care were more than 2 times as likely to die 
during follow up as those retained in care (367). Similarly the Department of Veterans Affairs 
found an increasing number of quarters with a clinic visit in the first year on ART was 
associated with reduced risk of mortality after adjusting for CD4 count, age, HCV co-infection 
and comorbidity score (369). One study that did not show a strong association between 
retention in care and mortality was a multicentre cohort in the US, which considered, over all 
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clinic follow-up, a gap of 12 months without a clinic visit to be not retained; once someone 
had experienced a gap they were classified as not retained for the remainder of follow-up. 
After adjusting for time-updated measures of CD4 count, viral load and AIDS, as well as 
baseline factors, having experienced such a gap in care was associated with a non-significant 
20% increased risk of mortality over five years. (370). This was one of the only studies so far 
to adjust for changing measures of HIV markers and is a possible explanation for the 
attenuated effect after adjustment. However, a similar measure of loss to follow-up was not 
associated with mortality in a smaller study of the Australian HIV Observational Database 
(361). 
Few studies linking retention in care to mortality have been conducted in the UK setting. In a 
recent analysis of the UK CHIC study a time-updated measure of retention in care was used 
which describes the proportion of time in care that is classified as adhering to a visit schedule 
(317). An advantage of a time-updated measure of retention in care to assess associations 
with mortality, is that individuals to not need to have survived for an initial period of time in 
order to be able to define retention in care, which may introduce bias. Whereas previous 
studies excluded individuals who did not survive for the 1 or 2 years necessary to define 
retention in care (367-369, 371), and so may be subject to a degree of survivorship bias, this 
study allowed all individuals with at least one attendance to be included. The findings of this 
study was that higher levels of engagement in care were associated with lower rates of 
mortality. However, this study also found that adjusting for the most recent CD4 count 
attenuated any association. This indicated that an association between engagement in care 
and mortality might be explained by the fact that people with better engagement in care also 
have higher CD4 counts and are more likely to be virologically suppressed if on ART (372).  
2.4.5 Terminology in this thesis 
In the continuum of care, and in much of the literature, the term retention in care is used to 
refer to many measures of frequency of attendance for care (Section 2.4.1.1). This is a 
different concept from LTFU, whereby individuals cease to attend for care, or are lost to the 
study cohort. Engagement in care in the context of the care continuum may be referred to in 
the literature to more generally encompass involvement with HIV services, i.e. optimal 
achievement of the stages of the care continuum, regular attendance of scheduled visits and 
adherence to treatment. In subsequent chapters in this thesis, I intend to use this terminology 
differently. I will refer to measures of attendance frequency as measures of EIC, as opposed 
to retention. The term retention in care will instead be used to indicate the absence of LTFU. 
Retention in care may occur, without individuals satisfying measures of visit frequency that 





2.5 ART uptake and use 
2.5.1 Definition 
The ART stage of the continuum of care indicates some level of ART use, usually in the year 
considered, but sometimes ever use of ART up to or including the period of study is used. 
Information on ART uptake utilised in continuum estimates has been obtained from 
prescription data, medical note review, patient report or clinician reporting (Table 2.5.1). 
Prior to recent guidelines changes, ART was not recommended in all individuals but would be 
initiated based on criteria that included CD4 count, pregnancy, co-morbidities, disease status 
and considerations of patient wishes and the potential for ongoing transmission. Leakage from 
the continuum prior to ART initiation therefore, may have indicated non-eligibility to initiate 
ART, and not merely been an indicator of sub-optimal progress along the care pathway. 
However, failure to initiate once eligible for therapy would indicate sub-optimal care. In order 
to be in a position to initiate ART once eligible, individuals need to be diagnosed and linked 
to care before they reach the eligibility criteria for ART initiation. Further they need to be 
retained in care and undergo regular CD4 monitoring in order to determine eligibility. A 
commonly used definition of late ART initiation in the literature is initiation with a CD4 count 
<200 cells/mm3, as ART initiation has been recommended in asymptomatic individuals at 
higher CD4 counts than this since 2008, with a recommendation to initiate by this threshold 
prior to this. Presence of an AIDS-defining illness is also an indicator to initiate ART. Currently, 
following the results of the START trial and changes to recommend immediate ART regardless 
of CD4 count, what constitutes late ART is less clearly defined. 
2.5.2 Prevalence of (late) ART uptake 
Amongst individuals accessing care in high income countries, ART use is very high (373). In 
2015 in the UK, 96% of people who attended for care were receiving antiretroviral therapy 
(70); 83% of all PLWH in the UK. This was an increase on 2011, where only 84% of people 
accessing care were on ART (218) and on 2004 when 66% were in receipt of treatment (74). 
In recent years, there have been declines in the proportion of individuals initiating ART with 
a CD4 ≤200 cells/mm3, from just over one-third in 2009 to approximately a quarter in 2013 
(311, 312). This decline in late ART initiation and higher CD4 counts at ART initiation over 
time has also been reported in other cohorts (374, 375) and reflects changes in treatment 
guidelines and increasing knowledge around the potential benefits of treatment as prevention 
for transmission. In the UK CHIC Study, of those to start ART with a CD4 count below 200 
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cells/mm3, 75% had also presented with a CD4 count below this threshold, indicating that late 




Table 2.5.1: Proportion of PLWH in receipt of ART according to continuum of care estimates 
Paper Country /population Data source Year Definition ART use Denominator %1 
Backus  
2015(328) 
US / Veterans 
Veterans Affairs Clinical Case 
Registry 
2013 
Prescription fills from >2 ART 
classes 
Diagnosed 





US / White MSM 
US / Black MSM 





US / General 
Medical monitoring Project and 
population-based chart review 
2009 ART prescription 






















Austria/ General Clinical cohort 
2013 Ever on ART HIV infected 
90% 
Belgium/ General Clinical cohort 96% 
Denmark/ General Clinical cohort 94% 
France/ General Clinical cohort 93% 
Germany/ General Clinical cohort 87% 
Greece/ General Clinical cohort 82% 
Italy/ General Clinical cohort 80% 
The Netherlands Clinical cohort 91% 
Spain/ General Clinical cohort 76% 
Sweden/ General Clinical cohort 92% 
UK/ General Clinical cohort - UK CHIC Study 82% 





Paper Country /population Data source Year Definition ART use Denominator %1 
Hall 
2013(217) 
US / General Medical Monitoring Project 2009 
Any ART prescription in past 12 
months 
HIV infected 33% 
Helleberg 
2013(329) 
Denmark / General Danish HIV Cohort 2010 Record of current ART Diagnosed 73% 
Horberg 
2015(232) 
US / General Kaiser Permanente database 2010-2012 





US / General 
Sero-prevelance study and cross-
sectional survey 
2007 Self-report ART use HIV Infected 27% 
Kirwan 
2016(70) 
UK / General HIV surveillance data 2015 Clinician reported ART use HIV Infected 83% 
Kohler 
2015(255) 
Switzerland / General 
SHCS 
Survey of SHCS clinicians 
ART prescriptions 
2012 
Started ART before June 2012 
Survey response 
ART sales data 
HIV Infected 71% 
Krentz 
2015(230) 
Canada / Newly 
Diagnosed 
Linked Surveillance and Southern 
Alberta clinic database 
2006-2013 Any ART use Diagnosed 75% 
Lagasca 
2015(233) 
US / Veterans 
Clinical Case Registry for HIV – 
Dept. of Veterans Affairs  
2008-2013 Pharmacy utilisation of any ART Diagnosed 67-84% 
Laisaar 
2016(229) 
Estonia / General 
Estonia HIV Database (clinical 
cohort) 
2013 On ART 
HIV Infected 





Canada / General Linked provincial datasets 2011 
>2 drug dispensations, >3 
months apart 
Retained in care 91% 
Mangal 
2014(231)  
US / General 
Atlanta Veterans Affairs Medical 
Centre database 






Paper Country /population Data source Year Definition ART use Denominator %1 
Okeke 
2016(258) 
US / White MSM 
US / Black MSM 
National HIV Behavioural 
Surveillance Surveys 
2004-2014 
Ever (in 2004) or in last 6 







Italy / General 
Infectious Disease Clinic 
Databases 
2013 Ever use Linked to care 96% 
Raymond 
2016(234) 
New Zealand / General 
Regional service database, 
hospital laboratory database 
2015 Self-report current use HIV Infected 71% 
Rosenberg 
2014(261) 
US / White MSM 
US / Black MSM 





US / General 
Denver metropolitan area 
surveillance 
2005-2009 









US / Transwomen 
Respondent driven sample testing 
study 
2010 Self-report current ART HIV Infected 65% 
Singh 
2014(227) 
US / MSM 
CDC surveillance, Medical 
Monitoring Project 
2010 ART prescription Diagnosed 50% 
Supervie 
2013(216) 




Belgium / General AIDS reference centres database 2011 ART prescription Diagnosed 83% 
van Sighem 
2014(376)  






Paper Country /population Data source Year Definition ART use Denominator %1 
Whiteside 
2014(228) 
US / Black ethnicity 
CDC surveillance, Medical 
Monitoring Project 
2010 ART prescription Diagnosed 46% 
Wirtz 
2016(249) 
Russia / MSM 
Respondent driven sample cross-
sectional study 
2010-2013 Self-report ART use HIV Infected 5% 
MSM=Men who have sex with men; SHCS=Swiss HIV Cohort Study; CDC=Centers for Disease Control 














2.5.3 Disparities in ART uptake and use 
2.5.3.1 Age 
In the only study to consider ART initiation in people with known dates of HIV seroconversion 
across Europe, each additional year older at the time of HIV infection resulted in a 20% 
increase in the likelihood of ART initiation (377). This study has the benefit of being 
independent of stage of HIV at diagnosis, but points to faster initiation of ART in older 
individuals. This could be due to more rapid CD4 decline with older age (305), making older 
people eligible to initiate ART sooner. Amongst newly diagnosed individuals, older people have 
again been shown to be more likely to initiate ART in the UK. Between 2002 and 2011, a 
higher proportion of older individuals initiated ART within 1 year of HIV diagnosis, increasing 
from 40% in those aged 15-24 to 56% in those aged 50 and above. However, in the same 
age groups 45% and 70% of people were diagnosed late respectively, meaning that more 
people in the older groups were eligible and in need to receive treatment (274). When 
considering time from HIV diagnosis or entry into care to ART initiation, therefore, 
comparisons between age groups should somehow account for stage of HIV disease at 
diagnosis to remove its effect. Some studies that have done so have still found an association 
with older age and increased likelihood of ART initiation (222, 274, 378, 379). However, three 
US studies found disparate results: one found no association between age and ART initiation 
in the first year of care in a small single centre study that accounted for late diagnosis and 
engagement in care (341); another found no association between age and time from diagnosis 
to ART initiation (380); another, based on surveillance data, reported that increasing age was 
associated with a decreased likelihood of ART initiation using a baseline time point that was 
the latest of diagnosis or 1st January 2007 (381).  
In comparisons only amongst those eligible for treatment, there is again evidence that older 
people are more likely to initiate ART. An increasing likelihood of ART initiation was seen up 
to age 59 in ART eligible individuals in North America, with a 23% increased likelihood in those 
aged 50-59 over those 18-29 years old. With small numbers of PLWH aged over 60 in this 
study, a non-significant 13% increased risk of ART initiation was found in this group (382). In 
the UK CHIC Study, the likelihood of starting ART after a first recorded CD4 count <350 
cells/mm3 between 2004 and 2008 increased by 15% for each 10 year increment in age, 
accounting for the value of the initial CD4 count and most recent CD4 count (383). CD4-level 
analyses have been performed to look at the probability of starting ART within 6 months of a 
given CD4 count in two analyses of UK CHIC with conflicting results. CD4- level analyses are 
a way of removing any influence of late diagnosis, where any CD4 counts below the eligible 
threshold should, in theory, be followed by ART initiation. The earliest study by Stohr et al., 
found no association between age and ART initiation (384). However, Sethi et al., performed 
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a similar analysis among a different population that included only MSM under follow up in later 
years and found 14% increased odds of initiating ART for each 10 year increment in age 
(385).  
There is consensus that compared to younger PLWH, older PLWH starting ART do so at a 
more advanced stage of HIV with lower CD4 counts, higher viral loads and more frequently 
having experienced AIDS events. A large European collaboration of nearly 50,000 PLWH 
starting ART between 1998 and 2006 observed decreasing median CD4 count with increasing 
age at ART initiation, with a difference of 83 cells/mm3 in the median CD4 count at starting 
ART between the oldest (>60 years) and youngest (18-29 years) adults. It was also observed 
that over 30% of adults in different age groups over 50 had an AIDS diagnosis prior to ART 
initiation, compared to only 18% of those aged 18-29 (306). Both single and multi-centre 
studies in France that compared the characteristics of PLWH over the age of 50 to those below 
the age of 50 at ART initiation found the older group to have a lower median CD4 count at 
ART initiation (in the region of 40-60 cells/mm3), with approximately 10% higher prevalence 
of ART initiation with CD4 count <200 cells/mm3 or a previous AIDS diagnosis (309, 386). In 
502 PLWH who started ART in the Toronto Hospital Immunodeficiency Clinic, 40% of people 
aged over 50 started their first-line ART regimen with a CD4 count <100 cells/mm3 compared 
to 29% of those younger than 50, and 32% and 27% respectively started ART having already 
had a prior AIDS diagnosis (387). In a much larger study of multiple provinces in the same 
country, those aged >50 years were approximately twice as likely to initiate ART late (defined 
as initiation with a CD4 count ≤200 cells/mm3) compared to those aged 18-29 (374). This is 
likely entirely explained by late diagnosis, with another Canadian study demonstrating 
consistent results for those diagnosed with a CD4 count ≤200 cells/mm3 and no association 
amongst those diagnosed with a CD4 count above 200 cells/mm3 (375). This implies that late 
diagnosis is the reason for later ART initiation in this setting. In the UK setting, those starting 
ART aged 50 and above had a median CD4 count 50 cells/mm3 lower than for those aged 
below 30 (388). 
2.5.3.2 Sex/mode of acquisition 
Several studies report no difference in time to treatment uptake between men and women 
independently of mode of HIV acquisition (377-379, 381, 389) or of late ART initiation (375, 
390). In the French Hospital Database, within mode of acquisition groups, excluding MSM, 
there was no difference in the time to ART initiation from study enrolment between men and 
women (391). However, in two analyses of UK CHIC data, women were shown to be more 
likely to initiate ART after any CD4 count (384) and were more represented amongst 
individuals starting treatment late who had been diagnosed late, than those diagnosed in a 
timely manner who initiated late or as per guidelines (223). These differences likely reflect 
differences between heterosexual men and women with HIV in the UK, rather than women 
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and MSM, as evidenced in another UK CHIC analysis in which heterosexual women had shorter 
time to ART initiation following a first CD4 count below 350 cells/mm3 than heterosexual men 
(383). Further, amongst only heterosexuals, women were more likely to initiate ART within 1 
year of diagnosis than men, despite the fact that men were more likely to be diagnosed late 
(274).  
PWID are less likely to initiate ART after diagnosis and more likely to start ART late (391, 
392). This was observed in the European cohort of people with known dates of HIV infection, 
with PWID 21% less likely to initiate ART over the course of HIV infection than MSM (377). 
This has also been shown in other European cohorts of diagnosed individuals accessing care 
in Spain (378) and Switzerland (393). In the US, similarly, PWID newly enrolled in HIV care 
(379) and eligible to start ART (382) were between 15 and 36% less likely to initiate therapy 
than MSM, with a study of San Francisco surveillance data showing a similar trend for 
heterosexuals and MSM who also inject drugs (381). Two UK CHIC analyses have 
demonstrated PWID are less likely to initiate ART following a CD4 <350 cells/mm3 (383) or at 
any given CD4 count threshold (384). Whilst these studies adjust for stage of disease and 
potentially higher rates of late diagnosis in PWID, it is possible that this delayed ART initiation 
could instead be due to levels of EIC, which have been shown to be lower. However, in a 
Canadian study of people accessing care in British Columbia, PWID who were classified as 
retained in care in 2011 were still 50% more likely not to use ART than similarly retained 
MSM, suggesting that other factors may also contribute to delayed ART initiation in PWID 
(225).  
2.5.3.3 Ethnicity 
In the UK, the role of ethnicity in late ART initiation is unclear. Black African individuals are 
over-represented amongst those starting ART with a CD4 count below 200 cells/mm3 due to 
late presentation to care (45% as opposed to 13% of timely initiators), with white individuals 
under-represented (38% vs. 73% in timely initiators) (223). ART initiation in the 6 months 
following any CD4 count, adjusted for its value, was 17% less likely amongst black and 
minority ethnicity MSM compared to white in one UK CHIC analysis (385), but a non-significant 
18% increased likelihood of ART initiation was found in those of black ethnicity compared to 
white in another analysis of CD4 counts in all acquisition risk groups (384). Neither black 
African or black Caribbean ethnicity was associated with ART uptake in the year following 
diagnosis amongst heterosexual men and women in the UK (274), or with ART uptake 
following a CD4 <350 cells/mm3 in the UK CHIC Study (383). In contrast, studies conducted 
in the US almost exclusively find that those of black or other non-white ethnicities are less 
likely to initiate ART (379, 381, 382, 394), with the HIV Outpatient Study also reporting lower 
CD4 counts at ART initiation in those of non-white ethnicity (380). This would suggest delayed 
initiation of ART once in care amongst people of non-white ethnicity, as opposed to late 
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diagnosis as a reason for late ART initiation. In a study of US military personnel, there was no 
difference in ART initiation for those of black ethnicity compared to white in people eligible to 
initiate ART according to clinical criteria, however, elective ART was less likely to occur (389).  
2.5.4 The impact of ART on mortality, according to timing of initiation 
Initiation of ART reduces the rate of clinical progression in PLWH regardless of the stage of 
HIV at initiation (395, 396). However, from early in the epidemic, observational studies have 
found that lower CD4 counts at the time of ART initiation are a risk factor for higher mortality 
(397-405). In an analysis of over 20,000 individuals who initiated ART, those with a pre-ART 
CD4 count between 200 and 349 cells/mm3 were less than half as likely to die over a median 
3 years of follow-up than those <25 cells/mm3. Mortality rates in those with a pre-ART CD4 
count >350 cells/mm3 were one-third of that in the lowest CD4 strata (406). This short term 
difference in mortality has been extended to the longer-term through the calculation of life 
expectancy in recent studies, one of which was an analysis of the UK CHIC cohort. In this 
study of people initiating ART between 2000 and 2008, the additional years of life expected 
to live at age 20 for those with a CD4 count between 200 and 350 cells/mm3 was 53, resulting 
in an expected age at death approximately 5 and 7 years below men and women in the 
general population. In contrast, those initiating ART with a CD4 count below 100 cells/mm3 
were expected to live an additional 38 years from age 20; a difference in life expectancy of 
15 years compared to the higher CD4 count group (205). Estimates based on observed 
mortality in a Canadian cohort found that at age 20, life expectancy for people initiating ART 
with a CD4 count below 50 cells/mm3 was 22, 29, 49 and 53 years for pre-ART CD4 counts of 
<50, 50-199, 200-349 and >350 cells/mm3, giving expected ages at death of 44, 49, 69 and 
73, respectively (407). An earlier study of people starting ART in the US using lower CD4 
count thresholds observed a 9 year difference in life expectancy at age 33 between those who 
started with a pre-ART CD4 count below 50 cells/mm3 and those with a CD4 above 200 
cells/mm3 (408). Compared to the general population, the excess risk of mortality is much 
greater in those initiating ART with lower CD4 counts. Whereas mortality rates in people 
starting ART with CD4 count above 200 cells/mm3 are approximately 2 to 3 times higher than 
in the general population, a CD4 count below 50 cells/mm3 is associated with 9-15 times 
higher rates of mortality (409, 410).  
Three analyses of the ART-CC cohort have considered whether the impact of lower baseline 
CD4 counts on mortality may diminish in the long term. The first study, including people 
initiating ART between 1996 and 2004, found that compared to a CD4 count >350 cells/mm3 
at ART initiation, differences in mortality rates for those with CD4 counts <50 cells/mm3 were 
somewhat attenuated after 2 years on ART, but a trend to higher mortality with lower CD4 
counts remained out to 6 years (411). However, more recent analyses with longer follow-up 
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have looked at the association between baseline CD4 count and mortality after 10 years on 
therapy finding no association (412). In people who initiated ART between 1996 and 1999 
and who survived at least 10 years on therapy, unadjusted analyses showed an association 
remained between the baseline CD4 count and mortality after 10 years, but adjusting for 
recent CD4 counts attenuated any association. This suggests that baseline CD4 may still 
impact mortality in the long term but that this is explained by subsequent sup-optimal 
responses to ART in people with lower baseline CD4 counts (195).  
Few studies have looked at cause-specific mortality, but have found a CD4 <200 cells/mm3 to 
be associated with a 2.8-fold increased risk of AIDS mortality compared to >350 cells/mm3 
and a one-log increase in CD4 count to be associated with a 40% decreased risk of HIV-
related mortality. Whilst a log increase in the CD4 count was not strongly associated with non-
HIV related deaths in a study of 3724 ART initiators in the Netherlands, a CD4 <200 was 
associated with a 2-fold higher risk of non-AIDS mortality in a group of women and MSM after 
age 35 in the US (413, 414); possibly a reflection of different classifications of non-AIDS or 
non-HIV related death or different methodologies. The combined analysis of MSM in the MACS 
Study and women in the Women’s Interagency HIV Study (WIHS) was one of the few studies 
to account for lead-time bias, which may occur in comparisons of CD4 count at ART initiation, 
as those starting with lower CD4 counts have ‘unobserved’ follow-up time prior to the baseline 
of the analysis in which they have survived from a higher CD4 count to their current lower 
CD4 count (415). Studies that have accounted for lead-time bias have seen no difference in 
results (414).  
The effect of delaying antiretroviral therapy at a given CD4 count is similarly associated with 
increased mortality in observational studies. However many of these studies were conducted 
with a goal to understanding whether ART should be initiated at higher CD4 counts than 350 
cells/mm3 and so compare relatively high CD4 count thresholds. In the Swiss HIV cohort 
Study, asymptomatic individuals initiating ART with a CD4 above 350 cells/mm3 between 1996 
and 1999 were matched to ART-naïve individuals with a visit within one year of ART initiation 
date who did not initiate ART with similar CD4 counts based on age, sex, viral load and mode 
of HIV acquisition. Those who initiated treatment had 80% lower risk of mortality compared 
to those who delayed therapy (416). Palella et al., looked within CD4 strata, at mortality rates 
for people initiating ART in this strata or delaying to a lower CD4 strata. Whilst there was no 
difference in mortality with delay of ART within CD4 strata 500-750 cells/mm3 or 350-500 
cells/mm3, individuals with a CD4 between 200-350 cells/mm3 who initiated ART had a 70% 
lower mortality rates than delaying ART (417). In similar analyses in a North American cohort 
collaboration, Amongst individuals with ART-naïve CD4 counts in the 351-500 cells/mm3 
range, deferral of therapy was associated with a 69% increased risk of mortality, even at this 
high CD4 values (418). Sterne et al., accounted for lead-time bias of deferring to lower CD4 
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count strata by imputing AIDS and mortality events in the deferral group prior to ART initiation. 
With this adjustment, they similarly noted a trend to higher mortality with deferral of therapy 
in all CD4 strata that had a lower limit below a lower limit of 350 cells/mm3, with significantly 
raised mortality in all CD4 count thresholds with a lower limits below 225 cells/mm3 that 
increased with each lower strata. Delaying to a CD4 count <100 cells/mm3 from a CD4 count 
between 100-199 cells/mm3 doubled the risk of mortality (415). The impact on mortality of 
initiating ART with 6 months of different CD4 count thresholds between 200 and 500 cells/mm3 
was assessed in the HIV CAUSAL collaboration, which includes UK CHIC data. Observational 
data were used to assess the mortality associated with different ART initiation thresholds, 
accounting for time-dependent confounding introduced by the fact that people at higher risk 
of mortality (i.e. those with lower CD4 counts) are more likely to initiate ART in clinical 
practice. Compared to initiating at a CD4 threshold of 500 cells/mm3, initiating at a CD4 count 
of 200 cells/mm3 demonstrated a non-significant 20% higher risk of mortality, with no other 
differences at intermediate CD4 count thresholds. The authors claim low mortality rates in the 
intervening time whilst CD4 count declines from 500 cells/mm3 to 200 cells/mm3 and the 
methods employed to account for bias may explain the different findings (419). Edwards et 
al., performed a similar analysis, estimating 5 and 10 year cumulative incidence of mortality 
for 3 initiation strategies at thresholds of 500, 350 and 200 cells/mm3, this time using g-
formula to account for time-depending confounding of ART initiation. However, this study 
agreed with previous findings, demonstrating increased 5 and 10 year mortality rates for both 
the 200 and 350 cells/mm3 CD4 thresholds compared with 500 cells/mm3. 10-year mortality 
was 25% higher with a treatment strategy for initiation below CD4 counts of 200 and 8% 
higher for a 350 cells/mm3 threshold (420). Although not designed to assess this problem, a 
sub-study of the SMART RCT, demonstrated a mortality disadvantage to delaying ART below 
350 cells/mm3. 
 
2.6 Virological response to antiretroviral therapy 
2.6.1 Definition 
Achievement of viral suppression is a commonly used indication of treatment success and the 
final stage of the HIV continuum of care. It is a marker for clinical benefit and potentially 
reduced risk of onward transmission of HIV. In a continuum of care, a cut-off of 200 copies/ml 
is most often used to indicate suppression, although this differs from setting to setting. This 
is to overcome heterogeneity of viral load assay lower detection limits over time and between 
settings (236). In clinical care, a viral load is considered suppressed when it is below 50 
copies/ml. This is the threshold that is commonly used by most assays, although in recent 
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years more sensitive assays have become available, and the threshold under which HIV has 
been shown to not be transmitted (152). In a snap-shot continuum of care, the last viral load 
in the calendar year of assessment is commonly used. Methods to account for those without 
a viral load measure are not well defined. One approach would be to exclude these individuals 
from the denominator. Another would be to include them and impute the value of the viral 
load measure, for example, to assume that it is detectable.  
Whilst a traditional continuum of care gives a cross-sectional measure of virological response 
to treatment, over many years on treatment an individual’s viral load status may change. In 
the literature, as in clinical practice, virological response is measured in many ways. An initial 
successful response to ART requires suppression of the viral load to undetectable within 24-
36 weeks of ART initiation. Individuals are considered to be experiencing virological failure if 
the viral load does not become undetectable in this time. Following initial suppression, people 
may experience a loss of virologic control. The extent of this virologic rebound may be 
characterised as transient ‘blips’ in which a single low (typically defined as below 400 
copies/ml), but detectable, viral load is recorded, or low-level viraemia, in which a more 
prolonged period of time where the viral load is low but detectable is experienced. How 
virological failure is defined varies, but could include 2 consecutive viral load measures above 
a threshold of either 200 or 400 copies/ml or a single viral load above 1,000 copies/ml. A 
measure not used in clinical practice but that has emerged in the literature is viraemia copy 
years (VCY). This measure aims to capture the total burden of HIV replication that occurs in 
the presence of ART. It is calculated as the area under the curve of an individual’s observed 
viral load measures over time, with undetectable viral loads contributing null values and is 
expressed in copies x years per ml or log10copies x years per ml (421). 
2.6.2 Rate of virological success 
In a HIV care continuum, a large number of populations, including the UK, report viral 
suppression levels of over 90% among people on ART. As a proportion of all PLWH, rates of 
viral suppression are hugely variable, ranging from 19% to 78%. Whilst differences may 
represent true disparities between different settings, they are also dependent on which earlier 
stages are included in the continuum, the denominator used and definition of viral suppression 
(Table 2.6.1). 
In clinical practice, the time taken to achieve initial virological response is short with a median 
3-5 months reported (387, 422-425); approximately 75-90% of people initiating ART will 
achieve virological suppression by 6 (426) or 12 months (424, 427-431). Following 
suppression, 15-45% can be expected to experience viral rebound or failure (428, 432-437), 
with the higher estimates generally reported in earlier studies when ART regimens were less 
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efficacious and less well tolerated. The rate of viral failure declines with longer time on ART, 




Table 2.6.1: Rates of virological response to ART  
Paper Country/population Data source Year Definition Suppression1 Denominator % 
Backus  
2015(328) 
US / Veterans 
Veterans Affairs Clinical 
Case Registry 
2013 Last VL ≤200 Linked/ in VA care 65% 
Beer 
2014(327) 
US / White MSM 
US / Black MSM 
Medical Monitoring 
Project 





US / General 
HIV surveillance, Medical 
Monitoring Project and 
chart review 







US / Ryan White Ryan White database 2011 Last VL ≤200 (M=F) 






US / Review of 
literature 










Austria / General Clinical cohort 
2013 Last VL <200 or undetectable HIV infected 
66% 
Belgium / General Clinical cohort 66% 
Denmark / General Clinical cohort 80% 
France / General Clinical cohort 72% 
Germany / General Clinical cohort 58% 
Greece / General Clinical cohort 52% 
Italy / General Clinical cohort 59% 
The Netherlands Clinical cohort 70% 
Spain / General Clinical cohort 50% 
Sweden / General Clinical cohort 77% 
UK / General Clinical cohort (UK CHIC) 54% 




Paper Country/population Data source Year Definition Suppression1 Denominator % 
Hall 
2013(217) 
US / General 
Medical Monitoring 
Project 
2009 Most recent VL ≤200 HIV infected 25% 
Helleberg 
2013(329) 
Denmark / General Danish HIV Cohort Study 2010 Most recent VL ≤500 Diagnosed 70% 
Horberg 
2015(232) 










UK / General HIV surveillance data 2015 Last VL in year ≤200 HIV infected 78% 
Kohler 
2015(255) 
Switzerland / General 
SHCS 
Survey of SHCS clinicians 
2012 
Closest VL to June 2012 <200 (SHCS) 







Canada / General 




VL undetectable for >12 months HIV infected 46% 
Laisaar 
2016(229) 







Canada / General 
BC Centre for Excellence 
in HIV/AIDS 
2011 >3 months undetectable in year On ART 85% 
Mangal 
2014(231) 
US / General 
Atlanta Veterans Affairs 
Clinic database 
2012 Last VL in year ≤200 Infected 52% 
Marks 
2011(439) 
US / General Literature review - Last VL in year ≤200 Infected 29% 
Rosenberg 
2014(261)  
US / MSM  CDC surveillance 2009 (327) 
Black HIV Infected 








Paper Country/population Data source Year Definition Suppression1 Denominator % 
Rowan 
2014(239) 





Most recent VL in last 12 months <200 







US / MSM CDC surveillance 2010 Last VL in year <200 Diagnosed 42% 
Supervie 
2010(216) 
France / General 
French Hospital 
Database 




Belgium / General 
Belgian HIV Cohort 
Study 







The Netherlands / 
General 
- 2014 - HIV Infected 58% 
Wester 
2016(333) 
US / General 
Tennessee HIV 
surveillance 
2013 Last VL in year <200 Diagnosed 56% 
Whiteside 
2014(228) 
US / Black ethnicity CDC surveillance 2010 Last VL in year <200 Diagnosed 35% 
Wiewel 
2015(237) 
US / General 
New York City HIV 
surveillance 
2011 
VL <200 within 6 months 












Patient report undetectable HIV Infected 3% 
VL=viral load; SHCS=Swiss HIV Cohort Study; CDC=Centers for Disease Control; MSM=Men who have sex with men; BC=British Columbia 






2.6.3 Disparities in virological response to ART 
2.6.3.1  Age 
There is strong evidence of improved virological response to ART in patients of older age (379, 
440). Viral load decline following ART initiation is greater on average amongst older individuals 
(441-443). In a large Europe-wide study of initial virological responses conducted by Sabin et 
al., amongst nearly 50,000 people initiating ART, a 24%, 24% and 18% increased risk of 
achieving viral suppression in was found in those aged 50-54, 55-59 and >60 years when 
compared to those aged 30-39 years (306). Several other European studies (402, 444), as 
well as Canadian (424, 425, 445-447) and American studies (380, 448-451) have similarly 
shown better initial virological response to ART with older age, with a large Canadian and US 
cohort collaboration including over 9000 PLWH showing very similar results to the European 
findings. Those aged 50-59 were 24% more likely to achieve virological suppression than 
those aged 18-29, whilst those aged over 60 only had a 12% increased likelihood of 
suppression (382). This smaller increased risk amongst the oldest individuals could be due to 
smaller numbers of individuals in this group or could indicate an impact of co-morbidities and 
potential drug-drug interactions occurring in an aging population (452). 
In a UK setting, a small single centre study of people initiating EFV-based regimens found 
each 10 year increment in age to be associated with a 30% decrease in the risk of viral failure 
(435) and in the UK CHIC study with a 30% decreased risk of extensive triple-class failure 
(453). Other studies from non-UK setting have similarly linked older age to a lower risk of 
virological failure or rebound (425, 432, 437, 445, 447, 454), including an analysis of clinical 
trials participants (455). When considering cross-sectional measures of virological response in 
a continuum of care context, again older age is associated with higher probability of VL 
suppression (314, 333, 335, 429). Using surveillance data from over 19 US jurisdictions, Cohen 
et al., found that 65% of 25-34 years olds compared to 82% of over 55’s retained in care 
were virologically suppressed, giving a prevalence ratio of 0.85 (456). Further, in a consortium 
of 22 HIV clinics in the US, those aged over 50 were approximately 2.5 times as likely to be 
suppressed in a given calendar year, after adjustment for measures of retention in care (457) 
This improved virological response has been attributed to poorer adherence in younger 
compared to older adults (458). Studies that have accounted for adherence have found little 
or no remaining association between older age and virological outcomes (459, 460). Silverberg 
et al found that accounting for adherence levels reduced the excess likelihood of achieving 
viral suppression in older adults from 15% in univariable analyses to only 3% after adjustment. 
This study also investigated sustained virological response by considering viral failure but 
found little difference in risk of failure after adjustment for adherence (308). Whilst a 1% 
increased risk of viral suppression and 2% decrease in the risk of viral rebound was observed 
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per year older in ART initiators in the HOMER cohort, adjusting for adherence differences 
attenuated this association (461). Amongst a cohort study of PWID in Canada, younger adults 
were found to have lower adherence than older adults (462), but in one of two studies in this 
cohort, adjusting for adherence did not alter the association between age and virological 
response. This study used a stricter definition of viral suppression and included fewer adults 
(463). Tumabarello et al. also adjusted for adherence and saw no effect of age on virological 
suppression in univariable or multivariable analyses (464). Analyses that have adjusted for 
measures of engagement in care, have similarly not seen an independent effect of age on 
virological response (436, 465). 
Studies that have not observed an association with age, even without adjustment for 
adherence, have often studied short-term virological response (422, 423, 431, 466, 467), 
considered more adherent groups (468), or compared age within demographic sub-groups 
(469-471). 
2.6.3.2 Sex/mode of acquisition 
Evidence of an association between sex and virological response to ART in the literature is not 
conclusive (472, 473), with the majority of studies reporting no differences between men and 
women in initial response (378, 423, 431, 444, 451, 474-476), viral load rebound (433, 455, 
459, 461, 477-480) or continuum of care measures (235, 314, 337, 457, 481). Whilst most 
have relatively small sample sizes, the largest study to find no difference in initial viral 
response was conducted amongst over 12,000 individuals in the NA-ACCORD. This study 
accounted for informative censoring due to loss to follow-up. But also combined Canadian and 
US cohorts (466). Amongst over 7,000 people accessing care in the Bronx, New York, there 
were no differences in the risk of suppression or rebound between men and women (429).  
In the UK, a small single-centre study in London, in which gender was the exposure of interest 
in people starting EFV regimens, saw no difference in time to virological failure after 24 weeks 
of treatment (435). A subsequent analysis of attendees at this centre, which considered all 
people initiating ART, found no association with initial virological response, but did find women 
to be at higher risk of experiencing virological rebound (224) and another larger study of this 
centre combined with a single centre in Germany, amongst ART initiators who maintained 
suppression for a year, found women were more likely to experience virological rebound (468). 
Similar findings were made amongst heterosexual women in a UK CHIC analysis as well as a 
clinical cohort in Washington, DC (440) and another a multi-cohort collaboration in Canada 
(445). In the UK CHIC Study no difference was found in the time taken to achieve suppression 
between men and women, but women appeared to experience virological rebound sooner; a 
difference that was attenuated in adjusted analyses. Further, these univariate differences in 
rates of viral rebound appeared to be explained by the inclusion of pregnant women in the 
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study sample (482, 483). An earlier study of the Canadian cohort collaboration that included 
half the number of individuals, in fact found women to be less likely to achieve an initial 
virological response than men but did not assess rebound (424). Amongst one Canadian 
province included in this study, women were both more likely to achieve suppression but also 
more likely to experience subsequent viral rebound (425), but in another Canadian province, 
women retained in care in 2011, were less likely to be classified as having viral suppression 
in a continuum of care than retained men (225). Weak evidence of faster time to initial 
response in men has been observed in some studies (446, 484). Poorer virological responses 
amongst women have been found in large US continuum of care studies (335, 343). Amongst 
over 200,000 PLWH across 19 US jurisdictions, 69% of women and 75% of men retained in 
care in 2010 were suppressed; giving a prevalence ration of 0.93 (456). These studies 
combined point towards a trend for poorer virological suppression in women, but some 
conflicting findings and lack of information on the large confounding factor of ART use in 
pregnancy in many studies mean this evidence is not strong. In continuum of care estimates 
generated using surveillance data in New York City and Tennessee, men were less likely to 
have viral suppression than women, though effect sizes were small, with only a 5% relative 
difference (332, 333). These were not the only studies to report poorer virological response 
among men, with both US (379, 437) and European studies (427, 485) reporting similar 
findings.  
People who acquired HIV through injecting drug use have poorer virological responses to ART 
(332, 333, 456, 457). In a European study of seroconverters, the rate of decline of viral load 
after ART initiation was significantly lower for PWID than MSM (443). The Danish HV cohort 
study demonstrated that, at 1 year after ART initiation, 55% of those reporting IDU as their 
main risk for HIV acquisition had a viral load below 500 copies/ml, compared to 77% of non-
IDU. This difference remained 5 years after ART initiation, with 65% of PWID and 79% of 
non-IDU having viral suppression (486). Several studies have similarly shown acquisition of 
HIV through IDU to be associated with a 15-43% decreased risk of achieving initial viral 
suppression in the year following ART initiation compared to MSM (379, 382, 431, 466, 487) 
and non-IDU (424, 447). Failure to achieve initial suppression is 1.8-2.6 times more likely 
amongst PWID starting ART than MSM (485, 488), and amongst people retained in care in 
Canada, PWID were more likely not to be virologically suppressed (225). Viral rebound after 
achieving suppression is between 30 and 150% more likely amongst PWID than MSM (429, 
445), with the largest increased risk observed amongst people also reporting MSM exposure 
risk in British Columbia (447). Few studies, however, can distinguish current from ever IDU. 
In British Columbia, a large 70% decreased risk of initial suppression was found for current 
IDU, and in the Swiss HIV cohort Study, a smaller 19% decrease was found of being currently 
undetectable for current use compared to never. Both studies found no difference between 




There are relatively few data on disparities in virological response to ART for different 
ethnicities in the UK, In a UK CHIC analysis, amongst people initiating ART with a routine 
baseline resistance test available, black African ethnicity was associated with a 15% increased 
likelihood of suppression but was not associated with the risk of viral rebound adjusting for 
viral subtype, but no other associations with ethnicity were observed (428). And amongst 
MSM initiating ART in the cohort, no differences were observed in time to virological 
suppression or having an undetectable viral load 12 months after ART initiation in black and 
minority ethnicities, compared to those of white ethnicity (385). 
Black ethnicity is a risk factor for poorer virological response to ART in other high income 
countries. Initial response to ART is between 9 and 40% less likely for those of black ethnicity 
(380, 431, 451, 466); viral rebound 30-100% more likely (436, 437, 440, 445, 455). Measuring 
viral suppression according to the last recorded viral load in a calendar year, 55% of black 
individuals with diagnosed HIV in New York City were suppressed in 2010, compared to 65% 
of white people translating to an 11% decreased odds of suppression (332). Similarly 
measured viral suppression using surveillance data in Tennessee, and across multiple US 
jurisdictions have shown 14% lower odds (333) and 15% lower prevalence (456) than those 
of white ethnicity. Amongst Ryan White beneficiaries in 2011, a 10% lower likelihood of 
suppression was found (335). The MMP in the US, which combines cross-sectional surveillance 
and patient interview data from sampled clinics and individuals, found differences in 
suppression between white men and black men and women were partially but not entirely 
explained by adjusting for poverty, homelessness and incarceration as well as demographic 
and clinical factors (490). Over periods of time longer than one year, stronger associations 
have been observed, showing those disparities in sustained viral suppression are greater 
between ethnic groups (314, 457). However not all studies have observed strong evidence of 
a difference between black and white ethnicity (343, 382, 429). Studies that have not found 
an association between black ethnicity and virological response on ART are generally smaller 
in size (448, 459, 476, 491), were conducted in a research study that only includes women 
(492, 493) and two studies consider rebound in a group of individuals shown to maintain 
suppression (468, 494), so restrict to a group who potentially have better adherence. 
2.6.4 The impact of level of viral suppression on mortality 
2.6.4.1 Initial response to therapy 
Several different measures of viral non-suppression on ART are associated with increased risk 
of mortality in PLWH, and this association appears largely independent of corresponding 
changes in CD4 count. The initial viral load response within 6-12 months of ART initiation has 
been found to be predictive of mortality in cohorts contributing to the ART-CC, but the 
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protective threshold of viral load that is needed to be achieved is relatively high. In an analysis 
that included 9,323 individuals initiating therapy in the early ART era (1998-2001), any viral 
load below 100,000 copies/ml at 6 months after ART initiation more than halved the risk of 
mortality compared to a viral load above 100,000 copies/ml. The relative mortality decrease 
with a viral load between 10,000 to 99,999 copies/ml was 55%, with a similar 59% decrease 
in those with a viral load <500 copies/ml (495). In the only analysis to formally assess cause-
specific mortality, unsuppressed viral load at 12 months after ART initiation was found to be 
strongly associated with AIDS related mortality (HR=3.61) as well as non-AIDS infections 
(HR=3.26). A trend to higher risk of all other causes of mortality except suicide was observed, 
with significant findings for liver-related and substance abuse related deaths (496). 
Interestingly these causes of death are more likely to occur in PWID, who also have poorer 
adherence and rates of suppression, but these analyses were mutually adjusted and still saw 
independent effects. Other studies have suggested that viral non-suppression on ART may 
play a greater role in HIV/AIDS-related mortality than for non-AIDS mortality, with poorer 
suppression noted amongst those dying of AIDS-related causes (497).  
In the Netherlands HIV cohort, ATHENA, which contributes to ART CC, 24 week viral load 
amongst 3,678 individuals initiating ART between 1998 and 2003 was similarly associated with 
mortality. Compared to a viral load below 500 copies/ml, those with a viral load above 100,000 
copies/ml had nearly 4 times the risk of mortality during the study period, whereas non-
significant 80 and 90% increases were observed for viral loads 500-9,999 and 10,000-99,999 
copies/ml (498). Amongst individuals with a suppressed viral load at 24 weeks in the ATHENA 
cohort, loss of virologic control to low (median 50-400 copies/ml over episode) or high (median 
>400 copies/ml over episode) level viraemia was associated with 22% and 157% increased 
risk of mortality over maintained suppression, but this was not significant. Interestingly, 
raising the threshold from 400 to 1,000 copies/ml in a sensitivity analysis, the relative increase 
in risk of mortality due to high level viraemia increased to 253% and was significant (499). 
This would again suggest that it is higher levels of non-suppression on treatment that are 
associated with mortality outcomes.  
In a US study, 24 week viral load among ART initiators was associated with a 74% increased 
risk of mortality per log10 copies/ml increase, independently of the current CD4 count (421). 
One other small study, not contributing to the ART-CC, was conducted in ART initiators 
between 1996 and 1998 attending the Johns Hopkins University clinic. Amongst these 444 
individuals, failure to achieve viral suppression below 500 copies/ml at any point in the 18 
months following ART initiation was shown to be associated with a 3.5-fold increased risk of 
mortality compared to maintained VL below this threshold. This study also considered another 
group, who achieved suppression below this threshold but experienced a loss of virological 
control to over 1,000 copies/ml over the first 18 months on ART, finding a non-significant 
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80% higher mortality risk (500). Similarly, in the Danish HIV cohort, ART initiators prior to 
2002 were grouped according to the proportion of time spent with a suppressed viral load 
between 6 and 18 months after ART was initiated. An increasing probability of mortality was 
observed with increasing proportion of time spent with a viral load above 400 copies/ml during 
this initial period; 93% of individuals with maintained suppression survived 7.5 years after 
ART initiation, compared to 76% of those who never achieved suppression (501).  
2.6.4.2 Viral load status over time on ART 
Different measures of non-suppression over time on ART have been linked to higher mortality 
risk, including time-updated viral load (502) and viraemia copy-years. Even after experiencing 
virological failure, presence of an undetectable viral load below 50 copies/ml at any time on 
ART may as much as half the risk of mortality compared to a detectable viral load (149). This 
association between viral response over time on ART and mortality translates into differences 
in the expected age at death, evidenced in a recent analysis of the UK CHIC Study. In this 
study of over 21,000 individuals, a viral load >400 copies/ml at 1, 2, 3, 4 and 5 years after 
initiating ART was associated with a 5-7 years lower life expectancy than for a suppressed 
viral load, within different CD4 strata (206).  
Greater viraemia copy years, over a median 4.1 years of follow-up, was associated with a 
50% increase in mortality risk in the Italian Master cohort of individuals starting ART between 
1998 and 2012. Using an early (before 8 months) and late (after 8 months) measure of VCY, 
the authors further noted minimal effect of low-level VCY after 8 months, again suggesting 
that low levels of viraemia do not have a meaningful impact on outcomes (503). The 
prognostic value of VCY and other measures of viral suppression on ART, have been compared 
in multiple studies. Whilst different measures were found to be independently predictive of 
mortality, the best marker is still unclear. Mugavero et al., combined VCY, baseline VL, 24 
week VL and most recent VL in a single multivariable model adjusted for baseline 
demographics, and current CD4, using inverse probability weights to allow for time-varying 
confounding. They found only VCY remained associated with mortality of all the VL measures 
considered (421). Conversely, in an earlier and smaller cohort in France, combining VCY, 8 
month VL and latest VL in a single multivariable model saw the association between VCY and 
mortality attenuated, with latest viral load was strongly associated with mortality (504). Laut 
et al., compared 5 measures of viral suppression: current viral load; VCY; number of 
consecutive months with a detectable viral load; percentage of time on ART spent suppressed; 
being stable on ART. Whilst higher rates of mortality were observed for current VL >10,000 
copes/ml (vs 0-50), >1128 copies x year/ml (vs 0), and lower rates for >95% time on ART 





The HIV continuum of care is a useful and widely used framework for monitoring programme 
performance and the potential for ongoing transmission in a given population. However, it’s 
cross-sectional design omits certain information on patient outcomes which makes it limited 
for understanding the success of HIV care programmes. Alternative longitudinal methods for 
describing patient engagement with the same stages of HIV care pathway, that may 
additionally include patient outcomes, are starting to be suggested in the literature, but 
equally have some disadvantages. Sub-optimal care, particularly late diagnosis, poor EIC, and 
late ART initiation may be prevalent in certain settings, with certain demographic groups 
identified as being at higher risk of sub-optimal care. However, fewer data on disparities are 
available in the UK compared to other settings, particularly the US. It has been shown that 
older individuals are more likely to be diagnosed late than younger individuals, who instead 
may have poorer EIC and viral suppression rates. Those of black ethnicity have been shown 
to be more likely to have sub-optimal diagnosis, EIC, ART uptake and viral suppression, but 
with data largely from a US setting, in which socioeconomic status may be an important 
contributing factor. Once diagnosed, PWID are more likely to have sub-optimal involvement 
with HIV care, having poorer EIC, being less likely to start ART and lower rates of viral 
suppression. The measures of sub-optimal care considered have all been found to be 
associated with mortality outcomes, but differences in the definitions used to define such sub-
optimal care can make direct comparisons difficult. Understanding the gaps in care 
experienced by PLWH in the UK and the mortality burden associated with this is important to 
improve outcomes in this population.  
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This thesis presents analyses that have been performed using data from the UK Collaborative 
HIV Cohort (CHIC) Study. This chapter gives a summary of the study, including methods of 
data collection, cleaning and preparation of datasets. Here I also describe some common 
statistical methods that have been used throughout the thesis. 
3.2 The UK CHIC Study 
The UK CHIC Study was initiated in 2001 to collate data that are routinely captured in HIV 
clinical care, with the initial objectives of describing the changing frequency of AIDS-defining 
illnesses, ART uptake and outcomes, and factors associated with virological and immunological 
responses to ART. Eligible participants are HIV-positive individuals aged 16 and above who 
have attended for care at any of the participating centres at least once since 1996. The study 
does not require informed consent and data from all eligible attendees at participating clinics 
are collected. The UK CHIC Study was approved by a multi-centre research ethics committee 
and local ethics committees (506).  
Originally, 6 centres provided data on 13,833 individuals: Chelsea and Westminster Hospital; 
Kings College Hospital; Royal Free Hospital; Brighton and Sussex University Hospital; Mortimer 
Market Centre; and St Marys Hospital. Since then, additional HIV centres have joined the 
collaboration: Barts and the Royal London (2004); Edinburgh (2005); North Middlesex Hospital 
(2005); Homerton University Hospital (2005); Bristol (2006); Leicester (2008); Middlesbrough 
(2009); Woolwich (2010); St George’s Hospital (2010); York (2011); Coventry (2012); 
Chertsey, Ashford and St Peter’s (2012); Wolverhampton (2012); North Manchester (2014) 
and Milton Keynes (2014). The most recent dataset holds data on 59,427 HIV-positive 
individuals from 21 HIV centres throughout England and Scotland (Figure 3.2.1). This makes 
the study the largest cohort of PLWH accessing care in the country, excepting national HIV 
surveillance datasets, which collate minimal clinical data. The objectives of the study have 
also evolved over time, and now additionally include a focus on comorbidities such as HBV 
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3.2.1 Data collection and checks 
For each annual update, the UK CHIC Study coordinator (Teresa Hill, TH) sends out a request 
to all participating centres outlining the specifications for the data items requested and the 
required variable formats (Appendix I). As the priorities of HIV care, and therefore the UK 
CHIC Study objectives, have changed over time (508, 509), so the data items collected have 
increased. Figure 3.2.2 shows the data items available for use in analyses in the UK CHIC 
Study. In brief, these include: demographics; date and cause of death; ART data; CD4 and 
CD8 counts; viral loads; AIDS diagnoses; Hepatitis serology testing; laboratory markers of 
ART-related and other adverse events; HLA-B*5701 testing; attendance; and serious non-
AIDS events. Although not all of the latter data items are consistently available, all 
participating centres are required to be able to provide at least the core data items that form 
the main analysis dataset, namely demographics, ART, CD4 and CD8, viral loads and clinical 
events. As such, certain data tables, namely serious non-AIDS events and clinic attendance, 
are not yet used for analysis as they are inconsistently reported. Patient identifying data 
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(initial, surname, soundex, clinic ID) are collected from centres for the purpose of tracking 
patient records through each annual upload and allowing de-duplication of records from 
individuals who appear more than once in the collated dataset. However, in-line with the 
study’s data protection and ethics policies, data are pseudonymised meaning that these 
identifiers are removed from the dataset and each entry is allocated a unique study number 
(patnum) before the dataset is prepared and distributed to approved personnel for analysis. 
The data request occurs in November of each year, with a submission deadline in December 
of that year. However, in recent years there have been delays of up to 9 months in data 
submission for some centres. Participating centres send all electronically available data at 
point of submission. For some centres there is a delay in making the routinely collected data 
available electronically, and so the information submitted does not cover the whole period of 
time up to the data request. Upon receipt of data from the participating centres, TH runs a 
set of queries to check for inconsistencies or errors in the formatting or quality of the data. 
Those found are returned to the appropriate centres for comment or correction. These checks 
ensure that all collected data items adhere to the specified formats, that dates are consistent 
and that all data items agreed to be submitted are received. At this stage changes are made 
to ART data so that co-formulated ARVs such as Atripla and Truvada are sub-divided into their 
component parts. For example, a record for an individual receiving Atripla becomes three 
separate records indicating receipt of the constituent components TDF, FTC and EFV. This is 
done as not all centres are able to provide information on whether drugs are taken as a co-
formulation or separately. Where ART data are available only through prescription records, 
ARV stop dates are imputed from the date of issue. Records without at least basic 
demographic data (sex, ethnicity, mode of HIV acquisition) are excluded at this stage but their 
clinic ID, initial, soundex and allocated patnum is kept on record at the Medical Research 
Council Clinical Trials Unit (MRC CTU), where the main dataset is stored.  
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(date of birth, sex, centre, 
ethnicity, mode of HIV 
acquisition, first and last  clinic 
attendance dates) 
Date and type of clinical 
events (AIDS/death)* 
Start and stop dates for 
all antiretroviral therapy* 
Hepatitis A/B/C 
laboratory tests 
Date and result of other 
laboratory tests 
Date and results of CD4 & CD8 
counts and percentages* 
Date and result of  
HLA-B*5701 tests 
Date and results of HIV 
resistance testing 
Dates, results, assay used 
and undetectable indicator of 
HIV viral load* 
Date and outcome of 
pregnancies 
* Core variables 







3.2.2  De-duplication of records 
PLWH will often attend more than one HIV clinic over the course of their HIV care. As such, 
a single individual may have different clinic IDs at different sites and subsequently hold 
multiple records. In addition, within a clinic an individual may be incorrectly allocated more 
than one clinic ID if they are not identified as having previously attended for care, for 
example, someone who has not attended for care for a long period of time might not be 
linked up to their old record when they re-attend, or a simple error in recording an 
individual’s name might lead to a new record and clinic ID being created. Thus, when data 
from all participating centres is collated, some individuals will be represented by more than 
one patient record in the dataset. Therefore, it is important to identify duplicate entries 
and combine these patient records (510). Potential duplicate entries are initially identified 
by looking for matching initial, soundex and date of birth. A computerised algorithm, based 
on demographic and certain clinical factors is then used to decide whether these entries 
are a definite match, a definite non-match or an indeterminate match. Indeterminate 
matches are investigated further. Each indeterminate match is assessed by two 
independent investigators from the UK CHIC Study team. Each investigator must decide, 
based on the available demographic and clinical data (example Table 3.2.1), whether they 
believe each pair of records is, in fact, a match. Where a consensus is reached by the two 
investigators, the pair is linked or un-linked depending on the decision reached. Where 
there is no consensus, a third investigator will check the records in the same way, and if 
no majority decision is reached, the pair will remain as separate records in the dataset. For 
entries that have been highlighted as a match, meaning that separate records exist relating 
to a single individual, a single record is generated that combines the data from each entry.  
A new study identifier is also generated for all patient records in the dataset and is referred 
to as the duppatnum. This identifier remains unchanged from the patnum where a record 
has not been linked to another. Where multiple records have been combined into a single 
record, patnum is changed to a distinguishable number that takes the form of the year that 





Table 3.2.1: Hypothetical example of demographic data of duplicate records for 
manual review and final merged record 
 Record 1 Record 2 Merged Record 
Duppatnum 138 14845 201300024 
Soundex:  J520 J520 J520 
DOB: 01/01/1985 01/01/1985 01/01/1985 
Sex M M M 
Ethnicity: Black African Unknown Black African 
Exposure: Heterosexual Unknown Heterosexual 
HIV-positive: 24/08/2009 - 24/08/2009 
Death: - - - 
 
3.2.3 Generating the final dataset for analysis 
The data collection and initial checks and de-duplication of the data take approximately 
one year to complete. Following the de-duplication process, clinic ID, soundex and initials 
removed leaving only the duppatnum. The data are sent to me in 14 separate text files 
(patnum, demographics, ART, CD4 and CD8, viral loads, AIDS, hepatitis serology, HLA-
B*5701 tests, attendance and four sets of laboratory test results). I perform a series of 
checks on each data file before combining them into a final dataset for use in analyses 
using SAS. This dataset is named according to the year in which the duppatnum is 
generated; this will be the year following the data request. For example, the CHIC2013 
dataset contains data requested at the end of 2012, with duppatnums indexed with the 
year 2013. The checks I perform are described in this sub-section 
3.2.3.1 Generating the main dataset 
All laboratory data, namely CD4 counts, CD8 counts, viral load measurements, HLA-B*5701 
tests and hepatitis serology tests must first be de-duplicated. This process, performed in 
SAS, removes any test of the same date and result that have been repeated for a patient 
record. Similarly for AIDS diagnoses, if there is a repeat of the same diagnosis on the same 
date, any duplicated entries are removed. For CD4 and CD8 test results, further checks are 
performed for implausible and null values. Any CD4 or CD8 percentage tests with values 
over 100 are deleted as 100 is the maximum possible value. CD4 and CD8 tests performed 




HIV viral load data are checked for consistency across the viral load value, lower level of 
detectability of the assay used and undetectable indicator value. For example, a viral load 
value below the known lower limit of detection of the assay used will be set to indicate an 
undetectable result in the undetectable indicator variable if it is missing or incorrect. 
Similarly, a result indicated to be undetectable with a specified assay will be given a value 
of the lower level of detection if this value is otherwise missing.  
For ART history and all corresponding start and stop dates, the first check performed is to 
ensure that all stop dates occur after start dates. Where this is not the case, the start and 
stop dates are assumed to have been entered under the wrong headings and are swapped. 
This correction was decided upon since previous checking of errors of this kind with centres 
found that this was often the reason for such errors. I then remove any ART episodes of a 
given drug that are contained fully within another treatment episode of the same drug. 
Overlapping episodes of a given drug are also looked for and the intermediate start and 
stop dates removed to leave one episode spanning the whole period of the two overlapping 
episodes. If a drug is reportedly started and stopped on the same day, the stop date is 
changed to be a day later so that one day of follow-up is generated. Finally, gaps of less 
than 2 weeks between two successive episodes of a given drug are removed.  
Birth dates, death dates, entry into the study and last seen dates are then checked for 
inconsistencies. Any dates of birth more than 100 years prior to the administrative 
censoring date of the dataset are assumed to be errors in data entry and are set as missing. 
A study entry date is created which takes the latest of 1st January 1996, earliest clinic 
attendance date in the dataset and the date at which someone turns 16. The records of 
those who won’t turn 16 until after the administrative censoring date of the current dataset 
are deleted. Date of death is checked against last seen dates and the date of the last 
recorded CD4 count, viral load, AIDS events and drug start dates for consistency. If any of 
these occur after death, this list is manually checked by me and amended if there is an 
obvious error. Any queries that cannot be simply resolved are sent to TH, who checks 
against the main dataset. By this time the next data submission has taken place so TH is 
able to check any more recent data submitted on the individuals to confirm whether the 
date of death or the conflicting clinical data is correct. 
Once each individual file has been cleaned, de-duplicated and a new SAS dataset created, 
these separate datasets are combined to create the main dataset. As a final step, if the 
sex, ethnicity or mode of HIV acquisition is missing for an individual, then these data points 
are completed using information from the previous year’s dataset, where available. 
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3.2.3.2  Generating the toxicity dataset 
In addition to the main dataset, data on laboratory testing of 29 markers of toxicity are 
collected. Due to differences in testing practices between centres, not all centres submit 
data on all of the laboratory markers requested. As UK CHIC is an observational database, 
tests are performed only as part of routine care and thus the frequency of testing is 
dependent on clinical status of the patient and the testing policies of centres. Furthermore, 
this information is not available from all centres. I perform the following checks. For each 
laboratory marker, the distribution of all test values is studied according to the unit of 
measurement used. Test results with implausible values for a given unit of measurement, 
are removed from the dataset. Where more than one unit of measurement may be used 
for a single laboratory marker, the most common unit of measurement is chosen and any 
test results not in this unit of measurement are converted wherever possible. For example, 
haemoglobin could be measured in g/L or g/dL. As g/dL is the chosen unit of measurement, 




Table 3.2.2: Laboratory marker normal ranges 
Laboratory marker Normal range (511, 512) 
Implausible 
value cut-off 
ALT 5-40 U/L >5000 
AST 5-45 U/L >5000 
Albumin 34-48 g/L >1000 
Albumin (urine) 0-2.8 mg/mmol >10000 
Albumin/Creatinine ratio (ACR) 2.3 mg/mmol - 
Alkaline phosphatase 
40-129 U/L (male) 
35-104 U/L (female) 
>5000 
Amylase 28-100 U/L >5000 
Bilirubin 0-21 µmol/L <0 or >1000 
Calcium 2.1-2.6 mmol/L  >100 
Cholesterol (total) <5.0 mmol/L >100 
Cholesterol (HDL) 0.9-1.7 mmol/L - 
Cholesterol (LDL) <4.0 mmol/L - 
Corrected calcium 2.2-2.7 mmol/L - 
Creatinine, serum 
62-106 µmol/L (male) 
44-80 µmol/L (female)  
>3000 
Creatinine phosphokinase 
40-320 U/L (male) 
25-200 U/L (female) 
>10000 
Glucose 3.0-6.0 mmol/L >100 
Gamma-glutamyl transpeptidase 
(GGT) 
10-71 IU/L (male) 
6-42 IU/L (female) 
>5000 
Haemoglobin 
13-17 g/dL (male) 
11-15 g/dL (female) 
>1000 
Lactate 0.7-2.1 mmol/L - 
Lactate dehydrogenase 135-255 U/L >10000 
Parathyroid hormone 1.6-6.9 pmol/L  
Phosphate 0.7-1.5 mmol/L >100 
Platelet count 150-400 x10
9 cells/L >10000 
Protein (Total) 60-80 g/L - 
Protein (24 hour) <150 mg/day >10000 
Protein/Creatinine ratio (PCR) 0-45 mg/mmol >5000 
Triglycerides <2.3 mmol/L >100 
Urea 1.7-8.3 mmol/L >500 




3.2.3.3 Date and cause of death 
Date and cause of death are data items that are requested from participating UK CHIC 
sites in the annual data request, with cause of death collected as a single free-text field. 
However, the amount and quality of information on mortality has been believed to be 
incomplete in the past. As part of this thesis I have undertaken a project to improve the 
ascertainment of mortality data in the UK CHIC Study in recent years, which is outlined in 
Chapter 4.   
3.2.4 HIV drug resistance data 
The UK HIV Drug Resistance Database (UK HDRD) is a database containing information on 
routinely performed HIV drug resistance tests in the UK since 2001 (513). There are 14 
participating virology laboratories who annually submit full genome sequences of all HIV 
resistance tests performed during the year. By the end of 2013, over 114,000 sequences 
were included in the database. These sequences are processed through the Stanford 
University Genotypic Resistance Interpretation Algorithm to generate lists of resistance 
mutations and drug susceptibility scores. Each year, once the pseudonomysed UK CHIC 
dataset has been generated for use in analyses, this dataset is linked with the UK HDRD. 
Records in the UK CHIC Study and UK HDRD that are believed to belong to the same 
individuals are identified and linked based on clinic ID. In the most recent dataset, 
resistance tests were available for 28,054 (51.8%) of 54,153 individuals in the UK CHIC 
Study. 
3.2.5 National Study of HIV in Pregnancy and Childhood 
In order to obtain information on pregnancies that have occurred in women in the UK CHIC 
Study, UK CHIC records are linked to those in the National Study of HIV in Pregnancy and 
Childhood (NSHPC) (514). The NSHPC receives mandatory quarterly reports from all 
maternity units in the UK detailing any HIV-positive pregnant women seen for care during 
that quarter. Information reported includes the dates of pregnancies, expected dates of 
delivery and the outcome, as well as information on ART, CD4 count and viral load at 
delivery. Details of all children born to HIV-positive mothers are also reported to the 
NSHPC, which includes information in the ascertained HIV status of these children. 
However, only data relating to HIV-positive mothers and their pregnancy are shared with 
the UK CHIC on an annual basis. These data are linked using an algorithm that matches 




3.3 The UK CHIC Study Population  
3.3.1 Overview 
In my thesis I have used the CHIC2013, CHIC2014 and CHIC2015 datasets for analyses, 
depending on the time at which analyses were undertaken. These datasets contain 
information that was requested from participating centres at the end of 2012, 2013 and 
2014, respectively, with administrative censoring dates of 31st December of the 
corresponding year. Between the CHIC2014 and CHIC2015 datasets, two additional centres 
joined the study and contributed data, increasing the number of participating centres from 
19 to 21. The centres attended by the largest number of patients were those primarily 
based in London, with over 12,000 of individuals having ever attended at the Chelsea & 
Westminster hospital for HIV care (Figure 3.2.2Figure 3.3.1). The demographic 
characteristics of the three versions of the dataset that were used are shown in Table 3.3.1 
and were similar. Seventy-two percent were male, just over half were of white ethnicity, 
28% were of black African ethnicity and 5% were of black Caribbean or other black 
ethnicity. The majority of people had acquired HIV through sex between men and 37% 
acquired HIV through heterosexual sex. Only 3% were reported to have acquired HIV 
through IDU.  
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Table 3.3.1: Demographic characteristics of individuals in the CHIC2013, 
CHIC2014 and CHIC2015 datasets 
Characteristic  CHIC2013 CHIC2014 CHIC2015 
N  50785 54153 59247 
Age at entry mean (SD) 36 (9.6) 36 (9.7) 35 (9.8) 
Sex, n (%) 
Male 36645 (72.2) 39180 (72.4) 42814 (72.3) 
Female 14134 (27.8) 14967 (27.6) 16400 (27.7) 
Ethnicity, n (%) 
White 26517 (52.2) 28266 (52.2) 31034 (52.4) 
Black Other 2686 (5.3) 2853 (5.3) 3208 (5.4) 
Black African 14107 (27.8) 15051 (27.8) 16502 (27.9) 
Other 4810 (9.5) 5125 (9.5) 5530 (9.3) 
Unknown 2665 (5.3) 2858 (5.3) 2973 (5.0) 
Mode of HIV 
acquisition, n (%) 
MSM 24799 (48.8) 27023 (49.9) 28778 (48.6) 
IDU 1710 (3.4) 1764 (3.3) 1874 (3.2) 
Heterosexual 18950 (37.3) 20422 (37.7) 22374 (37.8) 
Other 1861 (3.7) 850 (1.6) 1038 (1.8) 
Unknown 5326 (6.8) 4094 (7.6) 5183 (8.8) 
Year of entry, n (%) 
1996-1999 13670 (26.9) 13553 (25.0) 15622 (26.4) 
2000-2003 11225 (22.1) 11179 (20.6) 10682 (18.0) 
2004-2007 12437 (24.5) 12681 (23.4) 12696 (21.4) 
2008-2012 13361 (26.3) 14061 (26.0) 14398 (24.3) 
2013-2015 92 (0.2) 2679 (4.9) 5849 (9.9) 
 
3.3.2 Follow-up and monitoring 
For subsequent sections, the CHIC2015 dataset was used and individuals were classified 
as being in follow-up between study entry and the latest of: last clinic attendance as 
recorded by centres; last CD4 count; last viral load; last ART start date; death; 31st 
December 2014. The maximum length of follow-up was 19 years and the shortest 1 day; 
median (IQR) follow-up of individuals in the study was 5.6 (1.4, 11.4) years. The following 
results are presented from 2000 onwards, as future work in this thesis only utilises data 
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from this point. The number of individuals under follow-up in each calendar year increased 
from 14,883 in 2000 to a maximum of 35,961 in 2013. The number under follow-up 
decreased slightly in 2014, likely reflecting the reporting delay at some centres. The 
proportion under follow-up in each calendar year who had a CD4 count or viral load 
recorded in the corresponding year increased over time, from 71.9% and 73.5% in 2000 
to 89.0% and 95.5% in 2014. As individuals receiving care in the calendar years considered 
should have CD4 counts or viral loads performed at least every 6 months, people classified 
as in follow-up but without a viral load or CD4 count in a given calendar year may have, in 
fact, disengaged from care but were still included as being under follow-up.  
 
Figure 3.3.2: Number of individuals under follow-up, and proportion with 




3.3.3 Changes over time in demographics of PLWH attending a UK CHIC 
participating centre for care 
The demographic characteristics of the population under follow-up in each calendar year 
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2000, 79.7% of individuals under follow-up were male, declining to 72.4% in 2006 and 
then remaining constant, at 73.7% in 2014. Reflecting the close link between gender, mode 
of acquisition and ethnicity in characterising populations of PLWH in the UK, the proportion 
of MSM and individuals of white ethnicity similarly declined between 2000 and 2006, 
whereas the proportion of heterosexuals and those of black African ethnicity increased (72, 
274). Corresponding proportions in 2000 and 2006 were; 60.5% and 51.9% for MSM, 
66.2% and 56.2% white ethnicity, 27.5% and 38.8% heterosexual and 18.4% and 28.3% 
black African ethnicity (Figure 3.3.3). The proportion of IDU declined from 4.9% to 2.9% 
and was 2.1% in 2014. 
An aging population has been observed in the UK CHIC Study as in the rest of the UK and 
other high-income countries (70, 376). The mean (standard deviation, SD) age, calculated 
at the end of each year, of individuals under follow-up increased from 37 years (8.7) in 
2000 to 44 (10.8) in 2014. In 2000, only 1399 (9.4%) of individuals in follow-up were aged 
50 and above, with 298 (2.0%) aged over 60. This compared to 11,364 (31.6%) individuals 




Figure 3.3.3: (A) Ethnicity and (B) Mode of acquisition of individuals under follow-


























































Figure 3.3.4: Age in years of individuals under follow-up in each calendar year in 
the CHIC2015 dataset 
 
 
3.3.4 Changes over time in ART coverage  
Coverage of ART increased amongst individuals in the CHIC2015 dataset after 2000. In 2000, 
59.8% of individuals had started any ART and 55.9% had ever started combination ART 
consisting of at least 3 ARVs. By 2012, 88.8% had started ART; 86.9% had ever received a 











































<30 30-39 40-49 50-59 60+ Mean age
116 
 
Figure 3.3.5: Percentage of individuals that had ever received any ART or 
combination ART by the end of each calendar year in the CHIC2015 dataset 
 
 
3.3.5 CD4 count and viral load over time  
Taking the latest recorded CD4 count or viral load result in a given calendar year, the median 
(interquartile range, IQR) CD4 count in each year increased over time, from 382 (241, 552) 
cells/mm3 in 2000 to 604 (445, 791) cells/mm3 in 2014 (Figure 3.3.6). The proportion of 
individuals with a viral load <50 copies/ml increased from just 42.6% in 2000 to 83.7% in 
2012, reflecting greater ART coverage and more widespread use of viral load assays with a 
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Figure 3.3.6: Median (IQR) CD4 count and proportion with HIV RNA ≤50 and ≤400 
copies/ml in each calendar year in the CHIC2015 dataset 
 
 
3.4 Statistical Methods 
Throughout my thesis, I have frequently used regression model analysis techniques to 
investigate the association between one or more factors (explanatory, or independent, 
variables) and a single outcome (dependent variable) of interest. Although the specific 
analyses undertaken in each chapter are outlined in detail in each chapter, in this section I 
describe the general concept of regression modelling. The choice of the most appropriate 
regression model to use for a particular analysis will depend on the statistical distribution of 
the outcome of interest and the data being considered. 
Univariable regression is used to estimate the association of a single exposure variable with 
an outcome. Multivariable regression allows us to estimate, simultaneously, the effects of 
multiple explanatory variables on an outcome. Thus, each obtained parameter provides an 
estimate of the independent effect of a variable on the outcome, accounting for any potential 
confounding effects of other explanatory variables included in the regression model. A 
confounding variable is one that explains all or part of an observed association between an 
exposure and an outcome, and is associated with both the exposure and outcome of interest. 
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118 
 
explained by the fact that HIV-positive people are more likely to smoke than those without 
HIV (515). Here smoking is a confounding variable for the association between HIV and lung 
cancer. If data on the confounding variables are available, their effects can be accounted for 
in multivariable regression models. If information on confounding variables is not recorded, 
they are referred to as unmeasured confounders and cannot be adjusted for in analyses. 
3.4.1 Linear Regression 
Linear regression models are used when we wish to estimate the effect of one or more 
explanatory variables (x1, x2, x3, . . . ., xn) on a single numerical outcome variable (y). Linear 
regression models take the form 
Mean of y = µ = α+ β1x1 + β2x2 + . . . . + βnxn 
Where α is an intercept value, or the expected value of the outcome y, if the values of all 
explanatory variables are zero. For a quantitative explanatory variable, the corresponding 
regression coefficients (β1,β2,....βn) represent the difference in the outcome variable as the 
explanatory variable increases by one unit, if all other variables remain constant. For 
qualitative (categorical) explanatory variables, the regression coefficient gives the mean 
difference in the outcome variable for each level of the categorical exposure, compared to a 
chosen reference group. Assumptions of linear regression models are that the outcome 
variable is normally distributed, has constant variance and that the relationship between 
explanatory variables and the outcome are linear. There is also included in the model an error 
term (εi), which represents spread of the observed values about the estimated mean. These 
error term values are commonly referred to as residuals, and for the main assumptions of 
linear regression models to be satisfied, these residuals should be independent, follow a 
normal distribution around a mean of zero with a constant variance, usually denoted by σ2 
(516).  
The concept of linear regression can be extended to the more general family of regression 
models known as generalised linear models (GLMs). All GLMs take the same form, as shown 
in the equation below. The right hand side of the model is known as the systematic 
component, or linear component and describes the explanatory variables that are being 
considered in the model of interest. The left hand side of the model is known as the link 
function, and describes how the expected value (or mean) of the response μ relates to the 
linear combination of the covariates. In the linear regression example above, the link function 
was simply the identity function, and so g(y)=µ. Finally there is also a random component 
specifying the probability distribution of the outcome variable and the form of the model’s 
error terms (which is the Normal distribution in the case of linear regression).  
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g(y)= α +β1x1 + β2x2 +⋯+ βnxn 
Examples of generalised linear models include linear regression, logistic regression, log-linear 
models, and Poisson regression. 
3.4.2 Logistic Regression 
Logistic regression is typically performed in scenarios where the outcome of interest takes the 
form of a binary variable, for example, the presence or absence of a disease. For the binomially 
distributed probability (p) of the outcome event, it models the effect of a set of explanatory 
variables on the natural log (ln) of the odds, which are calculated as 
𝑝
1−𝑝
. This is otherwise 
known as the logit transformation or link function. The equation of a logistic regression model 
is as follows: 
Log-odds (y)= ln (
𝑝
1−𝑝
) = logit (p)= α + β1x1 + β2x2 + . . . . .βnxn 
The logistic regression coefficients (β1,β2,....βn) therefore provide an estimate of the (absolute) 
difference in the log-odds of the outcome associated with a one unit increase in the 
explanatory variable. As these coefficients are not easy to interpret, the exponential of the 
regression coefficients (𝑒βi) are usually presented instead as this provides an estimate of the 
relative change in the odds of the outcome associated with a one unit higher value in the 
corresponding explanatory variable, assuming all other variables remain constant. This is 
known as the odds ratio (OR).  
3.4.3 Poisson Regression 
Poisson regression models are traditionally used to model count data, with the outcome of 
the number of events occurring in a given interval following a Poisson distribution. However, 
these models may also be adapted to model the rate of an event (r). Considering the rate to 
be the number of events (n) that occur over a period of time (t), the Poisson regression model 




 )= ln (n)-ln (t) = α + β1x1 + β2x2 + . . . . . . . + βnxn 
and therefore 
ln (n)=ln(t) + α + β1x1 + β2x2 + . . . . . . . + βnxn 
120 
 
where ln(t) is the natural log of each individual’s total follow-up time and is called the offset 
(517). As Poisson regression is performed on the natural log transformation of the rate, the 
regression coefficients are usually back-transformed in order to provide the impact of 
explanatory variables on the rate of the outcome of interest. The exponential of the regression 
coefficient βi (𝑒βi) provides an estimate of the relative change in the rate of the outcome with 
a one unit increase in the explanatory variable, when all other variables remain constant. This 
is otherwise known as the relative rate or incidence rate ratio (IRR). 
3.4.4 Survival Analyses 
Survival analysis is a technique used to analyse censored binary outcomes in longitudinal 
studies. This occurs most commonly in studies with an outcome which is the time to an event 
occurring. It is often not possible to follow all individuals until they experience the event of 
interest. For example, the study might end or an individual may be lost to follow-up before 
the event occurs. Therefore, information about the time taken to experience the event of 
interest will be incomplete for some individuals; all that is known is that that they have not 
experienced the event by the time at which they were last under follow-up in the study. Such 
observations with incomplete information on time to event are referred to as censored, and 
statistical methods are needed which are able to take account of this censoring, as traditional 
methods such as linear regression cannot do so.  
3.4.4.1 Survival probability and Kaplan Meier Estimates 
The survival probability is the cumulative probability of remaining event-free at a given time. 
The Kaplan-Meier estimator is a nonparametric estimator of the survival function. For each 




 where 𝑛𝑡 is the number of people still at risk of experiencing the event at time t (the risk-
set) and 𝑑𝑡 is the number of people that experience the event at time t. Individuals whose 
follow-up up is censored prior to time t are no longer considered be in the risk-set at time t. 





and is equal to 1 for all times where no event has occurred (517). The cumulative survival 
probability at a given time point is then the product of the current and all preceding survival 
probabilities. 








Often the inverse of the survival probability (1 - ?̂?(t)) will be reported, denoting the probability 
of experiencing the event of interest by time t. As t increases, this probability will approach 1, 
as it is assumed that all individuals will experience the event if followed for long enough. 
3.4.4.2 Cox Proportional Hazards models 
Cox proportional hazards (CPH) models estimate the effect of one or more explanatory 
variables on the hazard of the outcome event of interest. This hazard at time t, denoted by 
h(t), is the instantaneous rate of an event occurring at time t, given that it has not yet occurred 
by time t. The log of this hazard rate can be modelled in a regression model to explore its 
association with a set of n explanatory variables as follows.  
Log [H(t)]=log(ho(t)) + β1x1 + β2x2 + . . . βnxn 
Similarly to the GLMs described above, ho(t) represents the baseline hazard, that is he hazard 
of the event at time t for the situation in which all explanatory variables take the value of zero 
(517). CPH models are semi-parametric models as no assumption is made as to a parametric 
form for the baseline hazard (518). The exponential of the regression coefficients (𝑒βi) are 
known as the hazard ratio (HR) for the corresponding explanatory variable 𝑥𝑖. For continuous 
explanatory variables, the hazard ratio is the relative change in hazard associated with a one 
unit increase in the explanatory variable when all other explanatory variables are fixed. For 
categorical variables it is the relative difference in hazard for a given level of the explanatory 
variable, compared to the reference level.  
A main assumption of the CPH model is that of proportional hazards, which is to say that the 
hazard ratio remains constant over time. An assumption of censored data in standard survival 
methods is that of non-informative censoring. This means that censoring occurs independently 
of the outcome, and that censored individuals continue to have a similar risk of experiencing 
the outcome of interest after censoring to those who remain in the risk set.  
3.4.4.3 Competing risks  
Competing risks occur when it is possible for an individual to experience an event (or events) 
that will alter the likelihood of them experiencing the outcome of interest or even prevent it 
from happening altogether. An example of this is an outcome of interest that is a specific 
cause of death such as an AIDS-related death. Deaths that occur due to causes other than 
AIDS-defining illness are not the outcome of interest here. However, individuals may die from 
such non-AIDS causes, and if they do it will be impossible for them to experience an AIDS-
related death, making death due to other causes a competing risk. This violates the 
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assumption of non-informative censoring described above, and therefore standard survival 
analysis techniques are no longer appropriate.  
The cumulative incidence function can be used as an alternative to the Kaplan-Meier estimate 
in the presence of competing risks. This is the cumulative probability of experiencing the event 
of interest at or before time t and before the occurrence of the competing event(s) (519), and 
is sometimes referred to as the subdistribution incidence function. An alternative method to 
CPH models are Fine-Gray methods. These models are analogous to CPH regression models, 
but model the outcome of the subdistribution hazard, rather than the hazard, giving 
subdistribution hazard ratios (sHR) (520).  
3.4.5 Methods for longitudinal or repeated measures data 
When an outcome is measured on more than one occasion for some or all individuals, as is 
the case for longitudinal studies, observations are no longer independent. Two observations 
made in the same individual will have higher correlation than two observations made in two 
different individuals. This clustering must be accounted for in the methods used for analyses. 
The methods used in this thesis are described below. 
3.4.5.1 Mixed-effects linear models 
These models are an extension of linear regression models, with the outcome of interest being 
a continuous variable (e.g. CD4 count) that is measured on more than one occasion for each 
individual (521). In a mixed effects model, the effect of each explanatory variable for an 
individual is parameterised by fixed component, but can also include a random component. 
The fixed effect component gives the average effect of that explanatory variable on the 
outcome across individuals and may be interpreted similarly to estimates obtained from 
standard linear regression. The random component represents the individual variation about 
the fixed effect mean estimate and varies for each individual around a mean of zero. These 
random effects therefore are generally of less interest than fixed effects and are used only to 
capture the additional variability introduced through within-subject correlation.  
In matrix notation, for i= 1, 2, 3, . . .N individuals with j=1, 2, 3, . . .ni observations per individual, 
a linear mixed effects model can be expressed by the following equation:  
Yi= Xiβ + ZiUi + εi 
where Yi is a (ni x 1) vector of observed outcomes in individual i. The fixed element of the 
model is represented by the term Xiβ. The matrix Xi for person i is of size (ni x p). It contains 
the values from the observed data of each of the p explanatory variables (x1, x2, x3, . . . ., xp) for 
individual i at each j=1, 2, 3, . . .ni time-point. The (p x 1) vector, β, represents regression 
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coefficients that are being estimated by the model (i.e. the β1, β2, β3,… βp, estimates analogous 
with those obtained in the linear regression).  
The random component of the model is represented by the two elements ZiU and εi (522). 
Whilst εi is analogous to the error term in standard linear regression, following a normal 
distribution with a mean of zero and variance σ, ZiU is an additional random component that 
represents variability, at the individual level, about the estimated fixed effect of a given 
variable xk. The matrix Zi is an (ni x r) design matrix for the random effects and U the 
corresponding (r x 1) vector of unknown random effects to be estimated by the model, which 
follow a normal distribution with mean zero and standard deviation 𝜎𝑐
2
. εi is a (ni x 1) vector 
of residual errors. 
3.4.5.2 Random intercept and random slope models 
A basic mixed effects model allows a random intercept term. This means that each individual 
is allowed to have their own intercept, which varies about the intercept of the overall mean. 
If we were to consider a random intercept model, we would get fixed and random effect 
regression lines as shown in Figure 3.4.1(A). We can see that each individual has their own 
regression line (dashed) with a different intercept, distributed about the fixed effect (bold). 
However, the effect of time is the same for all individuals, resulting in parallel regression lines. 
If we were to also include time as a random effect, allowing the effect of time, i.e. the slope, 
to vary between individuals, we would get random effect regression lines around the fixed 
effect regression estimate for each individual that were no longer parallel (Figure 3.4.1(B)). 
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4Chapter 4: Ascertainment and classification 




The study of mortality outcomes is central to understanding health outcomes within a 
population. Knowledge of the relative frequency of causes of death and how these may change 
over time can provide insight into which illnesses are of particular importance and thereby 
inform priorities of clinical care. By improving our understanding of the predictive factors of 
death, it is possible to identify the potential for interventions to improve outcomes and prevent 
future mortality. To reliably study mortality outcomes, it is important to have high 
ascertainment of accurate information on both date and cause of death. 
4.1.1 Difficulties in ascertaining mortality outcomes 
Ascertainment of information on date and cause of death is difficult in observational cohort 
studies and clinical databases. Reporting of date and cause of death in the UK CHIC Study is 
reliant on participating HIV outpatient clinics being aware of the death of a patient. Mortality 
outcomes for patients attending a particular HIV clinic for their care may be missed by that 
clinic for a number of reasons. Patients may be lost to follow up at a clinic, either through 
transferring to a different clinic for their HIV care, moving abroad, or ceasing to attend for 
HIV care at all. Also, place of death has changed in the ART era: in the pre- and early ART 
eras, PLWH were likely to die in hospital, probably on a HIV or Infectious Disease ward from 
illnesses related to AIDS. However, in the late ART era it is increasingly likely that people living 
with HIV will die in the community, either at home or in a nursing or palliative care home, for 
example (172, 192). Subsequently, even for patients retained in care, the care-giving clinic 
may not be notified of a patient’s death unless the information is reported by friends or family. 
As a result, vital statistics received from participating centres within the UK CHIC Study are 
thought to be under-ascertained. 
Accurate information on cause of death can similarly be difficult to obtain. A death certificate 
is issued for every death in the UK. This death certificate will state the conditions, illness or 
injuries that were believed to have been responsible for the death. They will be listed as direct, 
contributing or underlying causes of death depending on the role they were thought to play. 
There are some difficulties with using death certificates as a source of cause of death 
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information in observational research. Firstly, the death certificate is not always available to 
the HIV clinicians/clinic, or in hospital notes, particularly if the death occurred outside the 
hospital. If patients have moved abroad before they have died, a death certificate will not be 
available at all. This is thought to be fairly common in the HIV-positive population due to a 
relatively large proportion of the population having migrated to the UK from central and 
Southern Africa (324). In the absence of a death certificate, cause of death will be reported 
based on available information in medical records, physician reports, through information 
passed on by friends or family, or may not be reported at all. This information will be of 
varying detail and quality. Secondly, death certification itself may not be entirely accurate 
where an obvious cause of death is not seen. If multiple contributing illnesses are present at 
the time of death it may not be possible to determine which illness directly led to the death 
occurring. Autopsy to determine a true cause of death is only performed in certain instances, 
for example, where a death is unexpected and a medical cause of death is not known, or in 
cases where suicide is suspected. In the D:A:D study, 8% of all reported deaths had available 
autopsy findings (173). However, in the Swiss HIV Cohort Study, 19% of deaths occurring 
between 2005 and 2009 had an autopsy report; an increase from 7% in 1996. This increase 
likely reflected a decline in the proportion of deaths attributable to AIDS and an increase in 
non-AIDS deaths (172). 
4.1.2 Methods to improve mortality ascertainment 
At a clinic level, ascertainment of mortality can be improved through proactive tracing of 
individuals lost to-follow-up (524, 525). In some large HIV cohorts, linkage to national or 
regional mortality registries is used to obtain information on deaths (170, 171, 526, 527) as 
these registries contain information on all deaths occurring in a country/region. Thus, in such 
studies, ascertainment of deaths does not rely entirely on clinic reporting. In the UK, the Office 
of National Statistics (ONS) collects information on all deaths through mandatory reporting. 
However, linking to registries generally requires the use of patient identifying data such as 
date of birth, post code and/or a unique patient identity number. This can present difficulties 
to research studies, particularly in the field of HIV, as the sensitive nature of the data and the 
need to maintain confidentiality means that these personal identifiers are often not collected. 
In the UK, national HIV surveillance is performed by Public Health England (PHE) and collects 
information on date and cause of death through reporting to the HIV, AIDS and New 
Diagnoses Database (HANDD). Although reporting to this surveillance database is national, 
and is therefore not affected by patient movement between HIV clinics, it still relies largely 
on clinician report. Whilst HIV surveillance data can be requested for linkage to HIV clinical 
cohort studies, as no unique patient identifying information (such as an NHS number) is 
available, records can only be linked using the limited patient identifying information available.  
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In order to improve and standardise reporting of cause of death, the Copenhagen HIV 
Programme (CHIP) developed the Cause of Death (CoDe) protocol which includes a 
standardised case report form (CRF) and review process for reporting and establishing the 
date of death and immediate, contributing and underlying cause of death in HIV-positive 
individuals (528). This protocol has been adopted in several studies of PLWH (172, 173, 529-
533), with other HIV cohorts using their own study specific death reporting forms (534, 535).  
4.1.3 Classifying cause of death 
It is often the goal in research to group or classify deaths as being due to a single disease or 
condition. A widely used coding system and algorithm for classifying all illnesses and causes 
of death is the International Classification of Diseases (ICD). This is a general coding system 
that can be used in any disease area and is frequently utilised in surveillance systems (164). 
However, particular issues in classifying deaths of HIV-positive individuals may make a HIV-
specific system preferable. A difficulty within the field of HIV is classifying cause of death as 
either HIV or non-HIV related. Deaths are increasingly occurring that are not AIDS-defining, 
but that may still be considered to be the result of infection with HIV due to an infectious 
aetiology, an association with antiretroviral toxicity, or occurrence at much higher frequency 
and at younger ages in HIV-positive individuals than in the general population. However, it is 
possible that such non-AIDS deaths may not be attributed to HIV if HIV status is not known 
at the time of death. On the other hand, anecdotally, HIV may be reported as a cause of 
death in someone who has HIV, regardless of whether this was a contributing factor in the 
death. The CoDe protocol is a HIV-specific protocol for classifying cause of death using the 
HICDEP coding system which contains codes for over 30 different causes of death (528),  
Different sources of data and different classification systems may have poor agreement with 
regards to chosen cause of death (172, 533). In 1999, the existing ICD codes (ICD-9) for 
selecting underlying cause of death were updated to the currently used ICD-10 coding system, 
which resulted in more deaths classified with HIV as an underlying cause (536). In the 
EuroSIDA study, which utilises the CoDe CRF, a range of algorithms based on the timing of 
any AIDS defining illness prior to death were developed to classify cause of death as AIDS-
related or not. These classifications were then compared to the cause of death determined by 
a central review of data collected on the CoDe form with the best algorithm finding only 
moderate agreement with the CoDe cause of death (537). With a variety of different sources 
of cause of death information of varying quality and, in some instances, conflicting information 
available, classification of cause of death can be difficult and should involve a stage of 




Previous attempts to improve the ascertainment of death in the UK CHIC Study were made 
by contacting the lead clinician at participating centres and asking for information on new 
deaths not previously reported, as well as more detailed cause of death information for those 
that were. Unfortunately this was not successful, both due to poor response from centres and 
for the reasons discussed above, meaning that clinics had no other information to offer. Due 
to inconsistent and poor quality information on cause of death, this data has not previously 
been utilised in the study. 
This aims of the work presented in this chapter were: 
(i) To improve ascertainment of death in the UK CHIC Study through linkage with 
national HIV surveillance databases maintained by Public Health England (PHE).  
(ii) To develop, for the first time in the UK CHIC Study, a method to classify cause of 
death in this and future versions of the dataset, consolidating information from four 
different sources.  
 
Using the data resulting from this process, I undertook a descriptive analysis of cause-specific 
mortality rates in the UK CHIC population. 
 
4.2 Data sources 
For this chapter, I used data obtained from the four different data sources outlined below. 
4.2.1 UK CHIC data collection 
As discussed in Chapter 3, the date and cause of death are routinely collected from 
participating centres in the UK CHIC Study. Cause of death is collected as a single free text 
field, so the quality of the information provided is variable. The data included in the CHIC2013 
dataset was requested from centres in November 2012. The administrative censoring date of 
this dataset is 31st December 2012, however, data may be available as late as August 2013 
from certain centres, due to late submission of their data.  
4.2.2 CoDe Forms 
The use of CoDe forms was implemented as a means of collecting more detailed and 
standardised information in the UK CHIC Study in 2009. Participating centres were asked to 
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complete and return paper CoDe forms for any deaths from 2004 of which they were aware. 
These forms are generally sent in batches on an ad-hoc basis. In brief, the CoDe form is a 
case report form (CRF) consisting of 8 sections (Appendix II). As well as a section on cause 
of death, other information collected includes date of death and basic demographics, risk 
factors, comorbidities, ART status and HIV markers at time of death, autopsy findings (if 
applicable) and any potential role of medical treatment received. Information on cause of 
death is collected as direct, contributing and underlying causes (Figure 4.2.1).  
 
 





Although these forms have been completed since 2006, they were not used in the dataset 
until the CHIC2013 dataset. When centres completed the forms and returned them to TH at 
the MRC CTU, their own clinic ID was used as a means of identifying individuals. To facilitate 
the CoDe forms being used in the finalised UK CHIC dataset, it was first necessary to identify 
the correct patnum for each recorded death and ensure it was noted on the form. Next, it 
was necessary for the information on the paper forms to be made available in electronic 
format. Date of death was recorded straight from the form into the main UK CHIC dataset 
stored at the MRC CTU. I created a Microsoft Access database on which the information on 
cause of death could be entered (Appendix III). As the database was to be held and 
maintained at UCL, clinic ID had to be removed from the CoDe forms before they could be 
released to me for data entry. This was done manually at the MRC CTU by myself and TH. 
The database was created to have a front form for data entry that resembled the sections 
and fields on the CoDe CRF form. TH and I then transcribed the information from the back-
log of paper forms to the database over a series of months in 2013. From this point forwards, 
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the forms are entered onto the database on an ongoing basis, as and when they are received, 
by myself and TH. 
4.2.3 Office of National Statistics mortality registry 
In 2010, it was possible to perform a one-off linkage between UK CHIC records and ONS 
mortality data. At this time the MRC CTU had access to this ONS dataset, with permission to 
perform linkages with any other datasets held at MRC CTU. TH performed a linkage between 
UK CHIC and ONS mortality registry data to obtain information on date and cause of death 
for all deaths occurring between 2001 and 2008. Patient records in UK CHIC and the mortality 
registry were matched based upon date of birth, soundex, sex and clinic ID. In total, 424 
patient records were matched using this method. Cause of death information from this source 
was available as up to 6 text fields and up to 6 corresponding ICD-9 codes. 
4.2.4 HANDD database  
HANDD is collated by PHE and contains data on all new HIV diagnoses, AIDS events and death 
in adults aged greater than 15 with HIV infection. Data on new HIV diagnoses are submitted 
from laboratories and genito-urinary medicine clinics across England, Wales and Northern 
Ireland. HIV clinicians supply data on new AIDS diagnoses and death as well as new HIV 
diagnoses. As well as surveillance reporting from clinicians and laboratories as outlined above, 
information on date and cause of death in HANDD is also supplemented through provision of 
mortality data collected by the ONS mortality registry for all deaths occurring under the age 
of 65 since 1999 and AIDS-related deaths occurring over the age of 65. Therefore, the 
information on deaths in HANDD is thought to be near-complete under the age of 65. 
Information on all deaths over the age of 65 are not provided due to the large number of 
deaths occurring above this age that would make linkage to this data inaccurate. The linkage 
to ONS data is performed by investigators at PHE based on pseudo-anonymised identifying 
data items (189). Cause of death information from ONS is provided in the form of up to 6 text 
fields and their corresponding ICD10 codes. The combined information on death in HANDD 
from both ONS and clinician report is referred to as HANDD data for the remainder of this 
chapter. 
The Survey of Prevalent HIV Infections Diagnosed (SOPHID), initiated in 1995, contains data 
on all HIV-positive individuals aged 15 or older accessing care in in the UK. Every year a cross-
sectional survey is completed and submitted to PHE by NHS HIV clinical centres across 
England, Wales and Northern Ireland. The survey is completed twice yearly by centres in 
London. Separate data on HIV-positive individuals accessing care in Scotland are obtained 
from Public Health Scotland (PHS). Data items collected are initial and soundex code, clinic 
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identification code, date of birth, Primary Care Trust of residence, postcode, site of care, route 
of probable HIV infection, clinical stage of HIV infection, date of most recent AIDS event, 
ethnicity, current ART use, first ART start date, most recent CD4 cell count, most recent viral 
load, date of most recent viral load, previous care at another site, first HIV positive test or 
date first seen at site, date last seen in survey year or date of death if in survey year. As this 
database includes all individuals accessing care, all participants in the UK CHIC Study should 
also be present in SOPHID.  
Independent linkage of CHIC records to SOPHID and HANDD is performed, with records in 
SOPHID and HANDD also routinely linked internally by investigators at PHE. Whilst I will not 
be using information from SOPHID to supplement information on deaths in UK CHIC, the 
three-way linkage between UK CHIC, SOPHID and HANDD is used in certain instances to 
identify a match between a UK CHIC and HANDD record (Table 4.3.1). 
4.2.5 Consolidating the data 
Information on date, but not cause, of death from the one-off ONS linkage and upon receipt 
of CoDe forms is imported straight into the database held at MRC CTU, so that the final dataset 
for analysis includes date of death data from the annual data upload, ONS linkage and CoDe 
forms. The next sections of this chapter outline how this is further supplemented through 
linkage to HANDD. Prior to the CHIC2013 dataset, information on cause of death was not 
utilised at all in the UK CHIC Study. 
 
4.3 Methods 
4.3.1 Data Linkage 
Whilst data linkage is performed between UK CHIC and both HANDD and SOPHID, it is the 
linkage to HANDD that is of focus in this chapter as this dataset collects information on death. 
In order to match all patient records from the two data sources with 100% accuracy, a 
common and unique patient identifier which is present in both datasets is required. A good 
example of such an identifier would be NHS number. However, no such unique and common 
identifier exists in both UK CHIC and HANDD, so it was necessary to link patient records using 
deterministic linkage, based on the identifiable information available in both datasets. The 
data fields available in both datasets on which the linkage was based were clinic ID, soundex, 
date of birth, sex and centre. Clinic ID is the patient identifier assigned to each patient record 
at the centre they attended. The benefit of using clinic ID to link records is that within each 
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centre an individual’s clinic number will be unique. However, individuals who attend multiple 
centres will have a different clinic ID assigned by each centre, so linking records from different 
centres is not possible based on clinic ID alone. Soundex is a coding system that converts 
surnames into a string of letters and numbers. Soundex codes are not unique to a given 
surname and different surnames can generate the same soundex code if they are similarly 
spelled. However, when also combined with date of birth and sex, the potential uniqueness 
of this combination of information increases substantially.  
The linkage was performed to try and match all patient records in UK CHIC to a record in 
HANDD, but only records for which there was a date of death in either database were of 
interest here. The linkage process to match UK CHIC patient records to SOPHID and HANDD 
patient records was performed by PHE, who also have internal processes in place that link 
patient records in SOPHID and HANDD. This means that after the independent linkages were 
run between UK CHIC and HANDD records and UK CHIC and SOPHID records, if a patient 
record in UK CHIC was linked only to a SOPHID record, the internal SOPHID-HANDD linkage 
table was used to complete gaps wherever possible. I provided the following data items from 
the UK CHIC dataset to PHE in order for the linkage to be performed; duppatnum, date of 
birth, sex, last date seen at a UK CHIC centre and all centre attendance dates. Clinic ID and 
soundex were provided by TH as these data items are not kept in the dataset held by me at 
UCL.  
The agreement rules used in the deterministic linkage are shown in Table 4.3.1, along with 
the associated linkage score. These rules were defined by PHE, according to the linkage 
algorithm used. The agreement rule shows the minimum fields on which a record from HANDD 
and a record from UK CHIC must agree in order to be deemed a link. The strongest linkage 
showed an agreement on soundex, date of birth and sex between the two patient records and 
was allocated a matching score of 1. The weakest linkage was a link between a UK CHIC and 
a HANDD record that was based only upon the internal linkage available between SOPHID 
and HANDD, so was only linked via the SOPHID record. 
The linkage was performed after I had completed the final checks on the CHIC2013 dataset, 
immediately prior to it being made available for use in analyses (Section 3.2.3.1). Once the 
linkage had been performed, a dataset was returned to me which contained the data items 




Table 4.3.1: Linkage scores in linkage of UK CHIC to HANDD/SOPHID 
Agreement Rule Score 
Soundex, date of birth, sex  1 
Clinic number, site 2 
First 3 characters of soundex, date of birth, site  3 




4.3.1.1 Initial linkage results 
A total of 47,366 (93.2%) of 50,839 records in the CHIC2013 dataset were initially linked to 
a HANDD record, comprising 47,389 linked pairs, as 22 UK CHIC records linked to more than 
one HANDD record so appeared more than once. There were 1726 many-to-one links involving 
1,726 UK CHIC records linked to only 850 HANDD records. Of the 47,389 linked pairs, 43,167 
(91.1%) had a HANDD linkage score of 1, 1,467 (3.1%) had a linkage score of 2, 100 (0.2%) 
a linkage score of 3 and 2,655 (5.6%) a score of 4. 
The 3,473 individuals who weren’t linked to a HANDD record were more likely to be female 
(35.6% vs. 27.2%), of unknown ethnicity (18.8% vs. 4.3%) and unknown mode of HIV 
acquisition (30.0% vs. 5.2%) than those linked to a HANDD record ( 
 
Table 4.3.3). These individuals were also more likely to have entered the UK CHIC Study in 
an earlier calendar year than those who were linked to a HANDD patient record. The 
proportion of linked and unlinked patients who had a date of death in the UK CHIC dataset 
prior to linkage with HANDD was similar. 
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Table 4.3.2: Variables from PHE available from linkage 
Variable Description 
SOPHID ID SOPHID patient identifier 
HANDD ID HANDD patient identifier 
Patnum UK CHIC patient identifier 
S_Match Linkage score of SOPHID-CHIC linkage 
H_Match Linkage score of HANDD-CHIC linkage 
DDeath Date of death in HANDD 
CD4Count Earliest recorded CD4 count 
CD4Date Date of earliest recorded CD4 count 
Viralload Earliest recorded viral load measurement 
Viral load date Date of earliest recorded viral load measurement 
Max DLSeen Latest recorded date seen 
H_Soundex Soundex 
H_Date of birth Date of birth 
H_Sex Sex 
H_Ethnicity  Ethnicity 
H_Exposure Exposure 
cod1_text Cause of death (text) 
cod1 Cause of death (ICD10 code) 
cod2_text Cause of death (text) 
cod2 Cause of death (ICD10 code) 
cod3_text Cause of death (text) 
cod3 Cause of death (ICD10 code) 
cod4_text Cause of death (text) 
cod4 Cause of death (ICD10 code) 
cod5_text Cause of death (text) 
cod5 Cause of death (ICD10 code) 
cod6_text Cause of death (text) 









Table 4.3.3: Characteristics of those in UK CHIC who were and were not linked to 
a HANDD record 
Characteristics 




Sex, n (%) 
Male 2233 (64.4) 34464 (72.8) 
Female 1236 (35.6) 12900 (27.2) 
Ethnicity, n (%) 
White 1473 (42.4) 25070 (52.9) 
Black African 868 (25.0) 13239 (28.0) 
Black Other 134 (3.9) 2552 (5.4) 
Other 346 (10.0) 4464 (9.4) 
Unknown 652 (18.8) 2041 (4.3) 
Mode of HIV 
acquisition, n (%) 
Sex between men 1020 (29.4) 23808 (50.3) 
Heterosexual 1059 (30.5) 17894 (37.8) 
IDU 186 (5.4) 1526 (3.2) 
Other 165 (4.8) 1699 (3.6) 
Unknown 1043 (30.0) 2439 (5.2) 
Year of cohort entry 
1996-1999 1450 (41.8) 12274 (25.9) 
2000-2004 1084 (31.2) 13554 (28.6) 
2005-2008 539 (15.5) 11329 (23.9) 
2009-2013 400 (11.5) 10209 (21.6) 
Centre last attended 
Brighton 129 (3.7) 2970 (6.3) 
St Mary’s 342 (9.9) 4706 (9.9) 
Chelsea & Westminster 514 (14.8) 10271 (21.7) 
Mortimer Market Centre 355 (10.2) 6003 (12.7) 
King’s College 140 (4.0) 3643 (7.7) 
Royal Free 149 (4.3) 4145 (8.8) 
Barts/ Royal London 867 (25.0) 3699 (7.8) 
Edinburgh 179 (5.2) 976 (2.1) 
North Middlesex 229 (6.6) 1436 (3.0) 
Homerton 70 (2.0) 1341 (2.8) 
Bristol 39 (1.1) 1317 (2.8) 
Leicester 66 (1.9) 1428 (3.0) 









Woolwich 24 (0.7) 1537 (3.3) 
St George’s 239 (6.9) 1974 (4.2) 
York 7 (0.2) 282 (0.6) 
 
Coventry 15 (0.4) 243 (0.5) 
Chertsey 34 (1.0) 539 (1.1) 
Wolverhampton 38 (1.1) 333 (0.7) 
Died, according to UK CHIC dataset, n (%) 284 (8.2) 3612 (7.6) 
 
 
4.3.2 Multiple matches 
Ideally, when linking records from two datasets, we would want a single record in UK CHIC 
to be linked to only one record in HANDD according to the agreement rules above, and vice 
versa. However, this is not always possible with a deterministic linkage in the absence of a 
common and unique identifier. This was indeed the case here and the linkage performed 
allowed for one-to-many and many-to-one linked pairs to occur. A one-to-many link refers to 
the instance where one patient record in the UK CHIC dataset was linked with more than one 
patient record in HANDD. A many-to-one link meant that multiple patient records in the UK 
CHIC dataset could be linked to a single patient record in HANDD. One-to-many and many-
to-one linked pairs could be the result of incorrect linkage. However, it is possible that there 
are multiple records from the same individual within a dataset if the de-duplication methods 
employed by each study have not correctly internally linked records from the same individual. 
For UK CHIC records that had multiple associated clinic IDs through the deduplication process 
(Section 3.2.2), all of these numbers were used to match to the HANDD dataset. As the 
deterministic linkage is based on clinic ID, each clinic ID could link to a different HANDD 
patient record. Furthermore, whilst it is possible to determine where de-duplication has 
occurred in UK CHIC because of the distinguishing duppatnums used, this was not possible in 
HANDD. Many-to-one linkages could demonstrate a failure to correctly de-duplicate and link 
up multiple centre attendances as a single patient record within UK CHIC, or could be the 
result of incorrect linkage between independent records. As well as one-to-many and many-
to-one linked pairs, it was also possible that a patient record in the UK CHIC dataset could not 
be linked to an individual in HANDD, based on the data available. However, all patients in the 
UK CHIC Study should also be present in HANDD as all will have had an HIV diagnosis 
(although the converse is not necessarily true). 
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Demographic variables as recorded in HANDD were provided in order to establish whether 
one-to-many and many-to-one linked pairs were, in fact, true or false matches. This was only 
investigated for multiple linked pairs where a date of death existed in either dataset. There 
were 4,658 linked pairs that had a date of death available in either the UK CHIC or HANDD 
record. Among linked record pairs with a death recorded in either dataset, 4,230 (90.8%), 54 
(1.1%), 8 (0.2%) and 366 (7.9%) had linkage scores of 1, 2, 3 and 4 respectively.  
Of these 4,658 linked pairs of records, 4,480 (96.2%) were a one-to-one link so were not 
investigated further at this stage. Of the remaining linked pairs, 167 (3.6%) were a many-to-
one link, with 167 UK CHIC records linked to only 93 HANDD records. There were a total of 8 
(1.0%) one-to-many linked pairs, where a date of death was recorded in either record, 
involving 5 UK CHIC records linked to 8 HANDD records. These 8 one-to-many linked pairs do 
not include the additional linked pairs for 2 of the 5 UK CHIC records, for which there was no 
date of death in either the UK CHIC or HANDD record (i.e. in the linkage overall these were 5 
UK CHIC records linked to 10 HANDD records). The two linked pairs with no date of death in 
either UK CHIC or HANDD are not considered here. The process by which I decided on true 
matches is described below.  
For linked pairs where a single patient record in UK CHIC linked to more than one record in 
HANDD (one-to-many link), I needed to determine which HANDD record was the best match 
to the UK CHIC patient record in question to avoid duplication of UK CHIC patient records. For 
all 5 UK CHIC records that were part of a one-to-many link, the duppatnum indicated that the 
original records received from participating centres had been de-duplicated (all 2013xxxxx 
numbers). For manual review, each linked UK CHIC-HANDD pair was assessed on the HANDD 
linkage score, and similarity between date of birth, sex, ethnicity, exposure group, CD4 count 
and viral load measures and last seen dates. However, the date of death was often itself most 
indicative of the best match between a UK CHIC record and all possible linked HANDD records. 
The linked records that were most similar according to these data fields were chosen as the 
best match. I was able to select a best match for 3 of the UK CHIC patient records reviewed, 
meaning 3 linked pairs were retained and 3 were unlinked. The remaining 2 pairs had no date 
of death in the UK CHIC dataset and the demographic data available matched fully for all 
records and had the same linkage score. As these two UK CHIC records were also linked to 
another HANDD record without a date of death, they were unlinked from the HANDD record 
with a death. 
In the 167 instances where multiple UK CHIC records were linked to a single HANDD record 
(many-to-one links), upon review it was much more difficult to select a best match as outlined 
in the paragraph above. The links made between different UK CHIC records to a single HANDD 
record were often of similar quality. Therefore, a decision wasn’t made at this stage as to 
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whether a given link was a true match, unless there was sufficient contradictory evidence to 
suggest that one of the links was a false match. This evidence was conflicting ethnicity, sex, 
CD4 count or viral load data. Death was not used to assess the quality of a match unless the 
HANDD date of death was implausible based on the UK CHIC data e.g. the death occurred 
prior to the time after which there was information available in UK CHIC for a patient record. 
In this instance, the linked pair without conflicting death data would be selected as a match. 
I was able to select 64 linked pairs as a match. I disregarded 71 linked pairs and 12 UK CHIC 
records linked to 8 HANDD records could not be decided on; 24 of these 83 UK CHIC records 
had a date of death in the UK CHIC dataset. For a further 20 linked pairs consisting of 20 UK 
CHIC records linked to 10 HANDD records, all linked pairs were retained as matches for the 
time-being. This was done as the UK CHIC records were so similar it was likely these 20 
records were actually for 10 individuals that had not previously been identified as duplicates. 
Three linked pairs were part of both many-to-one and one-to-many links, and upon manual 
review two of these linked pairs were retained and one unlinked. 
4.3.3 Final linked pairs 
Excluding 89 UK CHIC records that were part of multiple linked pairs for whom I could not be 
certain of a correct link, there were a final 4,569 linked pairs with a date of death in either 
the UK CHIC or HANDD record. Of these, 3,588 had a date of death according to the UK CHIC 
record and 3,988 had a date of death in the HANDD record; 3,007 had a date of death in both 
datasets. A further 284 deaths were identified from UK CHIC records that could not be linked 
to a HANDD record and 24 in UK CHIC records that were unlinked through manual checks. 
4.3.4 Ascertainment of death (vital status) for individuals with conflicting 
information in UK CHIC and HANDD datasets 
4.3.4.1 Developing a matching score 
Once a final list of 4,569 linked pairs where at least one data source had a date of death was 
created, it was necessary to devise a set of rules to decide whether to change or update the 
data held in the UK CHIC dataset to the information held in HANDD, based on the information 
available for each match. As a general rule, my approach was to disregard HANDD data where 
there was conflicting data available in UK CHIC and to take the HANDD date of death where 
there was no conflicting data and I was confident that a correct match had been made. As 
PHE confirm their dates with ONS for all deaths under the age of 65, it is likely that, where a 
correct match is made, information from HANDD is more accurate than data from UK CHIC 
centres. Therefore, conflicting data could indicate an incorrect match. Disregarding HANDD 
data where there was conflicting information available in UK CHIC was fairly straightforward. 
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However, where there was no conflicting information available, I had to decide to include or 
disregard a date of death based on how certain I was of the strength of the match between 
UK CHIC and HANDD. I therefore investigated the HANDD linkage scores.  
Just over 90% of the 4,658 originally linked pairs had the highest linkage score of 1, meaning 
that the UK CHIC and HANDD records linked had the same soundex, date of birth and sex. 
However, of those with a linkage score of 1,794 (17.0%) had at least one demographic 
inconsistency. From the manual checks performed on one-to-many and many-to one matches, 
I had observed that it was possible to have a good linkage score but to find inconsistencies in 
the demographic data, CD4 count, viral load, death dates and last seen dates that would point 
to two records not being a true match. I therefore wanted to incorporate extra data available 
to improve the certainty of a match over and above that provided by the linkage score. I 
devised my own matching score to be used when deciding whether to incorporate the HANDD 
date of death into the UK CHIC Study. This score incorporated the demographic, CD4 count 
and viral load data available in each dataset as well as the HANDD linkage score provided by 
PHE (Figure 4.3.1).  
All linked pairs, regardless of previous checks for multiple matches, were given a score of 
zero. If inconsistencies were found in the demographic data between linked records or the 
linkage sore was greater than 1, a score was added. Therefore, a higher matching score would 
indicate a poorer match strength, as with the PHE linkage score. With regards to CD4 count 
and viral load data, an exact match in these data fields would be useful for ruling in correct 
matches, as the likelihood that two linked patient records with the same CD4 count occurring 
on the same date would belong to different individuals was low. However, a non-match in 
these fields would not be useful for ruling out matches as not all HANDD records had CD4 
count or viral load data available. Also, failure to find a match where these data were available 
could easily arise if the CD4 count in HANDD came from a diagnosis or attendance at a non 
UK CHIC centre, as the UK CHIC record would not be expected to contain this information. 
Therefore, if a CD4 count or viral load match was found, a score was taken away from my 
matching score, but no score was added if a match was not found. A suitably high score was 
taken away from the matching score for exact CD4 count or viral load matches so that 
demographic inconsistencies or a poorer linkage score did not rule out a match where a CD4 
count or viral load match was found. I also considered partial CD4 count and viral load matches 
where a CD4 count or viral load was present in both datasets that was within a 5 day interval 
and a given value range. For these partial matches, a smaller score was subtracted from the 
matching score. A partial match was defined as a CD4 count or viral load within 5 days and a 




Figure 4.3.1: HANDD matching score 
Scenario Score 
All linked pairs 0 
Sex inconsistent +2 
Ethnicity inconsistent  
white vs. black African/ black Caribbean/ Asian 
black African/ black Caribbean vs. Asian 





Mode of Acquisition inconsistent +1 
HANDD linkage score >1 +1 
CD4 count or viral load match 
Exact 






The possible scenarios that could then result in each score are shown in Appendix IV. A score 
<1 was chosen as evidence of a suitably strong match as a score higher than this would have 
to indicate that no CD4 count or viral load match was found, that at least one demographic 
inconsistency existed and/or the HANDD linkage score was greater than 1. This cut-off was 
then applied, alongside other criteria, when resolving inconsistencies in the date of death 
information between UK CHIC and HANDD [Section 4.3.4.2]. Of the 4,658 linked records, 
3,807 (81.7%) had a score of 0 or less including 936 (20.1%) who had a score of -6 indicating 
an exact CD4 count or viral load match, a HANDD linkage score of 1 and no differences in the 
sex, ethnicity and exposure of the linked patients in HANDD and UK CHIC. Including only one-
to-one linked pairs and those one-to-many and many-to-one linked pairs decided to be a 
correct link after manual checking, the proportion with a score less than or equal to 0 was 
82.3% (n=3,761) with 933 (20.4%) having a score of -6. The modal score was 0 with 2,224 
(48.7%) of linked pairs having this matching score. 
4.3.4.2 Selecting date of death 
Of the 4,569 linked record pairs, 2,365 (51.8%) had dates of death in both the UK CHIC and 
HANDD records that agreed. Next I resolved 2,204 record pairs with inconsistencies in the 
date of death information in UK CHIC and HANDD for a linked pair of records. To decide on a 
final date of death, matched pairs were considered separately according to whether they had: 
a date of death recorded in the PHE datasets but not in the UK CHIC dataset (n=981; 44.5%); 
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a date of death recorded in both datasets that was not the same (n=642; 29.1%); a date of 
death recorded in the UK CHIC dataset but not in HANDD (n=581; 26.4%).  
Firstly, I considered those linked records with a date of death recorded in HANDD but not in 
the UK CHIC dataset. For each individual, I needed to decide whether to add this new date of 
death to the UK CHIC dataset or to exclude it. The selection rules were as follows and are 
shown in Figure 4.3.2. I first rejected a date of death if it was prior to the date recorded as 
first being seen in the UK CHIC dataset (fstseen). I then considered those whose last recorded 
CD4 count, viral load, AIDS-defining event or drug start date (lastdate) in the UK CHIC dataset 
was later than the date of death for the linked HANDD record. I immediately excluded the 
date of death if the last recorded date of being seen in the UK CHIC Study was more than a 
year after the date of death. Where the lastdate was less than one year following the date of 
death, I reviewed the cases manually. I examined the data available for those with events in 
the year following the date of death by eye and decided to exclude anyone with any CD4 
counts or viral load measures more than 3 days after this death date only. This left me with 
only those matches for which I had no conflicting data with the HANDD date of death in UK 
CHIC. Here I decided whether to add the date of death based on how confident I was in the 
matching. I therefore excluded any deaths where my matching score was greater than 1. The 
result of these steps was to add 792 new deaths to the dataset. The characteristics of those 




Figure 4.3.2: Rules for adding HANDD date of death to a UK CHIC record if no death 
is recorded in the UK CHIC Study  
Death in HANDD record but not in UK CHIC record (n=981) 
Is Date of death prior to date first 
seen in UK CHIC? 
Are there any CD4 counts/viral 
loads/ART start dates/ AIDS events < 
1 years after the date of death? 
Are there any CD4 counts/viral 
loads/ART start dates /AIDS events 






























I next considered those with a death recorded in both datasets, but where the date was not 
the same (Figure 4.3.3). Here I had to decide whether to choose the date of death recorded 
in the PHE databases over the information we had already received from centres in the annual 
upload. My approach was to consider records separately according to whether: 
(i)  only the day differed between the two dates 
(ii)  only the month differed between the two dates 
(iii)  only the year differed between the two dates 
(iv)  only the year was the same between the two dates 
(v)  only the month was the same between the two dates 
(vi)  the dates were completely different 
 
In all of the above scenarios, I immediately excluded the PHE date of death for those who 
were first seen in the UK CHIC after this date and those whose lastdate was >6 months after 
this date. In scenario (i), as only very small differences existed between the two dates, I 
decided only to opt for the HANDD date of death where my matching score was <1 and the 
HANDD date wasn’t the 1st, 15th, 30th or 31st of the month, which are dates that are often 
recorded when the true date is unknown. Otherwise, the date of death in the CHIC database 
was retained. 
For scenarios (ii) and (iv) similar rules were applied. These differences in the date of death 
were likely to be small and could easily have arisen due to human error in data entry. The 
PHE date was only opted for where my matching score was <1 and there were no events in 
UK CHIC after the HANDD date of death. 
In the remaining scenarios (iii), (v), (vi), the differences in date of death were larger so an 
added check was included. If the HANDD date of death was prior to 1st January 1996, the 
earliest possible date of entry into the UK CHIC Study, then the HANDD date was rejected for 




Figure 4.3.3: Rules for choosing HANDD or UK CHIC death if there is a date of death in both datasets that is not the same 
HANDD date chosen unless: 
 
• Matching score >1 (n=9) 
• HANDD day was 1st, 15th, 30th or 31st  
(n=68) 
HANDD date chosen unless: 
 
• Matching score >1 (n=0) 
• Events in UK CHIC after HANDD date 
of death (n=7) 
HANDD date chosen unless: 
• Matching score >1 (n=4) 
• Events in UK CHIC after HANDD date of death 
(n=1) 
• HANDD date of death prior to 1996  (n=7) 
Death in both HANDD and UK CHIC that is not the same (n=642) 
Is HANDD date of death prior to date 
first seen in UK CHIC? 
Any CD4 counts/viral loads/ART start dates /AIDS 
events >6 months after the HANDD date of 
death? 
Only day differed (n=407) Only month differed (n=21) 
 / Only year the same (n=132) 
Only year differed (n=9) / Only month the same 
(n=8) / Dates completely different (n=51) 
HANDD date of death chosen (n=532)   /    UK CHIC date of death kept (n=110)  
Keep UK CHIC date of death (n=8) 
Keep UK CHIC date of death (n=6) 
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Finally, I considered the cases where a death was recorded in the UK CHIC dataset but not in 
the PHE datasets. This group consisted of 581 matched records but also a further 284 UK 
CHIC records that could not be linked to a HANDD record and 24 unlinked many-to-one links. 
For these records I retained the date of death recorded in the UK CHIC dataset. For the 20 
patnums linked to 10 HANDD records, 12 remained the same and 8 changed their date of 
death.  
In summary, 792 deaths were added to the 3,896 deaths originally in the CHIC2013 dataset 
and 532 dates of death were changed to the HANDD date of death. Of the new deaths added, 
54 occurred prior to 1996. Upon review of these patient records, no data was available after 
1996 so these individuals were removed from the dataset, giving a final 4,634 deaths in 50,785 
individuals. 
4.3.5 Methods for selecting principal cause of death in UK CHIC 
4.3.5.1 Compiling data on cause of death 
As previously mentioned, information on cause of death was available from four sources: 
annual data submission by participating centres; the one-off linkage to ONS mortality registry 
data; CoDe forms completed by participating centres; and the linkage of UK CHIC records to 
HANDD and SOPHID. The format in which cause of death was collected in each of these 
sources differed, with between 1 and 6 text fields used to describe cause of death (Table 
4.3.4, Table 4.3.5). A single dataset was created which contained all causes of death available 
from each of the different sources of information for each patient who had died. Of 4634 
deaths in the CHIC2013 dataset, 3,053 had any text information available on cause of death. 
There were a total 4,221 causes of death available for the 3,053 individuals. 2,108 (69.0%) 
had cause of death information from 1 data source only, 746 (24.4%) had information from 
2 data sources, 175 (5.7%) had information from 3 data sources and 24 (0.8%) had 
information from all 4 data sources. Most of the cause of death information (n=2,515) was 
provided was from the linkage to PHE data. Only 947 causes of death were available from the 
UK CHIC electronic upload provided by centres and 309 were available from linkage to ONS. 
440 causes of death were available from CoDe forms but for only 430 individuals; 10 people 
had two CoDe forms completed by different centres. The dataset was arranged as one line 
per source of data, and the below strategy was applied to each cause separately. When a 
principal cause of death had been determined and coded for each cause, these principal 




Table 4.3.4: Different sources of cause of death information in the UK CHIC Study 
Source Updated Time period Format  
UK CHIC data collection 
Annual 
Since 2001 
1996 - present Single text field 




Up to 6 text fields 












1996 - present 
Up to 6 text fields 
Up to 6 ICD10 codes 
 
 
4.3.5.2 Mortality Review Sub-group 
As clinical input would be important in interpreting and understanding the available text 
information on cause of death, a mortality review sub-group of the UK CHIC Study was 
convened including 3 clinical members as well as me and the UK CHIC Principal Investigator 
(CS). The clinical members of this subgroup were Dr Frank Post (FP), Dr Sarah Pett (SLP) and 
Dr Alejandro Arenas-Pinto (AAP). The first meeting of this sub-group was held in December 
2014, after the CHIC2013 dataset had been generated. In this meeting, FP, SLP and AAP were 
acquainted with the UK CHIC dataset and different data sources and our objectives were 
outlined: to determine a principal cause of death where information was available. This 
principal cause of death would be the end-organ disease or condition thought to ultimately be 
responsible for death. The decision to select only a single principal cause was based on 
pragmatic reasoning. It was not felt that there was enough consistently detailed and high-
quality information available for most deaths to allow selection of direct, contributing and 
underlying causes of death. It was, however, decided to retain and code information on other 
mentioned contributing conditions.  
As a first attempt to select a principal cause of death, two of the clinical members of the group 
and I were given a sample of data on 2,087 causes of death. We each selected a principal 
cause of death, based on the information available. Upon review of the group’s independent 
decisions it was found that there was only 22.5% agreement between the 2 clinical members 
and 6.0% agreement between all 3 of us in the choice of principal cause of death. In the 
second meeting of the mortality review group, the available data and decisions made were 
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discussed. It had been observed that certain causes appeared repeatedly, and that a principal 
cause of death could be assigned easily, whereas some cases were more complicated and 
would require detailed clinical review (Table 4.3.5). For example, a cause of death mentioning 
only one AIDS-defining illness would be a straightforward case, whereas a cause mentioning 
multiple non-AIDS conditions would require more detailed clinical input to decide which 
condition was ultimately responsible for death. Therefore it was decided to develop a set of 
guidelines for assigning and coding a principal cause of death that could be applied 
consistently and systematically for more straightforward cases and to then conduct a further 
review of those causes not covered in such a strategy, rather than attempting independent 




Table 4.3.5: Examples of (A) simple cause of death (B) complex cause of death 
(A) Examples of simple cause of death 
Source Cause text 1 Cause text 2 Cause text 3 Cause text 4 Cause text 5 Cause text 6 
CHIC Lung Cancer      
CoDe 
Multiple injuries from 
fall 
     




PHE End stage Liver 
Disease 








(B) Examples of complex cause of death 























Ischaemic hepatitis & 
acute kidney injury 
Severe right heart 
failure & severe 
pulmonary 
hypertension 




PHE Multiorgan failure Faecal peritonitis 
Necrosis and 















4.3.5.3 Adapted HICDEP coding 
The HICDEP coding system is widely used in HIV cohorts and collaborations, including the UK 
CHIC Study and collaborations in which UK CHIC participates. The HICDEP coding for cause 
of death is a coding system of over 30 codes, with further sub-categories, and is the coding 
system used in the CoDe protocol (Table 4.3.6). It was chosen as the most appropriate coding 
system for use in UK CHIC, to remain consistent with other studies and for ease of submitting 
data to cohort collaborations. Whilst this is a flexible coding system with a large number of 
possible codes, it was felt that some adaptions were needed in order to fulfil the needs of our 
study.  
The first and largest adaptation was to expand the coding system for death due to AIDS-
defining illness (ADI). The HICDEP coding system allows for deaths from ADI to be coded as 
AIDS infection, AIDS malignancy or non-specific AIDS (Table 4.3.6). We wanted to expand 
this coding system in order to allow for analyses of specific AIDS-defining conditions in future. 
We also wanted to have a code for HIV virus, as many conditions in the post-HAART era may 
be considered attributable or related to HIV without being classified as AIDS-defining 
according to the 1993 CDC list. The adapted coding is given in Table 4.3.7. By expanding the 
coding system, within the pre-existing HICDEP code categories, we allow for the original 
HICDEP codes to be easily re-applied when submitting data elsewhere. 
A further adaptation was to create a new code for pneumonias. In the UK CHIC adaptation, 
any bronchopneumonia, aspiration pneumonias, lobar or bacterial pneumonias were all coded 
under a single code since the underlying organism causing the pneumonia was, in most cases, 
unknown. However, these were still coded as distinct from deaths caused by infection. Slight 
adaptations were made to codes 14 (liver failure) and 15 (kidney failure). These codes were 
used to describe any severe disease of the liver or kidney respectively, as well as organ failure. 
The HICDEP code for unknown infection with sepsis (code 2.3.1) was used to indicate sepsis 






Table 4.3.6: HICDEP coding (version 1.8) 
HICDEP 
Code 
Cause of Death 
1 
 















02.2.1 Others with sepsis 
 
2.3 Unknown aetiology 
 
02.3.1 Unknown with sepsis 
3 
 




3.1.1 HCV with cirrhosis 
 




3.2.1 HBV with cirrhosis 
 
3.2.2 HBV with liver failure 
4 
 
Malignancy (other than 01.2 and 03, 03.1, 03.2) 
 
4.03 ANUS - Anal cancer 
 
4.04 BLAD - Bladder cancer 
 
4.05 BONE - Bone cancer 
 
4.06 BRAC - Brain cancer 
 
4.07 BRCA - Breast cancer 
 
4.10.1 ALL - Leukaemia: Acute lymphoid 
 
4.10.2 AML - Leukaemia: Acute myeloid 
 
4.10.3 CLL - Leukaemia: Chronic lymphoid 
 
4.10.4 CML - Leukaemia: Chronic myeloid 
 
4.10.9 LEUK - Leukaemia: unspecified 
 
4.18 COLO - Colon cancer 
 
4.11 COTC - Connective tissue cancer 
 
4.12 ESOP - Esophagus cancer 
 
4.13 GALL - Gallbladder cancer 
 
4.14 GYCA - Gynaecologic cancer 
 
4.15 HDL - Hodgkin lymphoma 
 
4.16 HENE - Head and neck (incl. face) cancers 
 
4.17 KIDN - Kidney cancer 
 
4.19 LIPC - Lip cancer 
 





Cause of Death 
 
4.21 LUNG - Lung cancer 
 
4.22 MALM - Malignant melanoma 
 
4.27 MULM - Multiple myeloma 
 
4.29 PANC - Pancreas cancer 
 
4.31 PENC - Penile cancer 
 
4.32 PROS - Prostate cancer 
 
4.33 RECT - Rectum cancer 
 
4.34 STOM - Stomach cancer 
 
4.35 TESE - Testicular seminoma 
 
4.36 UTER - Uterus cancer 
 
4.40.1 MEAC - Metastasis: of adenocarcinoma 
 
4.40.2 MEOC - Metastasis: of other cancer type 
 
4.40.3 MESC - Metastasis: of squamuos cell carcinoma 
 
4.40.9 META - Metastasis: unspecified 
 
4.9 OTH - Other Malignancy Type 
 
4.99 UNKP - Unknown Malignancy Type 
5 
 













8.1.1 Definitive AMI (Dundee 1) 
 
8.1.2 Possible AMI (Dundee 2/9) 
 






Gastro-intestinal haemorrhage (if chosen, specify underlying cause) 
11 
 






Chronic obstructive lung disease 
14 
 















Substrance abuse (active) 
 
19.1 Chronic Alcohol abuse 
 
19.2 Chronic intravenous drug-use 
 
19.3 Acute intoxication 
20 
 





Cause of Death 
21 
 
Endocrine disease (other causes) 
22 
 
Psychiatric disease (other causes) 
 
22.1 Mental and behavioural disorders due to use of psychoactive substances 
(other than alcohol and intravenous opioids)  
22.2 Schizophrenia schizotypal and delusional Disorders 
 
22.3 Mood /Affective disorders (Major depressive disorder Bipolar disorder and 
other mood disorders)  
22.4 Neurotic stress-related and somatoform disorders (including anxiety 
disorders phobias  OCD stress reaction dissociative disorders somatoform 
disorders)  
22.5 Behavioral syndromes associated with physiological disturbances and 
physical factors (including eating disorders sleep disorders sexual 
disorders)  
22.9 Other psychiatric disorders 
23 
 
CNS disease (other causes) 
 
23.1 Movement disorders (Parkinsons disease; dystonias and Parkinson-like 
syndromes)  
23.2 Degenerative disorders of the central nervous system (Alzheimer's 
disease; Creutzfeldt-Jakob disease and other degenerative diseases of 
nervous system)  
23.3 Demyelinating diseases of the central nervous system (Multiple sclerosis 
other demyelinating diseases)  
23.4 Epilepsy (including localised and generalized epilepsy and epileptic 
syndromes)  
23.5 Polyneuropathies (GuillainBarr syndrome and other 
polyneuropathies/disorders of the peripheral nervous system)  
23.6 Diseases of myoneural junction and muscle (Miastenia gravis and other 
myoneural disorders)  
23.9 Other disorders of the nervous system 
24 
 
Heart or vascular (other causes) 
25 
 
Respiratory disease (other causes) 
26 
 
Digestive system disease (other causes) 
27 
 
Skin and motor system disease (other causes) 
28 
 















Sudden infant death 
 















Table 4.3.7: Adapted HICDEP coding for AIDS-defining illness 
Code AIDS-defining event 
1.1.01 Candidiasis 
1.1.02 Coccidioidomycosis, disseminated or extrapulmonary 
1.1.03 Cryptococcosis, extrapulmonary 
1.1.04 Cryptosporidiosis, chronic intestinal for longer than 1 month 
1.1.05 Cytomegalovirus disease (other than liver, spleen or lymph nodes) 
1.1.06 Cytomegalovirus retinitis (with loss of vision) 
1.1.07 Encephalopathy (HIV-related) 
1.1.08 
Herpes simplex: chronic ulcer(s) (for more than 1 month); or bronchitis, 
pneumonitis, or esophagitis 
1.1.09 Histoplasmosis, disseminated or extrapulmonary 
1.1.10 Isosporiasis, chronic intestinal (for more than 1 month) 
1.1.11 
Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary 
1.1.12 Mycobacterium, other species, disseminated or extrapulmonary 
1.1.13 Mycobacterium tuberculosis, any site 
1.1.14 Pneumocystis jirovecii pneumonia (formerly Pneumocystis carinii) 
1.1.15 Pneumonia (recurrent) 
1.1.16 Progressive multifocal leukoencephalopathy 
1.1.17 Salmonella septicemia (recurrent) 
1.1.18 Toxoplasmosis of the brain 
1.2.01 Kaposi’s sarcoma 
1.2.02 Lymphoma, any 
1.2.03 Cervical cancer 
1.3 Wasting syndrome due to HIV 








4.3.5.4 Guidelines for selecting a principal cause of death 
AIDS-defining illness 
If a specific AIDS-defining illness (Table 4.3.7) was mentioned, this would be listed as the 
principal cause of death, irrespective of any other information that might be available. If other 
non-AIDS causes were also listed, these would be retained as contributing causes. If “AIDS”, 
“Acquired Immunodeficiency Syndrome”, “end stage HIV” or similar was listed as a cause of 
death, the principal cause was chosen to be AIDS (unspecified). If multiple AIDS-defining 
illnesses were listed, the principal cause of death chosen would be multiple AIDS-defining 
events, with the specific AIDS-defining illnesses each listed as a contributing cause of death. 
Where AIDS was chosen as the principal cause of death, an underlying cause of HIV was 
entered. 
Non-AIDS illnesses 
If information on only one non-AIDS illness was available, this was listed as the principal cause 
of death. If multiple non-AIDS conditions were listed, a hierarchical approach was followed. 
Multi-organ failure and sepsis are often reported as a cause of death but could be the result 
of any number of underlying causes or sequence of illness or events in the run up to death. 
Any sepsis, sepsis-like syndromes or multi-organ failure would be listed as a principal cause 
of death only if no other specifically named non-AIDS conditions were listed. Pneumonias 
were also treated as such, as these were believed to be a consequence of other underlying 
disease. Similarly general terms to describe death such as “cardiac failure” and “cardio-
respiratory arrest” were treated as secondary to other specifically named non-AIDS causes as 
these are vague terms and do not necessarily reflect cardiovascular disease. If only one such 
specific non-AIDS condition was mentioned, this would be the principal cause of death with 
infection, sepsis, pneumonia or cardiac failure listed as a contributing cause of death. If 
multiple specific non-AIDS causes of death were listed, these cases were further reviewed by 
the clinical team. 
For the choice of HICDEP code for some specific non-AIDS conditions, certain rules were 
applied. For example, hepatocellular carcinoma was always given a principal cause of death, 
with hepatitis virus entered as the underlying cause of death where it was also specified. All 
malignancies were coded according to the principal site (e.g. lung, liver, skin), regardless of 
whether the malignancy was known to be disseminated or metastasised. All end-organ liver 
disease was given a code relating to liver failure, regardless of the aetiology (e.g. hepatitis, 
alcohol), which was then listed as an underlying cause. For drug overdose and violent or 
156 
 
traumatic deaths, if suicidal intent was mentioned, suicide was entered as the principal cause 
of death, with other information entered as contributing causes as appropriate. An accidental 
or violent death or drug overdose with no mention of suicide was coded as such.  
Review of cases not assigned a principal cause of death 
Any cases that I couldn’t code using the above guidelines were sent for independent review 
by the 3 clinical members of the mortality review group, alongside 514 records where both 
AIDS and non-AIDS conditions had been listed, to confirm agreement with the selected 
strategy for these deaths. Each clinician chose a principal cause of death for each case, 
referring to the guidelines where possible. These decisions were made without consultation 
with each other and were returned to me for comparison. If a majority agreement existed 
upon comparison, this principal cause was chosen and other listed illnesses were entered as 
contributing causes. For 372 cases of complete disagreement, a further review of the cause 
of death was conducted in a meeting of the clinical team and me. 
Consolidating different sources of information 
Once a principal cause of death was chosen and coded for each case, principal causes for 
people with information from more than one data source were compared. This constituted 
2,113 causes of death in 945 individuals. Initially, cases were broadly grouped by cause of 
death: AIDS, infection, pneumonia, malignancy, heart/CVD, lung disease, kidney disease, liver 
disease, external causes (including suicide, drug overdose, accidental and other violent 
deaths), other causes and no code assigned. For 534 (56.5%) people, the principal cause of 
death chosen agreed exactly for different sources of information. For a further 131 (13.9%) 
people with different principal causes of death but the same broad classification, it was a 
straightforward task to assign a single cause of death upon manual review of all the data 
available. This left 280 (29.6%) people with assigned principal causes of death (640 cause of 
death records) that belonged to different broad groupings. A quarter of the 680 causes of 
death were classified as AIDS deaths, 14% were pneumonia, 11% unknown, 10% infection, 
8% other non-AIDS causes, 7% non-AIDS malignancy and 6% each for CVD and liver. In the 
majority of cases, information was not conflicting between the different sources of data, but 
the differences in assigned principal cause of death had arisen because one data source 
contained additional information over another. I was therefore able to select a principal cause 
of death for such cases using the guidelines above. For cases where a choice of the principal 
cause of death was not clear (n=55), a clinical member of the team reviewed the information 
available to select a principal cause of death. 
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4.3.6 Statistical Analysis 
Section 0 summarises the results of the processes outlined in Section 4.3. The changes made 
to the death data in the UK CHIC Study after linkage to supplement information on date of 
death are described. Differences in ascertainment of deaths in UK CHIC and HANDD are also 
considered by describing the demographic characteristics of deaths that were only recorded 
in one of the two datasets. Overall ascertainment of deaths following the linkage was assessed 
using capture-recapture methods. Capture-recapture is a method originally developed in the 
biological sciences for estimating the population size of a species within a given region. The 
basic concept is to sample a population within the region and mark those that are sampled 
(the capture stage). Then at a later point in time a second sample is taken and the number 
of this sample that were previously ‘captured’ is recorded. The total population size can be 
extrapolated from the numbers in the first and second sample and the number re-captured. 
These methods have been applied to the study of disease within a population and can be used 
to estimate the total number of cases within a population when cases are ascertained from 
two or more samples. The number of disease cases ascertained in each sample and the 
number common to both can be used to estimate the number of cases missed by both samples 
and therefore total number of cases in the population (538). If N1 is the number of cases in 
sample 1 but not in sample 2, N2 is the number of cases in sample 2 but not in sample 1 and 
N3 is the number of cases in both samples, then the number of cases missed by both samples 
(x) can be defined as 
x= (N1 x N2) ÷ N3 
and the total number of cases (N) is 
N= N1 + N2 + N3 + [(N1 x N2) ÷ N3] 
 
In order to estimate ascertainment of all deaths using combined UK CHIC and HANDD data, 
this approach was performed for all linked records in UK CHIC that matched with a HANDD 
record. This included all records where the date of death was the same, or where the date of 
death was not the same and the matching score was <1 and there was no conflicting data 
between records to indicate a linked pair were not a correct match, in line with the rules used 
to select a date of death previously mentioned (Figure 4.3.2 and Figure 4.3.3). 
The assigned principal causes of death in the UK CHIC Study are described. Differences in the 
proportion assigned a principal cause of death according to demographic characteristics are 
compared using chi-square tests. Deaths were broadly categorised as being AIDS-related, 
non-AIDS related or of unknown cause according to the chosen HICDEP code for the principal 
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cause of death. AIDS deaths were further categorised as being due to AIDS infection, AIDS 
malignancy and multiple or unspecified AIDS illness. Non-AIDS deaths were further 
categorised as: infection; sepsis (including sepsis-like syndromes and multiorgan failure); 
pneumonia; lung disease; malignancy; heart disease (including ischaemic heart disease, other 
cardiovascular disease and stroke); liver disease; kidney disease; external causes; other 
(specified); other (not specified but not AIDS-related); unascertained and unknown. The 
proportion of deaths attributable to each cause and rates of AIDS and non-AIDS deaths are 
described overall and by calendar time. Differences in the cause of death according to 
demographic characteristics are compared using chi-square tests for categorical and Analysis 
of Variance (ANOVA) or Kruskal-Wallis tests for normally distributed and non-normal numeric 
variables, respectively. Rates of cause-specific mortality in two-year intervals between 1996 
and 2012 were estimated. 
 
4.4 Results 
4.4.1 Changes to date of death in the UK CHIC Study as a result of linkage to 
surveillance datasets 
In 50,839 individuals initially included in the CHIC2013 dataset, 3,896 (7.7%) deaths were 
recorded prior to linkage with the HANDD database. The characteristics of these individuals 
with a recorded date of death are shown in Table 4.4.1. The majority of deaths occurred in 
the earliest calendar period between 1996 and 2000. Median (IQR) age at death was 41 (35, 
49) years. Almost 80% of people who had a recorded date of death in the UK CHIC Study had 
a CD4 count available within one year of death. The median (IQR) CD4 count prior to death 
was low at 120 (25, 302) cells/mm3. Fewer people had a viral load available within one year 
of death (68.7%) and the median (IQR) viral load at death was 2.7 (1.7, 4.9) log10copies/ml 
The demographic characteristics of those with a recorded date of death differed slightly to 
those of the wider UK CHIC population. A higher proportion of those that died were male 
(80.3% of those who died vs. 72.2% in the CHIC2013 dataset) and were reported as having 
an IDU route of HIV transmission (12.0% of those who died vs. 3.4% of the CHIC2013 
dataset).  
The characteristics of the final 4,688 deaths after incorporating information from HANDD are 
shown in Table 4.4.1. The changes made to the date of death did not alter the characteristics 
of those who had died in the UK CHIC dataset. The majority of those who had died were white 
men who acquired HIV through sex between men. The majority of those who had died had 
entered UK CHIC follow up in earlier calendar years. Median age at death was similar at 41 
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years prior to linkage and 42 years after. The median CD4 count and viral load at death 
remained unchanged with a small decrease in the proportion with an available CD4 count or 
viral load within one year of death. The proportion of deaths recorded in the latest calendar 
period increased after the linkage to HANDD was performed, reflecting a likely reporting delay 
in the original UK CHIC data that was improved by the deaths added to the dataset from 
HANDD.  
Excluding 54 people believed to have died prior to 1996 similarly did not change the 
characteristics of people who had died. These 54 people were of white (48.1%) or unknown 
(51.9%) ethnicity, and the majority acquired HIV through sex between men (53.7%) or had 
an unknown transmission route (31.5%). 
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Table 4.4.1: Patient characteristics at death before and after linkage to HANDD 
Characteristics 
Deaths in original 
dataset 
Deaths after linkage 
Deaths in final 
dataset 
N  3896 4688 4634 
Age [years], n (%) 
≤25 68 (1.7) 84 (1.8) 83 (1.8) 
26-35 956 (24.5) 1120 (23.9) 1102 (23.8) 
36-45 1528 (39.2) 1802 (38.4) 1779 (38.4) 
46-55 848 (21.8) 1045 (22.3) 1033 (22.3) 
56-55 341 (8.8) 434 (9.3) 434 (9.4) 
65+ 155 (4.0) 203 (4.3) 203 (4.4) 
Sex, n (%) 
Male 3128 (80.3) 3775 (80.5) 3723 (80.3) 
Female 768 (19.7) 913 (19.5) 911 (19.7) 
Ethnicity, n (%) 
White 2372 (60.9) 2846 (60.7) 2820 (60.9) 
Black African 700 (18.0) 819 (17.5) 819 (17.7) 
Black Other 146 (3.8) 174 (3.8) 174 (3.8) 
Other 307 (7.9) 347 (7.4) 347 (7.5) 




Mode of HIV acquisition, n (%) 
Sex between men 1911 (49.1) 2284 (48.7) 2255 (48.7) 
Heterosexual 1064 (27.3) 1251 (26.7) 1248 (26.9) 
IDU 469 (12.0) 533 (11.4) 531 (11.5) 
Other 119 (3.1) 146 (3.1) 143 (3.1) 








Deaths in original 
dataset 
Deaths after linkage 
Deaths in final 
dataset 
 
Year of cohort entry 
1996-1999 2518 (64.6) 3009 (64.2) 2955 (63.8) 
2000-2004 868 (22.3) 1019 (21.7) 1019 (22.0) 
2005-2008 399 (10.2) 501 (10.7) 501 (10.8) 














Centre last attended 
Brighton 271 (7.0) 391 (8.3) 371 (8.0) 
St Mary’s 373 (9.6) 430 (9.2) 427 (9.2) 
Chelsea & Westminster 828 (21.3) 1013 (21.6) 992 (21.4) 
Mortimer Market Centre 425 (10.9) 505 (10.8) 497 (10.7) 
King’s College 339 (8.7) 363 (7.7) 362 (7.8) 
Royal Free 428 (11.0) 484 (10.3) 484 (10.4) 
Barts/ Royal London 290 (7.4) 382 (8.2) 381 (8.2) 
Edinburgh 305 (7.8) 305 (6.5) 306 (6.6) 
North Middlesex 173 (4.4) 192 (4.1) 191 (4.1) 
Homerton 60 (1.5) 74 (1.6) 74 (1.6) 
Bristol 94 (2.4) 104 (2.2) 104 (2.2) 
Leicester 51 (1.3) 67 (1.4) 67 (1.5) 
Middlesbrough 25 (0.6) 30 (0.6) 30 (0.7) 
Woolwich 125 (3.2) 146 (3.1) 146 (3.2) 
St George’s 71 (1.8) 151 (3.2) 151 (3.3) 
York 6 (0.2) 10 (0.2) 10 (0.2) 








Deaths in original 
dataset 
Deaths after linkage 
Deaths in final 
dataset 
Ashford & St Peter’s 29 (0.7) 31 (0.7) 31 (0.7) 
Wolverhampton 3 (0.1) 4 (0.1) 4 (0.1) 
 
Calendar year of death 
<1996 - 54 (1.2) - 
1996-1999 1231 (31.6) 1437 (30.7) 1437 (31.0)  
2000-2004 1085 (27.8) 1180 (25.2) 1180 (25.5) 
2005-2008 934 (24.0) 1021 (21.8) 1021 (22.0) 
2009-2013 646 (16.6) 996 (21.2) 996 (21.5) 
CD4 count recorded in the year prior to death, n (%) 3092 (79.4) 3514 (75.0) 3484 (75.2) 
CD4 count prior to death, 
median (IQR) 
Cells/mm3 120 (25, 302) 121 (25, 313) 121 (25, 313) 
Viral load recorded in the year prior to death, n (%) 2677 (68.7) 2995 (63.9) 2984 (64.4) 
Viral load prior to death, median 
(IQR)  








4.4.2 Differences between UK CHIC and HANDD ascertainment 
Among linked records there were 581 individuals with a date of death recorded in UK CHIC 
but no date of death in the HANDD record. There were 792 linked patient records with a date 
of death in the HANDD record but not in the UK CHIC record. The majority of these individuals 
were white men who had acquired HIV through sex between men, as was seen for all deaths 
occurring in the UK CHIC dataset (Table 4.4.2). However, a higher proportion of people with 
a date of death reported in HANDD but not in UK CHIC had unknown ethnicity or mode of 
acquisition than of those with a date of death in UK CHIC only. Individuals who were known 
to have died in UK CHIC but who could not be linked to a HANDD record were much more 
likely to have acquired HIV through injecting drug use. 
The highest proportion of deaths reported in UK CHIC but not in HANDD occurred between 
2000 and 2004 (32.0% vs. 26.5% 2005-2008 and 22.2% 2009-2013). In contrast, deaths 
reported in HANDD but not in UK CHIC were most likely to have occurred between 2009 and 
2012, and were more likely to have occurred in the most recent calendar period than deaths 
found in the UK CHIC dataset only (43.7% vs 22.2% in linked records with a CHIC death only 
and 3.9% in records that were not linked). This again would be consistent with a reporting 
delay in the death data submitted to the UK CHIC Study from participating centres.  
A higher proportion of deaths reported in HANDD but not in UK CHIC occurred in individuals 
who had most recently attended clinics in Brighton and St George’s Hospital prior to the date 
of death. This would suggest poorer reporting of deaths to the UK CHIC Study from these 
centres, possibly due to higher rates of loss-to-follow-up prior to death as median time 
between last clinic contact and death were longer for these two centres. None of the deaths 
reported in HANDD but not in UK CHIC occurred in people who had recently attended the HIV 
clinic in Edinburgh, reflecting the fact that PHE HIV surveillance covers Wales and England 
only, with Scottish surveillance data collected by PHS. Further evidence of this is that 37.7% 
of individuals in UK CHIC who had died but could not be linked to a HANDD record were most 
recently known to be attending for HIV care in Edinburgh.  
Approximately three-quarters of deaths reported in UK CHIC but not HANDD had a CD4 count 
or viral load recorded within 1 year of the date of death in UK CHIC. The individuals in the 
group with a date of death in HANDD but not UK CHIC were less likely to have a CD4 count 
or viral load recorded in UK CHIC within one year of the date of death, with 47.6% vs. 76.9% 
having a CD4 count and 37.6% vs. 73.5% having a viral load. For those where a CD4 count 
was available, the median CD4 count was higher in those with a date of death in HANDD but 
not in UK CHIC. Correspondingly, the viral loads at death in this group were lower than in 
those with a date of death in UK CHIC but not in HANDD. 
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Table 4.4.2: Characteristics of deaths in either HANDD or UK CHIC 
Characteristics Deaths in HANDD 
but not UK CHIC 
Deaths in UK CHIC 
but not HANDD 
(linked) 
Deaths in UK CHIC but 
not HANDD 
(not linked) 
N  792 581 284 
Age [years], n (%) 
≤25 17 (2.2) 15 (2.6) 3 (1.1) 
26-35 159 (20.1) 124 (21.3) 101 (35.7) 
36-45 276 (34.9) 210 (36.1) 98 (34.6) 
46-55 199 (25.1) 113 (19.5) 56 (19.8) 
56-55 93 (11.7) 76 (13.1) 19 (6.7) 
65+ 48 (6.1) 43 (7.4) 6 (2.1) 
Sex, n (%) 
Male 647 (81.7) 478 (82.3) 206 (72.5) 
Female 145 (18.3) 103 (17.7) 78 (27.5) 
Ethnicity, n (%) 
White 474 (59.9) 340 (58.5) 183 (64.4) 
Black African 119 (15.0) 108 (18.6) 52 (18.3) 
Black Other 28 (3.5) 30 (5.2) 4 (1.4) 
Other 40 (5.1) 58 (10.0) 18 (6.3) 
Unknown 131 (16.5) 45 (7.8) 27 (9.5) 
 
 
Mode of HIV acquisition, n (%) 
Sex between men 373 (47.1) 306 (52.7) 80 (28.2) 
Heterosexual 187 (23.6) 167 (28.7) 83 (29.2) 
IDU 64 (8.1) 52 (9.0) 70 (24.7) 







Characteristics Deaths in HANDD 
but not UK CHIC 
Deaths in UK CHIC 
but not HANDD 
(linked) 
Deaths in UK CHIC but 
not HANDD 
(not linked) 
 Unknown 141 (17.8) 34 (5.9) 35 (12.3) 
 
Year of cohort entry 
1996-1999 491 (62.0) 323 (55.6) 209 (73.6) 
2000-2004 151 (19.1) 180 (31.0) 55 (19.4)  
2005-2008 102 (12.9) 62 (10.7) 17 (6.0) 










Centre last attended 
Brighton 120 (15.2) 16 (2.8) 2 (0.7) 
St Mary’s 57 (7.2) 57 (9.8) 17 (6.0) 
Chelsea & Westminster 185 (23.4) 164 (28.2) 57 (20.1) 
Mortimer Market Centre 80 (10.1) 80 (13.8) 16 (5.6) 
King’s College 24 (3.0) 50 (8.6) 8 (2.8) 
Royal Free 56 (7.1) 61 (10.5) 9 (3.2) 
Barts/ Royal London 92 (11.6) 60 (10.3) 28 (9.9) 
Edinburgh 0 (-) 19 (3.3) 107 (37.7) 
North Middlesex 19 (2.4) 17 (2.9) 20 (7.0) 
Homerton 14 (1.8) 10 (1.7) 2 (0.7) 
Bristol 10 (1.3) 22 (3.8) 1 (0.4) 
Leicester 16 (2.0) 9 (1.6) 4 (1.4) 
Middlesbrough 5 (0.6) 4 (0.7) 4 (1.4) 
Woolwich 21 (2.7) 5 (0.9) 2 (0.7) 







Characteristics Deaths in HANDD 
but not UK CHIC 
Deaths in UK CHIC 
but not HANDD 
(linked) 
Deaths in UK CHIC but 
not HANDD 
(not linked) 
Centre last attended 
York 4 (0.5) 0 (-) 0 (-) 
Coventry 6 (0.8) 0 (-) 0 (-) 
Ashford & St Peters 2 (0.3) 2 (0.3) 1 (0.4) 
Wolverhampton 1 (0.1) 0 (-) 0 (-) 
Calendar year of death 
<1996 54 (6.8) - - 
1996-1999 199 (25.1) 112 (19.3) 144 (50.7) 
2000-2004 100 (12.6) 186 (32.0) 87 (30.6) 
2005-2008 93 (11.7) 154 (26.5) 42 (14.8) 
2009-2013 346 (43.7) 129 (22.2) 11 (3.9) 
Days between last recorded clinic contact1 and death, 
median (IQR) 
217 (78, 844) 73 (28, 201) 47 (22, 138) 
CD4 count recorded in the year prior to death, n (%) 377 (47.6) 447 (76.9) 206 (72.5) 
CD4 count prior to death, 
median (IQR) 
cells/mm3 190 (35, 446) 147 (30, 348) 72 (16, 219) 
Viral load recorded in the year prior to death, n (%) 298 (37.6) 427 (73.5) 148 (52.1) 
Viral load prior to death, 
median (IQR) 
log10copies/ml 2.2 (1.7, 4.7) 2.9 (1.7, 4.9) 3.6 (1.9, 5.1) 







4.4.2.1 Capture-recapture estimate of death ascertainment 
In 4,328 linked record pairs, 3,536 deaths were recorded in the UK CHIC Study, 3,747 deaths 
were recorded in HANDD; and 2,955 (68.3%) deaths were recorded in both the UK CHIC and 
HANDD lists. Thus a 2x2 table can be drawn as in Table 4.4.3. The estimated number of 
deaths missed (x) by both UK CHIC and HANDD can then be calculated to be 156 as shown 
in Table 4.4.3. This gives a total number of deaths (N) amongst this group of 4,484 and an 
estimate of overall ascertainment amongst matched records of 96.5% (95% CI (95.9%, 
97.0%)).  
 
Table 4.4.3: Capture-recapture approach for ascertainment of deaths through 
linkage 
 HANDD death Total 
Yes No 
UK CHIC death 
Yes 2955 581 3536 
No 792 
x = (581x792)/2955 
=156 
- 
Total 3747 - 




Assuming a total 4,484 deaths amongst matched records, we could estimate that HANDD 
alone captures 83.6% of all deaths and that UK CHIC alone captures 78.9%. Applying this 
rate to the 360 un-matched records in UK CHIC with a death (that were not previously 
considered above) would mean an additional 97 deaths were missed amongst all UK CHIC 
Study participants. With 4,688 deaths observed and an estimated total of 253 missed deaths, 
the ascertainment of all deaths in the UK CHIC Study after linkage to HANDD would be 94.9% 
(95% CI (94.2%, 95.5%)). 
4.4.3 Assigned principal cause of death 
Despite the efforts to improve ascertainment on cause of death, using multiple sources of 
data, 34% of all deaths still could not be attributed a cause of death due to the fact that no 
information on cause of death was available from any of the four sources for these individuals. 
Of 4,634 deaths in the CHIC2013 dataset, some information on cause of death was available 
for 3,053 (65.9%) deaths. As seen in Table 4.4.4, information on cause of death was more 
likely to be available for those aged between 40 and 60 (p<0.0001), for women (p=0.037), 
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those of black ethnicity (p<0.0001) and those with a heterosexual route of HIV infection 
(p<0.0001). Those with unknown ethnicity or mode of HIV acquisition also had a lower 
probability of having available information on cause of death; only 48.1% of those with 
unknown ethnicity and 59.3% with unknown transmission route had any information on cause 
of death. There was much more information on cause of death available for deaths occurring 
in later calendar years, with only 43.3% of deaths between 1996-1999 but 83.4% of deaths 
occurring since 2008 having information on cause of death (p<0.0001),  
Where information on cause of death was available, 2,938 (96.2%) of deaths were assigned 
a principal cause of death. Amongst those where information on cause of death was available, 
there was little difference in the proportions assigned a principal cause of death according to 
demographic characteristics (Table 4.4.4).  
 
Table 4.4.4: Ascertainment of principal cause of death, according to patient 
characteristics 















































































































































4.4.4 Cause of death in the UK CHIC Study 
Of 4,634 deaths, 1,032 (22.3%) were classified as being due to AIDS-defining illness (ADI) 
and 1862 (40.2%) as being due to non-AIDS illness. A further 1,740 (37.6%) could not be 
classified as either AIDS or non-AIDS related deaths, of which 1,696 had an unknown cause 
of death; the remaining were unascertained/unclassifiable. The overall rate of AIDS and non-
AIDS deaths were 2.5 per 1,000 person years and 4.4 per 1,000 person years respectively. 
The rate of deaths with an unknown or unascertained cause was 4.1 per 1,000 person years. 
Amongst the 3,053 deaths that had information on cause of death, 33.8% were classified as 
AIDS deaths: 458 (44.4%) of these were AIDS infection, 386 (37.4%) were AIDS malignancy, 
99 (9.6%) were multiple AIDS events and 89 (8.6%) were unknown or unspecified AIDS 
events. Non-AIDS deaths accounted for 61.0% of deaths where information on cause of death 
had been available. Non-AIDS malignancy was the most common non-AIDS cause of death, 
accounting for 7.7% of all deaths and 11.7% of deaths with information on cause. Heart 
disease, including ischaemic heart disease, other cardiovascular disease and stroke, was the 
next most common cause of death accounting for 9.4% of deaths, followed by pneumonias 
(9.3%), deaths due to external causes including suicide, drug overdose and accidental death 
(8.7%) and liver disease (7.0%) (Table 4.4.5).  
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4.4.4.1 Mortality rates by cause in the UK CHIC Study over time 
Between 1996 and 2012 there was a decrease in the rate of AIDS deaths over time in the UK 
CHIC Study, with the most rapid decreases in the early-ART period. The rate of AIDS deaths 
in 1996/1997 was 10.7 per 1,000 person years, and decreased to 2.6 per 1,000 person years 
in 2000/2001. During subsequent years there was a more moderate decline, with a rate of 
1.1 AIDS-related deaths per 1,000 person years in 2010/11 (Figure 4.4.1). Whereas between 
1996-1999, the highest rates of AIDS-related deaths were deaths due to AIDS infections (5.7 
per 1,000 person years vs. 3.8 per 1,000 person years for AIDS malignancy and 1.5 per 1,000 
person years for multiple AIDS illnesses or AIDS unspecified), in 2010/2011 rates of death 
due to all three types of AIDS illness were similar (0.2, 0.4 and 0.2 per 1,000 person years 
for AIDS infection, AIDS malignancy and AIDS other respectively) ( Figure 4.4.2). 
The rate of non-AIDS deaths similarly declined in the early HAART period, from 11.4 per 1,000 
person years in 1996/1997 to 5.4 per 1,000 person years in 2000/2001. Between 2000/2001 
to 2010/11 a slower decline in the rate of all non-AIDS deaths was observed, with a rate of 
3.5 per 1000 person years in 2010/2011 (Figure 4.4.1). Considering specific non-AIDS causes 
of death, I observed a rapid and large decline in the rate of deaths due to pneumonia in the 
early-HAART period, from 6.8 per 1,000 person years in 1996/1997 to 1.3 per 1000 person 
years in 2000/2001. Rates of other non-AIDS causes remained relatively stable between 1996-
2012 (Figure 4.4.3). 
Rates of all non-AIDS deaths remained higher than the rate of AIDS deaths over the entire 
period studied. Deaths with an unknown cause occurred at a much higher rate in the early 
HAART period than either AIDS or non-AIDS deaths, due to the large amount of unavailable 
data on cause of death in earlier years; only 43% of deaths had available information on 
cause between 1996-1999. However, as the amount of available data increased in later years, 
the rate of unknown deaths markedly decreased, and was lower than the rate of AIDS and 






Figure 4.4.1: Rates of AIDS, non-AIDS and unknown causes of death over time in 







Figure 4.4.2: Rates of AIDS deaths over time in the UK CHIC Study stratified by 

















































































Considering deaths for which there was available information on cause, the proportion of 
deaths attributable to ADI decreased over time (Table 4.4.5). Of deaths occurring between 
1996 and 1999, 42.4% were due to AIDS. However, between 2008 and 2012 only 27.1% of 
deaths were classified as AIDS-related. The proportion of deaths attributed to AIDS infections 
halved, from 20.7% in 1996-1999 to 10.5% in 2008-2012. The proportion of deaths due to 
AIDS malignancy also decreased from 16.7% to 9.7%, however other, unknown or multiple 
AIDS events remained fairly stable as a proportion of deaths. Conversely, the proportion of 
deaths that were attributed to non-AIDS causes increased over time. This was largely driven 
by increases in the proportion of deaths due to non-AIDS malignancy, cardiovascular disease, 
external causes and liver disease. Pneumonias markedly decreased as a proportion of deaths 
in the HAART era. Other non-AIDS causes remained fairly stable over time but the proportion 






































Table 4.4.5: Principal cause of death after mortality review in the UK CHIC Study, 1996-2012 
Cause All deaths Deaths with any information on cause 











N 4634 3503 622 593 799 1039 
AIDS infection 458 9.9 15.0 129 (20.7) 109 (18.4) 111 (13.9) 109 (10.5) 
AIDS malignancy 386 8.3 12.6 104 (16.7) 79 (13.3) 102 (12.8) 101 (9.7) 
AIDS other  
(incl. wasting, multiple and unknown) 
188 4.1 6.2 31 (5.0) 24 (4.1) 62 (7.8) 71 (6.8) 
Infection 21 0.5 0.7 4 (0.6) 2 (0.3) 6 (0.8) 9 (0.9) 
Sepsis/sepsis-like syndrome  
(incl. multi-organ failure) 
117 2.5 3.8 23 (3.7) 25 (4.2) 28 (3.5) 41 (4.0) 
Pneumonias 284 6.1 9.3 137 (22.0) 62 (10.5) 42 (5.3) 43 (4.1) 
Lung disease 
(incl. COPD and respiratory failure) 
75 1.6 2.5 8 (1.3) 12 (2.0) 16 (2.0) 39 (3.8) 
Non-AIDS malignancy 357 7.7 11.7 16 (2.6) 44 (7.4) 117 (14.6) 180 (17.3) 
Cardiovascular disease/stroke/ischaemic 
heart disease 
286 6.2 9.4 21 (3.4) 50 (8.4) 91 (11.4) 124 (11.9) 
Severe liver disease/failure 215 4.6 7.0 26 (4.2) 43 (7.3) 68 (8.5) 78 (7.5) 
Severe kidney disease/failure 59 1.3 1.9 10 (1.6) 15 (2.5) 11 (1.4) 23 (2.2) 
 





Cause All deaths Deaths with any information on cause 











CNS disease 61 1.3 2.0 7 (1.1) 14 (2.4) 17 (2.1) 23 (2.2) 
Other (specified) 118 2.6 3.8 17 (2.7) 22 (3.7) 29 (3.6) 50 (4.8) 
Other (unclassified) 4 0.1 0.1 1 (0.2) 1 (0.2) 1 (0.1) 2 (0.2) 
Unascertained 45 1.0 1.5 5 (0.8) 9 (1.5) 13 (1.6) 17 (1.6) 
Unknown 1696/115† 36.6 3.8 52 (8.4) 42 (7.0) 9 (1.1) 12 (1.0) 
   
Total AIDS 1032 22.3 33.8 264 (42.4) 212 (35.8) 275 (34.4) 281 (27.1) 
Total non-AIDS 1862 40.2 61.0 301 (48.4) 330 (55.7) 502 (62.8) 729 (70.2) 
Unascertained/unknown 1741/160† 37.6 4.6 57 (9.2) 51 (8.6) 22 (2.8) 29 (2.8) 
*Including suicide, accidental or violent deaths, drug overdose and poisoning 









4.4.5 Patient characteristics at time of death, according to cause of death 
Age at death was significantly lower for those who died from AIDS-related or unknown causes 
compared to those who died from non-AIDS causes (p<0.001) (Table 4.4.6). Approximately 
three quarters (74.2%) of those who died from AIDS-related causes were male. This was 
lower than observed for deaths with non-AIDS and unknown causes where 81.6% and 82.6% 
were male, respectively. A higher proportion of those who died from AIDS-related illness were 
of black African ethnicity than those who died due to non-AIDS and unknown causes: 28.8% 
vs 16.3% and 12.6% respectively. Those with an unknown cause of death were also more 
likely to have unknown ethnicity. Differences were also observed in the mode of acquisition 
of people who died from AIDS, non-AIDS and unknown causes, with a higher proportion of 
people who died from AIDS-related illness having acquired HIV through heterosexual sex: 
38.6% vs. 26.9% and 20.1% respectively. Those whose cause of death was unknown were 
more likely to have died in the early HAART period, as was shown previously, and were 
therefore also more likely to have entered the UK CHIC cohort between 1996-1999 compared 
to those with a known cause of death (p<0.001). Approximately 78% of individuals with 
unknown cause of death entered the cohort between 1996 and 1999 compared with 51.4% 
and 57.5% of those who died due to AIDS and non-AIDS causes respectively.  
Considering HIV-related characteristics, deaths of unknown cause most closely resembled 
AIDS-related deaths as opposed to non-AIDS deaths. The majority of deaths occurred in 
follow-up i.e. within 6 months of the date last seen in UK CHIC. However, a slightly lower 
proportion of deaths due to non-AIDS causes occurred during follow-up than of deaths related 
to AIDS (77.4% and 83.0% respectively). Amongst 3,699 deaths that occurred in follow-up, 
less than half of those dying from AIDS and unknown causes were thought to be on ART at 
the time of last visit prior to death. Conversely, approximately 60% of deaths attributed to 
non-AIDs causes occurred in people who were on ART at their last visit. Whilst more likely to 
be in follow-up prior to death, those who died from AIDS and unknown causes were less likely 
to have a CD4 count or viral load available in the year prior to death than those who died 
from non-AIDS causes (p<0.001). The median (IQR) CD4 count in the year prior to death was 
very low for those dying from AIDS-related illness (49 (11, 141)) cells/mm3. This was 
significantly lower than the median CD4 count amongst those who died of non-AIDS illnesses 
(230 (79, 430)). Only 32% and 32.9% of those dying from AIDS-related and unknown causes 
had an undetectable viral load in the year prior to death compared to 49.8% of those who 
died of non-AIDS causes. 
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Table 4.4.6: Characteristics at death according to cause of death 









Age, median (IQR) years 40 (35, 47) 44 (37, 51) 41 (34, 49) <0.001 
Sex, n (%) Male 766 (74.2) 1519 (81.6) 1438 (82.6) <0.001 
 Female 266 (25.8) 343 (18.4) 302 (17.4)  
Ethnicity, n (%) 
White 522 (50.6) 1227 (65.9) 1071 (61.6) <0.001 
Black African 297 (28.8) 303 (16.3) 219 (12.6)  
Black Other 39 (3.8) 80 (4.3) 55 (3.2)  
Other 82 (8.0) 127 (6.8) 138 (7.9)  
Unknown 92 (8.9) 125 (6.7) 257 (14.8)  
Mode of HIV acquisition, n (%) 
Sex between men 438 (42.4) 944 (50.7) 873 (50.2) <0.001 
Heterosexual 398 (38.6) 500 (26.9) 350 (20.1)  
IDU 54 (5.2) 239 (12.8) 238 (13.7)  
Other 26 (2.5) 60 (3.2) 57 (3.3)  
Unknown 116 (11.2) 119 (6.4) 222 (12.8)  
 
 
Year of cohort entry, n (%) 
1996-1999 530 (51.4) 1071 (57.5) 1354 (77.8) <0.001 
2000-2004 209 (20.3) 393 (21.1) 241 (13.9)  
2005-2008 196 (19.0) 284 (15.3) 102 (5.9)  


























Centre last attended, n (%) 
Brighton 76 (7.4) 149 (8.0) 146 (8.4) - 
St Mary’s 55 (5.3) 184 (9.9) 188 (10.8)  
Chel & West 185 (17.9) 337 (18.1) 470 (27.0)  
Mortimer Market Centre 82 (8.0) 226 (12.1) 189 (10.9)  
King’s College 97 (9.4) 195 (10.5) 70 (4.0)  
Royal Free 186 (18.0) 213 (11.4) 85 (4.9)  
Barts/ Royal London 75 (7.3) 154 (8.3) 152 (8.7)  
Edinburgh 23 (2.2) 71 (3.8) 212 (12.2)  
North Middlesex 70 (6.8) 79 (4.2) 42 (2.4)  
Homerton 17 (1.7) 39 (2.1) 18 (1.0)  
Bristol 33 (3.2) 47 (2.5) 24 (1.4)  
Leicester 22 (2.1) 32 (1.7) 13 (0.8)  
Middlesbrough 10 (1.0) 17 (0.9) 3 (0.2)  
Woolwich 43 (4.2) 35 (1.9) 68 (3.9)  
St George’s 39 (3.8) 60 (3.2) 52 (3.0)  
York 4 (0.4) 5 (0.3) 1 (0.1)  
Coventry 5 (0.5) 1 (0.1) 0 (0.0)  
Ashford & St Peters 8 (0.8) 17 (0.9) 6 (0.3)  

















Calendar year of death, n (%) 
1996-1999 264 (25.6) 301 (16.2) 872 (50.1) <0.001 
2000-2004 212 (20.5) 330 (17.7) 414 (23.8)  
2005-2008 275 (26.7) 502 (27.0) 218 (12.5)  
2009-2013 281 (27.2) 729 (39.2) 236 (13.6)  
In follow up at time of death1, n (%) 857 (83.0) 1441 (77.4) 1401 (80.5) <0.001 
On ART2, n (%)  415 (48.4) 851 (59.1) 544 (38.8) <0.001 
CD4 count recorded in the year prior to death, n (%) 735 (85.8) 1300 (90.2) 1148 (81.9) <0.001 
CD4 count prior to death2, median (IQR) cells/mm3 49 (11, 141) 230 (79, 430) 88 (17, 264) <0.001 
Viral load recorded in the year prior to death, n (%) 640 (74.7) 1225 (85.0) 872 (62.2) <0.001 
Undetectable viral load (≤50) prior to death2, n (%) 205 (32.0) 610 (49.8) 287 (32.9) <0.001 
1 Defined where death occurred within 6 months of last follow-up date in UK CHIC i.e. last recorded CD4 count, viral load or ART start date 








4.5.1 Summary and Interpretation 
In this chapter I have demonstrated and applied a method for improving mortality 
ascertainment within an observational cohort study through linkage to HIV surveillance 
datasets, and through that, a national mortality registry. Further, I have described work 
undertaken to consolidate information on cause of death from a variety of different data 
sources in order to assign a principal cause to deaths occurring in the UK CHIC Study. This 
work has resulted in improved ascertainment of deaths in the UK CHIC Study, with 792 deaths 
added, and provided useable data on cause of death for the first time. Through this data we 
are able to observe a decline in rate of AIDS related mortality and an increasing proportion of 
deaths due to non-AIDS causes. However, a relatively large number of deaths have an 
unknown cause of death, particularly in earlier years. 
4.5.1.1 Ascertaining deaths through the linkage process 
As a result of linking to HANDD, I was able to add information on a further 792 deaths to the 
UK CHIC Study, including deaths in 54 patients that occurred prior to 1996, who were 
subsequently excluded from the dataset. This is a reasonably large number, given the 3,896 
deaths reported in the UK CHIC Study prior to the linkage. The proportion of deaths occurring 
in years since 2009 increased from 16.6% prior to linkage to 21.5% after the linkage process. 
In fact, of the 792 new deaths added to the UK CHIC Study dataset, 43.7% had occurred 
since 2009, with only 12.6% and 11.7% having occurred between 2000-2004 and 2005-2008 
respectively. This would suggest that there is a long delay in reporting recent deaths to the 
UK CHIC Study, so that deaths occurring in more recent years were more likely to be missed 
prior to linkage. This reporting delay would cause a bias for any time-trend analyses 
undertaken, underestimating mortality rates in more recent years. Of the deaths added, a 
higher proportion were amongst those with unknown ethnicity and route of acquisition than 
was seen in all deaths or for deaths only recorded in UK CHIC. I also observed that patients 
for whom a HANDD date of death was added were less likely to have a CD4 count or viral 
load available in UK CHIC in the year prior to death than for all deaths or deaths only 
ascertained in the UK CHIC Study. These findings suggest that prior to the linkage, the 
different processes of recording deaths in the UK CHIC Study, relying predominantly on 
clinician reporting, meant that deaths were more likely to be missing for people who have 
fewer interactions with participating centres and who are lost to follow-up or transfer care 
prior to the time of death. This would have important implications for any future analyses of 
mortality outcomes using UK CHIC data, resulting in an ascertainment (or detection) bias and 
under-estimating mortality rates for those individuals who have less frequent visits and are 
lost to study follow-up (539); likely those with poorer engagement in HIV care (540). Further, 
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those who are lost to follow-up may in fact have higher rates of mortality than those who 
remain in care (364, 366, 369). By performing this linkage and incorporating information on 
deaths from both national HIV surveillance and mandatory reporting of deaths, ascertainment 
of events is no longer reliant on clinician report only, and any ascertainment bias that may 
have been present previously has been minimised. This linkage has therefore proved to be a 
worthwhile process.  
My estimate of death ascertainment after combining the information in both datasets was 
high at 95%, using a capture-recapture approach. This was an increase from an estimated 
79% prior to the linkage process. Whilst only a relatively small number of deaths were 
therefore estimated to have been missed, the deaths not ascertained through either UK CHIC 
or HANDD will not be missing completely at random (541). As HANDD death data is only 
supplemented with data from ONS for deaths under the age of 65, deaths are more likely to 
be missing amongst individuals over 65. Any future assessments of age trends in mortality 
may therefore underestimate associations between mortality older age above this threshold.  
I observed that 581 linked records had a date of death recorded in UK CHIC that had not been 
ascertained in HANDD. The demographic characteristics of these individuals were largely 
similar to the characteristics seen for all deaths, with approximately 80% male and just over 
half being of white ethnicity and having acquired HIV through sex between men. However, a 
slightly higher proportion were amongst those of other non-white or non-African black 
ethnicity. Compared to all deaths originally available in the UK CHIC dataset, these deaths 
were less likely to occur in earlier calendar years. Compared to deaths occurring in HANDD 
only, they were also less likely to occur in the more recent calendar period, again indicating 
the reporting delay in the UK CHIC Study. Scenarios in which UK CHIC would have a record 
of a death that would not be recorded in HANDD, either through clinician report or ONS 
reporting are unclear. Deaths occurring abroad will not be captured on the ONS mortality 
registry but may reported to the HIV clinic by family or friends, this may explain why deaths 
are captured in the UK CHIC Study but not be present in ONS data. However, once reported 
to the HIV clinic, the death should also be reported to HANDD. It is possible that the method 
of clinician report may influence whether deaths are reported; clinician reporting to HANDD 
occurs through bi-annual survey completion (542), whereas UK CHIC data collection involves 
submission of all electronically available data in the patient record. Deaths occurring in 
individuals who attended for care in Scotland may not be reported to HANDD through clinician 
report as this surveillance system only covers England, Wales and Northern Ireland, but this 
only appeared to explain a small number of these deaths (Table 4.4.2). It is possible that 
incorrect linkage may explain some of these differences, however the majority (86%) of these 
matches had a linkage score of 1, meaning that a link to HANDD was made based on soundex, 
sex and date of birth. Also, 428 (73.7%) had a matching score <0, suggesting no demographic 
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inconsistencies between linked records. The availability of deaths in UK CHIC not reported to 
HANDD would imply that this is a mutually beneficial process for both the UK CHIC Study and 
HIV surveillance, and this information was fed back to investigators at PHE. 
4.5.1.2 Assigning a principal cause of death 
Of the final 4,634 deaths in the CHIC2013 dataset, only 3,053 (65.9%) had any information 
available on cause of death, despite consolidating information on cause of death from four 
different sources of data. A principal cause of death was assigned to 2,938 deaths; 63.4% of 
all deaths and 96.2% of deaths where there was any information available on cause. Amongst 
deaths where there was information on cause of death, the majority (61.0%) of deaths in the 
UK CHIC Study were classified as being due to non-AIDS illnesses according to the chosen 
HICDEP code for the principal cause of death, with only 33.8% due to AIDS-related illnesses. 
Where there was available information on cause of death, a principal cause of death was 
assigned in 96.2% of cases. However, for a large proportion (34.1%) of deaths, there was no 
information on cause of death available in any of the four data sources utilised. These deaths 
predominantly occurred in earlier calendar years and again were more likely in those with 
other missing data items i.e. those with unknown ethnicity and exposure. A higher proportion 
of those younger than 30 were also missing cause of death information when compared to 
the older age groups. Due to the early calendar period and young age at death, it is likely that 
a high proportion of these deaths were in fact due to AIDS-defining illness and that the true 
number of AIDS-related deaths is in fact under-estimated. This is also supported by the 
apparent lower rates of deaths due to AIDS-related compared to non-AIDS deaths observed 
prior to 2000. With combination ART only introduced in 1996, we would expect to see a high 
rate of AIDS-related deaths at this time, that is higher than the rate of non-AIDS events and 
that declines rapidly in the early HAART era, as has been reported in other studies (171, 193). 
In our study, this is the pattern observed for deaths of unknown cause. Further, the low CD4 
counts at time of death and low proportion on ART with an undetectable viral load would 
suggest that AIDS is a likely cause of death in those with currently unknown cause of death.  
The proportion of deaths with information on cause only reached high levels (approximately 
80%) for deaths from 2004 onwards, when rates of deaths of unknown cause are lower than 
for either AIDS or non-AIDS deaths for the first time also. It is unlikely that we will be able to 
improve the information on cause of deaths occurring in the early ART era (i.e. pre 2000) if it 
has not been possible to do so using the combination of data sources used here. This will 
need to be carefully considered in further analyses of cause of death in the UK CHIC Study. 
Any time-trend analyses should not include this early ART-era as cause-specific mortality rates 
will be incorrect, with a likely underestimate of AIDS deaths in the early era obscuring evidence 
of a decline over time. Further, factors associated with cause-specific mortality in earlier years 
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could be incorrectly estimated. Approaches used in future to account for this will depend on 
the analysis being undertaken but could involve restricting analyses to later calendar years 
when information on cause of death is more frequently available. Although this approach is 
not ideal as it excludes events, any events excluded may be less relevant to current mortality 
trends so should not reduce generalisability of findings to people currently living with HIV. 
Alternatively, if we are only interested in classifying deaths as related to AIDS or non-AIDS 
causes, an approach similar to that utilised by Kowalska et al., in the EuroSIDA study could 
be employed, which used clinical factors around the time of death to classify deaths as being 
AIDS related or not. However, this approach was shown to have only moderate agreement 
with cause of death when classified using the CoDe protocol and relies on data on CD4 count 
and AIDS-defining illness to be available prior to death (537). In the UK CHIC Study, this will 
not be the case for a large number of individuals who are LTFU or who transfer their care to 
a centre that does not participate in the study. 
4.5.1.3 Repetition of this process in future 
Due to the addition of new centres and patients to the UK CHIC Study and different results of 
the de-duplication process each year, the linkage to HANDD will need to be repeated when 
generating each new update of the UK CHIC Study dataset. Having established the steps 
required to select a best match from one-to-many and many-to-one record links, developed 
a matching score and algorithm to select a date of death in linked individuals, the process to 
improve ascertainment of mortality outcomes can now be undertaken quickly. Therefore it is 
possible to repeat this process each year to improve ascertainment of deaths as part of the 
annual process of updating the UK CHIC dataset for analysis. As this was the first time that a 
principal cause of death has been assigned in the UK CHIC Study, and information provided 
in hand-written CoDe forms needed to be made electronically available, this process took 
approximately one year to complete and required several face-to-face meetings with clinical 
members of the mortality review sub-group. It is aimed to streamline this process in future 
so that subsequent updates can be undertaken more rapidly. Firstly, now that the back-log of 
CoDe forms has been entered electronically, only smaller numbers new forms will need to be 
entered going forward. This can be conducted as and when forms are received throughout 
the year. For the majority of deaths where a principal cause of death is already assigned, it is 
likely that this information will not change. Exceptions to this situation may be where, in 
repeating the linkage each year, UK CHIC records link to different HANDD records. New CoDe 
forms or new information in the annual electronic upload, submitted by centres, will also need 
to be incorporated in future. This will involve review of information for substantially fewer 
deaths than were considered in this initial process. Further, as a strategy has now been 
decided to assign a principal cause of death in simple cases, this can be undertaken by me 
wherever possible. This will mean that cause of death can be assigned rapidly in some cases, 
with smaller numbers also requiring review by clinical members of the team. The frequency 
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of review by the clinical team will ideally be performed annually also, but this will rely on the 
support and availability of clinicians.   
4.5.2 Comparison to the literature  
I have used linkage to national surveillance data, which is in turn supplemented with national 
vital registry data, to improve ascertainment of death in the UK CHIC Study. I report on 4,634 
(9.1%) deaths occurring in 50,785 individuals accessing care in England and Scotland, with 
potential for approximately 253 extra missed deaths in these individuals. Recent reports from 
HANDD estimate 5,302 (6%) deaths to have occurred in 88,994 individuals diagnosed in 
England and Wales between 1997 and 2012 (189). The apparent higher risk of mortality in 
the UK CHIC Study participants could be due to the inclusion of deaths occurring in 1996, 
when ART was only just beginning to become widely available and mortality rates were still 
high, and the inclusion of patients attending for care in Scotland. I also observed 581 deaths 
in UK CHIC participants linked to HANDD records that were not recorded in HANDD. 
The majority of HIV cohorts obtain information on deaths through the care-giving hospital or 
clinic, either through direct extraction from medical records (193), prospective real-time 
reporting of deaths (173) or the use of CoDe or other similar study-specific data collection 
forms (172, 534). Additionally, cohorts may employ other methods such as linkage to national 
vital registries (171, 187) or other local registries (199, 543) alongside standard data collection 
methods to maximise ascertainment of mortality outcomes. Cohort collaborations such as the 
ART-CC and CASCADE rely on cohort-specific methods of data collection which may vary (197, 
544). Few studies have attempted to estimate the extent to which they are able to ascertain 
deaths. In the ART-CC, participating cohorts in Europe and North America were asked to 
report their estimated mortality ascertainment, none of which reported rates below 75%; 9 
of the 17 cohorts reported ascertainment rates between 90-95%, which is comparable to the 
UK CHIC Study, and 4 reported ascertainment above 95%. Ten of the cohorts linked to death 
registries to get information on deaths, alongside data from hospitals and family or friends. 
Where death registry data was not used, 4 studies reported receiving information through 
local registries also. However, the method by which ascertainment was estimated in each 
study was unknown. Importantly, ascertainment was associated with differences in the 
mortality rates between cohorts in the 2 years following ART initiation; studies with higher 
ascertainment reported higher mortality rates, highlighting the importance of linking to 
registries if possible (545). In France, ascertainment of mortality in HIV-positive adults has 
been assessed across three data sources; the Mortalité 2000 survey, the French Hospitals 
Database (FHDH) and a national registry of death certificates. The cross-sectional Mortalité 
2000 study, which surveyed HIV clinicians at 185 HIV wards across France, has assessed 
completeness of death ascertainment through further review of patients LTFU in a sample of 
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wards, and through a capture-recapture approach, matching to the remaining two data 
sources. With respect to patients LTFU, relatively small numbers of deaths appeared to be 
missed, giving an estimated ascertainment of 91% (535). However, a capture-recapture 
analysis found that only 55% of deaths were ascertained. The FHDH, correctly ascertained 
only 38% of all deaths in the capture-recapture analysis (546). Further, amongst individuals 
LTFU in the cohort study, 30% were reported to have died in either the Mortalité 2000 survey 
or the registry of death certificates, and accounting for this loss-to follow-up impacted survival 
estimates in the cohort (539).  
Our ability to classify cause of death in the UK CHIC Study is somewhat worse than other 
studies for deaths occurring in the early HAART period due to large amounts of missing data. 
Cause of death rates in the region of 80-98% have been reported in various cohorts (192, 
496, 534). However, few of these cohorts use linkage to external mortality registries to 
ascertain deaths (171, 547) so most rely on clinician report. If a reporting clinician is aware 
that a death has taken place they may also be more likely to have information on cause of 
death, so this could contribute to these high rates of deaths with known cause.  
In the UK CHIC Study we report a lower proportion of deaths attributable to AIDS compared 
to some other studies (193, 201, 534, 547). Data from HANDD and ONS for deaths in England 
and Wales between 1997 and 2012, classify 58% of deaths as AIDS-related. The proportion 
of deaths attributed to non-AIDS malignancy, CVD, liver disease and external causes including 
suicide were similar, however. This higher proportion of AIDS-related deaths is not entirely 
surprising, as investigators at PHE were able to assign a cause of death for 91% of all deaths 
in this period (likely through extra data provided only to HANDD) and further steps were taken 
by PHE investigators to classify AIDS or non-AIDS infections from clinical data if it was not 
otherwise clear (189). As the majority of deaths with missing information in UK CHIC occurred 
in the early ART era and were likely to be AIDS related. This may also explain differences 
observed in other cohorts. In the ART CC, classification rules such as those used in the UK 
CHIC Study were used to classify cause of death according to the same HICDEP coding 
system. They were able to assign a cause of death for 85% of cases, similar to the rate in UK 
CHIC in more recent years. For the period 1996-2006 the ART-CC reported higher proportions 
of deaths attributable to AIDS, in the region of 10% higher (197). This difference could reflect 
the periods of study. However, where we were able to assign a cause of death, we observed 
similar results to those reported in the D:A:D Study over a similar time-period, with 34% of 
deaths attributed to AIDS in the UK CHIC Study and 29% in the D:A:D Study. The proportion 
of deaths attributable to CVD and malignancy were also similar in both studies; 12% and 15% 
malignancy in UK CHIC and D:AD respectively and 9% and 11% attributed to CVD (173, 548). 
We also found similar causes of death to those seen in France in the Mortalite 2000, 2005 and 
2010 surveys (196, 549). 
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4.5.3 Strengths and Limitations 
A large proportion of patient records within the UK CHIC Study were succesfully linked to HIV 
surveillance data, and through this it was possible to incorporate national registry data on 
deaths in PLWH. Thus we now have a viable method for improving ascertainment of mortality 
outcomes that does not rely solely on reporting from HIV clinics. However, it was not possible 
to link all individuals to a HANDD record, based on the data fields available. Females, those 
of unknown ethnicity and acquisition risk and those who entered the UK CHIC cohort in earlier 
calendar years were less likely to be linked to a HANDD record. A high proportion (24.7%) of 
unlinked individuals for whom there was a date of death in the UK CHIC Study reported IDU 
transmission risk, a group shown to have high mortality rates (189, 550) and in whom it may 
be more difficult to capture complete information on deaths due to high rates of LTFU (539, 
551, 552). Unlinked individuals who were known to have died in the UK CHIC Study were also 
younger, more likely to be female, of white ethnicity, to have died in an earlier calendar year 
and to have most recently attended for HIV care at Edinburgh prior to death than individuals 
with a death in HANDD only or amongst all individuals who had died in the dataset. Edinburgh 
is a centre that is known to have a large proportion of IDU clients and it is unsurprising that 
these records were less likely to be linked and their deaths less likely to be recorded in HANDD, 
as this dataset provides surveillance of England, Wales and Northern Ireland only. It is likely 
that amongst those whose records were not linked, mortality may still be under-ascertained, 
which could result in the attenuation of mortality differences in future analyses or even the 
appearance of a mortality benefit (553). Further, my estimate of 95% ascertainment after the 
linkage process, assumes that death ascertainment prior to the linkage is the same for those 
who are and are not subsequently linked to HANDD, as I applied the ascertainment rate 
amongst matched individuals to those not linked to get an overall estimate of missing deaths. 
This may not be a valid assumption, and the overall proportion of deaths ascertained may 
actually be lower than 95%. However, due to the large number of records successfully linked, 
any impact should be small. 
Another limitation is the large amount of missing data on cause of death, particularly in the 
early HAART period. This missing data may affect our estimates of cause-specific death rates 
and proportions, and future analyses of cause of death may need to be restricted to later 
calendar years. The majority of analyses undertaken in the UK CHIC Study use 2000 as the 
earliest calendar year for analysis, as this is when viral load monitoring became more routinely 
available (Figure 3.3.2). From this point on, 76% of deaths had any information on cause of 
death and 74% were assigned a principal cause of death. The variable quality of cause of 
death reporting is a difficulty faced by all cohort studies and was an issue when classifying 
cause of death in the UK CHIC Study. We opted to classify cause of death as best we could 
according to the information available, regardless of how detailed that information was. This 
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resulted in probable misclassification in some instances and variable confidence in the selected 
principal cause of death. Despite these difficulties we found that causes of death in the UK 
CHIC Study were similar to estimates in another large HIV cohort in high income settings, and 
for non-AIDS deaths was similar to other reports from the UK. Further, cause of death 
classification did improve over time.  
4.5.4 Conclusion 
By linking UK CHIC patient records to HIV surveillance data, the ascertainment of deaths 
within UK CHIC participants has been improved, and is estimated to have increased from 79% 
to 95% of all deaths. For the first time in the UK CHIC Study, we have been able to classify 
cause of death and are now able to study these outcomes amongst PLWH in the UK. In 
subsequent chapters I shall utilise this newly available data to assess the impacts of late 
diagnosis on cause-specific mortality and associations between poor engagement in care and 
late ART initiation on all-cause mortality. 
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5Chapter 5: The role of late diagnosis on 
mortality in an aging HIV-positive population 
 
5.1 Introduction 
HIV diagnosis is the first step towards entering HIV care and initiating ART. Diagnosis once 
HIV has progressed to an advanced stage of disease, referred to as late diagnosis, is 
associated with high rates of morbidity and mortality (272, 292), particularly in the short-term 
following HIV diagnosis (251, 267, 271, 294). In the UK, as many as 95% of deaths in the 
year following HIV diagnosis occur amongst those diagnosed late (274). It is associated with 
high rates of AIDS-related morbidity, due to ongoing destruction of the immune system as 
HIV replicates in the absence of treatment, which leads to the occurrence of opportunistic 
infections and cancers (40, 58). In approximately 15% of instances, HIV will be diagnosed in 
concurrence with an AIDS-defining illness (288, 293, 294). Therefore, a large proportion of 
deaths occurring following late diagnosis are related to AIDS-defining illness (303).  
Recent studies have clearly demonstrated both the individual (141) and public health benefits 
(138, 152) of initiating ART early in the course of HIV infection. Therefore, timely diagnosis is 
a key element of achieving good outcomes in PLWH and reducing HIV incidence. However, 
for many countries, including the UK, undiagnosed HIV represents the largest gap along the 
care pathway depicted in the continuum of care (216, 229, 240, 376). In the UK it is estimated 
that 13% of PLWH in 2015 were undiagnosed and 39% of new diagnoses occurred after the 
individual’s CD4 count had dropped below 350 cells/mm3 (70).  
HIV-positive individuals that are diagnosed at an older age are more likely to be diagnosed 
with advanced HIV disease than younger HIV-positive individuals (265, 271, 272, 274, 275, 
277). This could be because older adults are less likely to test and test less frequently for HIV 
than younger adults (554, 555), although data on HIV testing patterns amongst older 
individuals in the UK are lacking. The apparent faster progression of HIV in older individuals 
may also be a contributing factor (304, 305, 556, 557). This higher rate of progression could 
also contribute to notably high rates of mortality that are observed amongst older newly 
diagnosed PLWH with advanced HIV disease, compared to older individuals who are not 
diagnosed late and to younger individuals also diagnosed late (296). However, it is not 
understood if the impact of late diagnosis on mortality is greater for older individuals than 
younger PLWH. One single-centre UK study to investigate the effect of late presentation to 
care and age on mortality did not find an interaction effect between these two factors (222). 
Furthermore, whilst it has been shown that approximately half of deaths occurring shortly 
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following HIV diagnosis may be attributed to AIDS-related illness, few studies have formally 
estimated the effect of late diagnosis on mortality according to cause of death (302).  
In this chapter I investigate the relationships between age, late diagnosis and mortality 
outcomes. As well as examining the association between older age and late diagnosis, I 
investigate the role of each of these factors in both AIDS and non-AIDS related mortality, 
further, considering whether the impact of late diagnosis on mortality is greater for older 




Included individuals were those who were diagnosed with HIV between 2000 and 2012 aged 
>16 years and entered the UK CHIC Study within 6 months of this diagnosis date. The 
CHIC2013 dataset was used for this analysis, using the causes of death as derived in Chapter 
4. 
5.2.2 Definitions 
5.2.2.1 Date of HIV diagnosis  
Date of first ever HIV positive test result is requested as part of the annual data submission 
received from centres. However, this information is not known for all individuals in the dataset 
and further, centres may often re-test patients who newly present for care at their clinic, 
meaning that the HIV-positive test date received is not the date of initial HIV diagnosis. In 
the past, date of diagnosis has been estimated by taking the earliest of: this HIV positive test 
date; the first available CD4 count; first recorded AIDS event; first drug start date; first date 
seen at a participating clinic. From the CHIC2013 dataset onwards, a date of HIV diagnosis is 
also available through the linkage to HANDD. Therefore, for the purposes of this analysis, 
date of diagnosis was selected using information on the recorded HIV positive test date, the 
earliest event date in UK CHIC and the HANDD date of diagnosis as follows. For UK CHIC 
records not linked to a HANDD record or those not considered to be a true match, the earliest 
of HIV positive test date and earliest event in the UK CHIC dataset was taken to be the date 
of diagnosis. For records linked to HANDD that were considered to be a true match, the 
earliest of HANDD date of diagnosis, UK CHIC HIV positive test date and earliest event date 
was chosen as the date of diagnosis, except in the circumstances outlined in Table 5.2.1. 
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Table 5.2.1: Scenarios when the earliest date NOT chosen as date of diagnosis for 
matched patient records 
Date order Scenario Date updated to: 
- 
(i) CD4 count, viral load, ART start 
date or AIDS event prior to 
HDD  
(i) Earliest of CHP / CEE 
(ii) CEE if CHP is 1st 
January 
HDD < CHP < CEE 
(i) HDD is 1st January 
(ii) All dates occur in same 
calendar year and month and 
HDD is 1st of month 
CHP 
HDD < CEE < CHP  CEE 
HDD < CEE = CHP 
(i) HDD is 1st January / 1st June / 
15th June / 1st July 
(ii) All dates occur in same calendar   
year and month and HDD is 1st      
of month 
CEE / CHP 
CHP < CEE (HDD missing) (i) CHP is 1
st January CEE 
CHP < HDD < CEE (i)  CHP is 1st January 
(ii) CHP is 1st of month with HDD 
and CEE <6 months apart 
HDD 
CHP < CEE < HDD CEE 
CHP < CEE = HDD 
(i) CHP is 1st January / 1st June / 
15th June / 1st July 
(ii) All dates occur in same 
calendar year and month and 
CHP is 1st of month 
CEE / HDD 
CEE < HDD < CHP 
(i) Only the first seen date is 
before HDD and any CD4, viral 
load, drug start or study entry 
date is still after HDD 
Diagnosis date 
(ii) As (i) with CHP before any 
CD4, viral load, drug start or 
entry date and HDD is 1st 
January in same year as CHP 
CHP 
CEE < CHP < HDD 
(i) Only the first seen date is 
before CHP and any CD4, viral 
load, drug start or study entry 
date is still after CHP 
CHP 
(ii) As (i) with HDD before any 




Date order Scenario Date updated to: 
entry date and CHP is 1st 
January in same year as HDD 
CEE < CHP=HDD 
(i) Only the first seen date is 
before CHP/HDD and any 
CD4, viral load, drug start or 
study entry date is still after 
CHP/HDD 
CHP / HDD 
HDD=HANDD date of diagnosis; CHP=CHIC HIV-positive test date; CEE=CHIC earliest event date 
 
5.2.2.2 Late diagnosis 
Individuals were defined as being diagnosed late if they had a CD4 count ≤350 cells/mm3 or 
diagnosis of an AIDS-defining illness up to 90 days after entry into the UK CHIC Study. This 
cut-off has been widely used to define late diagnosis as it has been shown to be predictive of 
poor outcomes and prior treatment guidelines have recommended this as the threshold for 
ART initiation (112, 250, 251). Individuals without a CD4 count result within this time period 
were included in the analysis and were classified as having a late diagnosis if an AIDS-defining 
event occurred within 90 days or non-late diagnosis otherwise. As defined in previous studies, 
advanced immunosuppression was defined as the presence of a CD4 count <200 cells/mm3 
or AIDS-defining illness within 90 days of entry into the UK CHIC Study (250, 251).  
5.2.2.3 Other definitions 
Older age was defined as those aged at least 50 years at presentation for care. Deaths were 
classified as AIDS-related, non-AIDS related or of unknown cause according to the principal 
cause of death HICDEP code (Chapter 4). Those without a selected principal cause of death 
and those with codes for unknown or unclassifiable causes of death were classified as 
unknown causes. 
5.2.3 Statistical Analysis 
Differences in characteristics between those who were older and younger at diagnosis were 
assessed using Chi-square and Mann Whitney U tests. The proportion of people with late 
diagnosis and advanced immunosuppression was compared by age group using chi-squared 
tests. The association between age and late diagnosis was further assessed using univariable 
and multivariable logistic regression with late diagnosis as the dependent variable. In the 
multivariable model, potential confounders that were considered were sex (male/female), 
ethnicity (white, black African, black other, other, unknown), mode of HIV acquisition (sex 
between men, heterosexual, other, unknown), location of HIV clinic (London, other UK), HBV 
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co-infection and HCV co-infection at diagnosis (no, yes, not tested). Interaction effects 
between age and all other independent variables were tested in the main model and stratified 
analysis were performed to determine what factors were associated with late diagnosis 
amongst those aged below 50 and those aged 50 and above. Factors that remained significant 
at 5% level in univariable analysis were included in the multivariable model. 
Follow-up was considered from date of entry into the UK CHIC Study until the earliest of: 6 
months after the date last seen at a UK CHIC participating centre, 31st December 2012 or 
death. Crude mortality rates were calculated according to time since diagnosis (0-0.5, 0.5-1, 
1-3, 3-5, 5-7 and >7 years) and cause of death (AIDS, non-AIDS, unknown). Mortality rates 
were then stratified by age and late diagnosis. The population attributable risk fraction 
(PAR%) was calculated for late diagnosis amongst those aged 50 and above and below 50, 
to determine the proportion of deaths that could be avoided if no-one were to be diagnosed 
late in either age group. The PAR% is estimated using the following equation: 
𝑃𝐴𝑅% =
𝑝 × (𝑅𝑅 − 1)
1 + (𝑝 × (𝑅𝑅 − 1))
× 100 
where p is the prevalence of late diagnosis and RR is the crude relative risk of mortality for 
those with late diagnosis. 
To assess formally the associations between age, late diagnosis and mortality, only mortality 
in the year following diagnosis was considered, and follow-up was censored after 1 year. This 
was done to generate ‘cleaner’ estimates of the association between late diagnosis and 
mortality. Previous studies have shown that the majority of mortality associated with late 
diagnosis occurs soon after diagnosis (267, 271). In the longer term, this association becomes 
mixed with ART effects as people start treatment, and with an individual’s ability to adhere to 
treatment and remain in care over time. It is hypothesised that, whilst some individuals once 
diagnosed late will engage well with care, for others, late diagnosis is a consequence of more 
chaotic lifestyles which would also affect adherence and engagement with care services that 
would not be adequately captured in UK CHIC data to allow this to be accounted for in analyses 
(558). The long-term effects of late ART initiation are studied in Chapter 6.  
Kaplan-Meier methods were used to estimate the probability of all-cause mortality over 1 year 
according to (i) age, (ii) late diagnosis and (iii) late diagnosis separately for those aged < or 
> 50 years. Cox Proportional Hazards models assessed the independent effects of age and 
late diagnosis on all-cause mortality in the year following diagnosis, adjusting for other factors. 
Factors considered in adjusted models were sex, ethnicity, mode of HIV acquisition, year of 
diagnosis, HIV viral load (log10copies/ml), HBV and HCV co-infection, with factors significant 
at the 5% level retained in the model, unless there was evidence of colinearity. In order to 
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determine whether the association between late diagnosis and 1 year mortality differed in 
older and younger individuals, an interaction effect between age and late diagnosis was tested 
for significance in the adjusted model.  
Competing-risks survival analyses were used to assess the impact of age and late diagnosis 
on AIDS and non-AIDS related mortality in the year after diagnosis, with follow-up censored 
at this point. For the outcome of AIDS mortality, deaths from non-AIDS or unknown causes 
were considered to be competing risk events. Similarly for non-AIDS mortality, AIDS deaths 
and deaths from unknown causes were considered competing risks. The cumulative incidence 
of both AIDS and non-AIDS mortality was estimated according to (i) age, (ii) late diagnosis 
and (iii) late diagnosis separately for those aged < or > 50. The SAS macro %CUMINCID was 
used to estimate cumulative incidence. Fine-Gray methods investigated relationships between 
age, late diagnosis and cause-specific mortality, adjusting for other factors that were 
significant at the 5% level. Again an interaction effect between age and late diagnosis was 
tested for significance in adjusted models. These analyses were performed using the SAS 
macro %PSHREG. 
5.2.4 Sensitivity Analyses 
A sensitivity analysis was performed in which individuals who did not have a CD4 count 
available at entry into the UK CHIC Study and who did not have an AIDS defining illness were 
assumed to be diagnosed late. Further, the factors associated with having a CD4 count at 
entry into the UK CHIC Study were investigated in a logistic regression analysis. 
 
5.3 Results 
5.3.1 Characteristics at entry into the UK CHIC Study 
Of 50,785 individuals in the UK CHIC Study, 32,283 had a date of HIV diagnosis between 2000 
and 2012. Of these, 24,691 entered the UK CHIC Study within 6 months of this diagnosis date 
and 24,675 were aged at least 16 at diagnosis.  
The median (IQR) age of study participants was 34 (28, 41) with a maximum recorded age 
of 84. Of 24,675 included individuals, 2203 (8.9%) were aged at least 50 at the time of 
diagnosis; 612 (2.5%) were aged at least 60. The majority of study participants were aged 
between 30 and 40 (9858 (40.0%)).  
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Those diagnosed with HIV aged at least 50 were more likely to be male (73.5% vs. 67.3%), 
white (54.0% vs. 44.4%) and have a heterosexual (49.0% vs. 44.0%) or unknown (11.9% 
vs. 6.9%) mode of HIV acquisition than those diagnosed aged below 50 (all p<0.001; Table 
5.3.1). Older age was also associated with being diagnosed in a more recent calendar year. A 
higher proportion of older newly diagnosed individuals presented to a UK CHIC centre that 
was located outside of London compared to the younger group (24.2% vs 19.2%). Whilst 
statistically significant differences were found in the HBV and HCV co-infection status by 10 
year age groups, the proportion of individuals that had either HBV or HCV co-infection was 
largely similar in each age category and no difference were found when comparing those aged 
at least 50 to those aged below 50.  
Median (IQR) time to entry in the UK CHIC Study after diagnosis was short in all age groups, 
but shortest in those aged below 30 at 1 (0, 23) days. The median CD4 count at study entry 
was lower amongst those diagnosed aged >50 and the proportion who experienced an AIDS-
defining illness increased with older age. CD4:CD8 ratio was low in both groups, but was 
lowest in those aged >60; median (IQR)=0.2 (0.1, 0.5). The median (IQR) viral load was 4.8 
(3.8, 5.4) log10copies/ml in those aged 50 and above compared to 4.5 (3.7, 5.1) log10copies/ml 
in those aged below 50.   
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value2 <30 30-39 40-49 50-59 >60 <50 >50 
N 24675 7492 9858 5122 1591 612 22472 2203 - - 
Follow-up [years],        <0.001 <0.001 
median (IQR) 24675 3.9 (1.2, 7.7) 4.4 (1.5, 8.0) 3.8 (1.3, 7.1) 3.2 (1.1, 6.5) 2.9 (1.0, 6.0) 4.1 (1.4, 7.7) 3.1 (1.1, 6.4)   
Time to entry [days],        <0.001 <0.001 
median (IQR) 24675 1 (0, 23) 5 (0, 25) 6 (0, 26) 7 (0, 28) 7 (0, 27) 4 (0, 24) 7 (0, 27)   
Age [years],           
median (IQR) 24675 26 (23, 28) 34 (32, 37) 43 (41, 46) 53 (51, 56) 64 (61, 67) 33 (28, 39) 55 (52, 60) - - 
Sex         <0.001 <0.001 
Male 16745 4682 (62.5) 6663 (67.6) 3782 (73.9) 1153 (72.5) 465 (76.0) 15127 (67.3) 1618 (73.5)   
Female 7927 2809 (37.5 3194 (32.4) 1339 (26.2) 438 (27.5) 147 (24.0) 7342 (32.7) 535 (26.6)   
Ethnicity         <0.001 <0.001 
White 11162 3315 (44.3) 4226 (42.9) 2432 (47.5) 855 (53.7) 334 (54.6) 9973 (44.4) 1189 (54.0)   
Black African 8264 2394 (32.0) 3640 (36.9) 1665 (32.5) 427 (26.8) 138 (22.6) 7699 (34.3) 565 (25.7)   
Black Other 1562 525 (7.0) 559 (5.7) 321 (6.3) 112 (7.0) 45 (7.4) 1405 (6.3) 157 (7.1)   
Other 2602 936 (12.5) 1036 (10.5) 473 (9.2) 113 (7.1) 44 (7.2) 2445 (10.9) 157 (7.1)   
Unknown 1085 322 (4.3) 397 (4.0) 231 (4.5) 84 (5.3) 51 (8.3) 950 (4.2) 135 (6.1)   
HIV acquisition         <0.001 <0.001 
Sex between men 10576 3538 (47.2) 4158 (42.2) 2110 (41.2) 571 (35.9) 199 (32.5) 9806 (43.6) 770 (35.0)   










value2 <30 30-39 40-49 50-59 >60 <50 >50 
Other 1308 355 (4.7) 544 (5.5) 319 (6.2) 71 (4.5) 19 (3.1) 1218 (5.4) 90 (4.1)   
Unknown 1823 501 (6.7) 649 (6.6) 410 (8.0) 178 (11.2) 85 (13.9) 1560 (6.9) 263 (11.9)   
Year of diagnosis         <0.001 <0.001 
2000-2003 6947 2300 (30.7) 3042 (30.9) 1145 (22.4) 332 (20.9) 128 (20.9) 6487 (28.9) 460 (20.9)   
2004-2007 8563 2602 (34.7) 3478 (35.3) 1766 (34.5) 511 (32.1) 206 (33.7) 7846 (34.9) 717 (32.6)   
2008-2012 9165 2590 (34.6) 3338 (33.9) 2211 (43.2) 748 (47.0) 278 (45.4) 8139 (36.2) 1026 (46.6)   
Centre         <0.001 <0.001 
London 19819 6059 (80.9) 7996 (81.1) 4095 (80.0) 1186 (74.5) 483 (78.9) 4322 (19.2) 534 (24.2)   
Outside London 4856 1433 (19.1) 1862 (18.9) 1027 (20.0) 405 (25.5) 129 (21.1) 18150 (80.8) 1669 (75.8)   
HBV co-infection         0.023 0.637 
No 6958 2138 (28.5) 2732 (27.7) 1480 (28.9) 449 (28.2) 159 (26.0) 6350 (28.3) 608 (27.6)   
Yes 359 83 (1.1) 149 (1.5) 91 (1.8) 30 (1.9) 6 (1.0) 323 (1.4) 36 (1.6)   
Not tested 17358 5271 (70.4) 6977 (70.8) 3551 (69.3) 112 (69.9) 447 (73.0) 15799 (70.3) 1559 (70.8)   
HCV co-infection         <0.001 0.449 
No 7021 2133 (28.5) 2705 (27.4) 1531 (29.9) 479 (30.1) 173 (28.3) 6369 (28.3) 652 (29.6)   
Yes 306 60 (0.8) 131 (1.3) 87 (1.7) 20 (1.3) 8 (1.3) 278 (1.2) 28 (1.3)   
Not tested 17348 5299 (70.7) 7022 (71.2) 3504 (68.4) 1092 (68.6) 431 (70.4) 15825 (70.4) 1523 (69.1)   
CD4 count [cells/mm3]          
median (IQR) 19193 386 (242, 557) 317 (153, 506) 271 (107, 469) 248 (89, 430) 198 (84, 402) 332 (166, 516) 230 (88, 421) <0.001 <0.001 
<200 6012 1072 (14.3) 2524 (25.6) 1614 (31.5) 559 (35.1) 243 (39.7) 5210 (23.2) 802 (36.4) <0.001 <0.001 










value2 <30 30-39 40-49 50-59 >60 <50 >50 
351-499 3880 1348 (18.0) 1535 (15.6) 718 (14.0) 223 (14.0) 56 (9.2) 3601 (16.0) 279 (12.7)   
>500 5019 1774 (23.7) 2024 (20.5) 902 (17.6) 231 (14.5) 88 (14.4) 4700 (20.9) 319 (14.5)   
missing 5482 2024 (27.0) 2005 (20.3) 1013 (19.8) 307 (19.3) 133 (21.7) 5042 (22.4) 440 (20.0)   
AIDS diagnosis         <0.001 <0.001 
No 22196 7126 (95.1) 8854 (89.8) 4436 (86.6) 1291 (81.1) 489 (79.9) 20416 (90.9) 1780 (80.8)   
Yes 2479 366 (4.9) 1004 (10.2) 686 (13.4) 300 (18.9) 123 (20.1) 2056 (9.2) 423 (19.2)   
CD4:CD8 ratio         <0.001 <0.001 
median (IQR) 15414 0.4 (0.3, 0.7) 0.4 (0.2, 0.6) 0.3 (0.1, 0.5) 0.3 (0.1, 0.5) 0.2 (0.1, 0.5) 0.4 (0.2, 0.6) 0.2 (0.1, 0.5)   
Viral load [log10copies/ml]          
median (IQR) 19247 4.3 (3.6, 5.0) 4.5 (3.7, 5.2) 4.7 (3.7, 5.3) 4.7 (3.8, 5.4) 4.9 (3.9, 5.5) 4.5 (3.7, 5.1) 4.8 (3.8, 5.4) <0.001 <0.001 
<10,000 6333 2045 (27.3) 2559 (26.0) 1226 (23.9) 376 (23.6) 127 (20.8) 5830 (25.9) 503 (22.8) <0.001 <0.001 
10,000-100,000 6979 2107 (28.1) 2929 (29.7) 1402 (27.4) 402 (25.3) 139 (22.7) 6438 (28.7) 541 (24.6)   
>100,000 5935 1349 (18.0) 2384 (24.2) 1475 (28.8) 508 (31.9) 219 (35.8) 5208 (23.2) 727 (33.0)   
missing 5428 1991 (26.6) 1986 (20.2) 1019 (19.9) 305 (19.2) 127 (20.8) 4996 (22.2) 432 (19.6)   
1Comparison between all age groups (<30, 30-39, 40-49, 50-59, >60) 
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5.3.2 Late diagnosis 
Of 24,675 included individuals, 10,680 (43.3%) were diagnosed late (95% CI (42.7%, 
43.9%)). Among those diagnosed late, 2,479 (23.2%) had experienced an AIDS-defining 
illness of whom 235 (9.5%) did not have a CD4 count. Amongst those aged <30, 30-40, 40-
49, 50-59 and >60, 2,420 (32.3%), 4,427 (44.9%), 2,596 (50.7%), 880 (55.3%) and 357 
(58.3%) were diagnosed late respectively (Figure 5.3.1(A)). 6,533 (26.5%) newly diagnosed 
individuals had advanced immunosuppression (95% CI (25.9%, 27.0%)). As with late 
diagnosis, the proportion of people with advanced immunosuppression increased with older 
age such that 271 (44.3%) of those aged 60 and above had advanced immunosuppression 
compared to 1156 (15.4%) of those aged below 30 (p<0.001; Figure 5.3.1(B)) 
 
Figure 5.3.1: Proportion of individuals with (A) late diagnosis and (B) advanced 
















5.3.2.1 Factors associated with late diagnosis 
The odds of late diagnosis increased with older age (Table 5.3.2). After adjusting for potential 
confounders including sex, ethnicity, mode of HIV acquisition and calendar year, older age 
was more strongly associated with late diagnosis. Compared to those aged <30 at diagnosis, 
those aged 50-59 had 186% higher odds of late diagnosis (adjusted OR (95% Confidence 
Interval; CI)=2.86 (2.55, 3.21)), whilst those aged 60 and above had a 242% increase in the 
odds of late diagnosis (aOR (95% CI)=3.42 (2.86, 4.08)).  
Late diagnosis was more prevalent amongst females (49.9%), those of black African ethnicity 
(57.7%), those who acquired HIV through heterosexual sex (55.7%) and those with HBV co-
infection (57.1%). Sex, ethnicity, mode of HIV acquisition, calendar year of diagnosis, HBV 
and HCV co-infection were found to be independently associated with late diagnosis (Table 
5.3.2). In adjusted analyses, compared to those of white ethnicity, those of black African and 
black other ethnicity were 99% (95% CI=1.82, 2.16) and 20% (95% CI=1.06, 1.35) more 
likely to be diagnosed late than those of white ethnicity. Those of any other known ethnicity 
were also more likely to be diagnosed late (aOR (95% CI)=1.43 (1.30, 1.56)). Heterosexuals 
and those with other known modes of HIV acquisition had higher odds of late diagnosis than 
MSM; aOR (95% CI)= 1.86 (1.70, 2.03) and 1.55 (1.37, 1.75) respectively. Those of unknown 
ethnicity or unknown mode of HIV acquisition had the lowest odds of late diagnosis compared 
to those of white ethnicity and MSM, respectively (aOR (95% CI)=0.72 (0.62, 0.84) and 0.66 
(0.58, 0.75)), likely due to the definition of late diagnosis used that classifies those without a 
CD4 count as non-late diagnosis. After adjusting for other demographic factors, females were 
17% less likely to be diagnosed late than males (95% CI=0.77, 0.89). The odds of being 
diagnosed late decreased by 3% each year (95% CI=0.97, 0.98). HIV/HBV co-infected 
individuals were 25% more likely to be diagnosed late (95% CI=1.00, 1.57) than HIV mono-
infected individuals. In both unadjusted and adjusted analyses those with an unknown HCV 
co-infection status were less likely to be diagnosed late that HIV mono-infected individuals. 
There was weak evidence that those presenting for care at a centre in London were less likely 
to be diagnosed late than those presenting outside London (aOR (95% CI)=0.94 (0.88, 1.00)). 
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Unadjusted estimates Adjusted estimates 
OR (95% CI) P-value OR (95% CI) P-value 
Age 
<30 32.3 1.00 <0.001 1.00 <0.001 
30-39 44.9 1.71 (1.61, 1.82)  1.66 (1.55, 1.77)  
40-49 50.7 2.15 (2.00, 2.32)  2.23 (2.06, 2.41)  
50-59 55.3 2.59 (2.32, 2.90)  2.86 (2.55, 3.21)  
>60 58.3 2.93 (2.48, 3.47)  3.42 (2.86, 4.08)  
Sex 
Male 40.1 1.00 <0.001 1.00 <0.001 
Female 49.9 1.49 (1.41, 1.57)  0.83 (0.77, 0.89)  
Ethnicity 
White 34.8 1.00 <0.001 1.00 <0.001 
Black African 57.7 2.56 (2.41, 2.71)  1.99 (1.82, 2.16)  
Black Caribbean 42.6 1.39 (1.25, 1.55)  1.20 (1.06, 1.35)  
Other 42.5 1.39 (1.27, 1.51)  1.43 (1.30, 1.56)  
Unknown 24.0 0.59 (0.51, 0.68)  0.72 (0.62, 0.84)  
Mode of 
acquisition 
Sex between men 33.3 1.00 <0.001 1.00 <0.001 
Heterosexual 55.7 2.52 (2.38, 2.66)  1.86 (1.70, 2.03)  
Other 45.1 1.64 (1.46, 1.85)  1.55 (1.37, 1.75)  
Unknown 25.1 0.67 (0.60, 0.75)  0.66 (0.58, 0.75)  
Year of diagnosis Per year - 0.98 (0.97, 0.98) <0.001 0.97 (0.97, 0.98) <0.001 
Centre Outside London 45.4 1.00 0.001 1.00 0.065 








Unadjusted estimates Adjusted estimates 
OR (95% CI) P-value OR (95% CI) P-value 
HBV co-infection 
No 45.0 1.00 <0.001 1.00 0.047 
Yes 57.1 1.63 (1.31, 2.01)  1.25 (1.00, 1.57)  
Not tested 42.3 0.90 (0.85, 0.95)  0.95 (0.88, 1.03)  
HCV co-infection 
No 46.3 1.00 <0.001 1.00 <0.001 
Yes 43.5 0.89 (0.71, 1.12)  0.86 (0.68, 1.10)  
Not tested 42.1 0.84 (0.80, 0.89)  0.73 (0.67, 0.79)  








5.3.2.2 Factors associated with late diagnosis amongst those aged 50 and above 
Amongst those aged 50 and above, there was strong evidence that ethnicity, mode of HIV 
acquisition and calendar year were associated with late diagnosis (Table 5.3.3). Those of black 
African and other known ethnicity were 45% (95% CI=1.13, 1.87) and 60% (95% CI= 1.12, 
2.30) more likely to be diagnosed late compared to those of white ethnicity. Those who 
acquired HIV through heterosexual sex were 29% more likely than MSM to be diagnosed late 
(95% CI=1.02, 1.62). Those of unknown ethnicity or unknown mode of HIV acquisition again 
had the lowest odds of late diagnosis when compared to those of white ethnicity and MSM 
(aOR (95% CI)=0.51 (0.33, 0.79) and 0.46 (0.33, 0.65), respectively). Late diagnosis was 
again less likely for older diagnosed individuals in more recent calendar years (aOR (95% CI) 
=0.96 (0.93, 0.98)). There was some evidence of increased odds of late diagnosis with older 
age amongst people aged 50 and above. Those aged 60 and above had 21% higher odds of 
late diagnosis than those aged 50-59 (95% CI=0.99, 1.47). As was seen in the main analysis, 
HCV co-infection status was found to be significantly associated with late diagnosis overall, 
with those without a HCV serology test being 36% less likely to be diagnosed late than those 
who were not co-infected with HCV (95% CI=0.52, 0.79). However, those who were co-
infected with HCV showed no statistically significant difference in the likelihood of late 









OR (95% CI) P-value OR (95% CI) P-value 
Age 
50-59 55.3 1.00 0.201 1.00 0.063 
>60 58.3 1.13 (0.94, 1.37)  1.21 (0.99, 1.47)  
Sex 
Male 55.9 1.00 0.661 - - 
Female 56.9 1.04 (0.86, 1.26)    
Ethnicity 
White 53.7 1.00 <0.001 1.00 <0.001 
Black African 65.5 1.63 (1.33, 2.01)  1.45 (1.13, 1.87)  
Black Caribbean 58.0 1.19 (0.85, 1.66)  1.06 (0.73, 1.52)  
Other 63.7 1.51 (1.07, 2.13)  1.60 (1.12, 2.30)  
Unknown 27.4 0.33 (0.22, 0.48)  0.51 (0.33, 0.79)  
Mode of 
acquisition 
Sex between men 54.4 1.00 <0.001 1.00 <0.001 
Heterosexual 63.8 1.48 (1.22, 1.78)  1.29 (1.02, 1.62)  
Other 54.4 1.00 (0.65, 1.55)  0.95 (0.60, 1.48)  
Unknown 30.4 0.37 (0.27, 0.49)  0.46 (0.33, 0.65)  
Year of diagnosis per year - 0.97 (0.95, 1.00) 0.023 0.96 (0.93, 0.98) 0.002 
Centre 
Outside London 57.1 1.00 0.606 - - 




No 63.2 1.00 <0.001 - - 
Yes 61.1 0.92 (0.46, 1.83)    










OR (95% CI) P-value OR (95% CI) P-value 
HCV co-infection 
No 63.2 1.00 <0.001 1.00 <0.001 
Yes 50.0 0.58 (0.27, 1.24)  0.55 (0.26, 1.19)  
Not tested 53.3 0.66 (0.55, 0.80)  0.64 (0.52, 0.79)  








5.3.2.3 Factors associated with late diagnosis amongst those aged below 50 
Whilst neither sex nor HBV co-infection were associated with late diagnosis amongst those 
aged 50 and above in adjusted analyses, these factors were found to be predictive of late 
diagnosis in those aged below 50 (Table 5.3.4). In younger diagnosed individuals, women 
were less likely to be diagnosed late than men (aOR (95% CI)=0.81 (0.75, 0.88)). Those with 
HIV/HBV co-infection were 30% (95% CI=1.02, 1.64) more likely to have a late diagnosis 
than HIV mono-infected individuals. As was seen in those aged 50 and above at diagnosis, 
ethnicity, mode of HIV acquisition and calendar year were also associated with late diagnosis 
amongst those younger than 50. In the younger group, a stronger effect of black African 
ethnicity was found than in over 50’s, with those of black African ethnicity being more than 
twice as likely to be diagnosed late than those of white ethnicity (aOR (95% CI)=2.02 (1.85, 
2.12)). Those of other black ethnicity were 20% (95% CI=1.06, 1.36) more likely to be 
diagnosed late. Compared to MSM, heterosexuals were 95% (95% CI=1.77, 2.14) more likely 
to be diagnosed late; again a greater relative difference than was seen in those aged 50 and 
above. In the younger group those with other known mode of acquisition were also more 
likely to be diagnosed late than MSM (aOR (95% CI)=1.61 (1.41, 1.82)), although such a 
difference was not observed in those aged 50 and above. As with the older age group, the 
odds of late diagnosis decreased over time in the younger age group, with a 2% decreased 
odds of late diagnosis per calendar year (95% CI=0.97, 0.99).  
Upon testing for interactions between age and other factors in the main model, significant 
interaction effects were found between age and mode of HIV acquisition (p=0.038) and age 
and calendar year (p=0.016) only. 
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Table 5.3.4: Factors associated with late diagnosis amongst those aged <50 years 
 % late 
diagnosis 
Unadjusted Adjusted 
OR (95% CI) P-value OR (95% CI) P-value 
Age 
<30 32.3 1.00 <0.001 1.00 <0.001 
30-39 44.9 1.71 (1.61, 1.82)  1.65 (2.22, 1.65)  
40-49 50.7 2.15 (2.00, 2.32)  2.22 (2.05, 2.40)  
Sex 
Male 38.5 1.00 <0.001 1.00 <0.001 
Female 49.4 1.56 (1.47, 1.65)  0.81 (0.75, 0.88)  
Ethnicity 
White 32.5 1.00 <0.001 1.00 <0.001 
Black African 57.1 2.77 (2.60, 2.94)  2.02 (1.85, 2.21)  
Black Caribbean 40.9 1.43 (1.28, 1.61)  1.20 (1.06, 1.36)  
Other 41.1 1.45 (1.32, 1.59)  1.42 (1.29, 1.56)  
Unknown 23.5 0.64 (0.55, 0.74)  0.75 (0.64, 0.89)  
Mode of 
acquisition 
MSM 31.7 1.00 <0.001 1.00 <0.001 
Heterosexual 54.8 2.62 (2.47, 2.77)  1.95 (1.77, 2.14)  
Other 44.4 1.73 (1.53, 1.95)  1.61 (1.41, 1.82)  
Unknown 24.2 0.69 (0.61, 0.78)  0.70 (0.61, 0.81)  
Year of diagnosis Per year - 0.97 (0.97, 0.98) <0.001 0.98 (0.97, 0.99) <0.001 
Centre 
Outside London 44.0 1.00 0.004 - - 
London 41.6 0.91 (0.85, 0.97)    
 
HBV co-infection 
No 43.3 1.00 <0.001 1.00 0.042 







 % late 
diagnosis 
Unadjusted Adjusted 
OR (95% CI) P-value OR (95% CI) P-value 
 Not tested 41.2 0.92 (0.87, 0.97)  0.96 (0.88, 1.04)  
HCV co-infection 
No 44.5 1.00 <0.001 1.00 <0.001 
Yes 42.8 0.93 (0.73, 1.19)  0.89 (0.69, 1.15)  
Not tested 41.0 0.87 (0.82, 0.92)  0.73 (0.67, 0.80)  










5.3.3.1 Mortality rates over time since HIV diagnosis 
A total of 823 (3.3%) individuals died over 115,068 person-years of follow-up (median follow-
up 3.9 years), giving a mortality rate (95% CI) of 7.2 (6.7, 7.6) per 1,000 person years in this 
study population. Mortality rates (95% CI) were markedly higher in the year following HIV 
diagnosis, with a mortality rate of 24.4 (21.6, 27.2) per 1,000 person years from 0-0.5 years 
and 10.5 (8.5, 12.4) per 1,000 person years from 0.5-1 years since HIV diagnosis (Figure 
5.3.2). Comparatively, between 1-3, 3-5, 5-7 and over 7 years since diagnosis, mortality rates 
were 5.2 (4.4, 6.0), 4.5 (3.7, 5.4), 4.3 (3.3, 5.3) and 3.5 (2.6, 4.4) per 1,000 person years, 
respectively.  
There was an initial rapid decline in the rate of AIDS-related deaths following diagnosis, but 
AIDS mortality rates remained relatively stable after 1 year: 12.1 (10.2, 14.1) per 1,000 
person-years 0-0.5 years following diagnosis; 1.7 (1.3, 2.2) per 1,000 person-years between 
1-3 years; 0.5 (0.2, 0.9) per 1,000 person-years after 7 years. The rate of non-AIDS mortality 
showed a less marked decline with time from HIV diagnosis, from 6.6 (5.2, 8.1) per 1,000 
person-years between 0-0.5 years to 2.3 (1.6, 3.1) per 1,000 person-years after 7 years. 
The proportion of deaths attributable to AIDS was highest in the first 6 months following 
diagnosis and declined with longer time since diagnosis; 50%, 46%, 33%, 18%, 27%, 15% 
between 0-0.5, 0.5-1, 1-3, 3-5, 5-7 >7 years respectively. Conversely, the proportion of 
deaths attributable to non-AIDS causes increased with longer time since diagnosis; 27%, 











Figure 5.3.2: Mortality rates by cause, according to time since HIV diagnosis 
 
 
Stratifying by age at diagnosis, there were 177 (8.0%) deaths amongst those aged 50 and 
above and 779 (2.9%) deaths among those aged below 50. Mortality rates (95% CI) were 
significantly higher in those aged 50 and above compared to those aged below 50 (20.3 (17.3, 
23.3) vs. 6.1 (5.6, 6.5) per 1,000 person-years; Figure 5.3.3). Considering mortality rates 
according to time since diagnosis, the rate remained higher in the older age group at all times. 
Mortality rates were extremely high in those aged 50 and above in the first 6 months following 
diagnosis at 57.2 (42.9, 71.7) per 1,000 person-years, an excess mortality rate of 37.3 per 
1,000 person years over those aged below 50.  
Amongst those aged 50 and above there was a steep decline in the rate (95% CI) of AIDS-
related deaths with longer time since diagnosis; from 25.2 (15.0, 33.8) per 1,000 person-
years 0-0.5 years to 1.7 (0.8, 6.1) per 1,000 person-years 5-7 years after diagnosis. No deaths 
occurring >7 years since HIV diagnosis in those aged 50 and above were attributed to AIDS-
related illness. Similar patterns were observed amongst those aged below 50 at diagnosis. 
The rate (95% CI) of AIDS-related mortality declined steeply within the first year of diagnosis, 
from 11.0 (9.0, 12.9) per 1,000 person-years between 0-0.5 years to 0.6 (0.2, 0.9) per 1,000 
person years after 7 years. The rate (95% CI) of non-AIDS deaths did not decrease as rapidly 
as for AIDS-related deaths with time since diagnosis in either those aged below 50 (5.6 (4.9, 
7.2) 0-0.5 years to 2.0 (1.3, 2.6) >7 years) or those aged 50 and above (16.9 (9.1, 24.7) 0-








































The proportion of deaths attributable to AIDS-related illness decreased with longer time since 
diagnosis in both age groups, with subsequent increases in the proportion of deaths 
attributable to non-AIDS causes. In the first six months of diagnosis, 42.6% and 51.7% of 
deaths were due to AIDS-related illness in those aged above and below 50 respectively, with 
29.5% and 26.5% due to non-AIDS causes. However, after this time point, deaths occurring 
amongst those aged 50 and above were more likely to be due to non-AIDS causes. Whereas 
no deaths occurring more than 7 years after diagnosis in the older age group were attributed 
to AIDS-related illness, 18.8% of deaths amongst those below 50 were AIDS-related.  
 
Figure 5.3.3: Cause-specific mortality rates with time from HIV diagnosis, 




Mortality rates amongst those with a late diagnosis were markedly higher than those who 
were not diagnosed late in the year following HIV diagnosis, but became similar after 3 years 
since HIV diagnosis (Figure 5.3.4). Between 0-0.5 and 0.5-1 years following HIV diagnosis, 
mortality rates (95% CI) in those diagnosed late were 44.6 (38.8, 50.3) and 17.6 (13.8, 21.4) 
per 1,000 person-years. This compared to 9.0 (6.8, 11.3) and 5.0 (2.8, 6.3) per 1,000 person-









































<50 <50 <50 <50
≥50
≥50 ≥50 ≥50 ≥50
210 
 
Of deaths occurring between 0-0.5 and 0.5 to 1 years since HIV diagnosis, 54.9% and 50.6% 
were attributable to AIDS amongst those diagnosed late but only 30.6% and 30.8% were 
AIDS-related amongst those with a timely diagnosis. Of all deaths occurring more than 7 years 
after HIV diagnosis, the proportion of AIDS-related deaths had decreased in both the late and 
timely diagnosis, but remained higher in the late diagnosis group (18.4% vs. 8.7%). A lower 
proportion of deaths in those diagnosed late were due to non-AIDs causes; 60.5% and 78.3%, 
respectively.  
 
Figure 5.3.4: Cause-specific mortality rates with time from HIV diagnosis, 




In the year following HIV diagnosis, older individuals with late diagnosis had the highest 
mortality rates; 82.1 (59.2, 105.2) per 1,000 person years <0.5 years, 33.9 (18.2, 49.6) per 
1,000 person years between 0.5-1 years (Figure 5.3.5). Older individuals who were diagnosed 
late had an absolute excess mortality rate of 31.2 per 1,000 person years compared to 
younger individuals with late diagnosis, and 40.2 per 1,000 person years compared to older 
individuals who were not diagnosed late in the year following diagnosis. The lowest mortality 
rates were found in younger adults who had a timely diagnosis. After one year since diagnosis, 































































5.3.3.2 Population Attributable Risk fraction for late diagnosis 
Over all follow-up the PAR% of late diagnosis was 46.2%; 44.7% amongst those <50 and 
43.3% amongst those aged >50. This would indicate that approximately 45% of all deaths 
over follow-up could be avoided if late diagnosis were removed from the population. Of deaths 
within the first year of HIV diagnosis, 61.6% could be avoided if late diagnosis was no longer 
present. Amongst those aged below 50 years, the PAR% was 61.3%, whereas for those aged 
50 and above 56.0% of deaths would be avoided if no-one were diagnosed late.  
5.3.3.3 One year mortality  
A total of 404 (1.6%) people died within one year of HIV diagnosis. Amongst those aged 
above and below 50 at diagnosis 83 (3.8%) and 321 (1.4%) died within 1 year of HIV 
diagnosis, respectively. These deaths accounted for 46.9% of all deaths amongst those aged 
50 and above and 49.7% of deaths amongst those aged below 50. Amongst those who were 
and were not diagnosed late, 316 (3.0%) and 88 (0.6%) died within the first year of HIV 
diagnosis. Deaths within the first year accounted for 55.2% of all deaths amongst those 
diagnosed late, compared to 35.1% amongst those not diagnosed late.  
In a Kaplan-Meier analysis, the probability of all-cause mortality by 1 year after diagnosis was 
4.0% in those aged 50 and above and 1.5% in those below 50 (p<0.001; Figure 5.3.6(A)). 
In a competing risks analysis, the cumulative incidence of AIDS-related and non-AIDS causes 
























































of death as the first event was also higher in the older age group compared to the younger 
group; 1.6% vs 0.8%, 1.4% vs 0.4% respectively by 1 year (Figure 5.3.7(A); Figure 5.3.8(A)). 
The probability of all-cause mortality was higher for those diagnosed late, than for those with 
a timely diagnosis (3.0% vs 0.7%) (Figure 5.3.6(B)). This was largely driven by AIDS-related 
mortality, which was higher for those diagnosed late than those not diagnosed late (1.6% vs 
0.2%) (Figure 5.3.7(B)). There were much smaller differences in the cumulative incidence of 
non-AIDS causes of death between those who were and were not diagnosed late (0.8% vs. 
0.3%) (Figure 5.3.8(B)).  
Older individuals diagnosed late showed the highest probability of death within 1 year of 
diagnosis due to all causes (5.6%), AIDS (2.5%) and non-AIDS (1.9%) mortality. This 
compared to 0.6%, 0.2% and 0.3% respectively in those aged less than 50 who were 




Figure 5.3.6: Cumulative incidence of all-cause mortality according to (A) age at 





















Figure 5.3.7: Cumulative incidence of AIDS-related mortality according to (A) age 






















Figure 5.3.8: Cumulative incidence of non-AIDS mortality according to (A) age at 






















5.3.3.4 Factors associated with all-cause mortality in the year following diagnosis 
In a Cox Proportional Hazards model, both older age and late diagnosis were independently 
associated with one year all-cause mortality. Those aged over 50 had 2.34 (95% CI=(1.78, 
3.07)) times the rate of death as those aged below 50 (Table 5.3.5). Late diagnosis was 
associated with a 4.4-fold (95% CI=(3.06, 6.23)) higher rate of death compared to timely 
diagnosis. The association between late diagnosis and all-cause mortality was similar in 
analyses stratified by age at diagnosis (Table 5.3.8) and there was no evidence of an 
interaction between age and late diagnosis on all-cause mortality when tested in the full model 
(aHR (95% CI)=1.11 (0.41, 2.96), p=0.84). 
Calendar year, mode of HIV acquisition, co-infection with HBV and HIV viral load were also 
independently associated with all-cause mortality (Table 5.3.5). For each year later an 
individual was diagnosed, the hazard of death from any cause decreased by 7% (95% 
CI=(0.90, 0.96)). MSM showed the lowest rate of mortality when compared those who 
acquired HIV through sex between men and women, other and unknown acquisition routes. 
Those not tested for HBV had 1.77 (1.25, 1.22) times the hazard of death over the year 
following diagnosis than those who were HBV negative. For each log10 copies/ml higher viral 
load at entry into the UK CHIC Study, the rate of mortality increased by 35% (95% CI=(1.21, 
1.51)), independently of the effect of late diagnosis. 
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Table 5.3.5: The effect of age and late diagnosis on all-cause mortality in the year 
following HIV diagnosis; results from Cox Proportional Hazards models 
 Unadjusted Adjusted 
HR (95% CI) P-value HR (95% CI) P-value 
Age 
<50 1.00 <0.001 1.00 <0.001 
>50 2.69 (2.12, 3.43)  2.34 (1.78, 3.07)  
Late 
diagnosis 
No 1.00 <0.001 1.00 <0.001 
Yes 4.62 (3.65, 5.85)  4.37 (3.06, 6.23)  
Sex 
Male 1.00 0.064 - - 
Female 1.21 (0.99, 1.48)    
Ethnicity 
White 1.00 <0.001 - - 
Black African 1.83 (1.46, 2.29)    
Black Other 1.14 (0.72, 1.80)    
Other 1.62 (1.17, 2.25)    
Unknown 2.09 (1.35, 3.23)    
Mode of 
acquisition 
MSM 1.00 <0.001 1.00 <0.001 
Heterosexual 2.59 (2.00, 3.36)  1.78 (1.33, 2.39)  
Other 3.40 (2.26, 5.10)  3.75 (2.42, 5.80)  
Unknown 6.83 (5.00, 9.33)  7.98 (5.47, 11.64)  
Year of 
diagnosis 
per year 0.92 (0.89, 0.94) <0.001 0.93 (0.90, 0.96) <0.001 
HBV co- 
infection 
No 1.00 <0.001 1.00 0.001 
Yes 2.36 (1.08, 5.16)  1.95 (0.89, 4.28)  
Not tested 2.40 (1.82, 3.17)  1.77 (1.31, 2.38)  
HCV co-
infection 
No 1.00 <0.001 - - 
Yes 0.90 (0.29, 2.87)    
Not tested 1.72 (1.34, 2.20)    
Viral load log10copies/ml 1.52 (1.37, 1.70) <0.001 1.35 (1.21, 1.51) <0.001 
HR=Hazard ratio; CI=Confidence interval; MSM=Men who have sex with men 
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5.3.3.5 Factors associated with AIDS-related mortality in the year following HIV 
diagnosis 
Older age and late diagnosis were also associated with AIDS-related mortality (Table 5.3.6). 
There was a 78% (95% CI=(1.20, 2.65)) increase in the subdistribution hazard of AIDS-
related mortality amongst those aged >50 compared to those <50. A very strong association 
was observed between late diagnosis and AIDS-related mortality in the year following 
diagnosis, with an 11.8-fold (95% CI=(5.27, 26.23)) higher subdistribution hazard for those 
diagnosed late. Amongst those aged below 50, being diagnosed late was found to increase 
the subdistribution hazard by greater than 10-fold (adjusted sHR=12.48; 95% CI=(5.24, 
29.76)) (Table 5.3.8). Amongst those aged >50, late diagnosis was associated with 9.29 (95% 
CI=(1.12, 76.91)) times the sub-distribution hazard of AIDS-related mortality. However, a test 
for an interaction effect between age and late diagnosis was not statistically significant (asHR 
(95% CI)=0.86 (0.10, 7.36), p=0.91). 
Mode of HIV acquisition, co-infection with HBV, and HIV viral load were also associated with 
one year AIDS-related mortality. Having acquired HIV through sex between men was 
protective against AIDS-related mortality, compared to other modes of acquisition. Those with 
HBV co-infection were more likely to die from AIDS-related causes than those without HBV 
co-infection (asHR (95% CI)=2.79 (1.07, 7.26)), as were those who were not tested for HBV 
(asHR (95% CI)=1.80 (1.18, 2.74)). Each log10 copies/ml higher viral load at entry into the 
UK CHIC Study, increased the subdistribution hazard of AIDS-related death by 49% (95% 
CI=(1.23, 1.81)), independently of the effect of late diagnosis. Unlike for all-cause mortality, 
no association was found between calendar year and AIDS-related mortality. 
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Table 5.3.6: The effect of age and late diagnosis on AIDS-related mortality in the 
year following HIV diagnosis; results from Fine-Gray models 
 Unadjusted Adjusted 
sHR (95% CI) P-value sHR (95% CI) P-value 
Age 
<50 1.00 <0.001 1.00 0.004 
>50 2.15 (1.49, 3.12)  1.78 (1.20, 2.65)  
Late 
diagnosis 
No 1.00 <0.001 1.00 <0.001 
Yes 8.08 (5.38, 12.13)  11.76 (5.27, 26.23)  
Sex 
Male 1.00 0.052 - - 
Female 1.33 (1.00, 1.77)    
Ethnicity 
White 1.00 <0.001 - - 
Black African 2.42 (1.75, 3.34)    
Black Other 0.87 (0.40, 1.90)    
Other 1.66 (1.02, 2.71)    
Unknown 2.14 (1.09, 4.20)    
Mode of 
acquisition 
MSM 1.00 <0.001 1.00 <0.001 
Heterosexual 3.27 (2.24, 4.77)  2.07 (1.33, 3.22)  
Other 2.11 (1.01, 4.38)  2.35 (1.10, 4.99)  
Unknown 7.93 (4.98, 12.61)  9.05 (5.31, 15.41)  
Year of 
diagnosis 
per year 0.96 (0.93, 1.00) 0.035 -  
HBV co-
infection 
No 1.00 <0.001 1.00 0.012 
Yes 3.27 (1.27, 8.43)  2.79 (1.07, 7.26)  
Not tested 2.26 (1.53, 3.34)  1.80 (1.18, 2.74)  
HCV co-
infection 
No 1.00 0.026 - - 
Yes 0.56 (0.08, 4.05)    
Not tested 1.56 (1.11, 2.20)    
Viral load log10 copies/ml 1.79 (1.48, 2.17) <0.001 1.49 (1.23, 1.81) <0.001 
sHR=Subdistribution hazard ratio; CI=Confidence interval; MSM=Men who have sex with men 
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5.3.3.6 Factors associated with non-AIDS mortality in the year following HIV 
diagnosis 
A weaker association between late diagnosis and non-AIDS mortality was observed than was 
seen for AIDS-related mortality. Late diagnosis was associated with an estimated 93% (95% 
CI=(1.19, 3.12)) increase in the sub-distribution hazard of non-AIDS mortality. Those aged 
over 50 had approximately 2.4 (95% CI=(1.51, 3.87)) times the subdistribution hazard of 
non-AIDS death of those aged below 50 years. There was no statistically significant interaction 
between age and late diagnosis in an adjusted model (asHR (95% CI)=1.52 (0.41, 5.65), 
p=0.53). In stratified models (Table 5.3.8), late diagnosis was associated with an increased 
rate of non-AIDS death amongst those aged over 50 years, but the evidence for this effect 
was weak (asHR (95%CI)=2.82 (0.81, 9.76)). Amongst those younger than 50, a 76% (95% 
CI=(1.03, 3.01)) increase in the subdistribution hazard of non-AIDS mortality was observed 
for ate diagnosis. 
Mode of HIV acquisition, co-infection with HBV and HIV viral load were associated with non-
AIDS mortality. Again, having acquired HIV through sex between men was protective against 
non-AIDS mortality, compared to other modes of acquisition (Table 5.3.7). Those who were 
not tested for HBV were more likely to die from non-AIDS causes than those without HBV co-
infection (asHR (95% CI)=1.67 (1.04, 2.67)). Each log10 copies/ml higher viral load at entry 
into the UK CHIC Study, increased the subdistribution hazard of non-AIDS mortality by 24% 
(95% CI=(1.00, 1.53)), a weaker association than was seen for AIDS-related mortality. Unlike 




Table 5.3.7: The effect of age and late diagnosis on non-AIDS mortality in the year 
following HIV diagnosis; results from Fine-Gray models 
 
Unadjusted Adjusted 
sHR (95% CI) P-value sHR (95% CI) P-value 
Age 
<50 1.00 <0.001 1.00 <0.001 
>50 3.11 (2.04, 4.75)  2.48 (1.55, 3.96)  
Late 
diagnosis 
No 1.00 <0.001 1.00 0.007 
Yes 2.99 (2.03, 4.41)  1.94 (1.20, 3.15)  
Sex 
Male 1.00 0.963 - - 
Female 0.99 (0.67, 1.45)    
Ethnicity 
White 1.00 0.370 - - 
Black African 1.50 (1.01, 2.24)    
Black Other 1.42 (0.69, 2.89)    
Other 1.34 (0.74, 2.43)    
Unknown 1.45 (0.58, 3.63)    
Mode of 
acquisition 
MSM 1.00 <0.001 1.00 <0.001 
Heterosexual 1.96 (1.27, 3.02)  1.61 (1.00, 2.64)  
Other 3.99 (2.15, 7.39)  4.34 (2.26, 8.32)  
Unknown 4.05 (2.21, 7.44)  3.77 (1.79, 7.94)  
Year of 
diagnosis 
per year 0.96 (0.91, 1.02) 0.159 - - 
HBV co-
infection 
No 1.00 <0.001 1.00 <0.001 
Yes 0.00 (0.00,0.00)  -  
Not tested 1.83 (1.17, 2.88)  1.64 (1.03, 2.64)  
HCV co-
infection 
No 1.00 0.321 - - 
Yes 1.65 (0.39, 6.92)    
Not tested 1.37 (0.90, 2.09)    
Viral load log10copies/ml 1.30 (1.06, 1.59) 0.013 1.22 (1.00, 1.50) 0.046 
sHR=Subdistribution hazard ratio; CI=Confidence Interval; MSM=Men who have sex with men 
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Table 5.3.8: Stratified analyses of the impact of late diagnosis on all-cause, AIDS-related and non-AIDS mortality in the year following HIV 
diagnosis for those aged < or >50 years 
  Age <50 Age >50 
Unadjusted Adjusted Unadjusted Adjusted 
s/HR (95% CI) P-value s/HR (95% CI) P-value s/HR (95% CI) P-value s/HR (95% CI) P-value 
All-cause 
Non-late 1.00 <0.001 1.00 <0.001 1.00 <0.001 1.00 0.001 
Late 
diagnosis 
4.69 (3.61, 6.09)  4.36 (2.96, 6.42)  3.18 (1.84, 5.48)  4.70 (1.86, 11.86)  
AIDS-related 
Non-late 1.00 <0.001 1.00 <0.001 1.00 0.001 1.00 0.039 
Late 
diagnosis 
8.23 (5.29, 12.78)  12.48 (5.24, 29.76)  5.69 (2.00, 16.24)  9.29 (1.12, 76.91)  
Non-AIDS 
Non-late 1.00 <0.001 1.00 0.034 1.00 0.030 1.00 0.10 
Late 
diagnosis 
2.81 (1.82, 4.33)  1.79 (1.05, 3.06)  2.70 (1.10, 6.64)  2.80 (0.81, 9.70)  








5.3.4 Sensitivity analyses 
5.3.4.1 Late Diagnosis 
A total of 5,428 (21.9%) individuals did not have a CD4 count result within 90 days of entry 
into the study. The likelihood of having a CD4 count at entry increased with older age, later 
year of HIV diagnosis and attending a London-based centre (Table 5.3.9). Unsurprisingly those 
with missing information with respect to other factors were less likely to have a CD4 count at 
entry into the study. Having an unknown mode of HIV acquisition (aOR (95% CI)=0.23 (0.20, 
0.26)) or unknown ethnicity (aOR (95% CI)=0.44, (0.38, 0.51)), no test for HBV (aOR (95% 
CI)=0.69 (0.62, 0.78)) or no test for HCV (aOR (95% CI)=0.22 (0.19, 0.25)) was associated 
with a significantly reduced likelihood of also having a CD4 count.  
Redefining late diagnosis to include individuals with a missing CD4 count (regardless of 
whether they also had an AIDS diagnosis), 15,927 (64.6%) individuals were classified as being 
diagnosed late; 74.3% amongst older individuals and 63.6% amongst younger. This indicates 
that the true prevalence of late diagnosis in this cohort lies between 43.3% and 64.6%. 
Factors associated with late diagnosis remained largely similar, however, missing or unknown 
data at diagnosis was now associated with an increased likelihood of being diagnosed late 
(Table 5.3.10). 
The associations between late diagnosis and mortality remained similar. Late diagnosis was 
associated with an increased likelihood of all-cause (aHR (95% CI= 5.39 (3.57, 8.14)) and 
non-AIDS (asHR (95% CI=2.64 (1.57, 4.45)) mortality. An extremely strong association was 
observed between late diagnosis and AIDS-related mortality (asHR (95% CI=23.13 (7.29, 
73.41)). Still there was no evidence that the effect of late diagnosis differed according to age 
at diagnosis for mortality due to any cause (p=0.69 all-cause mortality; p=0.59 AIDS-related 
mortality; p=0.83 non-AIDS mortality).  
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Table 5.3.9: Factors associated with presence of a CD4 count within 90 days of 
entry into the UK CHIC Study 
 Unadjusted Adjusted 
OR (95% CI) P-value OR (95% CI) P-value 
Age 
<30 1.00 <0.001 1.00 <0.001 
30-39 1.45 (1.35, 1.56)  1.51 (1.40, 1.63)  
40-49 1.50 (1.38, 1.64)  1.52 (1.38, 1.67)  
50-59 1.55 (1.35, 1.77)  1.76 (1.51, 2.04)  
>60 1.33 (1.09, 1.63)  1.65 (1.32, 2.06)  
Sex 
Male 1.00 <0.001 1.00 0.669 
Female 0.88 (0.82, 0.93)  0.98 (0.90, 1.07)  
Ethnicity 
White 1.00 <0.001 1.00 <0.001 
Black African 1.05 (0.98, 1.13)  1.28 (1.15, 1.42)  
Black Caribbean 0.76 (0.67, 0.86)  0.87 (0.75, 0.99)  
Other 0.95 (0.85, 1.05)  1.06 (0.94, 1.18)  
Unknown 0.21 (0.19, 0.24)  0.44 (0.38, 0.51)  
Mode of 
acquisition 
MSM 1.00 <0.001 1.00 <0.001 
Heterosexual 1.00 (0.94, 1.07)  1.14 (1.02, 1.27)  
Other 1.18 (1.01, 1.37)  1.08 (0.92, 1.27)  
Unknown 0.17 (0.15, 0.19)  0.23 (0.20, 0.26)  
Year of 
diagnosis 
Per year 1.11 (1.10, 1.12) <0.001 1.07 (1.06, 1.08) <0.001 
Centre 
Outside London 1.00 <0.001 1.00 <0.001 
London 1.19 (1.11, 1.28)  1.26 (1.16, 1.36)  
HBV co-
infection 
No 1.00 <0.001 1.00 <0.001 
Yes 1.01 (0.69, 1.48)  1.08 (0.73, 1.61)  
 Not tested 0.25 (0.23, 0.27)  0.69 (0.62, 0.78)  
HCV co-
infection 
No 1.00 <0.001 1.00 <0.001 
Yes 0.72 (0.46, 1.11)  0.76 (0.49, 1.19)  
Not tested 0.14 (0.13, 0.16)  0.22 (0.19, 0.25)  




Table 5.3.10: Factors associated with late diagnosis amongst those presenting for 
care at a UK CHIC centre: results from sensitivity analysis 
 Unadjusted Adjusted 
OR (95% CI) P-value OR (95% CI) P-value 
Age 
<30 1.00 <0.001 1.00 <0.001 
30-39 1.27 (1.20, 1.35)  1.23 (1.15, 1.31)  
40-49 1.58 (1.46, 1.70)  1.67 (1.54, 1.81)  
50-59 1.92 (1.70, 2.16)  2.05 (1.81, 2.33)  
>60 2.93 (1.97, 2.91)  2.47 (2.02, 3.03)  
Sex 
Male 1.00 <0.001 1.00 <0.001 
Female 1.69 (1.59, 1.79)  0.81 (0.75, 0.88)  
Ethnicity 
White 1.00 <0.001 1.00 <0.001 
Black African 2.62 (2.46, 2.79)  1.80 (1.65, 1.98)  
Black Caribbean 1.70 (1.52, 1.91)  1.34 (1.18, 1.51)  
Other 1.41 (1.30, 1.54)  1.37 (1.25, 1.51)  
Unknown 3.01 (2.59, 3.50)  1.84 (1.56, 2.17)  
Mode of 
acquisition 
MSM 1.00 <0.001 1.00 <0.001 
Heterosexual 2.54 (2.40, 2.69)  1.71 (1.55, 1.87)  
Other 1.46 (1.29, 1.64)  1.47 (1.30, 1.67)  
Unknown 4.35 (3.83, 4.94)  3.24 (2.81, 3.73)  
Year of 
diagnosis 
Per year 0.91 (0.90, 0.91) <0.001 0.93 (0.92, 0.93) <0.001 
Centre Outside London 1.00 <0.001 1.00 <0.001 
 London 0.83 (0.78, 0.89)  0.86 (0.80, 0.93)  
HBV co-
infection 
No 1.00 <0.001 1.00 0.002 
Yes 1.60 (1.29, 2.00)  1.20 (0.95, 1.51)  
Not tested 1.93 (1.82, 2.04)  1.15 (1.06, 1.25)  
HCV co-
infection 
No 1.00 <0.001 1.00 <0.001 
Yes 0.95 (0.76, 1.20)  0.88 (0.69, 1.12)  
Not tested 2.19 (2.07, 2.32)  1.45 (1.34, 1.58)  





5.4.1 Summary and interpretation 
Amongst adults newly presenting for HIV-outpatient care in the UK following diagnosis, older 
age was associated with much higher odds of late diagnosis. Amongst people aged 50 and 
above, the majority (56.2%) were diagnosed late and 41.3% had advanced 
immunosuppression. Whilst significantly lower, a large proportion (42.0%) of individuals aged 
below 50 were also diagnosed late. This high percentage of late diagnosis points to poor HIV 
testing rates in the UK, particularly amongst older individuals. This may be because older 
individuals do not perceive themselves to be at risk of HIV so do not seek a HIV test, and are 
less likely to attend sexual health clinics, where the majority of HIV tests in the UK are 
performed (559, 560). Further, healthcare providers may similarly not perceive older 
individuals to be at risk for HIV and so opportunities to provide a HIV test when these at risk 
individuals have interactions with health care services may be missed (560, 561). Strategies 
to improve HIV testing rates may involve education to improve perceptions of risk in older 
individuals for both those at-risk and healthcare providers (555). Better access to testing, 
including more routine testing at locations outside of sexual health services may also help to 
improve testing rates, for example, GPs, Accident and Emergency departments and at home, 
through self–sampling or self-test (560). Whilst universal and routine testing at GP surgeries 
or A&E departments would be an effective way of reaching a large number of individuals, this 
has been found to not be cost-effective in areas with HIV prevalence below 2 per 1,000 and 
still requires people to have contacts with healthcare services in order to be effective (562). 
Therefore targeted testing and promotion may be more appropriate in some settings, and 
identifying specific groups in need of testing interventions is important. Heterosexuals and 
those of black ethnicity were identified as having high rates of late diagnosis amongst both 
older and younger individuals in this study, as has been shown previously (221, 222, 563).  
Mortality rates were markedly high in the six months following diagnosis, with a rate of AIDS 
mortality that was double that for non-AIDS deaths. Whilst half of all deaths during this time 
were AIDS-related, a further 23% were of unknown cause and may also be AIDS-related 
(Chapter 4), meaning the true proportion could be as high as 73%. More than 1 year after 
diagnosis, the rate of AIDS-related mortality and proportion of deaths attributed to AIDS had 
declined and were, in fact, lower than the rate and proportion of deaths attributed to non-
AIDS causes. This shift in mortality is likely a consequence of people initiating ART following 
diagnosis, which protects against AIDS morbidity and mortality. Further, those with the most 
advanced disease at diagnosis are perhaps more likely to die from AIDS-related illness early 
on, such that those that survive this initial period are those with a lower risk of AIDS death. 
Amongst those who survive more than one year after diagnosis, non-AIDS morbidity and 
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mortality should become a focus of HIV care. Prior to this, AIDS-related mortality is of primary 
concern and the initiation of ART a priority to prevent this.  
Late diagnosis was found to increase the risk of mortality within one year of diagnosis. The 
attributable risk fraction for late diagnosis on one-year mortality was 62%, indicating that the 
majority of short-term mortality could be avoided if all PLWH were diagnosed in a timely 
manner. An extremely strong association was found with AIDS-related mortality, which is not 
unsurprising given the predictive value of low CD4 counts on AIDS morbidity and mortality 
(58, 557). However, although weaker, a strong association between late diagnosed and non-
AIDS mortality was also observed, independently of other factors. This association may arise 
through the effect of ongoing HIV replication on immunosuppression and inflammation, which 
have been identified as etiologic risk factors for certain non-AIDS illness such as cancer (150, 
564). Improvements in testing rates and earlier diagnosis, enabling earlier ART initiation, may 
therefore impact non-AIDS as well as AIDS-related mortality. However, according to the 
findings of this study, any reductions in rates of non-AIDS mortality would likely be smaller 
than for AIDS-related mortality. 
Those aged 50 and above at diagnosis were also at a higher risk of all-cause, AIDS-related 
and non-AIDS mortality within one year of HIV diagnosis, when compared to those aged below 
50. To some extent this higher mortality rate in older individuals might be expected due to 
natural aging. But it is also hypothesised that the impact of HIV is worse in older individuals, 
leading to faster clinical progression or so-called ‘premature aging’, which could contribute to 
shorter survival. However, in this study there was no strong evidence that late diagnosis 
carried a higher risk of short-term mortality for older individuals compared to younger. Despite 
this, a notably large absolute difference in the rate of mortality was observed in older 
individuals with late diagnosis. Considering the increasing number of new diagnoses amongst 
older individuals and large proportion of older individuals that are diagnosed late (296, 312), 
this excess mortality could contribute a disproportionate and increasingly large burden of 
mortality in the HIV-positive population in years to come. Reducing late diagnosis amongst 
older PLWH through improved testing strategies should therefore be a focus of future efforts 
to improve mortality outcomes. 
5.4.2 Comparison to the literature 
The association between older age and late diagnosis has been reported in much of the 
literature (Table 2.3.2)(265, 271, 272, 274, 275, 277). I observed that 56.2% of older and 
42.0% of younger were diagnosed late. Use of different definitions of ‘late’ diagnosis makes 
direct comparisons with some studies difficult. However, my estimates appear somewhat 
lower than UK surveillance data, which reported 68% and 57% of older and younger 
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individuals with CD4 counts <350 cells/mm3 at diagnosis between 2000 and 2007 (296). 
However, these rates were estimated excluding 25% of newly diagnosed individuals without 
a CD4 count. In our analysis, individuals without a CD4 count at study entry and no AIDS-
defining illness were assumed to have a timely diagnosis i.e. CD4 count >350 cells/mm3. With 
22.2% of individuals missing a CD4 count at entry into the study, the true proportion of late 
diagnoses in this cohort lies between 43% and 65%; 56-74% amongst older adults and 41-
59% amongst younger adults. Other European studies to similarly use a CD4 cut-off of <350 
cells/mm3 or AIDS to define late diagnosis have found overall estimates of late diagnosis 
between 42% and 56% (268, 269, 286), which are broadly in-keeping with my findings. 
In this study, 1.6% of newly diagnosed individuals died within a year of diagnosis; 3.8% of 
those aged 50 and above and 1.5% of those aged below 50. This is lower than the 10% of 
over 50s and 3% of newly diagnosed adults under 50 in the UK who died within a year of 
diagnosis according to surveillance data (294, 296). This likely reflects the fact that 
surveillance data will capture all newly diagnosed individuals, not only those who have linked 
to HIV care. Undiagnosed individuals who have extremely advanced HIV disease before 
becoming aware of their HIV status, are likely to be diagnosed in an emergency or in-patient 
care setting (293, 295) and have a high risk of mortality so may therefore die before linking 
to HIV outpatient care. In extreme cases these individuals may not be diagnosed with HIV 
until after they have died. This very high risk of mortality in those with the most advanced 
disease who do not link to care may partly explain the higher rate of mortality reported by 
HIV surveillance systems.  
I found increasing odds of late diagnosis with increasing age above 30, with an approximate 
3-fold increase in the odds of late diagnosis amongst those aged over 50. This is in agreement 
with several previous studies that have found similarly higher odds of diagnosis with advanced 
HIV with older age after adjusting for other factors, in the region of 2 to 4-fold higher (268, 
282, 283, 285, 289, 291). A multicentre study in France demonstrated individuals diagnosed 
with HIV between 50-59 and >60 to be 2.9 and 4.0 times as likely to present for care with 
advanced immunosuppression as those aged <30 (270). Reassuringly this is also consistent 
with data from UK HIV surveillance data, which reported 3.8 times higher odds of late 
diagnosis in those ≥50 compared to those aged 25-34 years (274).  
The fact that no statistically significant interaction was noted between age and late diagnosis 
supports the few studies to have assessed this previously (222). Whilst this current study 
includes a larger number of individuals, we may still be under-powered to detect an interaction 
effect, as evidenced by the large confidence intervals around these estimates. Larger studies 
with data on a larger number of events may be warranted to detect such an interaction, 
particularly bearing in mind the few studies to formally assess this question to date. 
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5.4.3 Strengths and limitations 
In this study we were able to formally assess whether there is a differential impact of late 
diagnosis on mortality for older and younger newly diagnosed HIV-positive individuals who 
entered into HIV care. Due to good ascertainment of mortality and collected information on 
cause of death, were able to do this not only for all-cause mortality but according to whether 
deaths were AIDS or non-AIDS related. A limitation of this study, as previously mentioned, is 
that we consider a group of individuals who have been able to link to HIV care. The highest 
burden of mortality amongst PLWH is following HIV diagnosis and prior to linkage to care 
(240); the sickest individuals with most advanced HIV disease at or prior to diagnosis are 
more likely to die before linking to HIV care and are therefore are not considered here. These 
results therefore may under-estimate the effect of late diagnosis on mortality. In the UK, 
approximately 92% of diagnosed individuals link to HIV care so only a small proportion of the 
diagnosed population are excluded and any impact to these analyses will hopefully be small 
(294). However, if older diagnosed individuals represent a sicker group with more advanced 
HIV disease and are less likely to link to care, it is possible that an interaction between age 
and late diagnosis exists that we are unable to capture. There may also be an under-
ascertainment of deaths in individuals over the age of 65, as ONS data is unavailable for 
deaths at ages above this cut-off (Section 4.2.4). This could attenuate any associations 
between older age and mortality. However in the whole dataset I estimated that only 156 
deaths have been missed, so the number of deaths missing in this analysis, which only 
considers one-year mortality, is likely small. 
It is possible that in using a CD4 count cut-off to define late diagnosis, individuals experiencing 
transient drops in CD4 count in acute HIV infection may be incorrectly classified as being 
diagnosed late. In the Swiss HIV Cohort Study, it was found that of all individuals considered 
to be diagnosed late according to the same criteria, 14% were actually experiencing acute 
infection (286). Further, by relying on CD4 count at diagnosis, we were unable to accurately 
define late diagnosis in individuals where the CD4 count was missing, unless an AIDS-defining 
illness was present. However, whilst making different assumptions about missing CD4 counts 
led to a difference in estimates of the proportion of late diagnoses, the factors found to be 
associated with late diagnosis and their magnitude remained unchanged, as did associations 
between late diagnosis and mortality. 
I calculated the PAR% as a measure of the amount of mortality that could be attributed to 
late diagnosis. However, a main assumption of this measure is that the association between 
late diagnosis and mortality is directly causal. This may not be a valid assumption and so 




Amongst a group of newly diagnosed PLWH that have linked to care, late diagnosis greatly 
increases the risk of short-term mortality, particularly from an AIDS-defining illness, regardless 
of the age at which HIV is diagnosed. With increasing numbers of new diagnoses amongst 
older individuals, of whom an increasing majority will be diagnosed late, we have and will 
continue to observe an extremely high excess mortality in this group. This excess mortality 
could potentially be avoided with earlier diagnosis which enables earlier uptake of ART and is 






6Chapter 6: Do the disadvantages of late 
ART persist over time in patients who 




Whilst CD4 counts at ART initiation have increased over time (374, 384), late ART initiation is 
still prevalent, and is increasingly due to late diagnosis (375). In a previous UK CHIC Study, 
nearly half of ART initiators started ART with a CD4 count <200 cells/mm3, and of those, 
approximately three-quarters did so due to late diagnosis (223).  
Initiating ART only when HIV has progressed to an advanced stage of disease with severe 
immunosuppression has been associated with poorer outcomes for people living with HIV 
(406, 417, 565-568). Recently the START trial reported on the further morbidity and mortality 
benefits of immediate ART initiation in people with CD4 counts above 500 cells/mm3, 
compared to deferring to the previous standard threshold for initiation of 350 cells/mm3 (141). 
However, these studies generally only consider outcomes over the relatively short-term 
(median follow-up <5 years), despite the fact that combination ART has now been accessible 
for over 20 years in high income countries such as the UK. Further, previous studies have 
shown that initial responses in the first few months of ART to be better predictors of outcomes 
than baseline values, with those achieving suppression and immunological response having 
better outcomes (406, 569, 570). In this study it is hypothesised that amongst those able to 
achieve and maintain a virological response on ART, differences in outcomes will reduce over 
the long-term on ART, with those starting ART with advanced immunosuppression having 
similar outcomes to those with higher CD4 counts.  
In this chapter I investigate the long-term clinical, immunological and virological outcomes of 
individuals who initiate ART with low CD4 counts who achieve and maintain viral suppression 
on ART during the first year. In particular, I consider whether differences in outcomes 
according to baseline CD4 count attenuate with longer time on ART. I then investigate whether 
any differences in outcome for those with low CD4 counts at ART initiation might be explained 





6.2.1 Patients and inclusion 
Individuals in the UK CHIC Study were eligible to be included in this analysis if they initiated 
a first-line PI- or NNRTI-based regimen (at least 1 NRTI with either a NNRTI or PI) between 
2000 and 2014 with a CD4 count <350 cells/mm3 in the 6 months prior to or up to two weeks 
following ART initiation, and at least one viral load measurement and one day of follow-up on 
ART. Individuals who died or were lost to follow-up from the study within a year of initiating 
ART were excluded, as were those who did not achieve an undetectable viral load (≤50 
copies/ml) within 6 months of ART initiation or who did not maintain viral suppression for the 
remainder of the first year. This was done as we aimed to study the effects of late ART 
initiation amongst a group of people who were able to achieve and maintain viral suppression 
for an initial period. 
6.2.2 Definitions and outcomes 
For all analyses, individuals were grouped according to the CD4 count at ART initiation: ≤100, 
101-200, 201-350 cells/mm3. The reference group for these analyses is those starting ART 
with a CD4 count between 201-350 cells/mm3, reflecting timely initiation of ART in line with 
UK HIV treatment guidelines during the period of analysis. Outcomes assessed were (i) 
changes in the CD4 count on ART, (ii) rate of viral rebound (2 consecutive viral loads >200 
copies/ml) after 1 year on ART and (iii) rate of AIDS event or death after 1 year on ART. A 
combined end-point of AIDS or death was used, with follow-up censored after the first event.  
EIC was defined using the REACH algorithm. This algorithm uses clinical factors including 
whether an individual is on ART, CD4 count, viral load and AIDS-defining illness within a 
calendar month to predict when an individual would next be expected to return for a clinic 
visit (Table 6.2.1). The predicted time-frames, as shown in Table 6.2.1, were derived from 
interviews with HIV clinicians who were asked, for their last 10 patients, what factors 
determined when the next clinic visit was scheduled to occur. For example, an individual who 
is stable on ART, with an undetectable viral load and CD4 count above 200 cells/mm3, would 
only be expected to be seen every six months. However, individuals newly diagnosed or those 
who have newly started ART would be scheduled to be seen more frequently, within two 
months. The presence of either a CD4 count, viral load, haemoglobin measure or ART start 
date was used as a proxy for a clinic visit, as data on actual clinic attendance are not reliably 
collected across all centres. If multiple visit events occurred within a single calendar month, 
these events were grouped into a single index visit. For each visit in the dataset, the next 
predicted visit is calculated, based on the algorithm in Table 6.2.1. For subsequent months of 
follow-up until the next observed visit, an individual will be classified as ‘in care’ providing 
they are not yet scheduled for a visit or they have attended within the predicted time-frame. 
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If an individual does not attend for another visit within the predicted time-frame, they will be 
classified as being out of care for those months between the predicted visit and their next 
observed visit.  
All months from the start of ART initiation to the last known visit at a UK CHIC centre classified 
as in care or not in care. The proportion of months classified as in care at any given time point 
gave the EICR. 
 
Table 6.2.1: Next scheduled visit according to clinical factors: REACH algorithm 
Conditions at time of care episode* 
Next care episode 
expected within 
Within 1 month of HIV diagnosis 2 months 
AIDS diagnosis 2 months 
Started ART 2 months 
Started new combination 2 months 
Not on ART  
CD4≤350 cells/mm3, any drop in CD4 since last visit 2 months 
CD4≤350 cells/mm3, no drop in CD4 4 months 
CD4=351-499 cells/mm3 4 months 
CD4≥500 cells/mm3, CD4 drop≥100 cells/mm3 4 months 
CD4≥500 cells/mm3, CD4 drop<100 cells/mm3, viral 
load≥100,000 copies/ml 
4 months 
CD4≥500 cells/mm3, CD4 drop<100 cells/mm3, viral 
load<100,000 copies/ml 
6 months 
Already started ART  
Viral load>200 copies/ml 2 months 
Viral load=51-200 copies/ml, does not appear to be blip § 2 months 
Viral load=51-200 copies/ml, appears to be blip 4 months 
Viral load≤50 copies/ml, CD4≤200 cells/mm3 4 months 
Viral load≤50 copies/ml, CD4>200 cells/mm3 6 months 
*If more than one condition applies at time of care episode, next care episode is expected within 
least number of months associated with those conditions 
§ Blips are defined as having a viral load of between 50 and 200 following a previous viral load of less 
than 50 
Table from: Howarth et al., Development and application of a new measure of engagement 
in out-patient HIV care (2016) (571) 
234 
 
6.2.3 Statistical Analyses 
Baseline characteristics were compared according to CD4 count at ART initiation using the 
Chi-squared test for categorical factors, Kruskal-Wallis and ANOVA for continuous factors, as 
appropriate. EICR over time on ART was described and compared according to baseline CD4 
count. Both the median (IQR) proportion of months engaged in care and percentage of 
individuals that were EIC for less than 80% of follow-up months were described. 
Both the rates of viral rebound and clinical progression to AIDS or death were compared 
according to baseline CD4 count using time-updated Poisson regression models. Time since 
ART initiation was fitted as a categorical covariate (1-3, 3-5, 5-7, 7+ years). Baseline 
covariates adjusted for included sex, ethnicity (white, black African, black other, 
other/unknown), mode of HIV acquisition (sex between men, heterosexual, other/unknown), 
baseline age, calendar year of ART initiation (2000-04, 2005-09, 2010-14), baseline viral load 
and initial regimen class (PI or NNRTI). Those covariates with p<0.1 in univariable analyses 
were included in multivariable models. To determine whether any effect of a lower CD4 count 
on these outcomes was attenuated with longer time on ART, an interaction between time and 
baseline CD4 count was then investigated. Finally, in order to assess whether any observed 
associations between baseline CD4 count and either virological rebound or clinical progression 
might be explained by differences in EIC, the full model including the interaction term was 
further adjusted for current EICR (per 10% decrease). In sensitivity analyses, EICR was 
lagged by 6 months. 
CD4 count changes were assessed as follows: Median (IQR) CD4 count, median (IQR) CD4 
count change from baseline and the proportion of individuals achieving CD4 counts ≤350, 
351-500 and >500 cells/mm3 at 1, 3, 5, 7 and 9 years after ART initiation were described and 
compared according to baseline CD4 count using univariate tests previously mentioned. The 
rate of change in CD4 count from 0-1, 1-7, 7+ years following ART initiation was then further 
compared according to baseline CD4 count in a piecewise linear mixed effects model. The 
effect of time was allowed to change and assessed separately during each time interval (0-1, 
1-7, 7+ years). These intervals were chosen based on descriptive changes in CD4 count on 
ART (Figure 6.3.4). An interaction effect between baseline CD4 count and time in each 
segment of the piecewise regression was tested to determine whether the rate of change in 
CD4 count in each time period was different for the different baseline CD4 categories. In order 
to assess whether EIC might play a role in any observed difference in changes in CD4 count, 






There were 14,236 individuals in the UK CHIC Study who had initiated a PI- or NNRTI-based 
regimen since 2000 with a CD4 count below 350 cells/mm3. Of these, 1,420 individuals died, 
were lost to study follow-up or administratively censored within 1 year of ART initiation. A 
further 3,341 failed to achieve a viral load <50 copies/ml within 6 months and 1,793 had a 
subsequent viral load >50 copies/ml during the first year on ART. The proportion of individuals 
with at least one year of follow-up who achieved viral load suppression by six months 
increased with higher baseline CD4 count (69.7% ≤100 cells/mm3, 72.4% 101-200 cells/mm3 
and 77.0% 201-350 cells/mm3). The proportion that experienced viral rebound within 1 year 
was lower with higher baseline CD4 count (14.3% ≤100 cells/mm3, 12.4% 101-200 cells/mm3 
and 9.6% 201-350 cells/mm3). There were a total of 7,682 individuals included in the present 
analysis. Those excluded were less likely to be male, white and to have acquired HIV through 
sex between men (p<0.001). They were more likely to have started between 2005 and 2009 
and to have started a PI-based regimen than those included (p <0.001).  
The characteristics of the 7,682 individuals included in the analysis are shown in Table 6.3.1, 
stratified by baseline CD4 count. Overall, 1,726 (22.5%), 1,991 (25.9%) and 3,965 (51.6%) 
initiated ART with CD4 counts ≤100, 101-200 and 201-350 cells/mm3, respectively. Those 
with a lower CD4 count at ART start were more likely to be female, heterosexual and of black 
ethnicity (all p<0.001). Those with a lower CD4 count were also more likely to have started 
ART prior to 2005 with a PI-based regimen and to have a higher baseline viral load. The 
median (IQR) years of follow-up in the dataset for those with CD4 count 201-350, 101-200 
and ≤100 cells/mm3 was 5.6 (3.4, 7.6), 7.2 (4.5, 9.8) and 7.3 (4.4, 10.3) years, with median 





Table 6.3.1: Characteristics at ART initiation according to baseline CD4 count 
 
Total 
Pre-ART CD4 count (cells/mm3) 
P-value 
≤100 101-200 201-350 
Number (%) of individuals 7682 1726 (22.5) 1991 (25.9) 3965 (51.6)  
Sex, n (%) 
Male 5876 (76.5) 1203 (69.7) 1492 (74.9) 3181 (80.3) <0.001 
Female 1804 (23.5) 523 (30.3) 499 (25.1) 782 (19.7)  
Age, median (IQR) Years 38 (32, 44) 38 (33, 45) 38 (32, 44) 37 (31, 43) <0.001 
Ethnicity, n (%) 
White 4256 (55.4) 712 (41.3) 1080 (53.5) 2464 (61.7) <0.001 
Black African 2145 (27.9) 696 (40.3) 621 (31.9) 828 (21.4)  
Black other 459 (6.0) 143 (8.3) 92 (5.0) 224 (5.6)  
Other/unknown 822 (10.7) 175 (10.1) 198 (9.7) 449 (11.3)  
Mode of acquisition, n (%) 
Sex between men 4195 (54.6) 657 (38.1) 1042 (52.3) 2496 (63.0) <0.001 
Heterosexual 3021 (39.3) 960 (55.6) 832 (41.8) 1229 (31.0)  
Other/unknown 466 (6.1) 109 (6.3) 117 (5.9) 240 (6.1)  
Year of ART, n (%) 
2000-2004 1713 (22.3) 598 (34.7) 572 (28.7) 543 (13.7) <0.001 
2005-2009 3703 (48.2) 748 (43.3) 1009 (50.7) 1946 (49.1)  
2010-2014 2226 (29.5) 380 (22.0) 410 (20.6) 1476 (37.2)  
Pre-ART VL, median (IQR) log10copies/ml 4.8 (4.3, 5.3) 5.2 (4.8, 5.6) 4.9 (4.4, 5.3) 4.6 (4.1, 5.1) <0.001 
Regimen, n (%) 
NNRTI 5815 (75.7) 1223 (70.9) 1540 (77.4) 3052 (77.0) <0.001 
PI(/r) 1867 (24.3) 503 (29.1) 451 (22.7) 913 (23.0)  







6.3.1 Engagement in Care 
EIC was high over the first 9 years on ART, but decreased over time, from 100% of months 
in care (IQR (100, 100)) after 1 year on ART, to 93.7% (87.5%, 97.7%) of months in care 
over 9 years on ART (Figure 6.3.1). The distribution of EIC differed significantly according to 
baseline CD4 count at each time point on ART, however the median proportion of months in 
care at each time point was not greatly different (Figure 6.3.1). The proportion of individuals 
with low EIC (<80%) increased with longer time on ART, from 5.4% after 1 year on ART, to 
12.9% after 9 years on ART. A small but significantly higher proportion of individuals with a 
CD4 count ≤100 cells/mm3 at baseline had low EIC at 7 and 9 years on ART (14.0% vs 11.5% 
101-200 and 11.9% 201-350 cells/mm3 after 7 years, p=0.041; 14.9% vs 12.5% and 12.2% 
after 9 years cells/mm3, p=0.017). 
 
Figure 6.3.1: Engagement in care of those still under follow-up over time on ART, 
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6.3.2 Virological rebound 
Overall, 245 (14.2%), 255 (12.8%) and 335 (8.5%) of those with a baseline CD4 count ≤100, 
101-200 and 201-350 cells/mm3 experienced virological rebound respectively. Over a total 
9,503, 10,756 and 16,810 person years of follow-up, the rate (95% CI) of virological rebound 
was 2.6 (2.3, 2.9), 2.4 (2.1, 2.7) and 2.0 (1.8, 2.2) per 100 person-years. The rate of 
virological rebound was highest in the 1-3 years after ART initiation and declined with time on 
ART in both unadjusted and adjusted analyses. The rate of rebound after 7 years on ART was 
one third of the rate 1-3 years after ART initiation (Table 6.3.2). Whilst a lower baseline CD4 
count was associated with a higher rate of virological rebound in unadjusted analyses, there 
was only a non-significant 13-14% increased rate of rebound for those with a CD4 count ≤200 
cells/mm3 compared to those with a CD4 count 201-350 cells/mm3 at baseline after adjusting 
for other factors. 
Other factors associated with virological rebound were age, ethnicity, mode of HIV acquisition, 
baseline viral load, regimen class and year of starting ART. The rate of rebound decreased 
with older age (aIRR (95% CI)=0.72 (0.66, 0.78) per 10 years older), whilst those of black 
ethnicity and heterosexual or other/unknown mode of acquisition were more likely to 
experience rebound. Starting a PI-based regimen (aIRR (95% CI)=1.72 (1.48, 1.99)) was 
associated with an increased rate of rebound. The rate of virological rebound decreased if 
ART was initiated in a later calendar year (aIRR (95% CI)=0.66 (0.57, 0.78) 2005-2009 and 
0.52 (0.41, 0.67) 2010-2014 vs. 2000-2004). 
There was no strong evidence of an interaction between baseline CD4 count and time on ART 
(p=0.12, Figure 6.3.2(A)). However, the rate of viral rebound declined fastest on ART in those 
with a baseline CD4 count ≤100 cells/mm3; from 3.2 (2.6, 4.1) by 1-3 years on ART to 0.8 
(0.6, 1.2) after 7 years on ART. Further, whilst EIC was associated with the rate of viral 
rebound in univariable (aIRR (95% CI)=1.31 (1.25, 1.36) per 10% decrease) and 
multivariable analyses (aIRR (95% CI)=1.30 (1.25, 1.35)), adjusting for current EICR did not 





Table 6.3.2: Results of Poisson Regression models showing the association 
between CD4 count at ART initiation and time on ART with the rate of viral rebound 
 Unadjusted Adjusted 
IRR (95% CI) P-value IRR (95% CI) P-value 
CD4 count (cells/mm3)    
≤100 1.29 (1.10, 1.53) 0.006 1.13 (0.95, 1.34) 0.24 
101-200 1.19 (1.01, 1.40)  1.14 (0.96, 1.35)  
201-350 1.00  1.00  
Time on ART     
1-3 years 1.00 <0.001 1.00 <0.001 
3-5 years 0.63 (0.54, 0.75)  0.61 (0.52, 0.72)  
5-7 years 0.47 (0.38, 0.58)  0.42 (0.34, 0.53)  
>7 years 0.43 (0.35, 0.54)  0.34 (0.27, 0.43)  
Age     
Per 10 years 0.71 (0.65, 0.77) <0.001 0.72 (0.66, 0.78) <0.001 
Sex     
Male 1.00 <0.001 1.00 0.92 
Female 1.53 (1.32, 1.77)  0.99 (0.81, 1.20)  
Ethnicity     
White 1.00 <0.001 1.00 0.071 
Black African 1.64 (1.42, 1.91)  1.26 (1.01, 1.57)  
Black Other 1.52 (1.16, 2.00)  1.31 (0.98, 1.75)  
Other/unknown 1.02 (0.79, 1.33)  0.93 (0.72, 1.21)  
Mode of acquisition     
Sex between men 1.00 <0.001 1.00 0.010 
Heterosexual 1.59 (1.38, 1.83)  1.27 (1.01, 1.59)  
Other/unknown 1.69 (1.29, 2.22)  1.52 (1.15, 2.01)  
Viral load at ART initiation    
Log10copies/ml 1.05 (0.95, 1.16) 0.33 -  
ART regimen class     
NNRTI 1.00 <0.001 1.00 <0.001 
PI 1.73 (1.49, 2.00)  1.72 (1.48, 1.99)  
Year     
2000-2004 1.00 0.029 1.00 <0.001 
2005-2009 0.82 (0.71, 0.95)  0.66 (0.57, 0.77)  
2010-2014 0.86 (0.69, 1.09)  0.52 (0.41, 0.67)  




Figure 6.3.2(A): Estimated rate of viral rebound over time on ART according to 
baseline CD4 count: Results from Poisson regression model test for interaction 
 
 
(B): Estimated rate of viral rebound over time according to baseline CD4 count, 








































































































6.3.3 Clinical Progression 
Of those with a baseline CD4 count ≤100, 101-200, 201-350 cells/mm3, 130 (7.5%), 103 
(5.2%) and 144 (3.6%) progressed to AIDS or death. Of those who progressed, 240 (63.7%) 
experienced an AIDS-defining illness and 137 (36.3%) died. Over a total 10,844, 12,117 and 
18,693 person years of follow-up in the ≤100, 101-200 and 201-350 cells/mm3 baseline CD4 
count groups, the corresponding incidence rates (95% CI) of clinical progression were 1.2 
(1.0, 1.4), 0.9 (0.7, 1.0) and 0.8 (0.6, 0.9) per 100 person-years of follow-up. 
Baseline CD4 count was associated with the rate of clinical progression on ART, with those 
with a baseline CD4 count <100 cells/mm3 having 1.60 (95% CI=1.24, 2.03) times the rate 
of progression as those with a baseline CD4 count 201-350 cells/mm3 after adjusting for other 
factors. The rate of clinical progression was highest in the 1-3 years following ART initiation, 
with a 16-35% lower rate of clinical progression after 3 years on ART (Table 6.3.3). The only 
other factor found to be associated with clinical progression was older age at ART initiation. 
For each 10 year increment in age at the start of ART, the rate (95% CI) of clinical progression 
was estimated to be 26% (1.12, 1.39) higher. 
There was no strong evidence of a significant interaction between baseline CD4 count and 
time on ART (p=0.63, Figure 6.3.3). The estimated rate of clinical progression declined over 
time on ART in all 3 baseline CD4 count groups. However, whilst the estimated rate (95% CI) 
of clinical progression was highest for the <100 cells/mm3 CD4 group after 1 year on ART 
(1.6 (1.2, 2.1) vs 0.9 (0.7, 1.3) and 1.0 (0.8, 1.3) per 100 person years) and up to 7 years, 
the rates (95% CI) of AIDS or death were similar amongst the three CD4 groups after 7 years 
on ART (0.8 (0.5, 1.2), 0.9 (0.6, 1.4) and 0.6 (0.4, 0.9) per 100 person years respectively, 
Figure 6.3.3). Adjusting for current EICR did not alter the associations observed between 
baseline CD4 count, time on ART and clinical progression (Figure 6.3.3(B)). However, lower 
EICR was associated with a 17% higher rate of clinical progression when included in the model 





Table 6.3.3: Results of Poisson Regression models showing the association 
between CD4 count at ART initiation and time on ART with the rate of clinical 
progression 
 Unadjusted Adjusted 
 IRR (95% CI) P-value IRR (95% CI) P-value 
CD4 count (cells/mm3)    
≤100 1.56 (1.23, 1.97) 0.001 1.59 (1.24, 2.03) 0.001 
101-200 1.10 (0.86, 1.42)  1.12 (0.87, 1.45)  
201-350 1.00  1.00  
Time on ART     
1-3 years 1.00 0.004 1.00 0.003 
3-5 years 0.65 (0.50, 0.85)  0.65 (0.49, 0.85)  
5-7 years 0.85 (0.64, 1.12)  0.84 (0.64, 1.11)  
>7 years 0.68 (0.51, 0.90)  0.65 (0.48, 0.87)  
Age     
Per 10 years 1.26 (1.13, 1.40) <0.001 1.25 (1.12, 1.39) <0.001 
Sex     
Male 1.00  -  
Female 0.93 (0.73, 1.19) 0.56   
Ethnicity     
White 1.00 0.82 -  
Black African 0.97 (0.76, 1.22)    
Black Other 1.05 (0.68, 1.61)    
Other/unknown 0.85 (0.58, 1.23)    
Mode of acquisition     
Sex between men 1.00 0.08 1.00 0.09 
Heterosexual 1.06 (0.86, 1.31)  0.97 (0.78, 1.20)  
Other/unknown 1.58 (1.09, 2.31)  1.50 (1.03, 2.20)  
Viral load at ART initiation    
Log10copies/ml 1.06 (0.91, 1.22) 0.45 -  
ART regimen class     
NNRTI 1.00 0.57 -  
PI 1.07 (0.85, 1.36)    
Year     
2000-2004 1.00 0.50 -  
2005-2009 0.94 (0.76, 1.17)    
2010-2014 0.81 (0.57, 1.16)    
IRR=Incidence Rate Ratio; CI=Confidence interval 
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Figure 6.3.3(A): Estimated rate of AIDS or death over time on ART according to 
baseline CD4 count: Results from Poisson regression model test for interaction 
 
(B): Estimated rate of AIDS or death over time on ART according to baseline CD4 
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6.3.4 CD4 count changes 
As expected, an increase in CD4 count on ART was seen across all baseline CD4 count groups. 
The median CD4 count at 1, 3, 5, 7, and 9 years after starting ART was consistently lowest 
amongst those with a baseline CD4 count ≤100 cells/mm3, and highest amongst those with a 
baseline CD4 count 201-350 cells/mm3 (Figure 6.3.4(A)). The median (IQR) change in CD4 
count up to 3 years on ART was similar across CD4 groups: 307 (218, 433) CD4 ≤100 
cells/mm3, 300 (200, 426) CD4 101-200 cells/mm3 and 305 (191, 430) CD4 201-350 
cells/mm3, respectively. There were differences in the median change in CD4 count after this 
point, with those with the highest baseline CD4 count showing the smallest changes in CD4 
count from baseline on average; 468 (350, 638) CD4 ≤100 cells/mm3, 466 (330, 610) CD4 
101-200 cells/mm3 and 437 (281, 602) cells/mm3 by 9 years, respectively (Figure 6.3.4(B), 
p=0.001). The proportion of individuals achieving a CD4 count above 500 cells/mm3 on ART 
increased over time on ART and was highest in those with a baseline CD4 count between 201-
350 cells/mm3. Amongst this group, 40.6% and 80.1% of those in follow-up at years 1 and 9 
had achieved a CD4 count above 500 cells/mm3. Conversely, amongst those with a baseline 
CD4 count ≤100 cells/mm3, only 4.3% and 53.5% had achieved a CD4 count above 500 
cells/mm3 by the same time-points (Figure 6.3.4(C), p<0.001). 
Results of piecewise mixed effects models are summarised in Figure 6.3.5. As before, CD4 
count was significantly lower on ART in those who commenced ART with a lower baseline CD4 
count (p<0.001). In the year after ART initiation, the rate of increase in CD4 count was 
significantly higher in those with baseline CD4 count ≤100 cells/mm3 compared to those with 
a CD4 201-350 cells/mm3 (14.3 (13.8, 14.9) cells/mm3 per month vs 13.0 (12.6, 13.4) 
cells/mm3 per month, p<0.001). Those with baseline CD4 count between 101-200 cells/mm3 
had a significantly lower increase in CD4 in the first year (12.1 (11.6, 12.7)) cells/mm3 increase 
per month. Compared to those with a baseline CD4 count 201-350 cells/mm3, the rate of CD4 
increase from 1-7 years after ART initiation was significantly higher in those with baseline CD4 
≤100 cells/mm3 (3.7 (3.6, 3.9) vs 4.1 (4.0, 4.2) cells/mm3 per month vs 3.3 (3.2, 3.5) 
cells/mm3 per month, p<0.001), but there was no evidence of a difference in CD4 increase 
for those with baseline CD4 101-200 (3.4 (3.2, 3.5) cells/mm3 per month, p=0.67). After 7 
years on ART, there was no significant difference in the rate of CD4 count increase according 
to baseline CD4 count: 1.3 (0.9, 1.6), 1.4 (1.0, 1.7) and 1.0 (0.7, 1.4) cells/mm3 per month 
respectively for baseline CD4 count <100, 101-200 and 201-350 cells/mm3. 
Restricting to those with high EIC, we saw similar results to the main analysis, with those with 
baseline CD4 count <100 cells/mm3 having lowest CD4 counts at all time-points on ART but 
with significantly faster increases in CD4 count between 0-1 and 1-7 years compared with the 
highest CD4 count group. There was no significant difference in CD4 change for those with 
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baseline CD4 count 101-200 cells/mm3 compared to the highest CD4 count group during these 
periods. After 7 years on ART, there was no significant difference in the rate of CD4 increase 
according to baseline CD4 count.  
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Figure 6.3.4 (A): Median (IQR) CD4 count over time since ART initiation, according 




































(C) Proportion of individuals achieving CD4 count thresholds by year since ART 
initiation and baseline CD4 count 
 































































(B) Median (IQR) CD4 count and CD4 count change over time since ART 
initiation, according to baseline CD4 count 
CD4 count (cells/mm3) 
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Figure 6.3.5: Estimated mean CD4 count over time on ART, according to baseline 
CD4 count: Results from piecewise linear mixed effects model including 
interaction term 
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6.4.1 Summary and interpretation 
Over a maximum 14 years of follow-up on ART, amongst individuals who achieved and 
maintained viral suppression during the first year of ART experience, virological, 
immunological and clinical outcomes improved for all groups, re-enforcing the benefits of ART 
for patient outcomes, regardless of the CD4 count at ART initiation. Virological and 
immunological improvement continued to be seen after seven years on ART, showing that 
ART continues to have benefits for PLWH in the long-term. 
The CD4 count at ART initiation was not strongly associated with virologic rebound after 
adjustment for other factors, and the rate of viral load rebound declined similarly over time 
for all CD4 count groups. This suggests that the CD4 count itself is not associated with the 
rate of viral rebound but that poor adherence is the primary driver of a loss of virologic control 
in those on treatment. Adjusting for ethnicity and mode of acquisition attenuated the 
association between CD4 count and viral rebound that was observed in unadjusted analyses, 
with those of black African or other black ethnicity and those who acquired HIV through routes 
other than sex between men having higher rates of rebound. This could point to lower rates 
of adherence in these groups, who were also more likely to also have a lower CD4 count at 
ART initiation. In a previous chapter, I similarly observed that these groups were more likely 
to be diagnosed late (Table 5.3.2). Further, this analysis is restricted to individuals who 
achieved and maintained viral suppression during the first year of treatment, in whom it is 
possible to assume relatively high levels of adherence overall.  
There was evidence that those with a lower CD4 count at ART initiation did not experience 
CD4 recovery to the same level as those starting with a CD4 count between 201 and 350 
cells/mm3 and were less likely to achieve CD4 counts approaching that in healthy HIV-negative 
individuals. Only half of those starting ART with a CD4 count ≤100 cells/mm3 had achieved a 
CD4 count above 500 cells/mm3 by 9 years on ART, whereas by only 3 years on ART, two-
thirds of those starting ART with a CD4 count 201-350 cells/mm3 had a CD4 count above 500 
cells/mm3. With CD4 counts in healthy HIV-negative individuals ranging from 500-1600 
cells/mm3 (54, 55), this shows that whilst the CD4 count can recover to normal levels in those 
who initiate ART late, it is less likely to occur in those starting ART with low CD4 counts and 
when it does occur takes considerably longer. In mixed effects regression models, small but 
significantly faster increases in CD4 count were observed from 0-1 and 1-7 years in those with 
a baseline CD4 count ≤100 cells/mm3. Despite this, the mean CD4 count did not recover to 
the same level as for those with baseline CD4 count 201-350 cells/mm3, remaining at least 
200 cells/mm3 lower. Similarly for those initiating ART with a CD4 count 101-200 cells/mm3, 
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CD4 counts remained at least 100 cells/mm3 lower. After seven years of ART, the rate of CD4 
count increase did not differ according to baseline CD4 count. Further follow-up is needed to 
definitively know whether CD4 counts in a similar range can be obtained for all individuals 
starting ART with CD4 ≤200 cells/mm3, however, my results suggest it is more likely that this 
group will always have a median CD4 count that does not fully recover to the level of those 
with higher baseline CD4 counts. This means that individuals who start ART in a state of 
immunosuppression are at higher risk of progression to AIDS for longer. Further, prolonged 
immunosuppression may also have consequences for non-AIDS morbidity (572, 573). These 
findings highlight the importance of prompt diagnosis and initiation of ART before severe 
immunosuppression can occur, in order to achieve optimal immune recovery. 
Whether this sub-optimal immunological response in those who start ART with 
immunosuppression will continue to have implications for clinical progression in the long-term 
on ART is unclear. Lower CD4 counts on ART are associated with a higher risk of clinical 
progression (557, 574), and, as discussed above, CD4 counts remained lower in those with 
immunosuppression at baseline, with many not recovering to levels of those in healthy HIV 
negative individuals. However, when modelling an interaction between baseline CD4 count 
and time on ART, the overall higher rate of clinical progression observed in those with a CD4 
≤100 cells/mm3 appeared to attenuate over time, with similar rates of progression after 7 
years on ART to those with a baseline CD4 count 201-350 cells/mm3. This was not a 
statistically significant interaction, but this apparent attenuation of differences after 7 years 
on ART corresponded with the time taken for the mean CD4 count in this group to reach levels 
above 500 cells/mm3 in mixed effects models. This could suggest that, although CD4 counts 
in those with immunosuppression are unlikely to reach similar levels to those with higher CD4 
counts at ART initiation, achieving CD4 counts that approach the normal range (i.e. 500 
cells/mm3) will be sufficient to remove any differences in the rate of clinical progression 
introduced by late ART initiation. In other words, it is perhaps unreasonable to expect CD4 
counts to recover to the same level as those initiating ART at a less advanced stage of disease. 
However, further follow-up including a larger number of individuals with long-term follow-up 
on ART is needed to support this hypothesis. Recently, a large European cohort collaboration 
published data on CD4 reference curves. This work followed a similar idea, identifying average 
CD4 growth trajectories after ART initiation according to baseline characteristics as a better 
indication of what constitutes a good CD4 count response than whether individuals achieve a 
pre-defined level of immune recovery such as a 100 cells/mm3 increase or CD4 count >500 
cells/mm3 (575).  
It was hypothesised that differential levels of adherence and EIC, might explain poorer 
responses to ART in those with a lower CD4 count, if observed. However, in this study there 
was no evidence that differences in EIC might explain those differences that were seen in 
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outcomes on ART. EIC was high on average in all CD4 count groups over time on ART. The 
proportion of individuals with low EIC was only significantly higher for those with a low 
baseline CD4 count (≤100 cells/mm3) after 7 years on ART. As this analysis considers a group 
who were able to achieve and maintain viral load suppression for at least 1 year on ART, we 
may have minimised any role of poor EIC by restricting to a group who have demonstrated 
an ability to remain engaged and adherent to medication. 
6.4.2 Comparison to the literature 
My finding that late ART initiation was not associated with viral rebound after 1 year on ART 
is consistent with previous analyses of UK CHIC data (576). Studies to report on an association 
between the CD4 count at which ART is initiated and virological rebound have found somewhat 
conflicting results with studies from Europe and Canada finding both evidence for (445, 447) 
and against (478, 577) an association. These studies did not have the same criteria for early 
and maintained viral suppression as in this study, and compared different thresholds of 
baseline CD4 count, which may explain the different findings. In a study of 2 outpatient clinics 
in the UK and Germany, Geretti et al., found no association between baseline CD4 count and 
virological rebound after 1 year on ART in patients who achieved and maintained viral load 
suppression during the first year (468). However, in an earlier analysis of the same two 
outpatient clinics, Phillips et al. found each 100 cells/mm3 increase in CD4 at ART initiation to 
be associated with a 17% decreased hazard of rebound, accounting for baseline viral load, 
ART drugs and demographic factors (578). The close correlation of baseline CD4 count with 
baseline viral load also makes ascertaining a true causal association difficult. At least one 
study found no association between CD4 count and rebound in univariable analyses that 
became significant after adjusting for other factors including baseline viral load (445). 
As was observed here, previous studies to consider CD4 changes on ART have almost 
exclusively found that those starting ART with a lower baseline CD4 count have poorer 
likelihood of CD4 count recovery (579-582) and consistently lower CD4 counts over time on 
ART (580, 583-585). Reports from the Swiss HIV cohort Study in the early ART era estimated 
that each 100 cells/mm3 increase at ART initiation doubled the odds of achieving a CD4 >500 
cells/mm3 and reduced the odds of a CD4 count <200 cells/mm3 by nearly 75%. However, 
changes from baseline over 4 years were similar according to baseline CD4 count and did not 
observe or explicitly model initial rapid increases in CD4 count in the first one to three months 
on ART that have been demonstrated elsewhere (565). A more recent study by Lifson et al., 
looking at CD4 responses in nearly 2000 military personnel in the US, similarly found rapid 
initial increases in CD4 count that plateaued after 4 years (586). Those with a baseline CD4 
count <200 cells/mm3 had CD4 counts on ART that were approximately 150-200 cells/mm3 
lower than for those with baseline CD4 count 201-350 cells/mm3, which is consistent with this 
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study’s findings. However, the average CD4 counts for those with a baseline CD4 count <200 
cells/mm3 remained below 400 cells/mm3 after 10 years on ART, whereas in our study they 
reached this point by 3-5 years on ART. This may have significant implications for clinical 
progression as a poor CD4 response on ART has been linked to higher rates of progression to 
AIDS and death (587). The PISCIS cohort demonstrated that achieving a CD4 count above 
200 cells/mm3 on ART was the most protective factor against clinical progression over a 
maximum 13 years of follow-up (588) and two other large cohorts demonstrated that 6 month 
CD4 response to ART predicted clinical regression, mediating any association with baseline 
CD4 count (589, 590).  
Several studies have found lower baseline CD4 count to be associated with clinical progression 
to AIDS and/or death on ART, either in comparison to a CD4 count above 350 (566, 567, 580, 
591) or in the very short-term (592). In this study, I similarly found baseline CD4 count to be 
associated with clinical progression when we did not consider the impact of time on ART, and 
found that differences in the rate of progression were greatest in the short-term. Over time 
on ART, the rate of clinical progression declined for all baseline CD4 count groups, with slightly 
(but not significantly) faster decline in the lowest CD4 count group, meaning the rate of clinical 
progression after 7 years on ART became similar. This is consistent with findings from the 
ART-CC, which found no significant difference in the rate of AIDS-defining illness according 
to baseline CD4 count between 4-6 years on ART, where one had been present prior to this 
point. However, there was still evidence of an association with all-cause mortality up to 6 
years (411). 
6.4.3 Strengths and limitations 
A strength of this study is that we were able to study nearly 8,000 individuals with a maximum 
follow-up of 14 years on ART, which is longer than all but a few other studies of this kind 
(585, 586). Despite the large number of individuals and long follow-up in this study, we may 
be underpowered to detect statistical interactions, particularly for clinical progression where 
there were a small number of events.  
Relatively few individuals were followed for more than 10 years in this cohort, meaning that 
estimates of very long-term effects are less reliable. Particularly for analysis CD4 count 
changes, LTFU or death may result in biased estimates of CD4 count responses. This is 
because those who are LTFU no longer contribute data after they leave the study, but may 
be more likely to have poorer CD4 count changes on ART than those who remain in follow-
up. This means that estimates generated amongst those remaining alive and in care may 
present a ‘best-case’ scenario of CD4 count response. In this study, LTFU was relatively low, 
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with 10% of individuals LTFU at least one year prior to the administrative censoring data of 
31st December 2014. 
Through the REACH algorithm we are able to consider the impact of EIC, but a lack of 
information on adherence is a limitation, as this is likely an important confounding factor, 
particularly for virologic outcomes. I excluded individuals who failed to achieve and maintain 
virologic suppression in the first year on ART so as to restrict to those with successful initial 
response to ART who likely adhered well. However this will probably over-estimate benefits 
of ART as compared to all starters. The reference group for these analyses is those starting 
ART with a CD4 count between 201-350 cells/mm3. For the period under study this would 
reflect timely initiation of ART in line with UK HIV treatment guidelines. Individuals starting 
ART at CD4 counts above 350 cells/mm3 in the study at this time would likely do so for reasons 
such as pregnancy, HBV co-infection or, in more recent years, for treatment as prevention, as 
opposed to for their own heath. However, following recent changes to guidelines world-wide 
as a result of evidence for treatment as prevention and the benefits of early ART for health, 
this CD4 threshold would now be considered late ART initiation. 
6.4.4 Conclusions   
In this chapter I have shown that immunological, clinical and virological outcomes improve 
over time on ART, regardless of how late ART is initiated. Individuals initiating ART with 
immunosuppression who are able to suppress their viral load and keep it suppressed during 
the first year on ART are less likely to recover their CD4 count to normal levels and are unlikely 
to have CD4 counts approaching that in those starting ART with higher CD4 counts. However, 
it is possible that clinical outcomes will become comparable to those with more timely ART 
initiation after approximately 7 years. Nevertheless, timely diagnosis and ART initiation are 
imperative to reduce the amount of time individuals spend with immunosuppression and 
increased risk of clinical progression. 
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7Chapter 7: The association between 
engagement in care and life expectancy 
 
7.1 Introduction 
Life expectancy is a main measure of health within a population. As HIV has shifted from a 
disease with extremely high mortality to a chronic disease that can be successfully managed 
with ART, so the life expectancy of the HIV-positive population has increased, contributing to 
an aging epidemic. Several studies have now shown life expectancies in the HIV population 
that are approaching that of the general population (208, 593). However, gaps between the 
HIV-positive and general population remain, particularly amongst those diagnosed late (205, 
207), those who have sub-optimal responses on ART (206) and smokers (210, 211).  
Measures of missed visits, visit frequency and visit constancy have been shown to be 
associated with higher rates of viral suppression and lower rates of mortality, independently 
of other clinical factors such as CD4 count (366, 367, 369, 371, 436, 456, 477). Whilst 
associations between such measures of EIC and mortality have previously been investigated, 
to my knowledge, its association with life expectancy has not been studied.  
In the HIV care continuum, as in the literature, frequently used measures of EIC based on 
missed visits, measures of visit frequency and time between visits are typically assessed over 
a short-term fixed period (e.g. 1 year) (215, 229, 257, 329, 335, 337, 341, 346, 367, 369). 
However, these short-term measures may over-estimate levels of EIC compared to when 
measured over the long-term (314, 316). Furthermore, they use definitions of visit frequency 
that do not allow for the fact that the frequency at which HIV care appointments are scheduled 
may change over time, as an individual’s health and clinical status changes (127). Further, 
individuals’ EIC may change over time and this may not be captured through cross-sectional 
or short-term measures. 
In this chapter I investigate differences in life expectancy in the UK CHIC Study according to 
levels of time-updated EIC during the first 5 years of ART, as measured using the REACH 
algorithm (317). In order to determine if there was any impact of EIC on life expectancy 
independently of ongoing adherence to ART, I also estimated life expectancy according to 






The CHIC2014 dataset was used for this analysis, with data requested from participating 
centres at the end of 2013. Individuals who initiated ART (≥1 drug) between 2000 and 2012, 
with at least 1 year of follow-up in the UK CHIC Study were initially included. Women who 
were pregnant at the time of starting ART were excluded from these analyses as they may 
have only initiated ART for short periods to prevent MTCT. PWID were also excluded from the 
analyses, as this was likely to be a major confounding factor, with these individuals likely to 
have both poorer engagement and higher rates of mortality.  
7.2.2 Defining Engagement in Care 
EIC was established using the previously described REACH algorithm (Section 6.2.2) (571). 
All months between ART initiation and the earliest of: 6 months after the date last seen in a 
UK CHIC centre, death or 31st December 2013 were classified as EIC or not in care. At 1, 2, 
3, 4 and 5 years after ART initiation, the engagement in care rate (EICR) was calculated as 
the proportion of months since starting ART for which an individual was classified as being in 
care. Any prolonged periods of non-engagement in care (i.e. >12 months) during the first 5 
years on ART were incorporated in the measure of EICR, as opposed to being separately 
treated as LTFU. EICR was treated as both a continuous variable and using an arbitrarily 
chosen cut-off of 80% to define high (>80%) and low (<80%) EICR. EICR was compared 
according to current viral load at each time-point on ART (1, 2, 3, 4, 5 years after ART 
initiation) using Mann-Whitney U and Chi-squared tests, as appropriate. 
7.2.3 Estimating Life expectancy 
Abridged life-tables were used for the estimation of life expectancy. Methods for constructing 
such tables were first introduced by Chiang (594). In brief, these tables apply the cohort-
observed age-specific mortality rates to a hypothetical cohort in order to estimate the 
expected number of additional years an individual can expect to live at a given age, otherwise 
known as the life expectancy at that age. Each row of the life-table refers to one of the 
specified age groupings, in this case: 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-
59, 60-64, 65+. Those aged over 65 are grouped into a single age band to allow meaningful 
estimates of mortality rates, owing to small numbers of individuals above this age in the 
cohort. In the methods for constructing abridged life-tables, special consideration is made for 
the oldest age group (65+), as this is an open-ended interval, in which the probability of death 
is assumed to be equal to 100%. Due to under-estimation of the mortality rate in the final 
open-ended age group in the cohort, the age-specific mortality rate in this age group is 
adjusted, as outlined in Table 7.2.1. This is done such that the mortality rate in this age group 
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is equal to the mortality rate in the general population (595), multiplied by an average of the 
rate ratio of mortality in the UK CHIC Study compared to the general population, for the 55-
59 and 60-64 age groups. Sensitivity analyses were performed in which the adjusted mortality 
rate in the 65+ age group was increased and decreased by 20%. The columns of the abridged 
life-table, their meaning and calculation are shown in Table 7.2.1. 
Traditionally the unadjusted age-specific mortality rate (𝑢𝑚𝑥) is calculated using observed 
deaths and person-years of follow-up in the cohort. To estimate life expectancy according to 
a factor of interest (e.g. gender), age-specific mortality rates would need to be calculated for 
men and women in the cohort separately, with separate abridged life-tables constructed for 
each sex. To estimate life expectancy according to more than one factor, mortality rates and 
abridged life tables would need to be generated for each possible combination of levels of all 
factors, thereby, splitting the cohort down into smaller sub-groups resulting in smaller 
numbers of events. This can prove problematic in practice, with estimates influenced by small 
numbers of events within each sub-group. Therefore, it is not possible to consider many 
factors at the same time when estimating life expectancy. Further, this does not allow for 
estimation of life expectancy according to continuous variables. An alternative approach is to 
use Poisson regression to estimate the age-specific mortality rates for different levels of a 
small number of independent variables that, in turn, construct the abridged life-tables. This 
approach has several advantages. Firstly, it provides smoother estimates of mortality rates 
across categories (e.g. age groups), but also allows estimation of mortality rates at any level 
of a continuous variable. Chiang also suggested methods for calculating the standard error of 
the estimated life expectancies, based on either the observed number of deaths in the cohort 
or the mortality rate in each age interval (594, 596). However, these methods are not 
appropriate when using Poisson regression to estimate mortality rates and so bootstrapping 
was used instead to generate standard errors. In order to generate bootstrapped standard 
errors, I first randomly sampled with replacement from the available dataset 1,000 times. 
Age-specific mortality rates and life expectancies were calculated for each of the 1,000 
samples. The standard deviation of the 1,000 generated life expectancies was used as an 















Trend of mortality in age 
interval x to x+n 
Fixed: 𝑎𝑖=0.5  
This assumes equal distribution of deaths 
throughout the interval 
𝒖𝒎𝒙 
unadjusted rate of death in 
age interval x to x+n 
Estimated by Poisson regression  
𝒂𝒎𝒙 
adjusted rate of death in age 
interval x to x+n 
Mortality rate in over 65 group assumed 
to be at least as high as mortality rate in 
UK population for that age band 
(www.mortality.org.uk) multiplied by the 
average rate ratio in 55-60 and 60-65 age 
groups (595).  
𝒒𝒙 
probability of death within age 
interval, x to x+n 
𝑞𝑥 =
𝑛𝑖  𝑎𝑚𝑥
1 + (1 − 𝑎𝑖)𝑛𝑖 𝑎𝑚𝑥
 
or           𝑞𝑥 = 1 , for open-ended interval 
𝒍𝒙 
survivors of hypothetical cohort 
to exact age x 
𝑙𝑥+𝑛 =  𝑙𝑥 − 𝑑𝑥 
or          𝑙𝑥 = 1000 ,   for 𝑥=20 
𝒅𝒙 
deaths experienced by 
hypothetical cohort in age 
interval x to x+n 
𝑑𝑥 = 𝑙𝑥𝑞𝑥 
or          𝑑𝑥 = 𝑙𝑥+𝑛 − 𝑙𝑥 
𝑳𝒙 
person-years lived by 
hypothetical cohort in age 
interval x 
𝐿𝑥 = 𝑛𝑖(𝑙𝑥 − 𝑑𝑥) + 𝑎𝑖𝑛𝑖𝑑𝑥 
or        𝐿𝑥 = 
𝑙𝑥
𝑎𝑚𝑥
 , for open-ended interval 
𝑻𝒙 
Summation of Lx column up to 
age x 
𝑇𝑥 = 𝐿𝑥 + 𝑇𝑥+𝑛 
or          𝑇𝑥 = 𝐿𝑥 , for open-ended interval 
𝒆𝒙
𝟎 
expected years of life 
remaining for individuals 







For these analyses, age-specific mortality rates were estimated from 1, 2, 3, 4 and 5 years 
after ART initiation, in those still known to be attending a UK CHIC centre at these time-points, 
using Poisson regression models. Separate regression models were fitted as outlined in Table 
7.2.2 for each time-point on ART, to generate age-specific mortality rates in five-year age 
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bands for different EICR and viral load criteria. An undetectable viral load was defined as a 
viral load ≤50 copies/ml and was based on the nearest viral in the 6 months prior to, or up to 
2 weeks after each time point of interest (1, 2, 3, 4 or 5 years). For calculation of mortality 
rates, follow-up was considered from each time-point of interest on ART until the earliest of 
last date seen in a UK CHIC centre plus 6 months, 31st December 2013 or death. Abridged 
life-tables were constructed for each of the EICR/viral load categories outlined in Table 7.2.2. 
For each abridged life-table I will focus on the exact ages 35 and 50 for illustration of the 
findings, and instead of life expectancy, I present expected age at death, which is calculated 
by adding the respective estimated life expectancy to each exact age.  
 
Table 7.2.2: Poisson Regression models fitted and levels of EIC and viral load 
considered in analyses 
Model Variables included in model, 
alongside age 
Levels at which life expectancy will 
be estimated 
1 (i) EICR (High (≥80%), low (<80%)) a) High EICR 
b) Low EICR 
2 (i) EICR (High (≥80%), low (<80%))  
(ii) Current viral load (≤50 copies/ml, 
>50 copies/ml) 
a) High EICR / Viral load ≤50 copies/ml 
b) High EICR / Viral load >50 copies/ml 
c) Low EICR / Viral load ≤50 copies/ml 
d) Low EICR / Viral load >50 copies/ml 
3 (i) EICR (continuous) a) EICR 100%  
b) EICR 75% 
c) EICR 50% 
d) EICR 25% 
4 (i) EICR (continuous) 
(ii) Current viral load (≤50 copies/ml, 
>50 copies/ml) 
a) EICR 100% / Viral load ≤50 copies/ml 
b) EICR 100% / Viral load >50 copies/ml 
c) EICR 75% / Viral load ≤50 copies/ml 
d) EICR 75% / Viral load >50 copies/ml 
e) EICR 50% / Viral load ≤50 copies/ml 
f) EICR 50% / Viral load >50 copies/ml 
g) EICR 25% / Viral load ≤50 copies/ml 




7.3.1 Baseline Characteristics 
There were 24,816 individuals who initiated ART between 2000 and 2012 in the UK CHIC 
Study. Of these, 1,032 (4%) pregnant women and 531 (2%) IDU were excluded from the 
analysis. After excluding those with <1 year of follow-up, a final 20,325 individuals were 
included in analyses.  
Given the exclusion criteria indicated, excluded individuals were more likely to be female, 
heterosexual or to have another non-MSM exposure, of black African ethnicity and to have 
HCV-coinfection than included individuals. Excluded individuals had a higher CD4 count and 
lower viral load at ART start and were less likely to have experienced an AIDS-defining illness 
than those included in the analysis. Excluded individuals were also more likely to have started 
ART in a more recent calendar year (all p<0.001, Table 7.3.1). 
Of those included in the analysis, the majority were male (74.3%), of white ethnicity (54.1%) 
and acquired HIV through sex between men (53.6%). Approximately 3% had either HBV or 
HCV co-infection. The median (IQR) CD4 count at starting ART was low at 240 (141, 349) 
cells/mm3, and 16.9% had experienced an AIDS event at the time of starting ART. Median 
(IQR) viral load was 4.6 (3.4, 5.2) log copies/ml. Two-thirds of individuals started an NNRTI-
based regimen; 56.7% of individuals received EFV. A quarter started treatment with a PI-
based regimens; 11.1% LPV/r, 8.1% ATV(/r) and 5.3% DRV(/r). TDF/FTC was the most 
common NRTI backbone, with half of the cohort starting this combination (Figure 7.3.1). 
Of 20,325 individuals included with at least 1 year of follow-up on ART, the median (IQR) year 
of ART initiation was 2007 (2004, 2010) and 17,463 (85.9%), 15,025 (73.9%), 12,812 
(63.0%) and 10,624 (52.3%) were still alive and retained in a UK CHIC centre by 2, 3, 4 and 










Age, median (IQR) years 35 (30, 41) 38 (32, 44) <0.001 
Sex, n (%) 
Male 2283 (50.8) 15097 (74.3) <0.001 
Female 2208 (49.2) 5228 (25.7)  
Ethnicity, n (%) 
White 1806 (40.2) 10996 (54.1) <0.001 
Black African 1877 (41.8) 6077 (29.9)  
Black other 245 (5.5) 1134 (5.6)  
Other 406 (9.0) 1806 (8.9)  
Unknown 157 (3.5) 312 (1.5)  
Year of starting 
ART, n (%) 
2000-2003 905 (20.2) 4422 (21.8) <0.001 
2004-2007 1304 (29.0) 6561 (32.3)  
2008-2012 2282 (50.8) 9342 (46.0)  
Mode of HIV 
acquisition, n (%) 
Sex between men 1147 (25.5) 10885 (53.6) <0.001 
Heterosexual 2438 (54.3) 8501 (41.8)  
Other 672 (15.0) 161 (0.8)  
Unknown 234 (5.2) 778 (3.8)  
HBV co-infection, n 
(%) 
No 1969 (43.8) 10743 (52.9) <0.001 
Yes 120 (2.7) 559 (2.8)  
Not tested 2402 (53.5) 9023 (44.4)  
HCV co-infection, n 
(%) 
No 2127 (47.4) 11858 (58.3) <0.001 
Yes 334 (7.4) 594 (2.9)  
Not tested 2030 (45.2) 7873 (38.7)  
CD4 count, median 
(IQR) 
 
cells/mm3 275 (150, 415) 240 (141, 349) <0.001 
<200 1299 (34.3) 6974 (38.0) <0.001 
CD4 count, n (%) 
200-349 1178 (31.1) 6808 (37.1)  
350-499 690 (18.2) 2768 (15.1)  
≥500 623 (16.4) 1794 (9.8)  
AIDS, n (%) 
No 3883 (86.5) 16882 (83.1) <0.001 
Yes 608 (13.5) 3443 (16.9)  
Viral load, median 
(IQR) 





Figure 7.3.1: ART regimens started in individuals with at least 1 year of follow-up 










7.3.2 Engagement in Care  
EICR was high in the first 5 years on ART, with the median proportion of months for which 
individuals were engaged in care remaining above 90% at all time-points (Figure 7.3.2). 
However, there was evidence that EICR declined with longer time on ART, with median (IQR) 
EICR of 100% (91.7, 100) at 1 year on ART and 93.3% (85.0, 96.7) at 5 years on ART 
(p<0.001). The proportion of individuals with EICR >80% was 83.4% after 1 year on ART, 
compared to 81.5% over all 5 years. 
Conversely, the proportion of individuals with an undetectable viral load increased with longer 
time on ART; 84.8%, 86.2%, 87.2%, 88.1% and 89.1% at 1, 2, 3, 4 and 5 years after ART 
initiation respectively (p<0.001). Median (IQR) CD4 count also increased with longer time on 
ART; 400 (270, 543), 450 (320, 600), 487 (350, 645), 510 (371, 673) and 530 (387, 700) 




















Regimen Class NRTI Backbone
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Figure 7.3.2: EICR at 1, 2, 3, 4 and 5 years after ART initiation 
 
 
1 year 2 years 3 years 4 years 5 years 













EICR >80% 83.7% 80.9% 82.3% 80.9% 81.7% 
 
 
7.3.2.1 Engagement in care according to viral load at each time-point on ART 
At each time-point following ART initiation, EICR was significantly lower in individuals whose 
viral load was >50 copies/ml compared to those with an undetectable viral load (Figure 7.3.3). 
There were declines in EICR with longer duration on ART for both those with undetectable 
and detectable viral load at each time point. Of those with an undetectable viral load (≤50 
copies/ml) at 1 year after ART initiation, 92% were engaged in care at least 80% of months 
(i.e. 10 out of 12 months), compared to only 80% of those with a detectable viral load 
(p<0.001). After 5 years on ART, 88.8% and 64.2% of individuals with undetectable and 




EICR was lower in individuals who did not have a viral load available at each time point on 
ART, compared to those with either detectable or undetectable viral load. However, this is 
partly due to the way that EIC is defined using the REACH algorithm, with presence of a viral 
load measure used as a proxy for a visit, alongside CD4 counts and ART start dates. With 
longer duration on ART, median (IQR) EICR in those with a missing viral load increased from 




Figure 7.3.3: EICR at 1, 2, 3, 4 and 5 years after ART initiation in those with latest 


































































≤50 c/ml 92.0% 89.5% 90.4% 88.4% 88.8% 
>50 c/ml 79.5% 71.0% 71.6% 65.3% 64.2% 
missing 19.0% 27.4% 33.6% 38.8% 42.3% 
P-value <0.001 <0.001 <0.001 <0.001 <0.001 
At 1, 2, 3, 4 and 5 years, n=1934, 1817, 1648, 1331 and 1120 were missing a viral load. 
 
7.3.3 Engagement in care and mortality  
Amongst individuals still known to a UK CHIC centre by 1, 2, 3, 4 and 5 years after ART 
initiation, there were 534 (2.6%), 410 (2.3%), 334 (2.2%), 271 (2.1%) and 216 (2.0%) 
deaths that occurred within 6 months of the last recorded visit date. Crude mortality rates 




initiation were therefore 5.2 (4.7, 5.6), 4.9 (4.4, 5.4), 5.0 (4.5, 5.6), 5.2 (4.6, 5.8) and 5.5 
(4.7, 6.2) per 1,000 person-years, respectively. 
In Poisson regression models that included age and EICR as a categorical variable (model 1), 
EICR <80% at all years after ART initiation was associated with an increased rate of mortality, 
compared to EICR ≥80% (Table 7.3.2). Whereas there was a 32% increase in the rate of 
mortality with low EICR after 1 year on ART (95% CI=1.06, 1.63), low EICR after 5 years on 
ART was associated with a 75% increased rate of mortality (95% CI=1.28, 2.37). After 
including viral load in the model (model 2), it was observed that an undetectable viral load at 
each time-point on ART was associated with a decreased rate of mortality (Table 7.3.2). The 
inclusion of viral load in the model attenuated the association between EICR and mortality 
somewhat, particularly the associations seen at 4 and 5 years after ART initiation in model 1. 
Low EICR after 4 and 5 years on ART respectively, was now only associated with a 24% (95% 
CI=0.88, 1.75) and 36% (95% CI=0.94, 1.97) increased rate of mortality after adjusting for 
viral load. There was only strong evidence of an association between EICR and mortality at 1 
and 3 years after ART initiation.  
Considering models that included age and EICR as a continuous variable (model 3), lower 
EICR was associated with an increased rate of mortality, although effect sizes were moderate 
(Table 7.3.2). As was seen in model 1, lower EICR was more strongly associated with 
increased mortality after a longer duration on ART: Incidence rate ratio IRR (95% CI)=1.04 
(0.99, 1.08) per 10% decrease in EICR by 1 year on ART and IRR (95% CI)=1.08 (1.01, 1.15) 
per 10% decrease in EICR by 5 years on ART. Including viral load in the models with 
continuous EICR (model 4), an undetectable viral load at each time-point on ART was 
independently associated with a lower rate of mortality. Contrary to what was found for 
categorical EIC, when adjusting for viral load, each 10% decrease in EICR by 1, 2, and 3 years 
on ART was associated with a greater relative increase in the mortality rate: 8% (95% 
CI=1.01, 1.16), 6% (95% CI=0.99, 1.14) and 9% (95% CI=1.01, 1.18) increase in mortality 
rate at 1, 2 and 3 years after ART initiation, respectively. The association between EICR at 4 
and 5 years and mortality was, however, attenuated by inclusion of viral load in the model: 
IRR (95% CI) of 1.02 (0.93, 1.12) per 10% decrease in EICR at 4 years and 1.06 (0.96, 1.17) 
at 5 years on ART. 
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Table 7.3.2: Associations between EIC, viral load and mortality; results from Poisson regression models to estimate mortality rates 
 Incidence rate ratio of mortality (95% Confidence Interval) 
Year 1 Year 2 Year 3 Year 4 Year 5 
Models 1  
EICR <80% (vs. >80%) 1.32 (1.06, 1.63) 1.32 (1.05, 1.67) 1.54 (1.19, 1.99) 1.64 (1.25, 2.16) 1.75 (1.28, 2.37) 
Models 2  
EICR <80% (vs. >80%) 1.31 (1.00, 1.70) 1.23 (0.94, 1.62) 1.47 (1.08, 2.01) 1.24 (0.88, 1.75) 1.36 (0.94, 1.97) 
Viral load <50 c/ml (vs. >50 c/ml) 0.43 (0.35, 0.52) 0.40 (0.32, 0.51) 0.46 (0.35, 0.60) 0.38 (0.28, 0.52) 0.35 (0.25, 0.49) 
Models 3  
EICR (per 10% decrease) 1.04 (0.99, 1.08) 1.03 (0.99, 1.08) 1.05 (1.00, 1.11) 1.06 (1.00, 1.13) 1.08 (1.01, 1.15) 
Models 4  
EICR (per 10% decrease) 1.08 (1.01, 1.16) 1.06 (0.99, 1.14) 1.09 (1.01, 1.18) 1.02 (0.93, 1.12) 1.06 (0.96, 1.17) 
Viral load <50 c/ml (vs. >50 c/ml) 0.43 (0.35, 0.52) 0.41 (0.33, 0.51) 0.46 (0.35, 0.60) 0.37 (0.27, 0.50) 0.34 (0.25, 0.48) 








7.3.4 Life expectancy 
Considering life expectancy according to level of EIC, it was found that the expected age at 
death was higher for those with higher levels of engagement at all time-points on ART (Figure 
7.3.4; Table 7.3.3). There was an approximate 5 year difference in life expectancy for those 
with >80% EICR over the first 5 years on ART, compared with <80% EIC. Similar findings 
were made for life expectancy at the exact age of 50 (Figure 7.3.4b, Table 7.3.3). The 
expected age at death at age 50 for someone with >80% EICR at all times on ART was 77, 
and for someone with EICR <80% was approximately 72 (ranging between 71.2 and 73.3). 
When EICR was considered as a continuous variable, the expected age at death remained 
stable over 5 years in those with 100% EIC, but declined in those with lower EICR over periods 
of more than 2 years on ART. Whereas the expected age at death at age 35 remained at 75 
for those with 100% EIC, the expected age at death (standard error; se) for those with 25% 
EICR at 1, 2 and 5 years on ART was 70.0 (0.7), 71.4 (0.7) and 67.9 (1.0), respectively. This 
meant a 7 year difference in life expectancy for those with 25% EICR over 5 years, compared 
to those with 100% EICR over the same period. Similarly, at exact age of 50, life expectancy 
was nearly 5 years lower in those with 25% EICR at 1 year compared to 100% EICR (expected 
age at death 72.2 vs. 76.6). Comparing levels of EICR over 5 years, life expectancy was nearly 
7 years lower with only 25% EICR as opposed to 100% EICR (expected age at death 70.4 vs. 
76.8).  
For both those with and without an undetectable viral load at each time point in ART, higher 
EICR still appeared to confer higher life expectancy and therefore older expected age at death 
compared to lower EICR (Figure 7.3.4; Table 7.3.3). Amongst those with an undetectable viral 
load at each time-point on ART, at exact ages of 35 and 50, the expected age at death (se) 
for someone with 100% EICR remained stable at 77 and 79, respectively. With 25% EIC, the 
expected age at death at age 35 was 69.0 (1.0), 71.3 (1.2), 69.0 (1.1), 74.2 (1.1) and 70.5 
(1.2) at 1, 2, 3, 4 and 5 years on ART; between 3 and 8 years lower than for 100% EIC. At 
exact age of 50, the expected age at death was 71.1 (0.9), 73.3 (0.8), 71.1 (0.8), 75.7 (0.8) 
and 72.2 (0.9) at 1, 2, 3, 4 and 5 years on ART, giving differences of between 4 and 8 years 
compared to 100% EIC. 
The expected age at death was considerably lower for those with a detectable (as opposed 
to undetectable) viral load at each time-point on ART (Figure 7.3.5, Table 7.3.3). For 
individuals with a detectable viral load but high levels of EICR (>80% or 100%), the expected 
age at death at age 35 was between 64 and 66. This was approximately 10 years lower than 
for those with an undetectable viral load and 100% EICR at all time-points on ART, and 
between 1-10 years lower than those with an undetectable viral load and only 25% EICR. At 
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exact age 35, the expected age at death (se) for someone with a detectable viral load but 
25% EICR at 1, 2, 3, 4 and 5 years on ART was very low at 61.0 (1.1), 62.3 (1.1), 61.6 (1.0), 
63.9 (1.1) and 60.7 (1.4). At exact age 50, findings were similar, with an approximate 2 year 
increase in the expected age at death than for exact age 35 (Figure 7.3.4; Table 7.3.3). 
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Figure 7.3.4: Expected age at death for exact ages 35 and 50, according to EICR 
as a (A) categorical and (B) continuous variable at 1, 2, 3, 4 and 5 years after 
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Figure 7.3.5: Expected age at death for exact ages 35 and 50, according to latest 
viral load and EICR as a (A) categorical and (B) continuous variable at 1, 2, 3, 4 
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Table 7.3.3: Expected age at death at exact ages 35 and 50, according to EICR and 
viral load criteria 
 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
Model1 
EICR >80%  
At age 35 74.7 (0.2) 75.0 (0.3) 75.2 (0.3) 75.2 (0.3) 75.2 (0.3) 
At age 50 76.6 (0.2) 76.7 (0.2) 76.8 (0.2) 76.8 (0.3) 76.8 (0.3) 
EICR <80% 
At age 35 70.1 (0.5) 71.3 (0.5) 69.9 (0.7) 69.0 (0.7) 70.2 (0.9) 
At age 50 72.3 (0.4) 73.3 (0.4) 72.1 (0.5) 71.2 (0.5) 72.7 (0.6) 
Model 2 
EICR >80% /  
VL <50 c/ml 
At age 35 77.4 (0.2) 77.7 (0.3) 77.7 (0.3) 77.9 (0.3) 77.6 (0.4) 
At age 50 79.0 (0.2) 79.2 (0.2) 79.2 (0.2) 79.3 (0.3) 79.0 (0.3) 
EICR >80% /  
VL >50 c/ml 
At age 35 65.8 (0.6) 66.3 (0.7) 67.3 (0.7) 65.7 (0.8) 64.4 (0.9) 
At age 50 68.4 (0.5) 68.8 (0.6) 69.6 (0.6) 68.4 (0.5) 67.1 (0.5) 
EICR <80% / 
VL <50 c/ml 
At age 35 72.8 (0.6) 74.9 (0.6) 71.6 (0.8) 75.0 (0.7) 71.8 (0.9) 
At age 50 74.7 (0.4) 76.6 (0.4) 73.4 (0.5) 76.6 (0.5) 73.5 (0.6) 
EICR <80% /  
VL >50 c/ml 
At age 35 63.3 (0.9) 64.1 (0.9) 63.7 (1.1) 63.9 (1.0) 61.8 (1.2) 
At age 50 66.4 (0.5) 67.0 (0.5) 66.7 (0.6) 66.8 (0.5) 65.1 (0.7) 
Model 3 
EICR 100% 
At age 35 74.6 (0.2) 75.0 (0.3) 75.1 (0.3) 75.2 (0.3) 75.2 (0.4) 
At age 50 76.6 (0.2) 76.7 (0.2) 76.8 (0.2) 76.8 (0.3) 76.8 (0.3) 
EICR 75% 
At age 35 72.8 (0.2) 74.6 (0.3) 73.2 (0.3) 73.1 (0.3) 72.9 (0.4) 
At age 50 74.8 (0.2) 76.5 (0.3) 74.9 (0.3) 74.9 (0.3) 74.8 (0.3) 
EICR 50% At age 35 71.3 (0.4) 72.8 (0.5) 71.5 (0.5) 71.3 (0.6) 70.1 (0.7) 
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 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
 At age 50 73.4 (0.3) 74.8 (0.3) 73.4 (0.4) 73.3 (0.4) 72.2 (0.5) 
EICR 25% 
At age 35 70.0 (0.7) 71.4 (0.7) 70.2 (0.8) 69.8 (0.9) 67.9 (1.0) 
At age 50 72.2 (0.4) 73.4 (0.5) 72.2 (0.5) 72.0 (0.6) 70.4 (0.5) 
Model 4 
EICR 100% / 
VL <50 c/ml 
At age 35 77.4 (0.2) 77.7 (0.3) 77.8 (0.3) 77.8 (0.3) 77.7 (0.4) 
At age 50 79.1 (0.2) 79.2 (0.2) 79.3 (0.2) 79.3 (0.3) 79.1 (0.3) 
EICR 100% /  
VL >50 c/ml 
At age 35 65.9 (0.6) 66.4 (0.7) 67.4 (0.8) 65.5 (0.8) 64.4 (0.9) 
At age 50 68.5 (0.5) 68.9 (0.6) 69.7 (0.6) 68.0 (0.6) 67.1 (0.7) 
EICR 75% /  
VL <50 c/ml 
At age 35 73.2 (0.4) 75.2 (0.4) 75.0 (0.4) 77.6 (0.4) 75.1 (0.5) 
At age 50 74.9 (0.3) 76.8 (0.3) 76.6 (0.3) 79.1 (0.3) 76.6 (0.4) 
EICR 75% /  
VL >50 c/ml 
At age 35 64.2 (0.8) 65.0 (0.8) 65.3 (1.0) 64.9 (1.3) 63.2 (0.8) 
At age 50 67.1 (0.6) 67.8 (0.6) 68.0 (0.8) 67.6 (1.2) 66.1 (1.4) 
EICR 50% / 
VL <50 c/ml 
At age 35 71.3 (0.8) 73.1 (0.7) 71.5 (0.8) 75.4 (0.7) 71.9 (0.9) 
At age 50 73.3 (0.5) 74.8 (0.5) 73.4 (0.6) 76.9 (0.5) 73.5 (0.7) 
EICR 50% /  
VL >50 c/ml 
At age 35 62.6 (0.9) 63.6 (1.6) 63.4 (1.9) 64.4 (1.9) 61.9 (1.0) 
At age 50 66.0 (0.5) 66.6 (1.3) 66.4 (1.6) 67.2 (1.6) 65.1 (1.1) 
EICR 25% /  
VL <50 c/ml 
At age 35 69.0 (1.0) 71.3 (1.2) 69.0 (1.1) 74.2 (1.1) 70.5 (1.2) 
At age 50 71.1 (0.9) 73.3 (0.8) 71.1 (0.8) 75.7 (0.8) 72.2 (0.9) 
EICR 25% /  
VL >50 c/ml 
At age 35 61.0 (1.1) 62.3 (1.1) 61.6 (1.1) 63.9 (1.0) 60.7 (1.4) 
At age 50 64.8 (0.9) 65.6 (0.9) 65.1 (1.0) 66.8 (1.0) 64.3 (1.1) 
VL=viral load; c/ml=copies/ml 
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7.3.5 Sensitivity analysis 
In a sensitivity analysis that changed the adjusted mortality rate in the over 65 age group in 
abridged life-tables, the same overall patterns were observed, with higher EICR and an 
undetectable viral load at each time point on ART associated with higher expected age at 
death (Table 7.3.4; Table 7.3.5). Varying the mortality rate in the over 65 age group resulted 
in differences in the expected age at death of approximately 5 years for those with an 
undetectable viral load. For those with a detectable viral load, in whom mortality rates were 
already higher, varying the mortality rate changed my estimates of life expectancy by 




Table 7.3.4: Expected age at death at exact age 35, changing mortality rate in over 
65’s by 20% 
 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
Model 1 
EICR >80%  
20% lower 77.6 (0.3) 78.0 (0.3) 78.2 (0.3) 78.2 (0.3) 78.2 (0.4) 
20% higher 72.7 (0.2) 73.1 (0.2) 73.2 (0.2) 73.2 (0.3) 73.2 (0.3) 
EICR <80% 
20% lower 72.0 (0.5) 73.5 (0.5) 71.8 (0.7) 70.7 (0.6) 72.2 (0.8) 
20% higher 68.8 (0.4) 69.9 (0.4) 68.7 (0.5) 67.9 (0.5) 68.8 (0.7) 
Model 2 
EICR >80% / 
VL <50 c/ml 
20% lower  80.9 (0.3) 81.3 (0.3) 81.2 (0.3) 81.4 (0.4) 81.1 (0.5) 
20% higher  75.0 (0.2) 75.3 (0.2) 75.3 (0.2) 75.5 (0.3) 75.2 (0.4) 
EICR >80% / 
VL >50 c/ml 
20% lower  66.9 (0.5) 67.5 (0.7) 68.7 (0.8) 67.0 (0.7) 65.3 (0.9) 
20% higher  65.0 (0.4) 65.5 (0.5) 66.4 (0.6) 65.1 (0.6) 63.9 (0.8) 
EICR <80% / 
VL <50 c/ml  
20% lower  75.3 (0.7) 77.8 (0.6) 73.8 (0.8) 78.0 (0.4) 74.0 (0.8) 
20% higher  71.2 (0.5) 72.9 (0.4) 70.1 (0.5) 73.1 (0.6) 70.3 (0.7) 
EICR <80% / 
VL >50 c/ml 
20% lower  64.0 (0.8) 65.0 (0.9) 64.5 (0.8) 34.7 (0.9) 62.4 (1.1) 
20% higher  62.8 (0.7) 63.6 (0.8) 63.2 (0.7) 63.3 (0.8) 61.5 (1.0) 
Model 3 
EICR 100% 
20% lower  77.6 (0.3) 77.9 (0.3) 78.1 (0.3) 78.1 (0.3) 78.1 (0.4) 
20% higher  72.7 (0.2) 73.0 (0.2) 73.1 (0.2) 73.2 (0.3) 73.2 (0.3) 
EICR 75% 
20% lower  75.3 (0.3) 77.5 (0.3) 75.7 (0.3) 75.6 (0.3) 75.4 (0.4) 
20% higher  71.1 (0.2) 72.7 (0.3) 71.5 (0.3) 71.4 (0.3) 71.2 (0.3) 
EICR 50% 20% lower  73.5 (0.5) 75.3 (0.5) 73.7 (0.5) 73.5 (0.6) 72.0 (0.6) 
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 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
 20% higher  69.9 (0.4) 71.2 (0.3) 70.1 (0.4) 69.9 (0.4) 68.8 (0.5) 
EICR 25% 
20% lower  72.0 (0.7) 73.6 (0.7) 72.1 (0.8) 71.6 (0.9) 69.4 (1.0) 
20% higher  68.8 (0.6) 69.9 (0.5) 68.9 (0.5) 68.5 (0.6) 66.9 (0.8) 
Model 4 
EICR 100% / 
VL <50 c/ml 
20% lower  81.0 (0.3) 81.3 (0.3) 81.4 (0.3) 81.4 (0.3) 81.2 (0.5) 
20% higher  75.1 (0.2) 75.4 (0.2) 75.4 (0.2) 75.5 (0.3) 75.3 (0.4) 
EICR 100% / 
VL >50 c/ml 
20% lower  67.0 (0.5) 67.6 (0.7) 68.8 (0.8) 66.5 (1.4) 65.3 (0.9) 
20% higher  65.1 (0.4) 65.6 (0.6) 66.5 (0.6) 64.8 (1.2) 63.9 (0.8) 
EICR 75% / VL 
<50 c/ml 
20% lower  75.8 (0.4) 78.2 (0.4) 77.9 (0.4) 78.6 (0.4) 78.1 (0.5) 
20% higher  71.5 (0.3) 73.2 (0.3) 73.0 (0.3) 75.3 (0.3) 73.1 (0.4) 
EICR 75% / VL 
>50 c/ml 
20% lower  65.0 (0.6) 66.0 (0.8) 66.4 (1.0)  65.9 (1.3) 63.8 (0.9) 
20% higher  63.6 (0.5) 64.3 (0.6) 64.7 (0.8) 64.3 (1.2) 62.7 (0.8) 
EICR 50% / VL 
<50 c/ml 
20% lower  73.5 (0.8) 75.6 (0.7) 73.7 (0.8) 78.4 (0.7) 74.2 (0.9) 
20% higher  69.9 (0.7) 71.4 (0.5) 70.0 (0.6) 73.4 (0.5) 70.4 (0.7) 
EICR 50% / VL 
>50 c/ml 
20% lower  63.3 (1.0) 64.3 (1.0) 64.1 (1.1) 65.3 (1.2) 62.4 (1.2) 
20% higher  62.2 (0.9) 63.0 (0.9) 62.9 (1.0) 63.8 (1.1) 61.5 (1.1) 
EICR 25% / VL 
<50 c/ml 
20% lower 70.6 (1.3) 73.5 (1.2) 70.7 (1.5) 77.1 (1.1) 72.4 (1.4) 
20% higher 67.8 (1.0) 69.9 (1.0) 67.8 (1.3) 73.2 (0.9) 69.2 (1.1) 
EICR 25% / VL 
>50 c/ml 
20% lower 61.5 (1.6) 62.9 (1.6) 62.1 (1.7) 64.7 (1.6) 61.1 (1.8) 
20% higher 60.7 (1.4) 61.8 (1.4) 61.2 (1.6) 63.4 (1.5) 60.4 (1.6) 
VL=viral load; c/ml=copies/ml 
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Table 7.3.5: Expected age at death at exact age 50, changing mortality rate in over 
65’s by 20% 
 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
Model 1 
EICR >80%  
20% lower  79.7 (0.3) 79.9 (0.3) 79.9 (0.3) 80.0 (0.3) 80.0 (0.3) 
20% higher  74.5 (0.2) 74.7 (0.2) 74.7 (0.2) 74.7 (0.2) 74.8 (0.3) 
EICR <80% 
20% lower  74.3 (0.3) 75.6 (0.3) 74.1 (0.4) 73.0 (0.4) 74.9 (0.6) 
20% higher  70.9 (0.3) 71.8 (0.2) 70.7 (0.3) 70.0 (0.3) 71.2 (0.5) 
Model 2 
EICR >80% 
VL <50 c/ml 
20% lower  82.7 (0.3) 82.9 (0.3) 82.9 (0.3) 83.0 (0.3) 82.7 (0.4) 
20% higher  76.5 (0.2) 76.7 (0.2) 76.7 (0.2) 76.8 (0.2) 76.6 (0.3) 
EICR >80% 
VL >50 c/ml 
20% lower  69.6 (0.4) 70.2 (0.3) 71.7 (0.4) 69.7 (0.3) 68.0 (0.6) 
20% higher  67.6 (0.3) 67.9 (0.2) 68.6 (0.3) 67.6 (0.4) 66.4 (0.5) 
EICR <80% 
VL <50 c/ml 
20% lower  77.4 (0.5) 79.7 (0.6) 75.8 (0.7) 79.7 (0.5) 75.8 (0.6) 
20% higher  72.9 (0.3) 74.5 (0.4) 71.8 (0.5) 74.6 (0.4) 71.9 (0.5) 
EICR <80% 
VL >50 c/ml 
20% lower  67.3 (0.5) 68.0 (0.5) 67.6 (0.6) 67.7 (0.6) 65.7 (0.7) 
20% higher  65.8 (0.4) 66.4 (0.4) 66.1 (0.5) 66.2 (0.5) 64.7 (0.6) 
Model 3 
EICR 100% 
20% lower  79.7 (0.3) 79.8 (0.3) 79.9 (0.3) 79.9 (0.3) 80.0 (0.3) 
20% higher  74.5 (0.2) 74.6 (0.2) 74.7 (0.2) 74.7 (0.3) 74.8 (0.3) 
EICR 75% 
20% lower  77.5 (0.3) 79.6 (0.3) 77.6 (0.3) 77.6 (0.3) 77.5 (0.3) 
20% higher  73.0 (0.2) 74.4 (0.3) 73.1 (0.3) 73.1 (0.3) 73.0 (0.2) 
EICR 50% 20% lower  75.7 (0.3) 77.4 (0.5) 75.8 (0.5) 75.6 (0.6) 74.3 (0.5) 
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 Expected age at death (Standard error) 
Year 1 Year 2 Year 3 Year 4 Year 5 
 20% higher  71.8 (0.3) 73.0 (0.3) 71.9 (0.4) 71.8 (0.4) 70.5 (0.3) 
EICR 25% 
20% lower  74.3 (0.4) 75.7 (0.7) 74.3 (0.8) 74.0 (0.9) 72.0 (0.6) 
20% higher  70.9 (0.3) 71.8 (0.5) 70.8 (0.5) 70.6 (0.6) 69.3 (0.5) 
Model 4 
EICR 100% 
VL <50 c/ml 
20% lower  82.7 (0.3) 83.0 (0.3) 83.0 (0.3) 83. (0.3) 82.8 (0.4) 
20% higher  74.0 (0.2) 74.9 (0.2) 74.9 (0.2) 75.0 (0.3) 74.6 (0.3) 
EICR 100% 
VL >50 c/ml 
20% lower  69.7 (0.4) 70.3 (0.7) 77.4 (0.8) 75.5 (1.4) 74.9 (0.6) 
20% higher  67.6 (0.3) 68.0 (0.6) 68.7 (0.6) 67.3 (1.2) 66.4 (0.5) 
EICR 75% VL 
<50 c/ml 
20% lower  77.6 (0.3) 79.9 (0.4) 79.7 (0.4) 82.8 (0.4) 79.7 (0.5) 
20% higher  73.6 (0.2) 74.7 (0.3) 74.6 (0.3) 76.7 (0.3) 74.6 (0.3) 
EICR 75% 
VL >50 c/ml 
20% lower  68.1 (0.4) 68.9 (0.8) 69.1 (1.0)  68.6 (1.3) 66.9 (0.6) 
20% higher  66.5 (0.3) 67.0 (0.6) 67.2 (0.8) 66.9 (1.2) 65.6 (0.5) 
EICR 50% VL 
<50 c/ml 
20% lower  75.6 (0.5) 77.5 (0.7) 75.7 (0.8) 80.0 (0.7) 75.9 (0.6) 
20% higher  71.7 (0.4) 73.1 (0.5) 71.8 (0.6) 74.8 (0.5) 72.0 (0.5) 
EICR 50% VL 
>50 c/ml 
20% lower  66.8 (0.6) 67.5 (1.6) 67.3 (1.9) 68.2 (1.9) 65.7 (0.8) 
20% higher  65.5 (0.5) 66.0 (1.3) 65.9 (1.6) 66.5 (1.6) 64.7 (0.6) 
EICR 25% VL 
<50 c/ml 
20% lower  73.0 (0.8) 75.6 (1.2) 72.9 (1.5) 78.9 (1.1) 74.3 (0.9) 
20% higher  69.9 (0.6) 71.7 (0.8) 69.9 (1.0) 74.7 (0.7) 70.8 (0.7) 
EICR 25% VL 
>50 c/ml 
20% lower  65.4 (0.9) 66.4 (1.0) 65.7 (1.3) 67.7 (1.1) 64.8 (1.1) 
20% higher  64.4 (0.8) 65.1 (0.8) 64.7 (1.1) 66.2 (1.0) 64.0 (0.9) 




7.4.1 Summary and interpretation 
In this chapter, I have shown that EIC is generally high amongst individuals who have initiated 
ART since 2000 in the UK CHIC Study, with at least one year of follow-up. The median 
proportion of months that individuals spent in care over five years on ART was 93.3%, 
corresponding to only 4 months of non-engagement in care over the five year period. Lower 
EIC was found to be significantly associated with higher rates of mortality in unadjusted 
analyses. The association between EIC and mortality became stronger at later time-points on 
ART. For EIC measured at years 1 and 5 on ART, respectively, there was a 30% and 75% 
increase in mortality rates for EICR <80%, and a 4% and 8% increase with each 10% 
decrease in EICR. The association between EIC and mortality was reflected in analyses of life 
expectancy, in which higher EIC was associated with greater life expectancy and therefore 
older expected age at death. Low EIC over a longer period of time resulted in lower expected 
age at death. This shows that this time-updated measure of EIC, which allows for differing 
frequency of scheduled visits, is a marker of long-term mortality outcomes. Further, 
interventions to improve EIC may result in increases in life expectancy for people on ART. 
Considering life expectancy according to both EIC and viral suppression, I observed a very 
clear difference in the expected age at death for those with and without viral suppression at 
all time-points on ART. Those individuals with 100% EICR but detectable virus still had 
substantially lower life expectancy than those with an undetectable viral load but only 25% 
EICR over the first 5 years on ART. Although these analyses were not adjusted for some 
important confounders, for example the CD4 count, this demonstrates the value of viral load 
as a highly predictive marker of long-term mortality. Further, this is a more important marker 
than EIC. This re-enforces the importance of good adherence and maintaining viral 
suppression on ART in order to achieve good outcomes. Interventions to improve rates of viral 
suppression, possibly through adherence support could result in the greatest improvements 
in mortality outcomes of PLWH who are receiving ART. 
However, amongst both those with and without an undetectable viral load, there still appeared 
to be an association between high EIC and greater life expectancy. For those who managed 
to achieve an undetectable viral load and who therefore could be assumed to have good 
adherence to ART, those with 100% EICR 5 years after ART initiation were estimated to be 
approximately 5 years older at death than those with only 25% EIC. This suggests that even 
amongst those who adhere well to ART and maintain good treatment responses, that there is 
a benefit to maintaining regular contact with HIV care providers. These benefits could arise 
through closer monitoring resulting in earlier detection and treatment for adverse events that 
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can influence mortality, such as viral rebound, treatment toxicity, AIDS-defining illnesses or 
other comorbidities unrelated to HIV. Another reason could be better access to other non-HIV 
care specialities for the treatment and management of co-morbid illnesses. However, as this 
is an observational study it is not possible to rule out the role of unmeasured confounding.  
Adjusting for the effect of viral suppression mostly attenuated the associations between EIC 
and mortality in Poisson regression models at later time-points on ART. This likely reflects 
greater differences in EIC according to viral suppression with longer time on ART, suggesting 
the association between EIC and viral suppression becomes stronger with longer time on ART. 
Amongst those with and without viral suppression at 5 years on ART, 88.8% and 64.2% 
respectively had high EICR; an absolute difference of 24.6% (vs. 12.5% at year 1). Due to 
the observational nature of this analysis, the direction of the association between EIC and 
viral suppression is not known. It is very likely that poor EIC may lead to lower levels of viral 
suppression, as if people are less likely to attend they may be less likely to receive 
prescriptions of ART. Conversely, both poor EIC and viral suppression may be consequences 
of other factors, including social, economic and lifestyle factors. Ongoing drug use (341, 352, 
360, 362, 460, 486), unstable housing (440, 598), care-giving responsibilities (598), low 
income (342, 348, 362) and poor mental, including depression and psychiatric illness (341, 
342, 355, 440, 492), have all previously been associated with both EIC and viral suppression, 
but are not collected in UK CHIC. The association between EIC and viral suppression suggests 
that interventions to improve either EIC or viral suppression may be better delivered in 
combination or designed such that they are able to improve both. In this cohort at each year 
after ART initiation, approximately 12% of the cohort under follow-up had a detectable viral 
load; 3% had a detectable viral load and low EIC. Therefore, it is potentially a small group of 
individuals who are in need of interventions to improve both adherence and EIC. The reasons 
for poor EIC and adherence, therefore, need to be understood and interventions tailored 
accordingly, with peer and social support likely to be important aspects of such interventions 
(599). However, the benefits of both EIC and adherence should be continuously promoted to 
all PLWH receiving ART, especially in light of the differences in life expectancy according to 
EICR for those with viral load suppression on ART in this study. 
7.4.2 Comparison to the literature 
EIC was extremely high in this group and remained so over 5 years on ART. This is consistent 
with HIV surveillance data which reports 95% retention in care from one year to the next in 
the UK (600). Other studies, mostly reporting from the United States, suggest rates of 
retention in care amongst HIV-positive individuals that are often considerably lower than in 
the current study, with estimates as low as 55% retained in care 5 years after diagnosis (239) 
and EIC of 85% in one year being considered high (335).  
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In Poisson regression analyses, the associations observed between EIC and mortality in this 
study were moderate after adjusting for current viral load in comparison to some US studies. 
Amongst newly diagnosed individuals in the Ryan White HIV/AIDS programme, missed visits 
in the year following diagnosis were associated with a 71% increase in mortality after 
adjusting for demographic factors, CD4 count and AIDS status at diagnosis (368). Failure to 
be retained in care in the 2 years following ART initiation was associated with a greater than 
2-fold increased risk of mortality adjusting for demographics and baseline HIV status in the 
CNICS cohort (371). Differences in EIC and its stronger association with mortality may, to 
some extent, be driven by the US Healthcare system, where access to care and treatment is 
not free, thus creating barriers and greater disparities in access to care and patient outcomes 
amongst those with lower socio-economic status. Substance abuse, mental health illness, 
black or other minority ethnicity and public or no health insurance are factors frequently shown 
to be predictive of poor engagement in HIV care in the US (335, 357, 367). However, the 
different measures of retention in care used also makes direct comparisons with these studies 
difficult. These different measures include measures of visit constancy, gaps between visits 
and missed visits. It has previously been shown that estimated rates of retention in care were 
dependent on the definition used. Mugavero et al., demonstrated retention in care rates that 
varied between 51% and 77% depending on the measure of retention in care that was used 
(313). 
For those with an undetectable viral load and 100% EIC, expected age at death was 
approximately 75 at exact age 35 and 77 at exact age 50. This is approaching, but still lower 
than, the expected age at death in the general population in the UK over the same period; 
which is estimated to be 82 at exact age 35 and 83 at exact age 50, using mortality statistics 
from the human mortality database (595). This is also slightly lower than was observed for 
individuals with viral suppression and good CD4 count responses on ART in previous UK CHIC 
analyses. In this analysis, men and women with viral suppression and CD4 count >350 
cells/mm3 at each time-point on ART had expected age of death of approximately 81 and 83 
at exact age 35 and 83 and 85 at exact age 50. This lower life expectancy is likely to be due 
to the fact that we have not conditioned on CD4 count in these analyses, or could reflect 
differences in the adjusted mortality rate in the abridged life tables, which can influence 
estimates of life expectancy. In this analysis I have assumed that the mortality rate in the 
over 65 age group in the HIV-positive cohort is higher than in the general population, by at 
least as much as for the 55-60 and 60-65 age groups. This means that the life expectancy in 
the UK CHIC cohort will always be lower than in the general population. In sensitivity analyses 
in which the mortality rate in the over 65 age group was lowered by 20%, the expected age 
at death increased by approximately 3 years.  
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7.4.3 Strengths and limitations 
Whilst several studies have investigated a link between retention in care and mortality, this is 
the first to my knowledge to relay this association in the context of life expectancy. Further, 
these previous studies have investigated retention as a fixed measure over a finite period of 
time. By using the REACH algorithm I was able to use a measure of EIC which is adaptive to 
changing health status of patients and more reflective of real-life changes in engagement with 
care services over time. A limitation of the REACH algorithm, as it has been developed to be 
used within the UK CHIC Study, is that it does not currently take account of co-morbidities, 
mental health, behavioural or social factors. It is likely that such factors will influence the 
decision as to timing of an individual’s next clinic visit, with more complex patients being 
scheduled for more frequent visits. As we are unable to factor these into the algorithm due to 
lack of data on these factors in the UK CHIC Study, we may over-estimate levels of EIC. 
Further, the use of CD4, viral load and ART start as proxy measures for clinic attendance may 
over-estimate engagement in care compared to actual clinic attendance (321). As this 
algorithm has not yet been validated outside of the UK CHIC Study, it is not clear to what 
extent the algorithm may over-estimate EIC.  
A large limitation of this study is that EIC was measured in a group of individuals who are 
known to still be in contact with a UK CHIC HIV clinic at each time point on ART. This, 
therefore, excludes individuals once they are LTFU from the study without re-engaging in care 
at a participating UK CHIC centre before the administrative censoring date, and leaves a group 
who are retained in care in some capacity in the analysis. Therefore these estimates of EIC 
may be higher than might be expected for all individuals starting ART, affecting the external 
generalisability of this analysis. Further, mortality rates in those retained in care may be 
somewhat lower than in those LTFU (364), resulting in an under-estimate of the association 
between EIC and mortality. Conversely, it is possible that individuals do not attend at a 
participating centre for long periods of time but are not be classified as LTFU as they were 
known to re-attend before the administrative censoring date. In this analysis, these months 
were classified as not in care and incorporated in the EICR. However, as will be discussed in 
Chapter 8, 30% of this follow-up time may be explained by individuals attending for HIV care 
elsewhere, who could be EIC. This could result in an underestimate of the true EICR in this 
group and could contribute to the small drop in EICR with longer time on ART, as there is 
more opportunity to dis-engage or transfer care with longer time on ART. However, only 0.5% 
of individuals were not in care for >9 consecutive months in the first 5 years on ART (as LTFU 
was defined in Chapter 5), meaning this is unlikely to affect my estimate of EICR.  
Some caution is needed when interpreting these results, as it cannot be assumed that the 
association between EIC and mortality/life expectancy is causal. This is the case in most cohort 
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studies, as high levels of EIC may reflect more general positive health seeking behaviours that 
result in good outcomes, but that are difficult to measure and therefore account for in 
analyses. EIC may not impact mortality directly but may be mediated through its impact on 
the CD4 count and viral load. Using the REACH algorithm to measure EIC in the CHIC cohort, 
it has been shown that the effect of EIC on mortality, lagged by 12 months, was mediated 
through the higher CD4 counts achieved by those individuals with higher EIC (372). 
Nevertheless, EIC may be a predictive marker of long-term mortality, and non-attendance for 
scheduled visits in clinical practice should be monitored and followed-up. In those with 
ongoing non-attendance, interventions are needed to re-engage individuals and promote good 
adherence. In these analyses particularly, by using life expectancy as a measure of patient 
outcomes we were not able to adjust for many confounding factors. We did however exclude 
IDU, who represent only a small proportion of the cohort, so as to exclude this as a potential 
source of confounding.  
The number of individuals aged above 60 in this cohort was low (<3%), which necessitated 
the grouping of those aged over 65, and may result in imprecise estimates of mortality rates, 
and therefore life expectancy, for older ages. By using Poisson regression models to estimate 
mortality rates I have ensured that the estimated mortality rates were smoother across age 
groups than if I were to have used crude rates. Also, by using Poisson regression, I was able 
to treat EIC as a continuous variable and estimate mortality rates at hypothetical and low 
levels of EIC. However, as previously mentioned, EIC was high in this group, and so estimates 
of mortality rates at low levels of EIC may be imprecise due to small numbers. 
Finally, I have only considered EIC over the first five years on ART. In the context of HIV as 
a life-long chronic condition, this is a relatively short period of time. It is possible for PLWH in 
this analysis to have been taking combination ART regimens for up to 14 years. EIC is likely 
to be highest after initial ART initiation, but may vary over time with changing life 
circumstances and this could influence future mortality. A possible limitation of life expectancy 
estimates is that they use current mortality rates in a population to predict future mortality. 
If mortality rates were to change significantly in future years, these estimates may not reflect 
the mortality actually experienced by this cohort as it ages. 
7.4.4 Conclusions 
Whilst adherence to ART and maintaining viral suppression is vital in order to achieve a normal 
life expectancy amongst PLWH, maintaining good engagement with HIV care services may 
also play a role in achieving good life expectancy. Interventions to improve EIC are likely to 
have the greatest impact amongst those with poor adherence to ART, who are a relatively 
small group of people. As levels of adherence and EIC are likely linked, it is important to 
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understand what factors influence both poor adherence and EIC, and target behavioural 
interventions that use a holistic approach to improving both.  
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8Chapter 8: A longitudinal continuum of care 
 
8.1 Introduction 
The HIV care continuum is traditionally depicted as a bar chart, displaying a ‘snap-shot’ of the 
proportion of all HIV-positive individuals at each stage of the HIV care pathway at a particular 
time-point (213). It is a useful monitoring tool to display up-to-date information on the 
potential for ongoing transmission and success of HIV care programs within a given population 
and has gained much popularity in recent years, particularly in light of UNAIDS targets to 
reduce HIV incidence (214). However, as previously mentioned in Chapter 2, this framework 
has some limitations for understanding programme success as measured by patient outcomes. 
Firstly, a traditional care continuum only includes those who are known to be alive and 
therefore does not consider mortality, which is a key measure of patient health. Those who 
are lost from the continuum at each stage, and potentially most in need of intervention are 
not well described and their outcomes are unknown. Further, the later stages of the continuum 
are assessed as fixed outcomes in a cross-sectional framework with assumed sequential 
progression through each level of the cascade. However, in practice, individuals’ EIC, ART use 
and viral suppression status may change over time.  
As a result, new methods of measuring the HIV care continuum have been utilised in cohort 
studies that combat some of these limitations. Powers et al., conceptualise a “states and 
transitions” framework that describes the numbers of individuals in each stage of the care 
continuum as well as the rate of transition both forward and backward between stages (243). 
Both Haber et al., and Lesko et al., consider time-to-event analyses of each of the stages of 
the cascade, with Lesko et al., also including the outcomes of death and loss to care relative 
to ART initiation with time from enrolment (242, 601). In contrast, Krentz et al., more simply, 
depict the proportion of deaths occurring at each stage of the continuum as a way of 
incorporating mortality and showing where the greatest burden of mortality lies along the HIV 
care pathway (240). Whilst the latter incorporate mortality and/or loss-to follow-up along the 
continuum of care, the outcomes along the continuum are still treated as fixed and are not 
allowed to vary with time. 
It is important to identify gaps in the HIV care continuum to understand what interventions 
should be targeted in which individuals to make the biggest improvements in outcomes. The 
biggest gaps in the care continuum may not be the same for all populations. Several cohort-
driven estimates of the care continuum have reported disparities in retention in care, ART use 
and viral suppression according to ethnicity (227, 232, 314, 328, 333, 335, 379), mode of HIV 
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acquisition (225, 235, 242, 333, 379), age (225, 227, 228, 232, 235, 237, 328, 335, 379, 602, 
603) and sometimes sex (225, 228, 256), with PWID, those of black ethnicity and young 
adults often doing worse. However, UK national surveillance estimates of the HIV care cascade 
for 2015 report little or no disparity in the proportions of HIV-infected individuals retained in 
care, in receipt of ART or virologically suppressed, with all except the undiagnosed proportion 
reaching the UNAIDS 90-90-90 targets. Extrapolating from the most recent estimates of the 
care continuum in the UK, 96% of those diagnosed and seen for care in 2015 were on ART 
and 90% had viral suppression (70). 
In this chapter, I present a method I devised to generate a longitudinal care continuum. This 
longitudinal continuum of care illustrates the passage through the HIV care continuum, after 
linkage to care, for a cohort of HV-positive individuals over a 10 year period, incorporating 
LTFU and mortality. I further estimate this according to demographic factors and CD4 count 
at diagnosis in order to describe potential disparities in HIV care experience and outcomes.  
 
8.2 Methods 
8.2.1 Inclusion criteria 
This analysis used data from the CHIC2015 dataset, for which data was requested at the end 
of 2014. The entry criteria for this analysis were broad and initially only restricted to individuals 
with a cohort entry date between 2000-2004, to allow for a maximum of 10 years’ follow-up. 
In a sub-set analysis that assessed transfer of care after loss to follow-up from the UK CHIC 
Study (LTCFU), only individuals whose UK CHIC record could be linked to a record in SOPHID 
were included. For analyses of CD4 count at diagnosis, I restricted to those with a diagnosis 
date no more than 6 months prior to entry. Individuals were required to have a CD4 count 
available within 3 months of entry to be included in analyses stratified by CD4 count at 
diagnosis.  
8.2.2 Generating the longitudinal continuum of care 
For the purposes of this analysis, individuals were followed from the date of entry into the UK 
CHIC Study. All individuals were given an artificial follow-up end date that was 10 years after 
entry into the cohort, regardless of death or loss to follow-up from UK CHIC (LTCFU). For 
each month during this 10 year period, individuals were classified into categories as defined 
in Table 8.2.1. These categories related to current EIC, ART and viral load status as well as 
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the occurrence of LTCFU and death. EIC was defined on a month by month basis according 
to the REACH algorithm (Table 6.2.1)(317).  
In order to assess transfer of care when individuals are LTCFU, the previously established 
linkage to SOPHID was used (Section 4.2.4). For records that had been identified as a match 
with a SOPHID record, data was provided which indicated whether an individual had been 
seen for care in a given calendar year at a HIV clinic that did not participate in UK CHIC.  
There were 10 stages defined in the longitudinal continuum of care. These are outlined in 
Table 8.2.1. Current viral load suppression was defined as a most recent viral load <200 
copies/ml, recorded in the previous 9 months. A cut-off of 200 copies/ml was used to be 
consistent with the cut-off used in a typical HIV continuum of care (70). If no viral load was 
recorded in the previous 9 months, then the individual was assumed to have a detectable viral 
load. Once an individual was reported to have died, they were categorised as dead for all 
remaining months, to the end of their 10 year follow-up period. LTCFU was considered to 
have started once an individual had been “not in care” (NIC), using the REACH algorithm, for 
at least 9 months consecutively. Thus, an individual who was next expected to return for care 
within 6 months would be classified as LTCFU once they had not attended for care for at least 
15 months. Similarly, an individual expected to next attend for care within 4 months would be 
considered LTCFU once they had not attended for at least 13 months. In the analysis that 
restricted to those linked to a SOPHID record, those LTCFU were further divided as either a 
transfer or true loss to care (LTC) as follows. Months in which individuals had been classified 
as LTCFU were defined as transfer providing there was a SOPHID record of attendance at a 
non-CHIC centre for that calendar year. If a month was classified as LTCFU and had not been 




Table 8.2.1: Stages of the time-updated Continuum of care 
Stage Definition Notation 
1 
Engaged in Care  
Not on ART with CD4 >350 cells/mm3  
Not undetectable 
EIC / ART_ (CD4 >350) 
2 
Engaged in Care  
Not on ART with CD4 <350 cells/mm3 or  
CD4 unavailable 
Not undetectable 
EIC / ART_ (CD4 <350) 
3 
Not in care  
Not on ART  
Not undetectable 
NIC / ART_ 
4 
Engaged in care  
Started ART  
Not undetectable 
EIC / ART+ /VL>200 
5 
Not in care  
Started ART 
Not undetectable 
NIC / ART+ / VL>200 
6 
Engaged in care  
Started ART 
Undetectable 
EIC / ART+ / VL <200 
7 
Not in care 
Started ART 
Undetectable 
NIC / ART + / VL <200 
8 Dead Dead 
9 
Lost from CHIC follow-
up (LTCFU) 
9* 
True loss to 
care 
True LTFU 
10* Transfer Transfer 
*Only defined for individuals linked to a SOPHID record. 
 
8.2.3 Statistical methods 
Each month of follow-up over the 10 years was represented on a stacked area chart to 
illustrate how people move between stages of the continuum over time. Changes over 
calendar time in the longitudinal continuum of care were next investigated by plotting the 
stacked area chart stratified by year of cohort entry. For this analysis, the period of follow-up 
was reduced to only 5 years and individuals who entered the cohort between 2004-2009 were 
additionally included. The longitudinal continuum of care was then drawn according to year 
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of entry; 2000-2003, 2004-2007, 2008-2009. These periods were chosen due to changes in 
HIV treatment guidelines over when to initiate ART in 2008.  
For this reason also, comparisons of the longitudinal continuum stratified by demographic 
factors (age (<30, 30-39, 40-49, 50+); sex (male, female); ethnicity (white, black, 
other/unknown); mode of acquisition (sex between men, heterosexual, other/unknown)) and 
CD4 count at diagnosis (≤200, 201-350, >350 cells/mm3) were also plotted, restricting 
analyses to the contemporaneous cohort with cohort entry dates of 2008-2009. 
8.2.4 Sensitivity Analyses 
Firstly we tested the definition of ART use by considering treatment interruptions. As ART 
should be life-long when initiated, the main analysis treats individuals who have initiated ART 
as ‘on ART’ thereafter. However, it is possible that individuals will interrupt treatment. 
Therefore, in a sensitivity analysis, any person-month after ART initiation for which an 
individual did not appear to be taking ART according to drug start and stop dates was classified 
as a treatment interruption. This approach was not taken for the main analysis due to a 
relatively low level of confidence in some drug stop dates, particularly as these are imputed 
for centres where UK CHIC receives only prescription ART data which only gives the date a 
new prescription is issued. Further, not all treatment interruptions will be captured through 
ART data as some individuals may stop taking their ART without their doctor’s knowledge. 
Analyses were also conducted that tested the definition of LTCFU by changing the number of 
cumulative months required to be not in care to either 6 or 12 months. Finally, the 10 year 
longitudinal continuum was re-estimated only including individuals who had at least 2 visit 
dates in the UK CHIC cohort. This is more consistent with previous analyses of the REACH 
algorithm (372, 571) and excludes attenders who have only one record of contact with a clinic. 
Such individuals would become almost immediately LTCFU and are less likely to have 
information available on demographic or clinical characteristics and outcomes. 
 
8.3 Results 
A total of 13,762 individuals entered the UK CHIC Study between 2000 and 2004. The 
characteristics of these individuals are displayed in Table 8.3.1. The majority were male 
(65.2%), with 6107 (44.4%) aged 30-39 at entry and 952 (6.9%) aged 50 years or above. 
Similar proportions were of white (43.5%) and black (43.6%) ethnicity. Approximately half of 
individuals reported heterosexual mode of HIV acquisition (49.0%) and 39.3% reported sex 
between men as their mode of HIV acquisition. A total of 10,611 (77.1%) had been diagnosed 
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less than 6 months prior to entry and just over a quarter of those newly diagnosed had a CD4 
count <200 cells/mm3 at diagnosis. In total, 12,811 UK CHIC records were linked to a SOPHID 
record; a 93.1% linkage rate. Characteristics of those linked to a SOPHID record were similar 
to that of the whole cohort (Table 8.3.1). 
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Table 8.3.1: Characteristics of included individuals 










<30 4287 (31.2) 3182 (32.0) 3344 (29.7) 1414 (26.6) 
30-39 6107 (44.4) 4458 (44.8) 4669 (41.5) 2030 (38.2) 
40-49 2404 (17.5) 1650 (16.6) 2379 (21.1) 1324 (24.9) 
>50 952 (6.9) 664 (6.7) 867 (7.7) 550 (10.3) 
Sex 
Male 8963 (65.2) 6565 (66.0) 7416 (65.9) 3686 (69.3) 
Female 4788 (34.8) 3389 (34.1) 3843 (34.1) 1632 (30.7) 
Ethnicity 
White 5990 (43.5) 4399 (44.2) 5106 (45.4) 2543 (47.8) 
Black 6001 (43.6) 4334 (43.5) 4914 (43.6) 2087 (39.2) 
Other/unknown 1771 (12.9) 1221 (12.3) 1239 (11.0) 688 (12.9) 
Mode of acquisition 
Sex between men 5414 (39.3) 4054 (40.7) 4617 (41.0) 2205 (41.5) 
Heterosexual 6739 (49.0) 4873 (49.0) 5477 (48.9) 2355 (44.3) 
Other/unknown 1609 (11.7) 1027 (10.3) 1165 (10.3) 758 (14.3) 
Newly diagnosed at entry 10611 (77.1) 7948 (79.9) 8110 (72.0) 3737 (70.3) 
CD4 at diagnosis 
<200 2957 (21.5) 2112 (21.2) 2599 (23.1) 1062 (20.0) 
201-350 1844 (13.4) 1310 (13.2) 1787 (15.9) 896 (16.8) 
>350 3112 (22.6) 2204 (22.1) 3223 (28.6) 1664 (31.3) 







8.3.1 A 10 year longitudinal continuum of care 
Figure 8.3.1 shows a time-updated 10 year continuum of care for the 13,762 individuals who 
entered the UK CHIC cohort between 2000 and 2004. Over 10 years, a total of 627,867 
(38.0%) person-months were spent on ART with a viral load <200 copies/ml. Of 317,320 
(29.2%) person-months spent ART-naive, 167,361 (44.7%) were classified as not in care, and 
85,967 (22.9%) were spent EIC but with a CD4 count <350 cells/mm3. A total of 670 (6.3%) 
individuals died within 10 years of cohort entry, meaning a total of 53,210 (4.2%) person-
months were lost. Just over a quarter of individuals who entered the cohort were LTCFU by 
10 years after cohort entry. 
The proportion of individuals not to have initiated ART decreased with time from entry (85.0% 
at entry to 6.7% at 10 years), and the proportion of time spent ART experienced increased 
(from 25.2% at entry to 57.8% at 10 years). Whilst 31.3% of individuals who had started ART 
at entry had a viral load <200 copies/ml (7.9% of all individuals), this increased to 78.0% 
after 10 years. Overall, 45.1% of individuals in the cohort had a viral load ≤200 copies/ml 10 
years after entry into care. As a proportion of all person-months spent ART naive, 25.8% of 
months were spent not engaged in care (NIC). However, of all person-months post-ART 
initiation, engagement in care was higher with 14.4% of months classified as NIC. 
Restricting to 12,811 individuals linked to a SOPHID record (Figure 8.3.2) showed similar 
results. The proportion of individuals that were LTCFU increased from 5.0% (n=637) at 12 
months after entry, to 28.2% (n=3612) at 120 months after entry. When further categorised 
as true LTC and transfer, true LTC remained constant at approximately 21% of person-months 
from 2 years onwards, whereas transfer increased from 4.3% of all person-months at 2 years 
to 7.4% of person months at 10 years. As a proportion of person-months LTCFU, transfer 
increased from 17.2% at 2 years to 26.4% at 10 years.  
In order to see how our longitudinal continuum of care was comparable to a national cross-
sectional continuum, we considered the proportion of individuals that have started ART and 
are suppressed, of all those still alive and in follow-up. By 2, 5 and 10 years after cohort entry, 
72.4%, 68.4% and 65.9% of all individuals in the cohort were still alive and not lost to UK 
CHIC follow-up. Of those still accessing care at a UK CHIC centre at 2, 5 and 10 years after 
cohort entry, 65.3%, 78.8% and 90.9% had started ART. Of those to have started ART, 
69.8%, 77.1% and 78.5% had a suppressed viral load; 45.6%, 60.8% and 71.4% of those 




Figure 8.3.1: Longitudinal Continuum of care over 10 years 
 
% in each stage of continuum Months from cohort entry 
1 24 48 72 96 120 
EIC / ART _ (CD4 >350) 16.8 12.4 8.2 6.1 4.4 3.3 
EIC / ART _ (CD4 <350) 52.7 7.4 5.1 3.6 2.8 2.3 
EIC / ART + / VL >200 15.5 8.3 7.2 6.5 6.2 6.8 
EIC / ART + / VL <200 7.6 30.4 35.9 40.0 42.7 42.6 
NIC / ART + / VL <200 0.3 1.6 1.5 1.8 2.0 2.5 
NIC / ART + / VL >200 1.8 5.7 5.8 5.4 5.7 5.9 
NIC / ART _ 4.7 5.6 3.7 2.5 1.6 1.1 
LTCFU 0.0 25.9 29.0 29.5 29.3 29.5 
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Figure 8.3.2: Longitudinal continuum of care over 10 years considering transfer 
amongst 12,811 individuals linked to a SOPHID record  
 
% in each stage of continuum Months from cohort entry 
1 24 48 72 96 120 
EIC / ART _ (CD4 >350) 17.0 12.7 8.5 6.3 4.4 3.3 
EIC / ART _ (CD4 <350) 52.5 6.9 4.4 2.9 2.1 1.6 
EIC / ART + / VL >200 16.0 8.4 7.3 6.7 6.2 6.9 
EIC / ART + / VL <200 7.8 31.5 37.2 41.6 44.5 44.5 
NIC / ART + / VL <200 0.3 1.5 1.6 1.8 2.1 2.5 
NIC / ART + / VL >200 1.7 5.9 5.9 5.5 5.8 6.0 
NIC / ART _ 4.3 5.6 3.8 2.4 1.7 1.1 
True LTC 0 20.7 21.9 21.5 20.7 20.7 
Transfer 0 4.3 5.9 6.8 7.2 7.4 
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8.3.2 Changes to the care continuum over time 
Restricting to only 5 years of follow-up we observed changes in the longitudinal care 
continuum over time (Figure 8.3.3). True LTC was lower in the cohort that entered the study 
in 2008-2009 than between 2000-2003. At 2 and 5 years after entry, 13.8% and 16.3% of 
person months were classified as true LTC amongst those who entered between 2008 and 
2009. In comparison, 22.0% and 23.1% were classified as true LTC at 2 and 5 years after 
entry between 2000 and 2003. The proportion of person-months classified as not in care prior 
to ART initiation was also lower in the year following cohort entry; 13.0% amongst the 2008-
2009 cohort and 23.2% in the 2000-2003 cohort. 
ART initiation appeared more rapid in the recent cohort compared to the earliest cohort; 
57.1% of individuals were classified as having initiated ART one year after entry in the 2008-
2009 cohort, compared to 44.9% and 50.3% between 2000-2003 and 2004-2007 respectively. 
Further, of person-months pre-ART, a lower proportion were considered engaged with a CD4 
count below 350 cells/mm3 in the 2008-2009 cohort. Whereas only 23.4% of all pre-ART 
months classified as engaged in care were with a CD4 ≤350 cells/mm3 in this group, 42.2% 
and 32.2% were categorised as such between 2000-2003 and 2004-2007. This would align 
with changes over time in treatment guidelines regarding the optimal CD4 count at which to 
initiate ART.  
Viral suppression also improved over time, with 68.1%, 75.5% and 77.9% of all person-
months on ART over 5 years classified as virologically suppressed in the 2000-2003, 2004-
2007 and 2008-2009 cohorts respectively. Finally, mortality very moderately improved in the 





Figure 8.3.3: Longitudinal continuum of care over 5 years according to calendar year of entry 




Months from cohort entry Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 16.1 12.5 10.4 8.4 7.3 19.3 14.6 11.8 9.7 7.8 19.4 14.2 10.0 7.9 6.3 
EIC / ART _ (CD4 <350) 8.9 7.1 5.7 4.6 3.7 7.9 5.6 4.0 2.8 2.1 4.8 3.1 2.4 2.0 1.5 
EIC / ART + / VL >200 9.6 8.6 8.3 7.6 7.2 7.1 7.0 6.8 6.5 6.2 6.0 6.0 6.4 5.8 6.9 
EIC / ART + / VL <200 26.0 29.3 33.0 35.6 37.9 34.1 38.1 41.3 44.8 46.9 41.6 45.5 47.7 48.1 48.0 
NIC / ART + / VL <200 1.3 1.7 1.4 1.6 1.5 1.7 1.6 1.7 1.8 1.8 2.0 2.1 2.0 3.3 3.4 
NIC / ART + / VL >200 8.0 6.3 5.5 5.6 5.5 7.4 5.5 5.7 5.8 6.1 7.5 5.5 6.2 7.1 7.6 
NIC / ART _ 23.2 5.6 4.6 3.9 3.0 16.5 5.5 4.0 3.0 2.4 13.0 4.5 3.7 2.6 2.2 
True LTC 3.7 22.0 22.8 23.0 23.1 3.3 15.7 16.8 17.0 17.0 3.6 13.8 15.1 15.9 16.3 
Transfer 1.3 4.3 5.2 6.0 6.6 1.2 4.4 5.3 5.5 6.1 0.9 3.5 4.3 4.9 4.9 
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8.3.3 Continuum of care according to demographic characteristics 
When split by age at entry into the cohort, ART initiation was more rapid with older age at 
entry (Figure 8.3.4). At 12 months after entry 40.8%, 57.9%, 67.5% and 70.8% of those 
aged 30, 30-39, 40-49 and >50 were on ART and a larger overall proportion of person-months 
over 5 years were spent on ART in the oldest group (68.4% vs. 47.3% amongst those aged 
<30). Higher levels of viral suppression were similarly seen amongst the older age group, with 
71.5%, 77.6%, 81.0% and 83.2% of person-months on ART amongst those aged 30, 30-39, 
40-49 and >50 spent with a viral load <200 copies/ml. The youngest age group spent the 
largest proportion of person months off ART and not engaged in care in the year following 
entry, and true loss to follow-up was highest over 5 years in this group (15.3% of person-
months vs. 9.0% for those aged 50 and above). However, the proportion of person-months 
lost due to death over 5 years increased with older age at entry. The proportion (n) of person-
months lost for those aged <30, 30-39, 40-49 and >50 was 1.1% (887), 1.6% (1895), 2.6% 
(2026) and 4.3% (1398), respectively.  
Differences in the 5 year continuum in men and women were less marked (Figure 8.3.5). 
Following cohort entry, ART initiation was more rapid amongst women, as 66.0% of women 
and only 53.2% of men had initiated ART by 12 months. Over the 5 year period, 57.6% 
person-months in men were spent on ART and 64.3% of person-months in women. Of those 
months spent on ART in men and women, 19.8% and 26.6% respectively were spent with a 
viral load >200 copies/ml, showing that viral suppression was poorer amongst women.  
Compared to those of white ethnicity, ART initiation was initially more rapid amongst those of 
black ethnicity, with 66.5% and 50.1% having initiated ART 12 months after cohort entry 
(Figure 8.3.6). However, those of black ethnicity spent a larger percentage of time on ART 
with a viral load >200 copies/ml (16.4% of person-months vs. 11.0%). This was also the case 
as a proportion of all person-time on ART (25.5% person-months on ART vs. 19.3%). Loss to 
follow-up was also somewhat higher for those of black ethnicity compared to white, with 
17.4% truly LTC at 5 years after entry. However, LTFU was highest amongst those of other 
or unknown ethnicity with 19.9% true LTC at 5 years, accounting for 14.3% of all person-
months in this group (10.7% amongst those of white ethnicity). Mortality was also slightly 
higher amongst those of other or unknown ethnicity, and only 48.8% were on ART with a 
viral load ≤200 copies/ml 5 years after entry, compared to 54.0% amongst those of white 
ethnicity. 
LTCFU and mortality were also higher amongst those of other or unknown mode of HIV 
acquisition compared to MSM or heterosexual acquisition. By 5 years after cohort entry, 5.1% 
of individuals of other or unknown mode of acquisition had died, compared to 1.5% of MSM 
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and 3.7% of heterosexual men and women. 14.7% of all person-months were classified as 
true LTC and a further 4.3% as transfer of care; these respective proportions were 10.9% 
and 2.7% amongst MSM. Over 5 years, 56.6%, 64.9% and 55.0% of all person-months were 
spent on ART amongst those of other/unknown, heterosexual and MSM respectively. Of 
person-months on ART in each respective group, 74.2%, 75.5% and 82.4% were spent with 
a viral load ≤200 copies/ml. 
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Figure 8.3.4: Longitudinal continuum of care over 5 years according to age 
















 Months from cohort entry Months from cohort entry Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 24.6 20.2 15.1 12.2 9.9 20.4 14.2 9.2 7.3 6.0 14.6 9.9 7.3 5.4 4.2 14.4 8.9 6.5 4.9 3.1 
EIC / ART _ (CD4 <350) 6.6 3.9 3.0 2.2 1.6 4.0 2.8 2.4 1.7 1.4 4.4 2.7 1.9 2.2 1.6 3.6 3.1 2.2 1.8 1.5 
EIC / ART + / VL >200 6.3 7.1 7.4 6.8 7.3 6.3 6.5 6.5 6.0 7.0 6.0 5.0 5.8 5.2 7.0 4.4 4.0 4.5 3.6 5.3 
EIC / ART + / VL <200 26.5 31.5 34.4 38.6 37.7 41.7 45.6 48.3 49.7 49.0 51.6 55.1 56.5 53.0 54.5 56.2 58.0 58.2 54.7 54.7 
NIC / ART + / VL <200 1.4 1.6 1.5 1.9 3.3 2.1 2.1 2.5 3.4 3.6 2.2 2.3 1.9 4.7 3.5 2.2 2.5 2.2 3.3 2.7 
NIC / ART + / VL >200 6.6 5.4 7.1 7.6 9.5 7.8 6.0 6.1 6.8 7.5 7.7 5.1 5.6 6.5 5.9 8.0 4.4 5.5 8.0 6.7 
NIC / ART _ 21.8 6.7 5.7 4.0 3.9 12.2 4.1 3.5 2.5 1.8 7.6 3.5 2.6 1.8 1.4 6.2 2.0 2.0 1.3 1.1 
True LTC 5.1 18.9 19.5 19.2 19.5 3.2 13.4 15.5 16.0 16.6 3.5 10.6 11.6 13.4 13.6 1.5 9.5 10.7 12.7 13.1 
Transfer 0.6 3.8 5.0 5.9 5.6 1.1 3.4 4.2 4.8 4.9 0.9 3.3 4.1 4.4 4.5 1.3 3.6 3.8 3.8 4.4 
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 Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 22.0 16.1 11.5 8.8 6.9 13.6 9.8 6.6 5.8 4.9 
EIC / ART _ (CD4 <350) 5.0 2.9 2.4 1.8 1.4 4.1 3.5 2.6 2.3 1.8 
EIC / ART + / VL >200 5.0 5.1 5.6 4.8 6.3 8.4 8.1 8.0 7.9 8.4 
EIC / ART + / VL <200 40.1 45.4 48.3 48.8 49.2 45.0 45.7 46.3 46.4 45.1 
NIC / ART + / VL <200 1.8 2.1 1.9 3.6 3.4 2.4 2.0 2.5 2.8 3.5 
NIC / ART + / VL >200 6.3 4.2 5.3 6.5 7.0 10.2 8.4 8.0 8.3 8.9 
NIC / ART _ 14.5 5.0 4.0 3.0 2.4 9.4 3.3 3.1 1.8 1.7 
True LTC 3.3 14.1 14.9 15.7 16.0 4.2 13.0 15.6 16.4 16.9 
Transfer 0.8 3.3 4.0 4.5 4.6 1.3 4.2 5.1 5.7 5.6 
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Figure 8.3.6: Longitudinal continuum of care over 5 years according to ethnicity 





 Months from cohort entry Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 25.3 18.3 12.7 9.5 7.7 12.4 9.1 6.4 5.6 4.4 19.3 14.2 11.0 9.0 6.7 
EIC / ART _ (CD4 <350) 5.7 3.3 2.4 1.7 1.2 3.8 2.5 2.3 2.1 1.7 4.1 4.2 2.9 2.6 1.9 
EIC / ART + / VL >200 5.3 4.8 6.0 5.1 6.2 7.4 7.8 7.3 6.9 7.9 4.7 5.1 4.8 4.8 6.5 
EIC / ART + / VL <200 38.2 45.2 48.7 49.7 50.1 46.0 46.6 47.8 47.0 45.7 41.3 43.0 43.5 45.2 46.9 
NIC / ART + / VL <200 1.2 2.2 1.5 3.5 3.9 2.8 2.1 2.6 3.4 3.3 2.2 1.3 2.2 2.5 1.9 
NIC / ART + / VL >200 5.4 3.7 5.4 6.5 6.8 10.3 7.7 7.1 8.1 8.9 6.7 5.2 6.0 6.0 6.3 
NIC / ART _ 14.6 4.4 4.1 3.0 2.5 10.5 4.2 3.2 2.1 1.7 14.2 5.2 4.2 2.6 2.5 
True LTFU 2.8 13.0 13.4 14.2 14.4 4.4 14.0 15.9 16.6 17.4 4.1 16.0 19.2 20.1 19.9 
Transfer 0.8 3.5 4.1 4.7 4.7 1.0 4.0 5.1 5.6 5.7 1.3 2.5 2.8 3.5 3.3 
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Figure 8.3.7: Longitudinal continuum of care over 5 years according to mode of HIV acquisition 
MSM Heterosexual Other/unknown 
   
 Months from cohort entry Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 28.3 21.0 14.9 11.0 9.1 13.0 9.5 6.5 5.9 4.7 13.7 8.8 6.5 5.1 2.9 
EIC / ART _ (CD4 <350) 5.1 3.1 2.4 1.6 1.0 3.7 2.5 2.0 2.0 1.6 7.3 5.0 3.8 3.2 2.8 
EIC / ART + / VL >200 4.6 4.3 5.7 4.7 6.1 7.4 7.4 6.8 6.5 7.5 5.7 6.9 6.9 6.5 7.5 
EIC / ART + / VL <200 37.2 44.2 48.1 50.1 50.5 46.5 47.9 49.3 47.6 47.4 39.4 41.6 41.3 43.7 42.2 
NIC / ART + / VL <200 1.2 2.0 1.4 3.5 3.8 2.9 2.0 2.6 3.6 3.3 1.3 2.5 2.1 2.1 2.6 
NIC / ART + / VL >200 4.1 3.3 5.0 5.5 6.4 10.1 7.4 6.9 8.3 8.2 9.4 5.7 7.3 7.9 8.8 
NIC / ART _ 16.3 5.4 4.4 3.4 2.8 10.2 3.7 3.1 1.8 1.6 11.7 4.2 3.6 2.8 2.1 
True LTC 2.3 13.3 13.5 14.6 14.5 3.5 13.2 15.2 16.1 17.0 7.7 17.0 19.4 18.9 19.0 
Transfer 0.6 2.6 3.5 4.3 4.1 1.0 3.9 4.8 5.3 5.1 1.7 4.9 5.4 5.5 6.9 
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8.3.4 Continuum of care according to CD4 count at diagnosis 
Results did not differ largely from the main analysis when considering 3,737 individuals who 
were newly diagnosed at entry into the UK CHIC Study between 2008 and 2009, results did 
not differ largely from the main analysis for this period (Figure 8.3.8). Over 5 years, 26.8% 
of person-months were spent off ART. During the first month of follow-up, 42.1% of 
individuals were EIC but off ART with a CD4 count <350 cells/mm3 or unavailable. This 
decreased to only 5.1% at 1 year and represented only 1.6% of individuals 5 years after 
cohort entry. Approximately half of newly diagnosed individuals who entered the study 
between 2008 and 2009 had started ART and were virologically suppressed 5 years after 
entry, as was seen amongst all entrants to the cohort at this time.  
Marked differences were seen in the longitudinal continuum of care according to CD4 count 
at diagnosis (Figure 8.3.9). ART initiation was much more rapid in those with a diagnosis CD4 
count <200 cells/mm3, in line with treatment guidelines to initiate ART. One year after cohort 
entry, 83.9%, 53.0% and 23.5% had initiated ART in those with diagnosis CD4 count ≤200, 
201-350 and >350 cells/mm3 respectively. Of all pre-ART person-months amongst those with 
a CD4 count >350 cells/mm3 at diagnosis, 66.9% were spent with a CD4 count >350 
cells/mm3 so would not necessarily indicate that treatment be initiated. However, 20.3% of 
these pre-ART person months were classified as not in care (6.6% of all person-months). The 
corresponding proportion of pre-ART months not in care amongst those with a diagnosis CD4 
count 201-350 cells/mm3 was 23.9%, however, overall only 3.2% of all person-months in this 
group were classified as not in care prior to ART initiation. A similar proportion (approximately 
14%) of all person-months were spent with a viral load >200 for each CD4 group. However, 
as a proportion of time on ART, 20.6%, 22.4% and 28.7% of person months were spent 
unsuppressed amongst those with a diagnosis CD4 count ≤200, 201-350 and >350 cells/mm3 
respectively. 
A larger proportion of person-months were lost due to death amongst those with a diagnosis 
CD4 count <200 cells/mm3 (7.5% vs 2.3% for 201-350 cells/mm3 and 1.7% >350 cells/mm3). 
Conversely, a smaller proportion of those with a diagnosis CD4 count <200 cells/mm3 were 
LTC; 14.0% at 5 years compared to 21.1% of those with diagnosis CD4 >350 cells/mm3. 
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Figure 8.3.8: Longitudinal continuum of care over 5 years amongst those newly 
diagnosed 
 
% in each stage of continuum Months from cohort entry 
1 12 24 36 48 60 
EIC / ART _ (CD4 >350) 30.8 22.5 17.0 11.9 9.2 7.3 
EIC / ART _ (CD4 <350) 42.1 5.1 3.3 2.6 2.2 1.6 
EIC / ART + / VL >200 20.6 5.5 5.2 5.4 5.0 5.9 
EIC / ART + / VL <200 4.1 38.8 43.8 46.8 48.4 48.9 
NIC / ART + / VL <200 0.0 1.7 1.8 2.1 3.0 3.3 
NIC / ART + / VL >200 0.3 6.2 4.8 5.6 6.6 7.2 
NIC / ART _ 1.8 15.4 5.0 4.4 3.0 2.5 
True LTC 0 3.1 14.5 15.9 16.6 16.9 
Transfer 0 0.6 2.7 3.3 3.8 3.7 
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Figure 8.3.9: Longitudinal continuum of care over 5 years according to CD4 count at diagnosis 
>350 cells/mm3 201-350 cells/mm3 ≤200 cells/mm3 
 
  
 Months from cohort entry Months from cohort entry Months from cohort entry 
12 24 36 48 60 12 24 36 48 60 12 24 36 48 60 
EIC / ART _ (CD4 >350) 49.3 33.5 26.4 19.1 15.7 11.9 6.7 3.9 2.3 1.6 1.0 0.8 0.9 0.6 0.4 
EIC / ART _ (CD4 <350) 8.0 9.0 6.9 5.3 3.0 17.2 10.2 5.8 2.9 1.6 4.2 1.2 0.7 0.1 0.04 
EIC / ART + / VL >200 8.4 9.1 8.9 7.9 7.6 11.9 8.9 9.2 8.5 7.8 10.8 9.0 8.0 7.1 6.1 
EIC / ART + / VL <200 8.9 14.5 20.2 27.1 33.3 32.5 42.1 46.7 49.5 53.8 61.2 61.4 60.7 59.6 58.7 
NIC / ART + / VL <200 0.8 0.8 0.9 1.3 1.2 1.6 1.1 1.8 1.9 1.6 2.9 3.0 2.3 2.0 2.7 
NIC / ART + / VL >200 5.4 5.5 5.6 5.3 5.6 7.0 6.4 6.3 6.3 4.0 9.0 5.7 6.3 6.2 5.2 
NIC / ART _ 16.7 11.4 9.2 8.0 5.8 15.6 7.1 3.6 3.1 1.9 5.2 1.0 0.5 0.2 0.1 
True LTC 2.0 13.0 17.2 20.0 21.1 1.5 13.0 16.3 18.1 18.7 1.0 9.1 10.2 12.6 14.0 
Transfer 0.2 2.7 3.9 4.7 5.0 0.0 3.2 4.8 5.4 6.4 0.4 2.8 3.8 4.5 4.9 
















NIC / ART -
NIC / ART + / VL >200
NIC / ART + / VL <200
EIC / ART + / VL <200
EIC / ART + / VL >200
EIC / ART - (CD4 <350)
EIC / ART - (CD4 >350)







8.3.5 Sensitivity Analyses 
8.3.5.1 Treatment interruptions 
Thus far, I have referred to people who have initiated ART as ‘on ART’. However it is possible 
that people will discontinue ART for short periods and so having started ART may not be 
equivalent to currently being on ART. Considering treatment interruption as a separate end-
point, we saw that this accounted for a relatively low percentage of person-months over 10 
years (4.7%; Figure 8.3.10). Discounting those undergoing a treatment interruption from the 
denominator of those on ART, I observed that of all person-months on ART over 10 years, 
80.1% of person months on ART were spent virologically suppressed. This figure was 74.9% 
in the main analysis. 
8.3.5.2 Loss to follow-up 
Changing to 6 or 12 months not in care to define LTCFU we saw very little change in the 
longitudinal continuum (Figure 8.3.11). Using 6 cumulative months not in care to define LTCFU 
saw that 20.9% of all person-months over 10 years were classified as true LTC and 6.0% as 
transfer of care. Using 12 months we observed that 17.6% and 5.3% were classified as true 
LTC and transfer, respectively. 
8.3.5.3 Excluding one-off attenders 
Restricting to those individuals who had at least two separate visits in the UK CHIC study 
(n=11,272), lower rates of true LTC were observed than in the main analysis; 16.2% at 10 
years compared to 20.7%. The proportion to transfer care did not change greatly and the 
percentage who had died by 10 years after cohort entry was also quite similar at 5.0%. A 
larger proportion of person-months in this sensitivity analysis were spent with viral 








Figure 8.3.10: Longitudinal continuum of care over 10 years including treatment 
interruptions 
 
% in each stage of continuum Months from cohort entry 
1 24 48 72 96 120 
EIC / ART _ (CD4 >350) 17.0 12.7 8.5 6.3 4.4 3.3 
EIC / ART _ (CD4 <350) 52.5 6.9 4.4 2.9 2.1 1.6 
EIC / ART + / VL >200 14.6 5.6 4.9 4.7 4.6 5.3 
EIC / ART + / VL <200 7.5 30.8 36.4 40.7 43.7 43.4 
NIC / ART + / VL <200 0.3 1.4 1.4 1.7 2.0 2.4 
NIC / ART + / VL >200 1.5 3.6 4.1 3.8 4.6 5.0 
Treatment interruption 1.8 5.9 5.2 4.7 3.8 3.8 
NIC / ART _ 4.3 5.6 3.8 2.4 1.7 1.1 
True LTFU 0 20.7 21.9 21.5 20.7 20.7 
Transfer 0 4.3 5.9 6.8 7.2 7.4 
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Figure 8.3.11: Time-updated continuum of care over 10 years using different definitions of LTCFU 




 Months from cohort entry Months from cohort entry 
24 48 72 96 120 24 48 72 96 120 
EIC / ART _ (CD4 >350) 12.7 8.5 6.3 4.4 3.3 12.7 8.5 6.3 4.4 3.3 
EIC / ART _ (CD4 <350) 6.9 4.4 2.9 2.1 1.6 6.9 4.4 2.9 2.1 1.6 
EIC / ART + / VL >200 8.4 7.3 6.7 6.2 6.9 8.4 7.3 6.7 6.2 6.9 
EIC / ART + / VL <200 31.5 37.2 41.6 44.5 44.5 31.5 37.2 41.6 44.5 44.5 
NIC / ART + / VL <200 1.5 1.6 1.8 2.1 2.5 1.6 1.6 1.8 2.1 2.5 
NIC / ART + / VL >200 4.7 4.6 4.2 4.7 4.8 6.9 6.9 6.5 6.5 6.7 
NIC / ART _ 4.3 3.0 1.9 1.2 0.9 6.6 4.3 2.9 1.9 1.3 
True LTC 22.6 23.7 22.9 22.0 22.0 19.0 20.7 20.3 20.0 20.1 
Transfer 4.9 6.3 7.2 7.5 7.7 3.9 5.6 6.6 7.0 7.3 
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Figure 8.3.12: Longitudinal continuum of care over 10 years amongst those with 
at least 2 visits 
 
% in each stage of continuum Months from cohort entry 
1 24 48 72 96 120 
EIC / ART _ (CD4 >350) 17.3 14.2 9.4 6.9 4.8 3.5 
EIC / ART _ (CD4 <350) 51.6 5.9 3.3 1.7 0.7 0.3 
EIC / ART + / VL >200 16.9 9.3 8.1 7.5 6.9 7.7 
EIC / ART + / VL <200 8.3 35.8 42.3 47.2 50.6 50.6 
NIC / ART + / VL <200 0.4 1.8 1.8 2.1 2.4 2.9 
NIC / ART + / VL >200 1.8 6.6 6.7 6.2 6.6 6.8 
NIC / ART _ 3.8 6.0 4.0 2.5 1.7 0.9 
True LTC 0.0 16.0 17.2 16.8 16.0 16.2 
Transfer 0.0 3.1 4.8 5.6 5.9 6.2 
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8.4.1 Summary and Interpretation 
In this chapter I devised and presented a longitudinal continuum of care composed of time-
updated measures of the stages of the HIV care pathway. This longitudinal continuum depicts 
the progress of a cohort of PLWH through the stages of the HIV continuum of care, giving 
population-level data as to the amount of person-time spent in each state over 10 years. This 
method has certain advantages over a traditional cross-sectional continuum of care for 
monitoring levels of engagement with HIV care and patient outcomes. By creating 
classifications that include sub-optimal responses along the HIV care pathway, gaps in HIV 
care are better described. By considering a closed cohort and not censoring follow-up when 
people drop out of the study this method allows estimation of rates of LTC and can ascertain 
the amount of person-time lost due to mortality.  
Using this method, I observed increasing ART uptake and viral suppression after entry into 
HIV care, as would be expected. Over 10 years of follow-up 39.5% of person-months were 
classified as virologically suppressed; 74.9% of all person-months spent ART experienced. 
Therefore, individuals had the potential to transmit HIV for the majority of person-time in this 
study. The potential for ongoing transmission is a primary output of a traditional continuum 
of care. The amount of person-time unsuppressed presented in this longitudinal continuum of 
care provides better understanding as to the potential for ongoing transmission than a cross-
sectional measure of the proportion of people unsuppressed. This demonstrates an advantage 
of this longitudinal continuum of care over a cross-sectional one. The context in which this 
person time occurs may also be an important factor. Transmission may be more likely to occur 
during periods of unsuppressed viraemia that are a consequence of poor adherence or that 
occur whilst individuals are poorly EIC, as this may also be associated with more risk-taking 
behaviour (604, 605). Further, unsuppressed viraemia whilst in receipt of ART is associated 
with poorer mortality outcomes. Conversely, viraemia occurring prior to ART initiation, with 
treatment guidelines during the period of study is of less concern for patient outcomes.  
LTCFU in this cohort was high, with 28.1% of individuals lost to the study 10 years after entry. 
Only around a quarter of LTCFU time was explained by individual’s transferring to a centre 
that does not participate in the UK CHIC Study for care. The remainder of this LTCFU was 
unaccounted for. It is possible, therefore, that those individuals who are LTCFU but did not 
transfer care are completely disengaged from HIV care. Individuals who are disengaged from 
care are more likely to transmit HIV (604, 605) and have poorer mortality outcomes (364, 
540). In light of the potentially high LTC shown in this study, reducing disengagement and 
encouraging those who are disengaged to re-engage with care should be a focus of efforts to 
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improve patient outcomes and reduce transmission. In a traditional continuum of care, those 
lost to cohort follow-up are not accounted for. Particularly, in the UK, the diagnosed population 
in a given calendar year is defined as those seen for care that year (Zheng Yin, personal 
communication, February 6, 2015), thereby excluding anyone already disengaged from care 
prior to this point, which, from estimates in this study, could be a considerable number. This 
cross-sectional continuum, therefore, may be biased as it represents those individuals who 
are accessing care and who are more likely to be on ART and virologically suppressed. 
However, it is possible that some of the LTC observed in this study could be explained by 
migration out of the country, as HIV-positive individuals born abroad may return to their 
country of origin. Data on levels of out-migration of HIV-positive individuals in the UK are 
unavailable, but in a single centre London study, over half of individuals lost to clinic follow-
up (of whom two-thirds were black African or black Caribbean ethnicity) had evidence of intent 
to leave the country in their medical notes, with 20% at risk of deportation (324). High levels 
of migration would mean that levels of true disengagement in care, and therefore the potential 
for ongoing transmission in the country, is not as high as the longitudinal continuum of care 
estimates.  
In this study, the longitudinal continuum changed over time, with increasing time spent ART 
experienced and virologically suppressed. Whilst this might suggest an improvement in the 
HIV continuum of care over time, it more likely reflects changes to treatment guidelines and 
developing knowledge as to the benefits of ART initiation at higher CD4 counts over this period 
(112). Therefore, whilst an earlier continuum of care might appear worse, it may in fact reflect 
optimum care under the guidelines that existed at that time. It is therefore important to 
consider the context when comparing either a longitudinal or cross-sectional continuum of 
care over time. However, LTCFU rates decreased in more recent periods showing that there 
were some improvements in retention in care over time. Improved retention in care may be 
an indirect consequence of earlier ART initiations, as previous studies have shown 
engagement in care to be better amongst ART experienced individuals, but may also be a 
consequence of better care and efforts to reduce disengagement. 
ART initiation was much more rapid amongst those with a CD4 count <200 cells/mm3 at 
diagnosis. This is as we would expect in relation to treatment guidelines in the UK. Despite 
this rapid ART uptake, mortality was by far higher amongst those diagnosed late, consistent 
with findings in Chapter 5 of this thesis. This re-enforces the need for better testing strategies 
to prevent late diagnosis in order to improve mortality outcomes in PLWH. Of time spent ART 
experienced, a much larger proportion of person-months were spent with detectable viral load 
in people with a CD4 count <200 cells/mm3. This could indicate poorer adherence amongst 
those initiating ART with low CD4 counts, highlighting those diagnosed late as a group who 
may be in need of adherence support. No difference in the rate of viral rebound was found 
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amongst those initiating ART late in Chapter 6. However, in that analysis, I restricted to those 
who initially maintained virological suppression, and so may have excluded those with lower 
levels of adherence. 
I observed differences in progression through stages of HIV care according to demographic 
factors. Despite more rapid ART initiation in those aged 50 and above, mortality was strikingly 
high in comparison to younger ages. To what extent this mortality is expected due to natural 
aging and how much is potentially preventable through earlier engagement in the HIV care 
cascade is unknown. As shown in Chapter 5, older individuals were significantly more likely to 
be diagnosed late and therefore be in need of immediate ART, with subsequently high rates 
of mortality. As a traditional continuum of care only includes those that are alive during the 
year of assessment, this mortality would not be considered, giving a more favourable 
impression of the success of HIV care for older individuals. It is important to consider this 
higher mortality when making inferences from a care continuum that may otherwise suggest 
better patient outcomes in older individuals. As discussed in Chapter 5, efforts to improve HIV 
testing rates amongst older individuals are needed to enable earlier initiation of ART and 
reduce rates of mortality, particularly AIDS-related mortality. In the younger age group, 
mortality was low but the continuum of care appeared worse than for older adults. A large 
proportion of person-time was spent ART naïve and disengaged from care. It would seem, 
therefore, that poorer EIC amongst younger individuals is leading to slower uptake of ART 
(341) and less time spent with suppressed viral load. This is of concern as delayed ART 
initiation can have negative impacts on morbidity and mortality outcomes (141, 417, 419), 
and unsuppressed viraemia in this group, who are likely more sexually active, could result in 
high HIV incidence. These low levels of EIC, do not appear to be explained by perinatally 
infected adolescents transitioning into adult care (who number only a few in this age group), 
in whom barriers to EIC have been identified (606). The reasons for poor EIC amongst 
younger PLWH who are not perinatally infected likely differ somewhat from those infected 
from birth, and may include fears of stigma, difficulties in accepting their diagnosis, disclosing 
to friends and family and managing a life-long chronic condition (607). Youth-focused services 
and additional peer and social support are needed when these young PLWH enter into adult 
care to help them effectively manage their HIV and reduce disengagement from care to 
improve the number of years lived in good health (608).  
Despite more rapid ART initiation in women and those of black ethnicity, a larger proportion 
of ART-experienced person-months were spent with a detectable viral load compared to men 
and those of white and other ethnicities. Sex and ethnicity are closely correlated amongst 
PLWH, as the majority of men are white MSM, whilst women are largely represented by those 
of black African ethnicity. In the UK, black African individuals, particularly women, are 
disproportionately affected by HIV, with a prevalence of around 56 per 1,000 population (312), 
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and contributing 61% of heterosexuals accessing care (70). But despite this, my findings 
suggest that they may have difficulties in successfully managing their illness compared to 
other groups and are a group need of adherence support.  
Those who acquired HIV through non- sexual or unknown transmission routes had poor 
longitudinal progression through the continuum of care. LTFU and mortality were high, with 
a smaller proportion of time on ART spent with viral suppression. Of time spent off ART, a 
higher proportion of months were spent not engaged in care or with a CD4 count below 350 
cells/mm3. This group is largely made up of those with an unknown mode of acquisition 
(67.4%) or people who inject drugs (PWID 21.4%), with perinatally infected individuals and 
blood products recipients only a small number of this group. PWID are known to have poorer 
engagement and high mortality rates. Missing data on mode of HIV acquisitions could arise 
through non-disclosure or an individual being unaware of HIV acquisition risk. This, in turn, 
may be indicative of multiple high-risk behaviours and would appear to align with poor 
engagement with HIV services and individuals having lower ability to manage their HIV, as 
demonstrated by a poor continuum of care in this analysis. Identifying and supporting these 
individuals to engage and adhere with care early on may be key for improving the long-term 
success of their HIV care. In order to achieve this, in-depth qualitative data on why these 
individuals have sub-optimal engagement and treatment responses will be useful.  
8.4.2 Comparison to the literature 
LTC was considerably higher in this longitudinal continuum than the estimated 5% annual 
LTFU nationally, despite linkage to national surveillance data to ascertain when care was 
transferred to a non-CHIC centre. Previous studies have shown that longitudinal measures of 
retention in care rates are worse than when assessed cross-sectionally (314). Further, my 
estimate of LTC is more consistent with 5-year cumulative LTFU rates of 20% found in 
previous studies in the UK (323, 324).  
Of all individuals still alive 10 years after cohort entry, less than half were virologically 
suppressed in this longitudinal continuum of care. This is considerably lower than reported in 
the cross-sectional continuum of care in the UK, which estimates 78% of all PLWH to be 
virologically suppressed (70). Reasons for this difference may be the fact that I have studied 
a historic cohort that entered care in the relatively early ART era, who have long-term ART 
exposure and experience of less effective and less tolerable agents. A cross-sectional 
continuum of care, on the other hand, provides more up-to-date information of all PLWH at 
that time. This group will include those more recently diagnosed and initiated on ART. The 
use of all recorded viral loads in the longitudinal continuum of care may also mean that I am 
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more likely to capture short-term periods of non-suppression that would be missed in a cross-
sectional continuum that uses only the latest available measure in the calendar year.  
This is not the first study to report a poorer continuum of care amongst younger individuals 
(217, 225, 231, 237, 328). Studies have also separately shown poorer EIC (333, 335, 336, 
343), decreased likelihood of ART uptake (235, 379, 602) and lower rates of viral suppression 
(306, 424, 448) amongst younger adults with HIV, which are consistent with the findings of 
this longitudinal continuum of care. UK HIV surveillance data also report lower ART coverage 
amongst younger individuals, with 88% of 15-24 year olds on ART in 2015 compared to 98% 
of over 50’s. However, in contrast to my findings, retention in care (defined by attendance for 
care in two consecutive years) is reportedly similar according to demographic subgroups, but 
estimates are not provided making any comparison difficult (70).  
My finding that a larger proportion of person-months were spent with unsuppressed viral load 
in women and those of black ethnicity is consistent with findings from the US. In a traditional 
continuum, black ethnicity has been shown to be associated with lower rates of viral 
suppression in comparison to white ethnicity (232, 237, 314, 328, 333). In US national 
estimates, 30% of all white PLWH are suppressed compared to 21% amongst black PLWH. 
This translates to 86% and 72% of people prescribed ART amongst white and black people, 
respectively (217). Evidence of lower viral suppression rates amongst those of black ethnicity 
in the UK is not as strong. Cross-sectional surveillance data estimates 90% viral suppression 
across ethnic groups and for both men and women (312). Whilst a single centre study found 
women and heterosexual men to have similar initial virological responses to MSM (224), other 
cross-sectional assessments from the ASTRA study showed that those of non-white ethnicity 
had lower rates of viral suppression explained by lower adherence (609). Previous data from 
the UK CHIC study have shown differing results in regards to ethnicity differences, possibly 
due to the different inclusion criteria of each study and different virological end-points 
assessed (385, 428). This study therefore adds to the limited UK data on differences in 
virologic responses according to ethnicity. 
8.4.3 Strengths and limitations 
This chapter presents a novel way of describing passage through HIV care. By defining an 
individual’s status in HIV care on a month-by month basis it is possible to capture the 
movement between stages of the continuum of care, which have previously been treated as 
fixed end-points. It is also able to give an overview of progress through HIV care on a 
population level and incorporates LTC and mortality. Because of the rich clinical data available 
in the UK CHIC study, and the ability to classify engagement on a month-by-month basis using 
the REACH algorithm, it is possible to get a more detailed picture of the care continuum. 
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Further, as with a traditional care continuum, this information is still displayed in a single 
figure that easily conveys this information. The detailed clinical data required to construct this 
longitudinal continuum of care might not be available in many settings, which means that is 
not suggested as an alternative to the traditional continuum of care, which is a useful public 
health monitoring tool. Instead this is better used as a research tool to complement the 
traditional continuum of care, investigate disparities in care and relate the stages of the care 
pathway to patient outcomes. The fact that it is a descriptive measure is a limitation as it is 
not possible to adjust for potential confounding in a formal way.  
A limitation in using a 10 year time-frame is that it is a historic cohort that is considered, with 
individuals required to have the potential for 10 years follow-up in order to be included. This 
historic cohort may not be entirely reflective of individuals entering care in more recent periods 
when guidance for treating and monitoring patients have changed and ART agents have 
become more effective and better tolerated than in the relatively early ART era. Further, the 
UK CHIC study is not a national cohort, so may not be representative of all PLWH that enter 
care in the UK. However, no restrictions besides year of entry were made to the inclusion 
criteria. Further, these methods can be applied to shorter time frame, enabling the study of 
more recent cohorts, and when we considered a 5 year continuum, similar patterns were 
seen, with small changes over time which reflected changes to treatment guidelines.  
Although some individuals LTCFU were identified as having transferred care to a centre that 
does not participate in UK CHIC, it was not possible to classify these individuals further 
according to EIC, ART use or viral suppression. This is because SOPHID contains only a single 
annual record of ART use and viral suppression and EIC could not be classified according to 
the REACH algorithm. Therefore these estimates of ART use and viral suppression may not 
be accurate for all individuals in care in the UK. Including those who transferred care into the 
denominator of those alive and accessing care in the UK, the true proportion of individuals on 
ART with virological suppression at 10 years after cohort entry would range from 64% if none 
who transferred were suppressed to 74% if all who transferred were suppressed.  
It should be noted that these graphs represent the care continuum in a group diagnosed and 
linked to care and need to be interpreted in context. For example, amongst those aged over 
50 and with a CD4 count <200 cells/mm3 we observed very rapid ART initiation and a large 
proportion of person-months on ART. Whilst ART uptake is considered a favourable outcome 
along the continuum of care we must remember that immediate ART initiation is necessary 
for this group because they are diagnosed with such advanced stage of HIV infection. Whilst 
these methods can be applied to a population of PLWH from HIV diagnosis onwards, they 
could not easily be adapted to incorporate all HIV-infected individuals. A baseline time point 
such as seroconversion would need to be known to calculate the person-time contributed as 
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undiagnosed. This information is rarely known, with few notable symptoms at the time of 
seroconversion, and is difficult to estimate due to different progression rates (610-612). This 
is a limitation as compared to a traditional continuum of care. 
Finally, whilst it is possible to account for changing viral load and EIC status over time by 
categorising on a month-by-moth basis (and ART status if including treatment interruptions), 
the relative timing of events is not known in this longitudinal continuum of care. But this was 
shown in other studies (242, 243). For example, it is not known whether death occurred 
before or after ART initiation, or achievement of viral suppression. This could be achieved by 
creating further categories, however, to improve readability due to the sometimes small 
number of person months and a wish not to generate too many categories, this was not done 
here. 
8.4.4 Conclusions 
Using a time-updated continuum of care it is possible to describe the progress of a cohort of 
HIV-positive individuals through the HIV care continuum over time, including the additional 
outcomes of mortality and loss to follow-up. My findings suggest that engagement with HIV 
care and patient outcomes may not be optimal for all groups, and for all individuals was lower 
than would be suggested in a traditional continuum of care. Further, different groups may 
require interventions in different aspects of HIV care to improve outcomes. Those in whom 
ethnicity and mode of HIV acquisition remain unknown had the poorest progress through the 
HIV care continuum and highest mortality and loss-to-follow-up rates. More in-depth 
qualitative research to improve understanding of barriers to these individuals successfully 
engaging with care and managing their HIV is needed in order to inform potential intervention 
designs. Whereas women and those of black ethnicity had poorer suppression on ART and 
would benefit from interventions to improve adherence, younger adults may benefit most 
from interventions to improve EIC, particularly whilst ART naïve, to increase ART uptake. For 
older adults, improved testing rates to prevent late diagnosis are key to reducing a large 
burden of mortality amongst PLWH. 
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9Chapter 9: Concluding remarks 
 
9.1 Summary and relevance of main findings 
The introduction of ART has drastically changed outcomes for PLWH, with reduced morbidity 
and mortality, increasing life expectancy and a shift from AIDS to non-AIDS causes of death. 
ART also has important public health implications as it reduces the risk of onward transmission 
which will, in turn, impact on HIV incidence. HIV is now a chronic condition requiring ongoing 
care and adherence to treatment regimens. The key elements of the pathway through HIV 
care, including diagnosis, ART uptake and viral suppression, are summarised in the continuum 
of care, aligning with global targets to reduce HIV incidence. In this context, the continuum 
of care is now a popular framework for monitoring programme success and the potential for 
ongoing transmission within a population. It has also been used to assess the successful 
engagement of PLWH with care and as an indicator of disparities in care on a population level. 
However, it’s cross-sectional design has some limitations. One important limitation being that 
it does not incorporate mortality outcomes, which are a key indicator of health in a population. 
Whilst the continuum of care is estimated to be good in the UK, meeting 2 of the 3 UNAIDS 
90% targets (214), it has been estimated for few subgroups of the population, in whom, 
observational studies have previously shown sub-optimal treatment responses and 
engagement with HIV care. As a result, the aims of this thesis were to investigate sub-optimal 
achievement of the stages of the continuum of care in the UK and, in particular, how these 
are associated with mortality outcomes. 
I undertook this research using data from the UK CHIC Study, which is the largest clinical 
cohort of HIV-positive individuals accessing care in the UK. Prior to the commencement of this 
work, information on mortality outcomes in the study relied almost entirely on clinician report, 
and data on cause of death was limited so was not used in analyses. In Chapter 4, I presented 
work undertaken to improve the ascertainment of mortality outcomes and to classify a 
principal cause of death based on a variety of data sources, including linkage to HIV 
surveillance datasets, which are supplemented by ONS national death registry data. This work 
was vital in order to be able to estimate the impact of sub-optimal care on mortality outcomes, 
as prior to this work estimates would have been biased. This is because deaths were under-
ascertained and were more likely to be missing in more recent calendar years, for those with 
missing information on demographic characteristics and those LTCFU. This also enabled 
analyses that considered end-points of cause-specific mortality. The result of this work was 
to add 792 deaths to the dataset and classify a principal cause for 2,938 deaths. With this 
data I was able to describe declining AIDS-related mortality and a shift towards non-AIDS 
316 
 
causes of death throughout the advancing ART era, as has been reported in other countries. 
However, a large amount of missing data on cause of death for deaths occurring in the early 
ART era is a limitation of this data. Any future analyses of mortality will likely need to be 
restricted to later years when the proportion of deaths with a classified cause improves. 
In Chapter 5 I studied associations between late diagnosis and both all-cause and cause 
specific mortality in the year following HIV diagnosis. In particular, I assessed whether the 
association between late diagnosis and mortality was stronger amongst older individuals, who 
are much more likely to be diagnosed late, than younger individuals. This was only formally 
assessed in one previous single centre study in the UK, which did not detect an interaction, 
but was likely under-powered to do so (222). The main finding of this chapter was that there 
was no interaction between age at diagnosis and late diagnosis observed, indicating that older 
individuals diagnosed late do not have a relatively poorer prognosis than younger individuals 
diagnosed late. Another important finding was that whilst the relative impact of late diagnosis 
on mortality in older individuals was not higher, an extremely high absolute excess risk of 
death, particularly for AIDS-related mortality, was observed amongst older individuals 
diagnosed late. Already higher rates of mortality amongst older individuals expected through 
aging, high rates of late diagnosis in this age group, and the strong association between late 
diagnosis and mortality are the likely causes of this excess mortality. Much of this mortality 
burden could potentially be prevented through more timely diagnosis, enabling earlier 
initiation of ART. Older individuals are therefore a group very much in need of interventions 
to improve HIV testing rates to reduce levels of late diagnosis.   
Late ART initiation is a consequence of late diagnosis and has previously shown to be 
associated with poor treatment responses and outcomes. In Chapter 7 I looked at whether 
those starting ART with immunosuppression (≤200 cells/mm3) who achieved and maintain a 
virological response, could eventually have similar outcomes to those starting in a less 
advanced stage of HIV disease. In those who maintained suppression during the first year, 
the rate of viral rebound continued to decline with longer time on ART and was not different 
for those with immunosuppression at ART initiation after accounting for demographic factors 
that may have represented differences in adherence. CD4 counts did not recover to the level 
of those without immunosuppression and it looked likely that even with further follow-up this 
would not be achieved. It took longer for the CD4 to recover to levels approaching that in 
HIV-negative individuals, during which time those with baseline immunosuppression were at 
higher risk of clinical progression. However, there was an indication that rate of clinical 
progression might become similar in the long-term on ART, as CD4 counts in those with 
immunosuppression approached normal levels. If supported by other studies, this is an 
important clinical message for those in care who have already, or may in future initiate ART 
with immunosuppression, as well as for HIV clinicians. However, despite the large numbers 
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included in this study, a small number of clinical events meant that a statistical test for 
interaction was not significant, meaning that these findings would need to be confirmed in a 
bigger study with more events in the long-term. Even if the risk of clinical progression does 
decrease in the long term, it is better to minimise the time spent at high risk of clinical 
progression. To this end, it is important to avoid late ART initiation by ensuring PLWH are 
diagnosed in a timely manner and are prepared and in a position to start ART before they 
become immunosuppressed. 
EIC has previously been shown to be associated with mortality. However, the studies which 
addressed this question were largely conducted in the US, where access to healthcare is not 
free, and used short term measures of visit attendance that did not account for the changing 
frequency of scheduled visits as individuals health status changes. The association between 
EIC and life expectancy was investigated in Chapter 6 using the REACH study time-updated 
measure of EIC. EIC over the first 5 years after ART initiation was found to correlate with life 
expectancy, with an approximate 5 year difference in age at death between those with low 
and high EIC. Maintained low EIC over each of the first 5 years on ART was associated with 
declines in life expectancy. This highlights the importance of achieving and then maintaining 
high EIC over time. In order to assess whether this correlation was partly explained by better 
viral suppression in those with higher EIC, life expectancy was also estimated according to 
both viral load and level of EIC. This analysis showed that viral suppression was the more 
important predictor of life expectancy, as those with a detectable viral load and 100% EIC 
had lower life expectancy than those with only 25% EIC but an undetectable viral load. 
However, in both those with and without viral suppression, higher EIC was associated with 
older age at death. Those with low EIC and non-suppressed viral load have particularly poor 
mortality outcomes, but are only a relatively small number of all ART experienced individuals. 
The benefits of higher EIC in those with suppressed viral load may arise through closer 
monitoring, which enables earlier detection and management of illness and better access to 
other health and support services such as mental health services. These findings highlight 
that adherence support interventions should be a key focus of efforts to improve mortality in 
those on ART. However, due to the apparent benefits of higher EIC in those with and without 
viral suppression and the close link between EIC and suppression, interventions to improve 
both EIC and adherence may have the largest benefits. 
My final results chapter presented a longitudinal continuum of care that I have devised. This 
longitudinal continuum characterises ART use, EIC and viral suppression on a month-by-
month basis to give a population-level picture of achievement of the stages of HIV care over 
time in care. This method additionally incorporated mortality and LTFU and described sub-
optimal care categories. This has certain advantages over a cross-sectional continuum of care 
for measuring disparities in care and success of HIV care. Quantifying LTFU and mortality is 
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not possible using a cross-sectional continuum, and this longitudinal analysis demonstrated 
higher levels of LTC than had previously been assumed in the UK. If true, these high levels of 
LTC need to be tackled as they have potential implications for individuals’ health and ongoing 
transmission in the UK. However, a lack of data on migration means this could be an 
overestimate of the number of HIV-positive individuals living in the UK and not receiving care. 
Person-time spent with unsuppressed viral load was also shown to be lower than previous 
cross-sectional estimates would suggest, and is a useful care indicator to monitor as it gives 
a better understanding of the potential for ongoing transmission than a cross-sectional 
measure. Further, cumulative measures of viraemia have been shown to be predictive of 
mortality outcomes. I therefore think this chapter has particular relevance, as this devised 
longitudinal continuum can be used to generate findings that have implications for both public 
health and clinical care. This longitudinal continuum of care also has disadvantages. In order 
to characterise long-term outcomes, a historic cohort is studied who likely have different 
experiences of care to individuals entering care currently. Further, it currently studies a group 
of individuals linked to care, as this is the population included the UK CHIC Study. Though it 
could similarly be applied to a population of newly diagnosed individuals, it could not 
incorporate measures of undiagnosed HIV infection, which is an important element of the 
continuum of care, and the global target least often achieved in many settings, including the 
UK. Due to the in-depth clinical data needed to generate the month-by-month classifications 
of care, it would not be useful as a country-wide programme monitoring tool, but is instead 
more useful for research.  
Generating a longitudinal continuum of care for different age, sex, ethnic and HIV acquisition 
risk groups highlighted certain differences in the care continuum. I observed that older people 
initiated ART more quickly but had higher mortality. This is supported by findings from Chapter 
5, in which older individuals were more likely to be diagnosed late, and therefore in need of 
immediate ART, and had markedly higher rates of mortality. The continuum of care in younger 
adults showed that those aged <30 years at cohort entry spent a larger amount of time 
disengaged from care, particularly whilst ART naïve, and uptake of ART was therefore slower. 
Women, and those of black ethnicity were found to spend more time with unsuppressed viral 
load whilst ART experience. These findings highlight that sub-optimal achievement of the key 
stages of HIV care is more likely amongst those other than middle-aged, white, men who 
acquired HIV through sex between men. Also, they show that the gaps in care that are likely 
to be experienced by these groups differs. This is important as, although such disparities in 
the continuum of care have been shown in other countries, it has not been shown in the UK 
where access to healthcare is free. Targeted support interventions focused on improving the 
biggest gaps in the populations at highest risk will be needed to achieve an equally good 





Though a randomised controlled trial is the gold-standard for evidence-based medicine, this 
thesis is interested in outcomes of care in a real-life clinical setting. Further, many of the 
research questions addressed investigate exposures to which it is not possible to randomise 
individuals (for example, EIC). Therefore, a cohort study provides the best quality evidence 
to answer these research questions. The specific limitations of each analysis are discussed in 
the relevant chapters, but there are some general limitations of cohort studies, and the UK 
CHIC Study particularly, that should be considered when interpreting these findings. 
Firstly, the majority of clinics that contribute data to the UK CHIC Study are large London-
based clinics whose attendees may have different demographic characteristics to attendees 
at centres outside London. Therefore, the UK CHIC population may not be a representative 
sample of all PLWH in the UK. The possibility of unmeasured confounding that cannot be 
accounted for in these analyses cannot be ruled out. A limitation of using data from the UK 
CHIC Study to answer the questions posed in this thesis is that it collates data from HIV clinics 
and only those data that are routinely collected as part of HIV care. This limits the potential 
confounding factors that I was able to account for in analyses to factors directly relating to 
HIV care. Adherence and socioeconomic status are two potentially important confounders for 
many of these analyses that are not captured in the UK CHIC Study and so cannot be 
accounted for in these analyses. The study also does not collate information on wider health 
outside of HIV, for example, mental health, which would be important to consider in relation 
to engagement in care. Reliable capture of non-AIDS illnesses would be an important outcome 
to consider in the context of an aging HIV-positive population, particularly in light of findings 
in Chapter 5, demonstrating an association between late diagnosis, older age and non-AIDS 
mortality. Whilst some information is collected on non-AIDS illness in the study, reporting is 
dependent on the HIV clinic being aware of a diagnosis and has been found not to be 
consistent or reliable, so is not used for analysis.  
Cohorts, particularly observational databases that utilise routine clinical data, may be subject 
to attrition bias as people become LTFU, with certain groups more likely to be LTFU than 
others. Further, those disengaged from care may be more likely to have poorer outcomes 
than those remaining in care and this can result in an under or over-estimate of the true effect 
as these outcome events are not included in the analysis. Those with poorer engagement in 
care are also more likely to have missing information on other variables, as there are fewer 
opportunities to gather information in the HIV clinic, and it may be harder to get individuals 
to participate fully in care when they do attend. As a consequence, it was not possible to 
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understand characteristics or investigate predictors of those lost to study follow-up and lost 
to care, which were an important outcome of interest in this thesis. 
Missing data are unavoidable in most studies and are present in this thesis. Mechanisms of 
missing data include data missing completely at random (MCAR), in which missingness is 
unlikely to introduce bias. This assumption is unlikely in most epidemiological studies. Data 
missing at random (MAR) are a more likely assumption and are missing in a systematic way 
that can be explained by the observed data. This missingness may introduce bias if not dealt 
with using appropriate methods, such as multiple imputation. Data missing not at random 
(MNAR) are missing in a way that is associated with unobserved data. This may also be a 
valid assumption for this study. Few analysis techniques currently eliminate bias in the 
presence of MNAR data (541, 613). Throughout this thesis I have dealt with missing 
information on demographic variables by creating an unknown category where data are 
missing. As previously mentioned, these unknown categories therefore likely represent a 
group of individuals with poorer engagement in care, who may have more difficult or chaotic 
lifestyles and who are more likely to experience poor outcomes. In Chapter 5 it was seen that 
those of unknown mode of acquisition had significantly higher rates of mortality than for any 
other exposure group. In regression analyses, particularly confounder-adjusted multivariable 
models such as those in chapters 5 and 6, the inclusion of an additional unknown category 
has the potential to introduce bias (541, 614). Whilst such individuals account for only a small 
proportion of the included population, the mechanisms behind the occurrence of this missing 
data may still cause biased estimates in regression models (541).  
A deterministic linkage to HARS data was used to supplement information on date and cause 
of death. As no unique identifier was available that was common to both datasets, it is possible 
that matches were made through this linkage that were incorrect. In order to avoid accepting 
information from incorrect matches, I generated my own matching score based on agreement 
between certain mutually available data items and only accepted information if this score was 
below a threshold of 1. I used a score so that these decisions were objectively and consistently 
made across all linked records. However, the matching score I used was derived only on my 
own feeling of what was sensible, in agreement with my supervisor. If this score does not 
perform well, I may still be accepting some incorrect matches whilst also disregarding 
information from correct matches. A more in-depth assessment of the validity and precision 
of the initial linkage may have been useful to assess the extent to which incorrect linkage may 
have occurred (615). 
Throughout this thesis I have used the REACH algorithm to generate measures of engagement 
in care. This was done to incorporate and allow for varying visit schedules between individuals 
according to current health status and to create a time-updated measure of engagement in 
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care. However, the performance of this algorithm for measuring true engagement in care has 
not been assessed and it has not been externally validated in another cohort. The visit 
intervals defined in the algorithm are estimates based on clinician experiences and a small set 
of available variables within the UK CHIC dataset. Due to the previously mentioned limitations 
of the UK CHIC Study in the scope of the data it collects, the set of variables on which the 
REACH algorithm is based relate solely to HIV care. It does not incorporate factors not related 
to HIV, such as mental health and non-AIDS comorbidities that could influence the frequency 
at which HIV visits are scheduled. It also currently reflects visit scheduling practices at the 
time that the REACH Study was conducted and will need to be updated over time as 
recommended intervals for visits in stable treated HIV-positive individuals become longer 
(322). Finally, by relying on laboratory tests and ART prescription data to measure attendance, 
we may not capture all visits to the HIV clinic that an individual makes. This is likely to be of 
increasing importance in future years as CD4 count monitoring is reduced (322). These factors 
have most likely lead to an underestimate of engagement in care in the presented analyses. 
For certain analyses I have created categories from continuous variables. In chapter 5, I 
grouped age into <50 or ≥50 years. This was done to be consistent with other HIV literature, 
where age ≥50 has widely been adopted as a threshold for older age in PLWH (222, 294, 
296). In Chapter 7, I grouped EIC as high (≥80%) or low (<80%), as it may be useful to have 
a definition of ‘engaged’ and ‘not engaged’ in care, but also analysed EIC as a continuous 
variable. Such dichotomisation of numeric data results in a loss of information, which could 
reduce the power to detect an association between the categorised variable and outcome of 
interest (616, 617). Categorisation assumes that the size of an association between an 
independent variable and the outcome variable is the same across all underlying values within 
a group, but is different as you cross the dichotomy (616, 617). This is to say, using EICR as 
the example, that an EICR of 25% has the same association with mortality as an EICR of 
79%, but the association between and EICR of 79% and mortality is different to an EICR of 
81%. This underestimates the variability in outcome responses within each group and is not 
a valid assumption. The choice of cut-off may also impact observed associations resulting in 
biased estimates (616, 617). As was seen in Chapter 7, the ‘low’ EIC group had a life 
expectancy similar to that of people with 25% EICR in analysis using continuous EICR, 
ignoring increases in life expectancy seen for those with 50% and 75% EICR in the continuous 
analysis. Therefore, the analysis using continuous EICR is a more valid analysis. 
9.3 Future work 
This thesis has highlighted issues of loss to HIV care in the UK, which has previously not been 
well recognised (70). This is an important finding as those lost to care are more likely to have 
poor outcomes and could contribute to the ongoing epidemic if not on treatment with a 
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suppressed viral load. Further work should focus on generating reliable estimates of the 
number of PLWH in the UK who aren’t receiving care, as well as understanding drivers of 
disengagement from care and barriers to re-engaging in care. Key to this would be to identify 
where individuals lost to follow-up have migrated out of the country and where they have 
remained but do not receive care. It would not be possible to investigate this in any detail 
using only the clinical HIV data collected in the UK CHIC Study. Mixed methods research that 
utilises surveillance data, data linkage and qualitative elements would ideally be needed to 
fully investigate loss to care. A quantitative element to reliably estimate rates and understand 
predictors of loss to care would require the ability to actively trace outcomes of those lost-to-
follow-up from clinics; in particular to establish whether individuals have migrated out of the 
UK. Previous attempts to actively contact and ascertain outcomes of individuals lost to care in 
a single centre were not able to trace the majority (324). However, this would likely be the 
best approach, as linking data on HIV status to migration data poses ethical concerns due to 
the stigma still surrounding HIV and fears over identifying, on a patient-level, those with 
unconfirmed immigration status or those remaining in the country illegally. The national HARS 
dataset could be used to determine whether individuals remain in HIV care in the UK. 
Alternatively, electronic patient records may provide a unique opportunity to establish whether 
individuals are accessing care in any health setting (for example, through their GP) in the UK, 
not only HIV care. However, this would require linking of the HIV record to NHS number. 
Currently, HIV clinic records are still often treated as a special case and are not linked to NHS 
number and an individual’s wider health record. If it were possible to utilise electronic patient 
records, it may also present an opportunity to access additional data on individuals lost to 
care such as mental health, socioeconomic status and psychosocial factors that would be of 
benefit to understand predictors of disengagement. However, as many barriers to 
engagement in care may be related to individuals’ circumstances, a qualitative element to 
understand drivers of this loss to care would be useful inform potential targeted interventions 
to prevent disengagement and encourage re-engagement. Such a study would need to 
purposively sample and recruit those individuals identified as lost to care, so may be small in 
size, as it may be difficult to access and recruit individuals who are not engaged in care to a 
research study.  
Recent changes to HIV treatment guidelines as to when to start ART may affect the relevance 
of some of these findings to newly diagnosed PLWH now and in future. If people newly 
diagnosed with HIV start ART as soon as they are ready to do so as part of routine care, whilst 
the continuum of care will likely improve in those who are diagnosed early, disparities in 
outcomes between those with late as opposed to timely diagnosis and ART initiation could 
increase. Immediate ART could contribute to reductions in HIV transmission in combination 
with pre-exposure prophylaxis in HIV–negative individuals, meaning that the largest burden 
of HIV in future years will remain amongst those who have poorer engagement with care and 
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are slower to be diagnosed and initiate ART. These individuals, will become increasingly 
important to the epidemic in the UK. For these reasons further follow-up in the era of 
immediate ART is needed to assess the impact of these changes on the continuum of care 
and whether disparities will continue or even worsen across different populations of PLWH in 
the UK. In the coming years, the longitudinal continuum of care will need to be re-assessed 
to determine the impacts of immediate ART in different age, ethnic and HIV risk groups. 
 
9.4 Concluding remarks 
The aims of this thesis were to investigate the occurrence of sub-optimal achievement of some 
of the key elements that make up the HIV continuum of care, and the impact of such factors 
on mortality outcomes. I have shown that late diagnosis is common and associated with a 
high mortality burden soon after diagnosis. I have also seen that whilst viral suppression is a 
hugely predictive marker of mortality, better EIC independently correlates with life expectancy 
amongst both those with and without a virological response to ART. Whilst those who initiate 
ART with immunosuppression have poorer CD4 recovery, the risk of clinical progression may 
reach similar levels to that in those who start ART earlier in the long-term, if viral suppression 
is achieved. Finally, a longitudinal continuum of care has demonstrated disparities in care and 
treatment response amongst demographic groups. 
Interventions to improve testing rates, and adherence and engagement support are needed 
for those populations identified as being at high risk of sub-optimal engagement with HIV 
care. Above all, these findings highlight the importance of achieving a truly optimal continuum 
of care across all demographic groups to reduce the burden of mortality in PLWH in the UK. 
It is hoped that this thesis will provide needed data for a UK setting that can inform discussions 
















10Appendix I: UK CHIC Study data request 
















We are now requesting the next data download from centres. It is appreciated that some 
centres may not be able to provide all of this data electronically for all files. If certain data 
items are not available at present, could you let me know if they may be available in future?  
If you have any queries, please contact Teresa Hill (020 7670 4730 or 020 7794 0500 ext 
36762)  




We ask that you submit all data by Friday 19th December 2014.  
 
Format 
▪ Please provide data on all HIV positive patients seen for care at any time at your HIV 
clinic  
▪ All data can be submitted as Access tables, Excel spreadsheets, or text files with the 
variables comma or tab delimited  
▪ All dates should be provided in dd/mm/yyyy format, including leading zeros, and without 
time after dates 
▪ All files should include the clinic ID and date of birth for each patient so that the files can 
be easily merged 
▪ DO NOT send patient names, addresses or postcodes 
 
Coding 
▪ Codes for the variables in the data tables (Files 1 – 12) are listed on page 5 onwards. 
Data must be coded using UK CHIC codes otherwise it will not be accepted. If you need 
help with coding or mapping your data please contact us 
 
How to submit data securely (Encryption plus secure transfer) 
▪ Data encryption: please encrypt data using either 7-Zip or Winzip (select 256-bit AES 
encryption). 
Please DO NOT USE AXCRYPT as this is no longer an approved encryption software. 
The encryption password (minimum 10 characters long, include upper/lowercase, 
numbers and special characters, do not use ‘ukchic’, or the clinic name), to be 
communicated by telephone or separate email  
▪ Secure Data transfer/submission: submit the encrypted files by the FTP secure 
transfer system.  
Email teresa.hill@ucl.ac.uk or telephone if you need FTP details 
 
Feedback on data quality 
Following data submission and some general format checks, we will contact you if there are 
issues that need to be resolved. At a later date, we may send you more detailed data 




Anything new this time?  
As a result of Steering Committee discussions, we may collect new data some years. These 
items will be highlighted in blue here and in the data specifications. NO NEW DATA ITEMS 
THIS YEAR.  
 





File 1 – PATIENTCENTRE table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Soundex Soundex code text (4) 
Initial Patient initial/s text (2) 
SexID Patient sex code integer 
HIVPos Date of first known positive HIV antibody test dd/mm/yyyy 
HIVNeg Date of last negative HIV antibody test dd/mm/yyyy 
Firstseen Date of first HIV attendance at centre dd/mm/yyyy 
Lastseen Date when last seen by a clinician at the 
centre 
dd/mm/yyyy 
ExposureID HIV exposure category  integer 
EthnicityID Ethnicity code integer 
CountryID Country of birth code text (30) 
DiedID Is patient known to have died code integer 
DDeath Date of death dd/mm/yyyy 
Cause Cause of death (where known) text (100) 
TransferFr Transfer in from which previous centre text (100) 
TransferFrDate Transfer in from previous centre date dd/mm/yyyy 
TransferTo Transfer out to which other centre text(100) 
TransferToDate Transfer out to other centre date dd/mm/yyyy 
 
File 2 – AIDSEVENT table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAIDS Date of AIDS event dd/mm/yyyy 
AIDSID AIDS event code  integer 
 
File 3 – ANTIRETRO table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DStart Date started taking drug dd/mm/yyyy 
DStop Date stopped taking drug dd/mm/yyyy 
DrugID Drug code integer (15) 
ReasonStopID1 Reason for stopping drug integer 
ReasonStopID2 Reason for stopping drug (if multiple codes) integer 
ReasonstopID3 Reason for stopping drug (if multiple codes) integer 
 
File 4 – CD4 table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Dlab Date of lab measurement dd/mm/yyyy 
CD4A Absolute CD4 count in cells/mm3 integer 
CD4P CD4 percentage number (1dp) 
CD8A Absolute CD8 count in cells/mm3 integer 
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CD8P CD8 percentage number (1dp) 
 
File 5 – RNA/HIV Viral Load table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
Dlab Date of lab measurement dd/mm/yyyy 
RNA HIV Viral Load level in copies/ml  long integer 
UndetID Result status: below/within/above assay limit integer 
AssayID HIV RNA assay code  integer 
 
File 6 – HEPATITIS table  
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DHeptest Date of hepatitis test dd/mm/yyyy 
HepTestID Hep test code  integer 
HepResultID test result (-/+/indet) integer 
Hepvalue test result value, e.g. RNA copies long integer 
UndetID Result status: below/within/above assay limit integer 
HepUnitID test result units integer 
HepAssayID please ignore this integer 
 
File 7 – ADHERENCE table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAdherence Date of clinic visit dd/mm/yyyy 
AdherPeriodID Adherence period codes  integer 
AdherPerOther Adherence period other text (50) 
DosesMiss Number of doses missed (approximately) integer/text 
ReasonMissID  Reason for missing treatment code integer 
AdhComment Text description relating to adherence text (50) 
 
File 8 – PCPPROP table (PCP prophylaxis data are no longer required - PLEASE DO NOT SEND) 
 
File 9 – TOXICITY table  
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DToxtest Date of toxicity test dd/mm/yyyy 
ToxTestID Tox test code  integer 
ToxResult Test result value integer/number,single 
(if dec places in result) 
ToxUnitID Test result units, coded integer 
 
File 10 – HLA-B57 table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
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DOB Date of birth dd/mm/yyyy 
DHLAB57 Date of HLA-B*5701 test dd/mm/yyyy 




File 11- Attendance table 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DAttend Date of attendance dd/mm/yyyy 
AttSeenBy Who patient is seen by eg doc, nurse, 
virtual, dietician, psycologist, other etc 
integer 
AttType Attendance: scheduled, walk-in, virtual,  in-
patient, other 
integer 
Ddischarge Date of discharge if in-patient dd/mm/yyyy  
 
 
File 12 - SeriousNonAIDS 
 
Field Name Description Type 
ClinicNo HIV Clinic’s unique patient identifier  text (12) 
DOB Date of birth dd/mm/yyyy 
DSerNA Date of serious Non-AIDS event dd/mm/yyyy 
SNAID Serious Non-AIDS event code integer 
SNAConf Serious Non-AIDS event status, whether 
Confirmed/Probable/Status unknown 
integer 
ICDcode  ICD code if used text 
SNOMEDcode SNOWMED code if used text 
 
 
Coding/Mapping Tables – see below
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CODING / MAPPING TABLES 
Coding Description 
AdherPeriodID AdherPeriod 
1 Last 3 days  
2 Last 14 days/2 weeks  
3 Last 30 days/1 month  
4 Last 90 days/3 months  
98 Other adherence period 
99 Not known 
AIDSID AIDS 
1 Bacterial infections (multiple or recurrent) at age < 13 years 
2 Candidiasis, oesophageal 
3 Candidiasis, trachea/bronchi/lungs  
4 Candidiasis, site unknown  
5 Cervical cancer, invasive  
6 Coccidioidomycosis, extrapulmonary  
7 Cryptococcosis, extrapulmonary  
8 Cryptosporidiosis, duration > 1 month  
9 Cytomegalovirus retinitis  
10 Cytomegalovirus disease, other  
11 Cytomegalovirus, site unknown  
12 Herpes simplex disease, duration > 1 month  
13 Histoplasmosis, extrapulmonary and/or disseminated  
14 HIV Encephalopathy  
15 Isosporiasis, duration > 1 month  
16 Kasposi’s sarcoma  
17 Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia at age <13 years  
18 Lymphoma, Burkitt’s, immunoblastic or equivalent  
19 Lymphoma, primary in brain  
20 Mycobacterium avium, extrapulmonary (MAI/MAC) 
21 Mycobacterium tuberculosis, pulmonary  
22 Mycobacterium tuberculosis, extrapulmonary  
23 Mycobacterium, other (disseminated)  
24 Pneumoncystis carinii pneumonia (P. jiroveci) 
25 Pneumonia, recurrent in a 12-month period  
26 Progressive multifocal leukoencephalopathy  
27 Salmonella Septicaemia, recurrent  
28 Toxoplasmosis, cerebral  
29 HIV wasting syndrome  
31 Lymphoma Site Unknown 
51 Mycobacterium tuberculosis, Site Unknown 
98 AIDS disease, not specified  
99 Not Known 
AssayID Assay 
1 Roche Amplicor HIV-1 Monitor v1.0 (<400)  
2 Roche non-B (<400) 
3 Roche Amplicor HIV-1 Monitor v1.5 (<400) 
4 Roche Amplicor HIV-1 Monitor v1.5 US (<50) 
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5 Roche – version unknown 
6 Cobas v1.5 (<400) 
7 Cobas v1.5 US (<50) 
9 Cobas – version unknown 
10 NASBA (<400) 
11 NASBA US 
12 NASBA – version unknown 
13 Chiron b-DNA v1.0   
14 Chiron b-DNA v2.0 (<500) 
15 Chiron b-DNA v3.0 US (<50) 
16 Chiron – version unknown 
17 Nuclisens (<400) 
18 Nuclisens US (<50?) 
19 Nuclisens – version unknown 
21 Cobas<10 copy assay 
22 Abbott RealTime HIV-1 (ultra-sensitive)  
23 Abbott LCx HIV RNA 
29 Roche Cobas TaqMan v1.0 (<40)  
30 Roche Cobas TaqMan v2.0 (<20) 
31 Abbott RealTime HIV-1 (<40) 
98 Other 




3 Health advisor 
4 Pharmacy/Pharmacist 
5 Dietician 
6 Psychologist / Counsellor 
98 Other 
99 Not known 
AttType Type of attendance 
1 Scheduled or booked 
2 Walk-In 
3 Virtual – telephone or email contact 
4 In-patient 
98 Other 




99 Not known 
DrugID Drug 
1 Zidovudine (AZT)  
2 Zalcitabine (ddC)  
3 Didanosine (ddI)  
4 Stavudine (d4T) 
5 Lamivudine (3TC) 
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6 Abacavir  
7 Combivir (AZT+3TC)  
8 Lodenosine 
9  Trizivir (AZT + 3TC + abacavir) 
10 Tenofovir (TDF) 
11  Emtricitabine (FTC) 
12 Kivexa (3TC + abacavir) 
13 Truvada (tenofovir/TDF + emtricitabine /FTC) 
14 Tenofovir alafenamide fumarate (TAF) 
19 Other NRTI 
20 Nevirapine  
21 Efavirenz  
22 Loviride  
23 Delavirdine  
24 Etravirine / TMC125 
25 Rilpivirine (RPV) 
26 Eviplera (rilpivirine + tenofovir/TDF + emtricitabine/FTC) 
39 Other NNRTI  
40 Saquinavir hard gel (invirase)  
41 Indinavir  
42 Ritonavir – any dose  
43 Nelfinavir  
44 Saquinavir soft gel (fortovase)  
45 Amprenavir  
46 Lopinavir (ABT 378) (kaletra) 
47 Saquinavir (form unknown)  
48 Atazanavir  
49 Other PI  
50 Hydroxyurea / hydroxycarbamide 
51 IL-2 
60 Acyclovir 
61 Fos amprenavir 
62 Tipranavir 
63 Darunavir / TMC114 
70 Enfuvirtide / T20  
80 Adefovir 
90 Blinded treatment in clinical trial  
95 Maraviroc 
96 Vicriviroc 
97 Other Entry (CCR5) Inhibitor 
98 Other ART drug (ART drug is known, but not on this list) 
99 Not known (ART, but not known which drug) 
110 Raltegravir / MK-0518  
111 elvitegravir 
112 dolutegravir 
119 Other Integrase Inhibitor 
120 Atripla (Efavirenz/Tenofovir/Emtricitabine) 
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4 Black – unspecified/black-other 
5 Indian/Pakistani/Bangladeshi 
6 Other Asian/Oriental 
7 Other/mixed 
98 Other 
99 Not known 
ExposureID Exposure 
1 Homosexual/bisexual (including homo / bi sex who also injected drugs) 
2 Injecting drug use  
3 Heterosexual 
4 Blood/blood products recipient 
5 Mother-to-child transmission 
98 Other 




2 Indeterminate /weakly reactive/equivocal 
HepTestID HepTest 
1 Hep A antibody (total IgG+IgM) 
2 Hep B surface antigen     (HbsAg) 
3 Hep B surface antibody    (anti-HBs) 
4 Hep B core antibody      (anti-HBc) 
5 Hep B e antigen 
6 Hep B e antibody 
7 Hep C antibody 
8 Hep C virus PCR/bDNA 
9 Hep B core antibody (IgM) 
10 Hep A antibody (IgM) 
11 Hep B DNA (Genotype unknown) 
12 Hep D antibody (total) 
13 Hep B surface antigen (titre) 
14 Hep D antibody (IgM) 
98 Other  












2 Indeterminate /weakly reactive/equivocal 
PCPpDrugID PCPpDrug  (PCPp Drug data no longer collected - please do not send) 
1 Co-trimoxazole/septrin 
2 Dapsone  
3 Pentamidine  
4 Atovaquone  
5 Azithromycin  
6 Clarithromycin  
7 Clindamycin  
8 Fansidar (=pyrimethamine + sulphadoxine) 








17 Maloprim (pyrimethamine + dapsone)  
18 Eflornithine 
98 Other 
99 Not known 
ReasonMissID ReasonMiss 
1 Forgot 
2 Ran out of medicaiton 
3 Wanted a short break 
4 Side effects 
5 Away from home/supply  
6 In company 
7 Treatment holiday 
98 Other 
99 Not known 
ReasonStopID ReasonStop 
10 Failure-cause unknown  
11 Virological  
12 Immunological   
13 Clinical  
14 VL / CD4 
20 Toxicity-type unknown  
30 Skin  
31 Hypersensisity – Abacavir  
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32 Rash  
40 GI  
41 Nausea/Vomiting 
42 Diarrhoea  
43 Pancreatitis  
44 Abnormal LFT  
50 Neuro  
51 CNS Disturbance  
52 Peripheral Neuropathy  
53 Headache  
60 Metabolic  
61 Lipids  
62 Glucose Intolerance  
63 Hyperlactataemia  
64 Osteopaenia  
70 Lipodystrophy  
80 Myelotoxicity  
81 Anaemia  
82 Neutropenia  
83 Thrombocytopenia  
91 Myotoxicity  
92 Nephrolithiasis/Renal Dysfunction   
100 Patient Choice  
110 Clinician decision 
120 Interaction  
130 Simplification  
140 Poor Adherence  
150 Joined clinical trial  
160 Study/Trial End  
170 New drug available  
180 Known treatment interruption  
190 Protocol amendment  
200 Pregnancy  
201 At start/during pregnancy  
202 End of short-course ART  
210 Intercurrent illness, not HIV/ drug related  
220 VL sufficiently low  
230 CD4 sufficiently high  
240 Regimen change 
250 Transfer of care 
260 Drug Experience / Resistance 
998 Other   
999 Not Known 
SNAConf Serious Non-AIDS event Confirmed 
1 Confirmed 
2 Probable 
99 Status Unknown (not known whether Confirmed or Probable) 
SNAID Serious Non-AIDS  
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10 Acute Myocardial Infarction (AMI) 
11 Congestive Heart Failure (CHF) 
12 Coronary Artery Disease Requiring Drug Treatment  
13 Coronary Revascularization (coronary angioplasty, artery by-pass grafting, stent, carotic 
endarterectomy 
50 Decompensated Liver Disease (DLD) 
51 Alcoholic liver disease 
52 Liver Cirrhosis 
53 Liver Fibrosis 
56 HAART associated liver disease (including non-alcoholic steatohepatosis, nodular 
regenerative hyperplasia, hepatoportal sclerosis 
58 Liver disease, other  
59 Liver disease, chronic, unspecified 
70 Diabetes Mellitus (DM) 
75 Lactic acidosis, symptomatic 
80 End Stage Renal Disease (ESRD) 
81 HIV nephropathy 
82 HAART associated renal failure (including Fanconi syndrome) 
89 Renal disease, other 
100 Anal cancer 
101 Bowel cancer 
102 Breast cancer 
103 Castleman’s disease 
104 Cervical cancer 
105 Hodgkins Lymphoma (HL) 
106 Liver cancer 
107 Lung cancer 
108 Stomach cancer 
109 Prostate cancer 
110 Other Non-AIDS-Defining cancer (NADC), unspecified 
120 Peripheral Arterial Disease (PAD) 
121 Pulmonary Embolism (PE) 
122 Deep Vein Thrombosis (DVT) 
123 Stroke 
129 Other vascular / thromboembolic disease 
130 Osteopenia 
131 Osteoporosis 
132 Fracture, fragility 
133 Fracture, traumatic 
134 Fracture, mixed (traumatic+fragility) 
135 Fracture, unspecified 
138 Other bone disease 
139 Bone disease, unspecified 
140 Sepsis (or Sepsis Syndrome) 
141 Multi-organ failure 
142 Haemophagocytic Syndrome 
143 Bacterial infection, severe (non-sepsis) 
144 Fungal infection, severe 
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145 Viral infection, severe 
149 Infection, severe, unspecified (non-AIDS), other 
998 Serious Non-AIDS event, other 












7 Cholesterol total (non fasting or unknown) 
8 CPK (creatine phosphokinase) 
9 Creatinine (serum) 
10 Glucose 







18 Lactate dehydrogenase  
19 Cholesterol (fasting) 
20 Protein Total (urine) 
21 Creatinine (urine) 
22 Protein/Creatinine Ratio (PCR) (urine) 
23 Albumin (urine) 
24 Albumin/Creatinine Ratio (ACR) (urine)  
25 Protein 24hr (urine) 
26 Platelet count 
27 Vitamin D 
28 Phosphate (serum) 
29 Calcium (serum) 
30 Parathyroid hormone (PTH) 
31 Calcium (serum, corrected) 
98 Other 





4 mol/L  




7 mmol/L (urine) 





13 g/L  




18 nmol/L  
19 pmol/L 
98 Other 
99 Not known 
UndetID Undet  
-1 < Below lower limit of detectability  
0 Any value that is detectable but below the upper limit of quantification 
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Figure s1: Data entry form, page 1 
 
 







Figure s3: Data entry form, page 3 
 
 
























Table s1: Possible matching scores and the corresponding combinations of CD4 or viral load match, HANDD linkage score and demographic 
inconsistencies that could result in each 




-6 CD4 count OR VL exact match 1 No demographic inconsistencies 
-5 
CD4 count OR VL exact match 1 Exposure inconsistency 
CD4 count OR VL exact match 1 “Partial” ethnicity inconsistency 
CD4 count OR VL exact match 2,3,4 No demographic inconsistencies 
-4 
CD4 count OR VL exact match 1 Sex inconsistency 
CD4 count OR VL exact match 1 Ethnicity inconsistency 
CD4 count OR VL exact match 1 Exposure inconsistency and 'partial' ethnicity inconsistency 
CD4 count OR VL exact match 2,3,4 Exposure inconsistency 
CD4 count OR VL exact match 2,3,4 “Partial” ethnicity inconsistency 
-3 
CD4 count OR VL exact match 1 Sex inconsistency and exposure inconsistency 
CD4 count OR VL exact match 1 Sex inconsistency and 'partial' ethnicity inconsistency 
CD4 count OR VL exact match 1 Ethnicity inconsistency and exposure inconsistency 
CD4 count OR VL exact match 2,3,4 Sex inconsistency 
CD4 count OR VL exact match 2,3,4 Ethnicity inconsistency 
CD4 count OR VL part match  1 No demographic inconsistencies 
-2 CD4 count OR VL exact match 1 Sex inconsistency and ethnicity inconsistency 
CD4 count OR VL exact match 1 Sex inconsistency and exposure inconsistency and 'partial' ethnicity inconsistency 
CD4 count OR VL exact match 2,3,4 Sex inconsistency and exposure inconsistency 
CD4 count OR VL exact match 2,3,4 Sex inconsistency and partial ethnicity inconsistency 
CD4 count OR VL part match  1 Exposure inconsistency 
CD4 count OR VL part match  1 “Partial” ethnicity inconsistency 










CD4 count OR VL exact match 2,3,4 Sex inconsistency and ethnicity inconsistency 
CD4 count OR VL part match 1 Sex inconsistency 
CD4 count OR VL part match 1 Ethnicity inconsistency 
CD4 count OR VL part match 2,3,4 Exposure inconsistency 
CD4 count OR VL part match 2,3,4 "Partial" ethnicity inconsistency 
0 
CD4 count OR VL part match 1 Sex inconsistency and exposure inconsistency 
CD4 count OR VL part match 1 Sex inconsistency and "partial" ethnicity inconsistency 
CD4 count OR VL part match 1 Ethnicity inconsistency and exposure inconsistency 
CD4 count OR VL part match 2,3,4 Sex inconsistency 
CD4 count OR VL part match 2,3,4 Ethnicity inconsistency 
CD4 count OR VL part match 2,3,4 Exposure inconsistency and 'partial' ethnicity inconsistency 
No CD4 count or VL match 1 No demographic inconsistencies 
1 
No CD4 count or VL match 1 Exposure inconsistency 
No CD4 count or VL match 1 "Partial" ethnicity inconsistency 
No CD4 count or VL match 2,3,4 No demographic inconsistencies 
2 
No CD4 count or VL match 1 Sex inconsistency 
No CD4 count or VL match 1 Ethnicity inconsistency 
No CD4 count or VL match 1 "Partial" ethnicity inconsistency and exposure inconsistency 
No CD4 count or VL match 2,3,4 Exposure inconsistency 
No CD4 count or VL match 2,3,4 "Partial” ethnicity inconsistency 
3 No CD4 count or VL match 1 Sex inconsistency and exposure inconsistency 
No CD4 count or VL match 1 Sex inconsistency and "partial" ethnicity inconsistency 
No CD4 count or VL match 2,3,4 Sex inconsistency 
No CD4 count or VL match 2,3,4 Ethnicity inconsistency 
No CD4 count or VL match 2,3,4 Exposure inconsistency and 'partial' ethnicity inconsistency 











No CD4 count or VL match 2,3,4 Sex inconsistency and exposure inconsistency 
No CD4 count or VL match 2,3,4 Sex inconsistency and "partial" ethnicity inconsistency 
5 
No CD4 count or VL match 2,3,4 Sex inconsistency and ethnicity inconsistency 
No CD4 count or VL match 2,3,4 Sex inconsistency and exposure inconsistency and 'partial' ethnicity inconsistency 
6 No CD4 count or VL match 2,3,4 Sex inconsistency and ethnicity inconsistency and exposure inconsistency 
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